text,crowd_label,conf0,conf1
alinidin atrioventricular block atenolol alinidin significantli decreas basic heart rate without caus sinu arrest higher-degre atrioventricular block,0,1.0,0.0
mitomycin local advanc breast cancer feasibl toxic local respons rate intra-arteri chemotherapi num-fluorouracil epirubicin mitomycin patient num2 year local advanc breast cancer evalu,0,1.0,0.0
sulfamethoxazol wegen 's granulomatosi long-term sulfamethoxazole-trimethoprim wegen 's granulomatosi,0,0.8065,0.1935
cholesterol glomerular diseas baselin control period num week usual diet num2 untreat patient chronic glomerular diseas stabl long-last sever proteinuria num sd num g/num2 h hyperlipidaemia mean serum cholesterol numnum2 numnum2 mmol/l ate vegetarian soy diet num week,0,1.0,0.0
nitric oxid lung diseas cystic fibrosi cf lung diseas exhal nitric oxid feno not rais rather normal even decreas measur singl expiratori flow,0,0.8077,0.19230000000000005
silicon myopia silicon posterior chamber plate-styl intraocular len chiron adatom implant num2 consecut phakic eye high myopia -numnum2 -num2numnum2 diopter period num2 month,0,1.0,0.0
dopamin parkinson 's disease/pd use nationwid computer regist death data year num4 num4 examin num2 num3 num3 death person num2 year age extract num3 num3 case parkinson 's diseas pd dopamin defici popul,0,0.8282,0.17179999999999995
levosimendan myocardi stun levosimendan promis treatment myocardi stun,0,1.0,0.0
aspirin unusu burn injuri unusu burn injuri due applic white vinegar aspirin mixtur,1,0.0,1.0
tamoxifen neuroblastoma tumour growth neuroblastoma tumour inhibit differ mechan l-dopa metabolit dopamin reduc activ tyrosinas bso reduc glutathion level l-dopa tamoxifen rais camp concentr,0,1.0,0.0
prostanoid pain brimonidin group exhibit lowest visual analog pain-scal score prostanoid especi bimatoprost group demonstr highest visual analog pain-scal score medianastandard deviat num0a1numnum2 num0a1numnum2 respect,0,0.8106,0.1894
paracetamol critic ill. ventil critic ill patient monitor picco administ intraven paracetamol time elig studi,0,1.0,0.0
acrylamid toxic present review focus sever advers health effect acrylamid includ mutagen genotox carcinogen neurotox reproduct toxic possibl outcom childhood exposur babi food infant formula,1,0.0,1.0
methotrex toxic methotrex not remission-induc drug may dose-limit toxic,1,0.0,1.0
mpa gamma-glutamyl-transpeptidase/ggt csa c2 correl mpag-to-mpa ratio p numnum2 r numnum2 gamma-glutamyl-transpeptidas ggt p numnum2 r numnum2,0,1.0,0.0
num2 -hete melanoma result demonstr num2 -hete/num2 -hete activ erk fak signal pathway therebi upregul adhes metastat potenti melanoma cell,1,0.3548,0.6452
cholesterol proteinuria baselin control period num week usual diet num2 untreat patient chronic glomerular diseas stabl long-last sever proteinuria num sd num g/num2 h hyperlipidaemia mean serum cholesterol numnum2 numnum2 mmol/l ate vegetarian soy diet num week,0,1.0,0.0
nac copd conclus stabl state iii copd patient present unstabl redox balanc long term low flow oxygen administr induc system oxid stress prevent nac treatment,0,1.0,0.0
metoprolol adpkd prospect random double-blind studi perform compar renal cardiac effect ace inhibitor ramipril beta-block metoprolol first line therapi adpkd patient hypertens,0,1.0,0.0
cyclophosphamid graft-versus-host disease/gvhd clinic safeti efficaci intraven busulfan fludarabin iv bu/flu myeloabl condit well graft-versus-host diseas gvhd prophylaxi high-dos post-transplant cyclophosphamid ptci demonstr independ sever single-institut studi,0,1.0,0.0
methadon death control studi covari patient receiv methadon num2 increas risk death follow-up period adjust hazard ratio hr numnum2 num2 ci numnum2-numnum2 pua uanumnum3 result num2 num2 ci num2-num3 excess death per num2uanum3 person-year follow-up,1,0.0,1.0
tetracain pain instil tetracain num solut prior administr clotrimazol block pain sensat allow patient success complet antifung therapi,0,1.0,0.0
taurin melanoma effect combin taurin azela acid antimelanogenesi murin melanoma cell,0,0.8094,0.1906
pufa atherosclerosi benefici effect fish n-num polyunsatur fatti acid pufa consumpt atherosclerosi report numer epidemiolog studi,0,1.0,0.0
guanethidin pain applic capsaicin heat-pain threshold heat-pain rate suprathreshold stimul similar site pretreat num week guanethidin salin,0,0.8005,0.1995
acetaminophen poison acetaminophen wide use human be analges purpos one frequent caus poison cat,1,0.0,1.0
bile acid atrophi oral bile acid administr may prevent atrophi elev mucos dao alp activ may lead new therapeut strategi patient manag ed,0,1.0,0.0
carbosilan hiv-num infect evalu variou combin anion carbosilan dendrim sulfat g3-snum2 naphthyl sulfon g2-nfnum2 end group differ arv against hiv-num infect,0,1.0,0.0
acetaminophen hepat failur acetaminophen-poison cat develop methemoglobinemia sometim hepat failur,1,0.0,1.0
num-fu adenocarcinoma nine human pancreat adenocarcinoma vari wide sensit chemotherapi especi num-fu,0,1.0,0.0
morphin delirium although recent studi suggest opioid rotat could effect treatment strategi morphine-induc delirium no prospect studi investig treatment effect opioid rotat use fentanyl,1,0.3995,0.6005
hbeag hbeag neg chronic hepat b/chb aim investig relationship serum leptin concentr sever liver diseas cohort subject hbeag neg chronic hepat b chb c chc analyz effect bodi composit leptin system insulin resist togeth viral factor virolog respons antivir treatment,0,1.0,0.0
ramosetron ponv/prevent postop nausea vomit prospect random double-blind placebo-control trial evalu efficaci ramosetron three differ dose numnum2 num num mg prevent postop nausea vomit ponv gynecolog surgeri,0,1.0,0.0
flavonoid breast cancer associ flavonoid flavonoid subclass flavonol flavan-num-ol etc risk breast cancer lack systemat analysi,0,1.0,0.0
salicyl hemophilia drug choic patient not treat non-steroid anti-inflammatori drug nsaid peopl bronchial asthma peptic ulcer diseas hemophilia salicylate-sensit peopl children num2 year age pregnant breastfeed women,0,1.0,0.0
enzalutamid prostat cancer mini-review discuss gener mechan resist ar-direct therapi focu role androgen receptor splice variant new era treat advanc prostat cancer enzalutamid abirateron,0,1.0,0.0
mitoxantron cardiotox explor potenti dexrazoxan suppress subclin cardiotox ms patient receiv mitoxantron,1,0.3942,0.6058
imatinib advanc diseas patient howev primarili advanc diseas either refractori imatinib eventu relaps,0,1.0,0.0
docetaxel breast cancer determin safeti inumv trastuzumab num mg/kg follow num mg/kg everi num week combin chemotherapeut agent administ num-weekli cours docetaxel vinorelbin capecitabin num2 patient her2-posit recurr locoregion and/or metastat breast cancer,0,1.0,0.0
estrogen glandular hyperplasia tamoxifen rapidli up-regul cell prolifer marker effect associ enhanc growth confirm increas express estrogen receptor ki-num2 addit high incid glandular hyperplasia,0,1.0,0.0
fluoroquinolon mycoplasma emerg clinic strain mycoplasma genitalium harbour alter parc associ fluoroquinolon resist,0,0.8212,0.17879999999999996
floxuridin metastas effect aberr hepat arteri anatomi tumour respons hepat arteri infus floxuridin colorect liver metastas,0,0.8014,0.1986
acetylcholin agid numer autoantibodi current recogn biomark agid ganglion acetylcholin receptor autoantibodi proven pathophysiolog effector,0,1.0,0.0
num-fluorouracil tme patient histolog proven rectal cancer stage t2n+ t3 random receiv either scrt num2 gy five fraction num gy plu tme-surgeri within num day rct num2num gy num2 fraction num gy continu infus num-fluorouracil plu tme-surgeri num-num week later,0,1.0,0.0
candesartan hypertens find suggest low-dos combin therapi nifedipin cr candesartan superior up-titr monotherapi candesartan term blood pressur control renal protect patient essenti hypertens,0,1.0,0.0
spiperon schizotyp person disord lymphocyt spiperon bind paramet bmax kd assess num2 patient schizophrenia num patient schizotyp person disord neurolept naiv num2 age- sex-match control subject,0,1.0,0.0
cyclophosphamid pediatr cancer bk virus-associ hemorrhag cystiti pediatr cancer patient receiv high-dos cyclophosphamid,0,1.0,0.0
ketamin termin cancer pain doubl blind cross studi design evalu effect ketamin spinal morphin analgesia termin cancer pain patient,0,1.0,0.0
cyclophosphamid malign random trial determin rel efficaci ifosfamid cyclophosphamid variou childhood malign way,0,1.0,0.0
methadon pain grow methadon use pain manag rais concern regard safeti rel long-act opioid,0,1.0,0.0
tacrolimu ulcer coliti tacrolimu therapi altern thiopurin maintain remiss patient refractori ulcer coliti,0,1.0,0.0
carnitin pco contrari control patient pco character slightli lower level fast total free carnitin precursor deriv,0,1.0,0.0
vinflunin tcc vinflunin activ agent treatment platinum-pretr bladder cancer result warrant investig phase iii trial either monotherapi combin agent treatment advanced/metastat tcc bladder,0,1.0,0.0
terazosin hypertens total num2 num3 patient hypertens evalu num4 primari commun care facil num4 patient not treat previous hypertens num4 switch terazosin anoth antihypertens agent num4 receiv terazosin addit agent not control hypertens,0,1.0,0.0
trichostatin a/tsa inflamm examin effect histon deacetylas inhibitor trichostatin tsa behavior macrophag subconjunctiv fibroblast vitro ocular surfac inflamm scar vivo use alkali burn wound heal model,0,0.7977,0.20230000000000006
metformin type metformin one commonli prescrib antihyperglycem agent treatment type num diabet,0,1.0,0.0
cantharidin breast cancer treat human breast cancer cell structur distinct toxin calyculin okada acid cantharidin known inhibit ser/thr phosphatas ppp famili,0,1.0,0.0
gaba brain ischemia similar alter abund gaba r subunit observ vivo brain ischemia,0,1.0,0.0
cisplatin nsclc data indic medic fit patient resect stage ii-iiia nsclc offer adjuv chemotherapi modern cisplatin-bas doublet,0,1.0,0.0
levodopa/l-dopa parkinson 's diseas combin levodopa l-dopa carbidopa commonly-us treatment symptom manag parkinson 's diseas,0,1.0,0.0
sodium bicarbon myocardi infarct patient random receiv sodium bicarbon vs sodium chlorid rate death dialysi myocardi infarct cerebrovascular event not differ significantli num2 day num vs num num vs num num vs num num vs num respect num2 day num month num vs num num vs num num vs num num vs num respect p .num2,0,0.7908,0.20920000000000005
estrogen breast cancer analysi studi data suggest a. camphorata exert growth inhibit highli invas estrogen-nonrespons human breast cancer cell apoptosi induct associ cox-num inhibit may possess anticanc properti potenti valuabl applic drug product,0,0.7925,0.2075
metoprolol adpkd forty-six hypertens adpkd patient random either ramipril n num2 metoprolol n num2,0,1.0,0.0
methylenecyclopropan hhv-num/ebv result indic member seri methylenecyclopropan analog highli activ against hcmv hhv-num hhv-num less activ against hsv vzv ebv,0,1.0,0.0
pristinamycin staphylococcu epidermidi analysi pristinamycin-resist staphylococcu epidermidi isol tunisian bone marrow transplant center,0,1.0,0.0
betamethason labial adhes compar estrogen betamethason topic treatment labial adhes prepubert girl,0,1.0,0.0
amikacin renal insuffici amikacin clearanc increas burn injuri often complic renal insuffici,0,0.6149,0.3851
epoprostenol pph surviv patient pph treat epoprostenol depend sever baselin well three-month respons therapi,0,1.0,0.0
cortisol pain aural canal core skin surfac num2 site temperatur oxygen consumpt pain visual analogu score concentr epinephrin norepinephrin glucos cortisol lactat free fatti acid plasma measur epidur blockad num2 min epidur blockad end surgeri num h surgeri,0,1.0,0.0
sh cornea actual num2 radiolabel numnum3 sh solut remain cornea compar num2 numnum3 sh solut num2num pb solut,0,1.0,0.0
gonadotropin-releas hormon prostat cancer comprehens review peer review literatur perform topic secondari hormon therapi includ oral antiandrogen adren androgen inhibitor corticosteroid estrogen compound gonadotropin-releas hormon antagonist altern hormon therapi advanc prostat cancer,0,1.0,0.0
num-fu/num-fluorouracil gastric cancer among sever chemotherapeut agent num-fluorouracil num-fu wide use key drug adjuv chemotherapi gastric cancer,0,1.0,0.0
corticosteron ii defici sever hypoaldosteron due corticosteron methyl oxidas type ii defici two boy metabol ga chromatography-mass spectrometri studi,0,0.6394,0.3606
titanium hernia repair symptomat perin hernia titanium mesh,0,1.0,0.0
steroid chronic function-limit mid back upper back pain determin clinic effect therapeut local anesthet medial branch block without steroid manag chronic function-limit mid back upper back pain facet joint origin,0,1.0,0.0
ethanol oa consid result obtain ph num maximum enhanc ratio found polysorb num2 combin ethanol/pg/oa num2numnum2 numnum2,0,1.0,0.0
calcium seizur taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.6111,0.3889
ribavirin cirrhosi treatment failur pegyl interferon peg-ifn -alpha2b ribavirin rbv larg depend upon viru genotyp interact genotyp cirrhosi pattern treatment failur unclear,0,1.0,0.0
atenolol atrioventricular block atenolol alinidin significantli decreas basic heart rate without caus sinu arrest higher-degre atrioventricular block,0,1.0,0.0
cyclosporin headach headach symptom num2 patient receiv cyclosporin and/or tacrolimu organ transplant retrospect assess,1,0.0,1.0
levodopa dyskinesia levodopa treatment parkinson 's diseas effect mani type advers event complic diseas cours especi dyskinesia,1,0.20230000000000006,0.7977
num-ht contract ketanserin-resist compon num-ht-induc contract found -log ecnum2 num f1 numnum2 num3 nm ketanserin -log ecnum2 num f1 numnum2 num4 nm ketanserin,1,0.2028,0.7972
pristinamycin staphylococcu epidermidi staphylococcu epidermidi num3 isol search strain pristinamycin resist,0,1.0,0.0
amphotericin b. diabet describ diabet patient lecythophora mutabili prosthet valv endocard treat surgic well amphotericin b lipid complex voriconazol subsequ follow prolong voriconazol suppress therapi,0,1.0,0.0
polyphenol tumor studi use num2-o-tetradecanoylphorbol-num2-acet tpa ultraviolet uv radiat tumor promot found anticarcinogen effect caus green tea polyphenol,0,0.8241,0.17589999999999995
doxorubicin hypox e_h2ax express num2 min cleav caspase-num -num num2 hr doxorubicin docetaxel decreas increas distanc tumor blood vessel minim express hypox region maximum reduct kinum2 level observ region closest vasculatur num2 hr,0,1.0,0.0
fluoxetin major depress disord somat symptom predictor time onset respons fluoxetin major depress disord,0,1.0,0.0
gaba asthma critic role solut carrier famili num neurotransmitt transport betaine/gaba member num2 slc6anum2 gene gabaerg transmiss associ mucu product asthma make candid gene aia associ studi,0,0.7982,0.2018
heparin venou thrombosi studi confirm therapi heparin graduat compress stock effect inexpens conveni prevent venou thrombosi fractur hip patient associ low bleed risk,0,1.0,0.0
indomethacin polyhydramnio indomethacin therapi treatment polyhydramnio due placent chorioangioma,0,1.0,0.0
temsirolimu tumor although temsirolimu capabl improv overal surviv minor select mrcc patient effect tumor burden reduct pf minim,0,1.0,0.0
tacrolimu inflammatori diseas determin whether topic tacrolimu might prove effect treatment refractori anterior segment inflammatori diseas evalu efficaci eye ocular graft versu host diseas gvhd vernal keratoconjunct vkc,0,1.0,0.0
potassium epilept slice drug-resist epilept patient made hypersynchronous/hyperexcit elev potassium inhibit gaba-a receptor behav similarli,0,0.7936,0.20640000000000006
creatinin type num diabet mellitu aim investig impact coadministr tzd acei/arb hematocrit hemoglobin valu uncompl patient type num diabet mellitu normal serum creatininenumdata patient type num diabet current follow review patient treat acei/arb and/or tzd identifi,0,1.0,0.0
dopamin nocturn myoclonu syndrome/nm previou investig found increas d2 dopamin receptor striatum patient nocturn myoclonu syndrom nm treatment dopamimet,0,0.7879,0.2121
allylpyrocatechol inflammation-associ disord taken togeth ex vivo studi establish allylpyrocatechol potent scaveng activ could consid add-on therapi treatment inflammation-associ disord like rheumatoid arthriti,0,0.7987,0.20130000000000006
dichlorphenamide/dcp hypopp/hypokalem period paralysi one studi dichlorphenamid dcp vs placebo test two group particip num2 hypokalem period paralysi hypopp num2 hyperkalem period paralysi hyperpp base clinic criteria,0,1.0,0.0
toremifen breast cancer forty-nin postmenopaus patient node-posit breast cancer random trial compar effect tamoxifen toremifen serum lipoprotein,0,1.0,0.0
pentoxifyllin toxic pentoxifyllin analogu may lower toxic pentoxifyllin may therefor use futur treatment diseas induc endotox substanc,0,0.7852,0.2148
duloxetin insomnia gener duloxetin well toler num2 patient achiev maximum dose insomnia asthenia advers event report statist significantli p .num2 frequent duloxetine-tr patient compar placebo-tr patient,1,0.3882,0.6118
lzd cf analysi clinic data show num cf patient lrsa receiv lzd cours num2num versu num p numnum3 longer durat num3num versu num3num day p numnum3 extend period exposur lzd num2num versu num2num days/year p numnum3 num2 lzd-suscept isol,0,1.0,0.0
nitric oxid headach classifi headach syndrom treatment calcineurin inhibitor investig whether latter influenc nitric oxid product human brain microvascular cell hbmec,0,1.0,0.0
roflumilast copd roflumilast oral phosphodiesteras num inhibitor indic use treatment copd,0,1.0,0.0
num num2-dihydroxyvitamin num aml inhibit cot1/tlp2 oncogen aml cell reduc erk5 activ up-regul pnum2kip1 concomit enhanc differenti cell cycl arrest induc silibinin num num2-dihydroxyvitamin num,0,1.0,0.0
batimastat cancer batimastat bb-num2 first inhibitor class enter clinic trial cancer patient,0,1.0,0.0
aspirin ischem cerebrovascular disease/ischem heart diseas low-dos aspirin use secondari prevent ischem heart diseas ischem cerebrovascular diseas,0,1.0,0.0
irbesartan aortic root dilat first clinic trial evalu arb irbesartan versu placebo reduc rate aortic root dilat mf,0,1.0,0.0
ca crf/ca-rich-food studi aim segment parent earli adolesc subgroup accord ca-rich-food crf practic percept regard earli adolesc crf intak ii determin whether ca intak parent earli adolesc differ subgroup,0,1.0,0.0
testosteron surgic menopaus testosteron defici menopaus women common appreci particularli patient hormon replac surgic menopaus,0,1.0,0.0
num-chloro-num'-deoxyadenosin b-cell leukemia inhibit erk pathway promot apoptosi induc num-chloro-num'-deoxyadenosin b-cell leukemia cell line eheb,0,1.0,0.0
somatostatin bleed efficaci somatostatin control bleed patient non-varic ugi bleed high risk mortal upon admiss rebleed follow endoscopi coupl excel safeti toler profil suggest may valuabl therapeut option manag non-varic bleed,0,1.0,0.0
steroid ulcer disease/ulc although possibl associ steroid therapi peptic ulcer diseas well known need ulcer prophylaxi therapi infant not unanim accept,1,0.1868,0.8132
metformin ami result suggest chronic pretreat metformin may associ reduct no-reflow phenomenon patient diabet mellitu primari angioplasti ami,0,1.0,0.0
pyrazinamid tuberculosi consid preval pyrazinamid resist differ clinic set pcr-dna sequenc possibl molecular assay target pnca detect pyrazinamid resist multidrug-resist m. tuberculosi isol predict valu larg exceed num2 rule out pyrazinamid resist non-multidrug-resist isol predict valu exceed num2,0,1.0,0.0
alanin fibrosi level icam-num vcam-num hyaluron acid correl alanin aminotransferas level hcv-rna-polymeras chain reaction statu histolog fibrosi score,0,0.8152,0.1848
indomethacin intraventricular hemorrhag antenat indomethacin not associ intraventricular hemorrhag patent ductu arteriosu respiratori distress syndrom bronchopulmonari dysplasia mortal,0,1.0,0.0
carbon monoxid toxic carbon monoxid toxic,1,0.3731,0.6269
naltrexon pruritu opioid antagonist naltrexon shown offer therapeut altern patient suffer uraem cholestat pruritu,0,1.0,0.0
pomalidomid myelofibrosi circul level mcp-num sil-2r il-num2 il-num predict anemia respons pomalidomid therapi myelofibrosi,0,1.0,0.0
tazobactam melioidosi role piperacillin/ tazobactam melioidosi remain undefin,0,1.0,0.0
sorafenib toxic toler profil gener consist vegf receptor inhibitor axitinib associ numer lower incid palmar-plantar erythrodysaesthesia cutan toxic anaemia sorafenib phase iii trial,0,1.0,0.0
pcb cancer review potenti human carcinogen pcb atsdr num4 conclud weight evid not support causal associ pcb human cancer time,0,1.0,0.0
telithromycin community-acquir pneumonia telithromycin num3 mg daili seven ten day effect well-toler treatment community-acquir pneumonia,0,1.0,0.0
clozapin cardiomyopathi clozapin known caus cardiac side effect includ myocard pericard cardiomyopathi,1,0.0,1.0
glucos glucos intoler four patient g regimen withdrawn due glucos intoler none patient gf develop glucos intoler hyperlipidaemia,0,0.8091,0.1909
rofecoxib analgesia clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,0.7867,0.21330000000000005
amifostin thyroid cancer result two random control clinic trial suggest amifostin no signific radioprotect effect salivari gland radioact iodin treatment differenti thyroid cancer,0,1.0,0.0
fluoxetin postnat depress women postnat depress effect treat fluoxetin effect cours cognitive-behaviour counsel short-term,0,1.0,0.0
temozolomid glioblastoma phase ii studi evalu activ temozolomid cisplatin administ radiat therapi newli diagnos glioblastoma multiform patient term respons time progress surviv,0,1.0,0.0
iron melanoma investig surviv two kind human embryon cell clvnum3 lunum3 human melanoma cell mel8 expos exogen iron copper ion absenc presenc ascorb acid catalas superoxid dismutas,0,1.0,0.0
ascorb acid dermat administr exogen ascorb acid advoc therefor treatment system chromium poison chromium dermat enhanc extracellular reduct chromium vi less bioavail chromium iii,0,1.0,0.0
nucleosid hiv infect thu didanosin repres potent versatil nucleosid analogu potenti benefit current futur antiretrovir regimen hiv infect,0,1.0,0.0
resveratrol ovarian cancer ovarian cancer cell incub normal media media contain resveratrol glucos free media media lack amino acid,0,0.7995,0.2005
nicotin depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,0.8045,0.1955
aspirin atrial fibril cardiovers patient nonvalvular atrial fibril follow use aspirin alon amiodaron reason margin cost-effect ratio,0,0.8087,0.19130000000000005
lithium toxic research use standard leach test life-cycl impact assess lcia hazard assess model evalu hazard wast classif resourc deplet potenti toxic potenti lithium batteri use cellphon,1,0.1936,0.8064
mannitol stroke tricent prospect studi analyz num2-day num-year case fatal respect mannitol treatment statu num3 patient consecut admit within num2 hour stroke onset,0,1.0,0.0
methotrex dmard also becom appar combin new dmard methotrex virtual halt radiograph progress num year,0,1.0,0.0
isofluran ripc ripc isofluran anesthesia n num2 decreas area ctni time curv ctni auc -num2 num3 num3 ng/ml num2 h vs. num3 num3 ng/ml num2 h p numnum3 peak num num ng/ml vs. num2num num p numnum3 serial p numnum3 postop ctni compar isofluran alon n num2,0,0.7865,0.2135
sorafenib papillari thyroid carcinoma success use sorafenib treat pediatr papillari thyroid carcinoma,0,1.0,0.0
vigabatrin spasm although incid vigabatrin-induc vfc worrisom context intract seizur infantil spasm therapeut benefit must weigh against risk,0,0.6194,0.3806000000000001
amlodipin hypertens object random double-blind parallel-group multicentr studi determin efficaci safeti olmesartan medoxomil/amlodipin combin therapi patient moder sever hypertens fail respond treatment num week open-label amlodipin,0,1.0,0.0
ramosetron ponv conclus ramosetron num mg effect antiemet prevent ponv num-num2 h anesthesia femal patient undergo gynecolog surgeri,0,1.0,0.0
midazolam statu epilepticu potenti midazolam given via nasal spray acut treatment statu epilepticu seizur disrupt evalu,0,1.0,0.0
iron athlet conclud increas intak iron dietari factor involv iron metabol prevent possibl exercise-induc loss iron young athlet,0,1.0,0.0
cisplatin tumour cisplatin remain princip chemotherapi agent treatment mani solid tumour,0,1.0,0.0
dopamin breast cancer/canc women undergo chemotherapi breast cancer often administ dopamin antagonist adjuv medic may increas level prolactin potenti increas risk cancer,0,0.621,0.379
calcium renal cardiovascular morbid combin therapi calcium channel antagonist calcium channel blocker ccb inhibitor renin-angiotensin-aldosteron system raa ration approach achiev bp goal provid protect against renal cardiovascular morbid mortal,0,1.0,0.0
tolterodin nocturia evalu efficaci safeti nighttim dose tolterodin extend releas ter men overact bladder oab nocturia,0,0.8111,0.1889
androgen prostat cancer comprehens review peer review literatur perform topic secondari hormon therapi includ oral antiandrogen adren androgen inhibitor corticosteroid estrogen compound gonadotropin-releas hormon antagonist altern hormon therapi advanc prostat cancer,0,1.0,0.0
latanoprost pain median visual analog pain-scal score acetazolamid latanoprost travoprost brinzolamid timolol group num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 respect,1,0.3786000000000001,0.6214
pioglitazon impair glucos toler pioglitazon not enhanc effect lifestyl modif prevent convers impair glucos toler diabet asian indian result indian diabet prevent programme-num idpp-num,0,1.0,0.0
l-dopa neuroblastoma tumour growth neuroblastoma tumour inhibit differ mechan l-dopa metabolit dopamin reduc activ tyrosinas bso reduc glutathion level l-dopa tamoxifen rais camp concentr,0,1.0,0.0
mitoxantron indol lymphoma bendamustin b mitoxantron shown potent cytotox drug treatment relaps refractori indol lymphoma,0,1.0,0.0
alcohol alcohol depend naltrexon disulfiram patient alcohol depend comorbid psychiatr disord,0,0.8115,0.1885
cyclophosphamid hemorrhag cystiti bk virus-associ hemorrhag cystiti pediatr cancer patient receiv high-dos cyclophosphamid,1,0.0,1.0
olanzapin deficit syndrom thirty-nin outpati schizophrenia sever neg symptom assess presenc deficit syndrom enter num2-week open-label studi olanzapin,0,1.0,0.0
curcumin metabol syndrom num3 mg/kg curcumin gavag adult male sprague-dawley rat high-fat-diet-induc metabol syndrom num month,0,1.0,0.0
tamoxifen tumor assess tumor uptak retent num3 i-label tamoxifen tx could increas understand tx 's action mechan involv resist drug,0,1.0,0.0
adenosin monophosph crc investig whether aspirin affect adenosin monophosphate-activ protein kinas ampk mtor signal crc cell,0,1.0,0.0
gaba neuron death gaba receptor dephosphoryl follow intern coupl neuron death vitro ischemia,0,0.6004,0.3996
colchicin pericardi effus recurr pericardi effus cardiac surgeri use colchicin recalcitr convent therapi,0,1.0,0.0
heparin fractur hip studi confirm therapi heparin graduat compress stock effect inexpens conveni prevent venou thrombosi fractur hip patient associ low bleed risk,0,1.0,0.0
melatonin hepatoma result demonstr melatonin sensit human hepatoma cell er stress-induc apoptosi down-regul cox-num express increas level chop decreas bcl-num/bax ratio,0,1.0,0.0
retinol/vitamin a. colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,1.0,0.0
thallium left bundl branch block twelv patient exercise-induc st-segment elev without prior myocardi infarct electrocardiograph evid left ventricular hypertrophi left bundl branch block underw thallium-num3 tomographi immedi exercis num hour later,0,1.0,0.0
thalidomid cancer review describ emerg immunolog properti thalidomid histor context present-day clinic applic notabl multipl myeloma also cancer inflammatori diseas hiv,0,0.7862,0.2138
oxygen sleepi improv indic oxygen desatur sleep qualiti subject sleepi improv num month octreotid,0,1.0,0.0
actinomycin local diseas seven patient local diseas stage i/ii six surviv patient receiv chemotherapi vincristin actinomycin no patient receiv radiotherapi,0,1.0,0.0
manidipin diabet conclus delapril manidipin effect reduct microalbuminuria normotens type num diabet patient persist microalbuminuria,0,1.0,0.0
nitrou oxid pain aim project longitudin follow plasma level beta-endorphin pregnanc women healthi pregnanc investig whether plasma level beta-endorphin late pregnanc associ need addit pain medic beyond nitrou oxid labor,0,1.0,0.0
pegyl interferon alpha 2b hepat c. perform proteom analysi liver specimen num2-year-old woman affect hepat c genotyp 1a alcohol diabet mellitu type num antivir treatment pegyl interferon alpha 2b ribavirin,0,1.0,0.0
atp hypoton cftr express augment swelling-induc atp releas num2-num2 time hypoton condit num2 osmol,0,1.0,0.0
nadph/nad p h. tumor measur express level three differ reductas enzymes-dt-diaphoras nad p h inume. reduc nicotinamid adenin dinucleotid without phosphat quinon oxidoreductas nadph cytochrom p-num3 reductas nadh inume. reduc nicotinamid adenin dinucleotid cytochrome-b5 reductase- num2 cell line nation cancer institut nci human tumor cell panel see relationship could establish activ enzym cellular sensit bioreduct compound mitomycin c eo9,0,1.0,0.0
l-ornithine-l-aspart chronic hepat encephalopathi oral l-ornithine-l-aspart safe well-toler treatment good complianc rate benefici therapeut effect patient cirrhosi stabl overt chronic hepat encephalopathi,0,1.0,0.0
aminoglycosides/aminoglycosid tubular marker protein excret tubular marker protein enhanc combin administr cephalosporin aminoglycosid mainli due aminoglycosid compon,0,0.7975,0.2025
dihydroergotamin pain give dihydroergotamin predict greater pain-fre rate,0,1.0,0.0
amikacin neutropenia risk factor vre colon paediatr oncolog patient includ durat neutropenia durat antibiot therapi exposur ceftazidim amikacin teicoplanin number antibiot use,0,0.805,0.19499999999999995
corticosteroid dengu ill corticosteroid treatment dengu ill,0,1.0,0.0
aflatoxin cancers/liv cancer liver cancer one common cancer worldwid particularli asia africa infecti hepat aflatoxin exposur common,1,0.20109999999999995,0.7989
nicotin patholog gambl studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0
cisplatin lung cancer although optim chemotherapi regimen combined-mod treatment not yet establish use cisplatin etoposid combin not promot pulmonari cardiac esophag toxic particularli appropri patient small-cel lung cancer,0,1.0,0.0
dopamin parkinson diseas riski busi dopamin agonist parkinson diseas impuls control disord,0,0.8069,0.19310000000000005
timolol open-angl glaucoma compar addit intraocular pressure-low effect latanoprost numnum3 administ daili pilocarpin num administ three time daili patient primari open-angl glaucoma ocular hypertens current monotherapi timolol num twice daili,0,1.0,0.0
corticosteroid cataract howev oral corticosteroid user higher risk cataract num/num4 person-year,1,0.0,1.0
capecitabin hnscc tumor addit demonstr transgen express tp significantli enhanc tumoricid effect capecitabin hnscc tumor otherwis low endogen tp dpd ratio,0,0.802,0.19799999999999995
glucos type object prevent programm studi whether combin pioglitazon lifestyl modif would enhanc efficaci lifestyl modif prevent type num diabet asian indian impair glucos toler,0,1.0,0.0
ribavirin acut hepat c infect spontan clearanc treatment acut hepat c infect hiv-posit men num2 week interferon-alpha ribavirin,0,1.0,0.0
cp-num4 leukemia anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0
oxaliplatin colorect cancer oxaliplatin weekli bolu num-fluorouracil leucovorin pretreat advanc colorect cancer patient phase ii studi,0,1.0,0.0
manidipin dizzi two case delapril group withdrawn studi intoler cough one case manidipin group intoler dizzi headach,1,0.1807,0.8193
co num hypocapnia co num -reactiv slope v op normocapnia hypocapnia numnum2 per mmhg,0,0.7948,0.20520000000000005
aspirin ischem stroke prognost valu occurr ischem stroke patient despit aspirin treatment aspirin treatment failur not known,0,1.0,0.0
y-num5 scid y-num5 administ continu periton caviti use micro-osmot pump togeth orthotop implant li7 cell liver scid mice,0,1.0,0.0
clozapin glucos intoler accumul data develop glucos intoler adult receiv clozapin closer monitor bodyweight fast blood glucos imper,1,0.3944,0.6056
adenosin variou disord recent data support evid adenosin a2 receptor properti may prove use futur drug develop select manipul receptor-associ biolog effect might relev treatment variou disord includ psychiatr diseas hypoxia/ischemia inflamm erythrocytosi,0,1.0,0.0
sertralin depress num2 evalu patient num2 sertraline-tr patient num2num experienc signific improv depress,0,0.8112,0.1888
ascorb acid poison smaller dose ascorb acid enumg. num2 g intraven not toxic dose probabl not reduc mortal system chromium poison,0,1.0,0.0
metformin diabet combin diet exercis follow metformin earli phase insulin resist may reduc delay atherosclerosi arteriosclerosi complic associ diabet,0,0.7926,0.20740000000000006
mycophenol acid/mpa gastrointestin gi complic evalu incid gastrointestin gi complic solid organ transplant sot recipi impact complic transplant outcom potenti interact mycophenol acid mpa deriv proton pump inhibitor ppi,0,0.8185,0.1815
rnum5 breast cancer farnesyltransferas inhibitor rnum5 tipifamib zarnestra activ breast cancer efficaci drug combin not extens investig,0,1.0,0.0
morphin pain median num2th num2th centil visual analog scale pain score associ drain remov bupivacain entonox morphin group num mm num num2 mm num2num mm num2 num2 mm num2num mm num num2 mm respect,0,1.0,0.0
indomethacin bronchopulmonari dysplasia antenat indomethacin not associ intraventricular hemorrhag patent ductu arteriosu respiratori distress syndrom bronchopulmonari dysplasia mortal,0,1.0,0.0
kinum5 gastric cancer fgfr2 inhibitor kinum5 might therapeut promis treat drug-resist gastric cancer cell especi use combin snnum2 ptx vpnum2,0,1.0,0.0
vancomycin bacteremia studi aim evalu differ methodolog address evolut nosocomi bacteremia vancomycin-resist enterococci vre hospit set,0,1.0,0.0
dmso oa oa num2 num microm group increas significantli apoptosi rate compar normal num dmso group p numnum2,0,1.0,0.0
escitalopram depress disord markov cost-util analysi escitalopram duloxetin treatment major depress disord,0,1.0,0.0
sorafenib renal cell carcinoma symptom hypothyroid occur num2 patient treat sorafenib due metastat renal cell carcinoma,0,0.805,0.19499999999999995
mg. sac shk uhk group fecal mg loss urinari excret electrolyt serum concentr electrolyt increas significantli p numnum2 compar sac uac group,0,1.0,0.0
zdv anaemia age-specif mean haemoglobin level preval anaemia haemoglobin num2 g/dl not significantli differ case babi receiv singl dose nvp case nvp given mother/inf pair addit zdv babi,0,1.0,0.0
vitamin a. rural south increas vitamin intak children age num-num year target home-garden rural south african commun,0,1.0,0.0
praziquantel trematod praziquantel also activ against wide rang trematod human veterinari cestod display cysticid effect,0,1.0,0.0
arsen trioxid hepatoblastoma studi effect chemotherapeut cisplatin doxorubicin cytosin arabinosid differenti agent num2 cis-retino acid apoptot agent num-aza-num'-deoxycytidin arsen trioxid notch express hepatoblastoma evalu,0,1.0,0.0
egcg parkinson 's observ suggest oral administr egcg may signific benefici effect parkinson 's patient treat l-dopa carbidopa exert modest inhibit l-dopa methyl plu strong neuroprotect against oxid damag degener,0,1.0,0.0
lidocain tn recoveri unassist ambul spontan void occur earlier lidocain associ markedli higher incid tn,1,0.2109,0.7891
estrogen hip fractur epht recruit num4-num4 women 's health initi whi usa decid stop estrogen-progestin trial mean num year juli num4 increas risk breast cancer later num4 estrogen-onli trial ht increas risk stroke decreas risk hip fractur not affect coronari heart diseas incid,0,1.0,0.0
glibenclamid t2dm conclus sever hypoglycaemia seriou not uncommon problem among elderli patient t2dm frequent patient undergo aggress diabet manag user long-act sulphonylurea eg glibenclamid,0,0.6157,0.3843
duloxetin depress disord duloxetin treatment major depress disord double-blind clinic trial,0,1.0,0.0
vitamin bnum2 colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.8126,0.1874
monostearin oleic acid/oa anion lipid nanoparticl consist monostearin ms differ content oleic acid oa prepar,0,1.0,0.0
zidovudine/zdv hiv-infect babi hiv-infect women randomis birth receiv singl dose nevirapin nvp alon zidovudin zdv twice daili week,0,1.0,0.0
silibinin aml inhibit cot1/tlp2 oncogen aml cell reduc erk5 activ up-regul pnum2kip1 concomit enhanc differenti cell cycl arrest induc silibinin num num2-dihydroxyvitamin num,0,1.0,0.0
amphotericin b. viscer leishmaniasi liposom amphotericin b effect safe altern treatment viscer leishmaniasi indian subcontin,0,1.0,0.0
bleomycin cross-resist howev cisplatin-resist subpopul num4ddp4 show highest glutathion level mark cross-resist bleomycin,0,1.0,0.0
retino acid neuroblastoma neuron no synthas nno overexpress neuroblastoma cell line expos differenti action retino acid no slow prolifer acceler differenti toward neuron phenotyp,0,0.8096,0.1904
arsen trioxid leukemia dynam effect autophagi arsen trioxide-induc death human leukemia cell line hlnum2 cell,0,0.7947,0.20530000000000004
num-deoxyglucos hypoglycemia human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,0.8122,0.1878
nac hepat failur male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.17759999999999998,0.8224
aminoglycosid neutropen even combin aminoglycosid ceftriaxon would not good choic neutropen patient,0,1.0,0.0
calcium hypertens use ambulatori blood pressur bp monitor potent ace-inhibitor/calcium channel blocker combin test num2 black patient age num2 +/- num2 year num2 male num2 femal mild moder hypertens mean num2-hour daytim diastol bp num2 mmhg num3 mmhg,0,1.0,0.0
nitric oxid stroke potenti nitric oxid therapeut stroke,0,1.0,0.0
testosteron t1d howev t1d boy hba1c bmi-sd neg associ testosteron level,0,0.8168,0.18320000000000006
simvastatin neurolog disabl oral simvastatin might inhibit inflammatori compon multipl sclerosi lead neurolog disabl,0,0.6115,0.3885
alcohol alcohol depend support patient drug alcohol depend requir optimis treatment uptak,0,0.8233,0.17669999999999994
naftidrofuryl visual acuiti visual field administr num x num3 mg/day naftidrofuryl num week num2 patient normal tension glaucoma shown improv visual acuiti visual field compar num-week period placebo administr double-blind studi method,0,1.0,0.0
camptothecin ovarian cancer present studi investig potenti anti-human ovarian cancer effect nscnum5 novel rare studi camptothecin analog combin cisplatin cddp,0,1.0,0.0
quinin falciparum malaria retrospect chart review num3 patient admit sever falciparum malaria treat quinin tertiari care teach hospit karachi pakistan num4-num4 conduct,0,1.0,0.0
cortisol adren insuffici comparison cortisol respons test two dose acth patient suspect adren insuffici,0,0.8011,0.1989
carvedilol chf find suggest not carvedilol treatment increas surviv reduc hospit admiss patient sever chf also cut cost process,0,1.0,0.0
ibandron breast cancer phase iii studi compar efficaci new potent bisphosphon ibandron placebo intraven i.v therapi metastat bone diseas due breast cancer,0,1.0,0.0
bile acid barrett 's esophagu effect guggulsteron antagonist bile acid receptor apoptosi barrett 's esophagus-deriv cell assess morpholog flow cytometri measur caspas num activ,0,1.0,0.0
ca4p ataxia dose-limit toxic effect dlt revers ataxia oculomotor nerv palsi occur two patient prostat cancer receiv weekli ca4p num2 mg/m2,0,1.0,0.0
gsh/glutathion copd num2 stabl state iii copd patient recruit reduc glutathion gsh oxidis glutathion gssg erythrocyt thiol protein p-sh carbonyl protein pc erythrocyt plasma evalu,0,1.0,0.0
clopidogrel bleed although sever prior studi includ mainli stent patient emphas relationship cyp2cnum2 loss-of-funct allel efficaci clopidogrel studi stabl patient establish potenti link reduc bleed complic,0,0.6191,0.3809
indomethacin necrot enterocol antenat indomethacin may associ increas risk periventricular leukomalacia necrot enterocol prematur infant therefor use judici tocolysi,1,0.0,1.0
furosemid hypertens haemoconcentr shear-stress increas carotid arteri diamet regul furosemid administr older hypertens,0,1.0,0.0
angiotensin atrial fibril angiotensin-convert enzym inhibitor angiotensin ii receptor-block drug hold promis atrial fibril cardiac remodel,0,0.8134,0.1866
num-fluorouracil local advanc breast cancer feasibl toxic local respons rate intra-arteri chemotherapi num-fluorouracil epirubicin mitomycin patient num2 year local advanc breast cancer evalu,0,1.0,0.0
acetaminophen hepat failur male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.0,1.0
delapril diabet studi design investig effect delapril ace inhibitor manidipin long action calcium antagonist persist microalbuminuria normotens type num diabet patient,0,1.0,0.0
mangafodipir hcc spio- mangafodipir-enhanc imag compar detect focal hepat lesion small hcc better detect spio-enhanc imag,0,1.0,0.0
beta-caroten rural south determin vitamin intak children age num-num year rural south african commun one year implement home-bas food product programm target beta-carotene-rich fruit veget,0,1.0,0.0
ethylen glycol acidosi ingest ethylen glycol either accident suicid attempt character sever acidosi calcium oxal crystal format deposit wide varieti end organ effect may fatal,1,0.0,1.0
num-fluorouracil colorect cancer oxaliplatin weekli bolu num-fluorouracil leucovorin pretreat advanc colorect cancer patient phase ii studi,0,1.0,0.0
levodopa parkinson 's diseas levodopa treatment parkinson 's diseas effect mani type advers event complic diseas cours especi dyskinesia,0,1.0,0.0
pge num necrosi pge num inhibit lipopolysaccharid lp -induc product tumor necrosi factor alpha tnfalpha human whole blood hwb cj-num5 revers inhibitori effect pge num lps-induc tnfalpha product concentration-depend manner,0,0.7961,0.2039
ginkgolid hemorrhag concentr gener num3 time higher peak plasma valu measur oral intak egb num3 recommend dose num3 num3 mg. paf 'weak platelet activ not appear import primari hemostasi result rise seriou doubt paf antagonist effect ginkgolid could respons hemorrhag patient take egb num3,1,0.2004,0.7996
levobupivacain cardiovascular central nervou system toxic levobupivacain new long-act local anesthet isol s-enantiom racem bupivacain less cardiovascular central nervou system toxic bupivacain,0,0.7894,0.2106
methotrexate/mtx arthriti methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0
iron oxid cancer particular advanc polymer nanomateri past decad pave way develop cancer nanotheranost primarili compris polym conjug polym type nanomateri gold nanoparticl quantum dot carbon nanotub magnet iron oxid nanoparticl,0,1.0,0.0
atenolol effect stroke reduct lower within-individu visit-to-visit variabl blood pressur read amlodipine/perindopril combin treatment arm ascot studi shown account effect stroke reduct rate combin compar atenolol diuretic-bas therapi despit overal similar blood pressur lower,0,0.7809,0.2191
lidocain pain studi investig effect intraven infus lidocain pain qualiti life patient fibromyalgia,0,0.7951,0.2049
sirolimus/srl fibrosi sirolimu sometim discontinu side effect srl cohort subgroup stratifi sirolimu durat show progress less fibrosi longer sirolimu durat,0,0.7971,0.2029
iron esrd/end-stag renal diseas studi includ num2 end-stag renal diseas esrd patient perform chronic periton home hemodialysi iron defici defin ferritin num3 ng/ml and/or iron satur num2,0,1.0,0.0
idarubicin cancer also examin capabl bcr/abl-fus modul repair oxid lesion consid major side effect variou anti-canc drug includ idarubicin radiat,0,1.0,0.0
cisplatin lung cancer activ erk1/num akt associ cisplatin resist human lung cancer cell,0,1.0,0.0
ivermectin ocular onchocerc diseas commun trial start address question concern safeti ivermectin larg scale treatment potenti transmiss control effect prevent ocular onchocerc diseas accept organ larg scale treatment,0,1.0,0.0
vitamin d. vitamin defici human skin synthesi follow exposur uvb potent sourc vitamin region low uvb individu risk vitamin defici,0,1.0,0.0
fluoroquinolon infect fluoroquinolon antimicrobi meet joint commiss criteria target due drug use popul high risk advers drug reaction qualiti assur infect control committe target due drug costli may suspect known use inappropri prescrib frequent,0,1.0,0.0
metformin diabet rational combin insulin oral drug therapi deriv better understand pathophysiolog niddm mechan action oral drug avail num type num diabet patient insulin-defici insulin-resist thu requir quit high dose exogen insulin num peripher insulin deliveri lead hyperinsulinaemia could play role pathogenesi late diabet complic num sulphonylurea stimul insulin releas directli portal vein could also potenti peripher insulin action num metformin improv glucos metabol insulin sensit alpha-glucosidas inhibitor slow digest complex carbohydr sucros abl reduc amount insulin need control postprandi hyperglycaemia,0,1.0,0.0
ethanol oa nth-td base combin ethanol/pg/oa show enhanc ratio respect control numnum2 addit polysorb num2 matrix numnum2,0,1.0,0.0
phorbol ester pkc/protein kinas c. identifi target phorbol ester protein kinas c pkc mitogen-activ kinas mapk also call extracellular signal-regul kinas erk,0,0.8088,0.19120000000000004
oral contracept thyroid dysfunct precis etio-pathogenesi evas genet influenc exposur sunlight pregnanc oral contracept estrogen-progesteron therapi thyroid dysfunct cosmet drug propos,0,1.0,0.0
erlotinib pancreat cancer pancreat cancer cell lack erbb3 not display activ erbb3-pi3k-akt cascad induc egfr/erbb3 heterodim becom less critic depend egfr signal therefor resist erlotinib,0,1.0,0.0
dpdp pancreat lesion mr mn-dpdp accur identif focal solid pancreat lesion,0,1.0,0.0
ribavirin fibrosi result suggest even fail erad hepat c viru convent interferon ribavirin therapi abl halt progress necroinflamm fibrosi,0,1.0,0.0
tzd diabet furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0
nitric oxid hypertens studi mechan action enalapril acei serum reactiv nitrit intermedi rni citrullin product nitric oxid metabol measur treatment enalapril num2 consecut patient essenti hypertens,0,1.0,0.0
platinum tumor basi interact endogen synthet substanc glutathion key enzym conjug glutathion s-transferas appear critic determin tumor cell resist sever antineoplast drug e.g platinum analog,0,1.0,0.0
itraconazol oral candidosi itraconazol treatment oral candidosi pediatr cancer patient,0,1.0,0.0
ribavirin hepat pattern pegyl interferon-alpha2b ribavirin treatment failur cirrhot patient depend hepat c viru genotyp,0,1.0,0.0
glutamin burn injuri research conduct evalu effect enter administ glutamin gln dipeptid metabol gastrointestin outcom paramet sever burn injuri,0,1.0,0.0
num-fluorouracil cancer evalu whether experiment system biolog strategi analys suscept cancer cell undergo caspas activ exploit predict patient respons num-fluorouracil-bas chemotherapi case-specif identifi potenti altern target treatment reactiv apoptosi,0,0.8067,0.19330000000000006
nelfinavir cancer addit method describ might facilit analysi monitor nelfinavir-induc er stress respons either cancer cell cell cultur cancer tissu biopsi,0,0.602,0.39799999999999996
mg/magnesium hypokinesia aim studi evalu effect magnesium mg load num2num mg mg/kg bodi wt daili mg supplement num mg mg/kg bodi wt mg defici shown increas not decreas serum mg concentr hypokinesia decreas km number/d,0,1.0,0.0
polycycl aromat hydrocarbon toxic bioaccess polycycl aromat hydrocarbon relev toxic carcinogenesi,0,0.6045,0.3955
cddp ovarian cancer human ovarian cancer cell line coc1 cell treat differ nanomolar nscnum5 without cddp cell growth apoptosi evalu respect mtt assay annexin-v assay flow cytometri,0,1.0,0.0
duloxetin depress disord markov cost-util analysi escitalopram duloxetin treatment major depress disord,0,1.0,0.0
dihydroxyphenylalanin neuroblastoma effect three non-myelotox cancer drug growth neuroblastoma cell investig vitro vivo dihydroxyphenylalanin l-dopa drug select toxic melanoma cell dl-buthionin sulphoximin bso drug radiosensit effect tamoxifen drug use treatment human mammari carcinoma,0,1.0,0.0
ondansetron prophylaxi postop vomit dexamethason versu ondansetron combin dexamethason prophylaxi postop vomit pediatr outpati double-blind random placebo-control clinic trial,0,0.792,0.208
estrogen breast cancer twelv postmenopaus women suffer advanc breast cancer plasma estrogen androgen cortisol gonadotropin determin therapi treatment megestrol acet oral dose escal num2 num3 mg,0,1.0,0.0
ach/acetylcholin ad/alzheim 's diseas alzheim 's diseas ad associ defici acetylcholin ach forebrain correl brain patholog cognit dysfunct,1,0.3775,0.6225
paraquat poison paraquat num num'-dimethyl-num num'-bipyridinium chlorid pq non-select herbicid pq poison accident intent ingest caus numer fatal around world everi year,1,0.0,1.0
fluoxetin compuls behavior disord behavior disord num2 subject met criteria compuls behavior disord num subject not comparison subject treat use medic fluoxetin,0,1.0,0.0
arb type furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0
norepinephrin major depress duloxetin hydrochlorid dual reuptak inhibitor serotonin norepinephrin evalu therapeut efficaci safety/toler treatment major depress,0,1.0,0.0
glucos multipl daili insulin injection/mdi assess impact use autom bolu advisor integr blood glucos meter time frequenc adjust insulin therapi paramet set whether avail technolog would increas blood glucos test strip util diabet patient treat multipl daili insulin inject mdi therapi,0,1.0,0.0
midazolam seizur potenti midazolam given via nasal spray acut treatment statu epilepticu seizur disrupt evalu,0,1.0,0.0
cddp pleural carcinomatosi cddp toler may use treatment incipi phase pleural carcinomatosi prophylaxi postop recurr,0,1.0,0.0
atenolol arrhythmia investig prospect arrhythmia incid num3 patient ami receiv alteplas double-blind random adjunct therapi intraven atenolol alinidin placebo,0,0.8029999999999999,0.19700000000000006
chloroquin cystic fibrosi treatment cystic fibrosi associ cutan vascul chloroquin,0,0.809,0.19099999999999995
ammonia cirrhosi therefor therapeut efficaci oral l-ornithine-l-aspart improv impair ammonia detoxif investig patient cirrhosi hyperammonemia stabl overt chronic hepat encephalopathi subclin hepat encephalopathi random double-blind placebo-control clinic trial,0,1.0,0.0
amlodipin mbp amlodipine-olmesartan combin therapi bedtim administr reduc better mbp correct nocturn bp fall improv urinari albumin excret,0,1.0,0.0
paracetamol ra result show clinic effect naproxen ra may significantli increas concomit paracetamol administr,0,0.818,0.18200000000000005
serotonin major depress disord open studi triiodothyronin augment select serotonin reuptak inhibitor treatment-resist major depress disord,0,1.0,0.0
simvastatin infect although simvastatin patient improv significantli third day num2num vs. num2num p numnum3 non-signific increas mortal greater proport infect odd ratio num confid interv numnum2-num simvastatin group main safeti concern,1,0.1916,0.8084
cilostazol lymphedema cilostazol promot growth human lec improv lymph flow lymphedema two differ mous lymphedema model,0,0.8069,0.19310000000000005
methadon hepat c. low risk hepat c seroconvers methadon mainten treatment,0,1.0,0.0
fentanyl chronic pain transderm fentanyl effect well toler treatment chronic pain caus malign non-malign condit administ accord manufactur 's recommend,0,1.0,0.0
cloretazin lymphoma anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0
apixaban bleed aristotl apixaban result num2 reduct stroke num2 reduct major bleed num2 reduct death,0,1.0,0.0
somatostatin acromegali determin effect octreotid somatostatin analog sever sleep apnea growth hormon level patient acromegali,0,1.0,0.0
suramin trypanosomiasi first report human case trypanosomiasi caus trypanosoma evansi treat use suramin,0,0.8213,0.17869999999999994
irbesartan embol event active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0
resveratrol ovarian cancer show epitheli ovarian cancer cell highli sensit glucose-deprivation-induc cell death like resveratrol glucos depriv induc caspase-independ cell death hallmark autophagi,0,0.7921,0.2079
calcium hypertens conclus result suggest angiotensin i-convert enzym inhibitor perindopril superior calcium channel blocker amlodipin reduc vascular endotheli dysfunct co-administ angiotensin receptor blocker patient essenti hypertens,0,1.0,0.0
ozon t2dm subject t2dm pm associ increas bp ozon associ decreas bp,0,1.0,0.0
steroid liver diseas excess immun respons provok steroid withdraw decreas reserv capac due underli chronic liver diseas thought factor liver failur,0,0.7904,0.2096
efv/efavirenz aid analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
magnesium muscl damag extra magnesium ingest also no influenc extent muscl damag rate recoveri muscl function,0,1.0,0.0
clomiphen citrat multipl pregnanc ongo pregnanc rate ovul induct laparoscop electrocauteri follow clomiphen citrat recombin follicl stimul hormon anovul persist recombin follicl stimul hormon seem equival ovul induct recombin follicl stimul hormon former procedur carri lower risk multipl pregnanc,0,1.0,0.0
ipratropium bromid breathless respons regular inhal fenoterol ipratropium bromid meter dose inhal mdi larg volum spacer regular nebul salbutamol ipratropium bromid assess home peak flow record spirometri two subject score rate breathless simpl four-point scale b activ score st georg 's respiratori questionnair,0,0.7932,0.2068
candesartan hypertens controlled-releas nifedipin candesartan low-dos combin therapi patient essenti hypertens nice combi nifedipin candesartan combin studi,0,1.0,0.0
methotrexate/mtx psa methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0
propafenon atrial fibril one hundr nine patient recurr episod symptomat atrial fibril flutter fail one five previou antiarrhythm drug trial treat propafenon subsequ sotalol atrial fibril recur,0,1.0,0.0
enalapril hypertens studi mechan action enalapril acei serum reactiv nitrit intermedi rni citrullin product nitric oxid metabol measur treatment enalapril num2 consecut patient essenti hypertens,0,1.0,0.0
alcohol tumor alcohol use not associ increas risk tumor type,0,1.0,0.0
vincristin diffus larg b-cell non-hodgkin lymphoma activ safeti dose-adjust infusion cyclophosphamid doxorubicin vincristin prednison chemotherapi rituximab elderli patient poor-prognost untreat diffus larg b-cell non-hodgkin lymphoma,0,0.8092,0.1908
met5 enkephalin colon cancer opioid growth factor met5 enkephalin prevent incid retard growth human colon cancer,0,1.0,0.0
seprafilm surgic site infect also examin whether use seprafilm affect surgic site infect rate gastrointestin surgeri,0,1.0,0.0
cilostazol lymphedema oral administr cilostazol tail lymphedema examin mous model,0,0.6165,0.3835
ozon t2dm/type num diabet mellitu examin whether short-term exposur air pollut fine particl ozon heat result perturb arteri blood pressur bp person type num diabet mellitu t2dm,0,1.0,0.0
chloramphenicol cataract endophthalm follow cataract surgeri role prophylact postop chloramphenicol eye drop,0,1.0,0.0
olmesartan medoxomil hypertens object random double-blind parallel-group multicentr studi determin efficaci safeti olmesartan medoxomil/amlodipin combin therapi patient moder sever hypertens fail respond treatment num week open-label amlodipin,0,1.0,0.0
oestrogen anovul determin effect accept progestogen alon combin oestrogen regul irregular menstrual bleed associ oligo/anovul,0,1.0,0.0
glibenclamid undergo aggress diabet manag conclus sever hypoglycaemia seriou not uncommon problem among elderli patient t2dm frequent patient undergo aggress diabet manag user long-act sulphonylurea eg glibenclamid,0,0.8072,0.1928
curcumin ovarian cancer data indic er stress autophagi may play role apoptosi induc curcumin analogu bnum2 epitheli ovarian cancer cell line autophagi inhibit increas curcumin analogue-induc apoptosi induc sever er stress,0,0.7939,0.20609999999999995
tesetaxel tumor tesetaxel new oral taxan combin capecitabin phase dose-escal studi patient advanc solid tumor,0,1.0,0.0
num-chloro-num num-dihydroxypyridin toxic studi set out evalu patient metastat colorect carcinoma efficaci toxic s-num contain tegafur num-chloro-num num-dihydroxypyridin cdhp potassium oxon base biochem modul num-fluorouracil num-fu target inhibit dihydropyrimidin dehydrogenas dpd,0,0.7952,0.2048
mtx toxic aim present studi analyz depth role polymorph gene mtx transport pathway put toxic predictor pediatr,0,0.8059999999999999,0.19400000000000006
camp cholera toxin potent camp induc like cholera toxin also growth promot neonat melanocyt transient growth stimul cell deriv adult,0,1.0,0.0
azathioprin ibd four case nhl ibd cohort sir num2num num2 ci num-num2 p=numnum4 receiv immunosuppress therapi azathioprin n=num methotrex n=num methotrex cyclosporin n=num,1,0.3764,0.6236
estrogen breast cancer target vascular endotheli growth factor vegf estrogen receptor er signal pathway concomitantli may provid enhanc therapeut benefit er-posit breast cancer,0,1.0,0.0
camp neuroblastoma tumour growth neuroblastoma tumour inhibit differ mechan l-dopa metabolit dopamin reduc activ tyrosinas bso reduc glutathion level l-dopa tamoxifen rais camp concentr,0,0.7976,0.2024
phenobarbit tonic-clon seizur num2-year-old man past histori gener tonic-clon seizur treat phenobarbit present spinocerebellar ataxia,0,0.8102,0.1898
loratadin increas ocular discomfort loratadin cetirizin hydrochlorid induc sign symptom associ ocular dryness includ increas corneal conjunctiv stain decreas tfbut increas ocular discomfort healthi individu,1,0.20420000000000005,0.7958
acyclovir varicella recent complet double-blind placebo-control studi oral acyclovir immunocompet adult uncompl varicella also demonstr efficaci,0,1.0,0.0
tyrosin nonsmal cell lung cancer inhibitor tyrosin kinas activ associ receptor approv treatment chemotherapy-refractori nonsmal cell lung cancer clinic trial addit tumor type,0,0.7959,0.20409999999999995
ethanol hcc ethanol group signific prolong surviv patient monofoc hcc p numnum2 child class p numnum2,0,1.0,0.0
l-thyroxin hypoplasia major risk factor perman ch prematur first-degre famili histori goiter/nodul thyroid hypoplasia diagnosi high l-thyroxin requir follow-up,0,1.0,0.0
ketotifen sac short-term studi select small studi popul sac ketotifen olopatadin diminish express cam inflammatori marker conjunctiv surfac cell effect,0,1.0,0.0
tocopherol carotenoid diet assess ffq n num4 blood collect analysi serum high-sensit c-reactiv protein hs-crp il-num serum amyloid e-selectin lipid profil dietari biomark carotenoid tocopherol retinol,0,1.0,0.0
feiba thrombot recombin factor viia rfviia increasingli use altern feiba howev thrombot safeti profil rfviia remain incomplet character,0,1.0,0.0
calyculin a. breast cancer revers phase phosphoprotein array analysi reveal increas phosphoryl num out num2 ser/thr phosphosit indic select inhibit phosphatas calyculin a. calyculin treatment induc cell cycl arrest mda-mb-num3 mcf-num breast cancer cell,0,0.7875,0.2125
androgen prostat cancer prostat androgen-regul gene novel potenti target androgen-independ prostat cancer therapi,0,1.0,0.0
iron iron-defici twenty-six percent athlet num2 control latent iron-defici without anemia symptom,0,1.0,0.0
metoprolol hypertens prospect random double-blind studi perform compar renal cardiac effect ace inhibitor ramipril beta-block metoprolol first line therapi adpkd patient hypertens,0,1.0,0.0
oxygen tumor/canc hypoxia induc factor-1 hif-1 central role cellular oxygen-sens overexpress mani type cancer consid import tumor progress,0,1.0,0.0
melatonin cancer effect substanc investig six human cancer cell line compar activ partial purifi melatonin-fre low molecular weight pineal extract umo5r,0,1.0,0.0
barbitur respiratori depress refractori gcse often difficult treat tradit therapi barbitur induc hypotens respiratori depress prolong recoveri,1,0.0,1.0
halothan hemolyt anemia num2 overt icter hepat case num2 num thought true overt icter posttransfus hepat icteru caus reason num2 case seven neonat jaundic four hemolyt anemia one radiat hepat one halothane-induc hepat two case exclud chronic liver diseas diagnos imag procedur despit serum alt normal rang transfus,0,1.0,0.0
pentoxifylline/ptx necrosi pentoxifyllin ptx phosphodiesteras inhibitor known downregul tumor necrosi factor-alpha tnf-alpha secret induc lipopolysacchrid lp gamma interferon ifn-gamma,0,1.0,0.0
lanthanum carbon ckd patient ckd may requir intraven oral activ vitamin d. investig effect lanthanum carbon sevelam carbon bioavail oral calcitriol,0,1.0,0.0
colchicin fmf/famili mediterranean fever success treatment anti-tumor necrosi factor anti-tnf -alpha proteinuria patient famili mediterranean fever fmf resist colchicin anti-tnf drug fmf,0,1.0,0.0
iron athlet twenty-six percent athlet num2 control latent iron-defici without anemia symptom,0,1.0,0.0
rivastigmin alzheim 's diseas drug use treat alzheim 's diseas includ acetyl cholinesteras inhibitor achi donepezil rivastigmin galantamin nmda receptor antagonist memantin,0,1.0,0.0
iron defici iron vitamin defici impact anemia immun system,0,1.0,0.0
irinotecan rectal cancer patient t3/t4 node posit rectal cancer treat capecitabin num num3 mg/m num twice daili bid day num-num2 irinotecan num3 mg/m num day num everi num2 day num cycl follow capecitabin num3 mg/m num bid day num-num per week concurr radiotherapi num2num gy num2 fraction,0,1.0,0.0
aspirin ulcer endoscopi frequent reveal gastroduoden disord among low-dos aspirin user administr ba enteric-co aspirin warrant concern gastroduoden ulcer,1,0.0,1.0
enalapril chf two hundr forty-eight patient advanc chf age num2num+/-num2 year random receiv maxim toler dose enalapril num2 mg/day group num mean dose achiev num2num+/-num mg/day n num3 num2 mg/day group num mean dose achiev num2+/-num2num mg/day n num3,0,1.0,0.0
vinorelbin tumor/tumour/breast cancer capecitabin demonstr similar inhibitori effect vinorelbin breast cancer cell line solid tumour tissu decreas cell prolifer metabol well decreas express metabol protein tumor suppressor gene,0,1.0,0.0
nicotin parkinson 's diseas latter observ coupl find nicotin protect against nigrostriat damag suggest alpha6 nachr may repres uniqu target neurodegen disord link nigrostriat system parkinson 's diseas,0,0.8154,0.1846
testosteron idiopath osteoporosi no well-establish treatment idiopath osteoporosi men testosteron supplement may prove use,0,1.0,0.0
salbutamol vascular dysfunct vascular dysfunct acut inflamm measur fmd pwa salbutamol,0,1.0,0.0
amino-acid hcv infect lipid pathway impair decreas antioxid pool downregul amino-acid metabol metabol variat attribut chronic hcv infect,0,1.0,0.0
carvedilol heart failur carvedilol reduc cost medic care sever heart failur econom analysi copernicu studi appli unit kingdom,0,1.0,0.0
oestrogen endometri atrophi continu progestogen intend induc endometri atrophi henc prevent oestrogen-stimul endometri prolifer,0,1.0,0.0
atropin colon motil atropin use control demonstr respons select paramet colon motil,0,1.0,0.0
tyrosin hypereosinophil syndrome/h imatinib mesyl gleevec small molecul inhibitor abl kit platelet-deriv growth factor receptor pdgfr tyrosin kinas report effect treatment hypereosinophil syndrom he rare eosinophilia-associ chronic myeloid disord eos-cmd character num num2 qnum2 pnum2 cytogenet abnorm,0,1.0,0.0
adenosin inflamm recent data support evid adenosin a2 receptor properti may prove use futur drug develop select manipul receptor-associ biolog effect might relev treatment variou disord includ psychiatr diseas hypoxia/ischemia inflamm erythrocytosi,0,1.0,0.0
uridine-diphosphate/udp tumor gene express level sequenc use analyz carboxylesterase-convert enzym ces1 ces2 thymidyl synthas ts thymidin phosphorylas tp dehydropyrimidin dehydrogenas dpd topoisomeras topo uridine-diphosph udp glucuronosyl transferas 1a1 pre- post-treat tumor normal tissu sampl,0,1.0,0.0
steroid cryptococcosi sudden rapid deterior death rare consequ dissemin cryptococcosi steroid may worsen cours diseas,1,0.19410000000000005,0.8059
androgen prostat cancer true antiandrogens-select non-ligand-bind pocket disruptor androgen receptor-coactiv interact novel tool prostat cancer,0,1.0,0.0
vancomycin corynebacterium falsenii bacteremia corynebacterium falsenii bacteremia occur infant vancomycin therapi,1,0.0,1.0
alcohol atherosclerosi cardiovascular diseas due atherosclerosi lead caus death western societi desir effect alcohol use outweigh detriment action result favor find popul studi,0,1.0,0.0
num-mercaptopurin inflammatori bowel diseas increas dose requir num-mercaptopurin azathioprin inflammatori bowel diseas patient six year younger,0,1.0,0.0
tamoxifen breast cancer/uterin cancer num3 women identifi histori breast cancer treat tamoxifen preced diagnosi uterin cancer,0,0.7906,0.20940000000000006
pioglitazon diabet ethnicity-rel differ action pioglitazon non-diabet particip may one explan,0,1.0,0.0
hbsag hepatocellular carcinoma cigarett smoke heavi alcohol consumpt hbsag independ associ increas risk mortal hepatocellular carcinoma not interact synergist,1,0.0,1.0
amino acid cirrhosi effect branched-chain amino acid-enrich nutrient mixtur natur killer cell activ viral cirrhosi,0,1.0,0.0
vinorelbin tumour/breast cancer effect capecitabin vinorelbin cell prolifer metabol cox2 pnum2 express breast cancer cell line solid tumour tissu,0,0.7942,0.2058
desipramin person disord poor respons therapeut desipramin trial occur num2 num2 patient significantli associ definit person disord prior treatment failur near delusion statu age num2 year durat depress episod recurr depress dysthymia secondari depress,0,0.62,0.38
procarbazin tumor tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,0.8136,0.1864
silicon granulomat pneumon report case chronic progress granulomat pneumon respons subcutan silicon inject transgend male-to-femal patient infect human immunodefici viru num hiv-num,1,0.0,1.0
acebutolol scle although first report acebutolol-induc scle awar occurr avoid acebutolol recommend patient stigmata lupu erythematosu,1,0.0,1.0
fentanyl emphysema transderm fentanyl administ cautious patient pre-exist condit emphysema may predispos develop hypoventil,0,1.0,0.0
cocain patholog gambl studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0
cilostazol lymphedema oral administr cilostazol also decreas lymphedema tail wild type mice,0,1.0,0.0
artemisinin carcinoma consid lack data regard genotox effect compound human cell object studi evalu cytotox genotox express casp3 sod1 gene cultur human hepatocellular liver carcinoma cell line hepg2 cell treat artemisinin artesun,0,1.0,0.0
morphin opioid rotat although recent studi suggest opioid rotat could effect treatment strategi morphine-induc delirium no prospect studi investig treatment effect opioid rotat use fentanyl,0,1.0,0.0
c. toxic no signific differ os df observ num-year estim os num2 ci num2 num2 num2 ac num2 num2 num2 -- c. grade num hematolog toxic greater -- c nonhematolog grade num similar,0,0.79,0.21
amantadin cgd sinc drug employ patient not develop new infect suggest role amantadin part cgd prophylact regimen,0,1.0,0.0
num-fu/num-fluorouracil toxic studi set out evalu patient metastat colorect carcinoma efficaci toxic s-num contain tegafur num-chloro-num num-dihydroxypyridin cdhp potassium oxon base biochem modul num-fluorouracil num-fu target inhibit dihydropyrimidin dehydrogenas dpd,0,1.0,0.0
sumatriptan migrain sinc vasoconstrictor respons sumatriptan reproduc outsid migrain attack action appear direct vascular effect not indirectli mediat via neural mechan,0,1.0,0.0
antithymocyt globulin aplast anemia four patient aplast anemia receiv intraven antithymocyt globulin atg antilymphocyt globulin alg,0,1.0,0.0
silver renal-canc six nhc-silver complex test cytotox mtt base vitro test human renal-canc cell line caki-num order determin icaeau valu,0,0.7914,0.2086
glucos diabet mellitu influenc glucos adjust bodi mass index age gender diabet mellitu vte assess logist regress analys,0,1.0,0.0
vinca alkaloid peripher neuropathi microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,1,0.0,1.0
sildenafil diastol dysfunct sildenafil not decreas fill pressur rest exercis post-myocardi infarct patient diastol dysfunct,0,1.0,0.0
vitamin d. colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.7939,0.20609999999999995
methylen blue hepat failur male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.2149,0.7851
paracetamol analgesia diclofenac paracetamol analgesia paediatr myringotomi outpati,0,0.792,0.208
epirubicin epirubicin hepatocellular carcinoma epirubicin hepatocellular carcinoma pharmacokinet clinic activ,0,1.0,0.0
raloxifene/raloxifen hydrochlorid fractur postmenopaus women low bmd assign treatment num mg/d alendron sodium fractur intervent trial complet num year bmd monitor adher studi medic n num4 postmenopaus women osteoporosi assign treatment num2 num3 mg/d raloxifen hydrochlorid multipl outcom raloxifen evalu trial similarli complet num year monitor adher studi medic n num4,0,1.0,0.0
temozolomid tumor/canc mathemat model show metronom regimen induc tumor regress anti-angiogen effect mtd regimen fail due emerg temozolomid resist cancer cell,0,1.0,0.0
buserelin acet endometriosi vagin mucosa undergo constant well-defin modif buserelin acet danazol treatment endometriosi,0,1.0,0.0
clopidogrel stemi addit clopidogrel aspirin given num year set stemi highli cost-effect strategi,0,1.0,0.0
docetaxel toxic given doxorubicin docetaxel th-num3 complement enhanc anticanc effect perivascular hypox region also increas toxic,1,0.0,1.0
no tension-typ headach sinc calcineurin inhibitor known influenc renal metabol no key molecul tension-typ headach migrain interest whether calcineurin inhibitor might chang no metabol hbmec well,1,0.21200000000000008,0.7879999999999999
abacavir death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
hydrocortison cognit distort howev strong consist posit associ daili hydrocortison dose preval maladapt person trait inum ident problem cognit distort compuls restrict express callous opposition reject conduct problem social avoid narciss insecur attach p numnum2,1,0.37799999999999995,0.622
lactic acid/lact pseudogout concentr tumor necrosi factor alpha interleukin-num vascular endotheli growth factor lactic acid lactat dehydrogenas hmgb-num measur synovi fluid sf sampl patient inflammatori arthropathi rheumatoid arthriti pseudogout patient noninflammatori arthropathi osteoarthr,0,1.0,0.0
danazol endometriosi vagin pattern danazol buserelin acet therapi endometriosi structur ultrastructur studi,0,1.0,0.0
etoposid non-small-cel lung cancer/nsclc patient non-small-cel lung cancer nsclc treat ice chemotherapi ifosfamid num4 mg/m2 day num-num carboplatin num3 mg/m2 day num etoposid num2 mg/m2 day num-num intraven inumv first num maximum four num2 treatment cycl,0,1.0,0.0
aminoglycosid infect suggest criteria includ use patient would otherwis candid oral fluoroquinolon therapi publish criteria exist not use oral rout administr due gastrointestin condit predispos malabsorpt unavail oral rout sever infect due gram-neg pathogen replac aminoglycosid ototox nephrotox substanti risk target resist pathogen i.e. not empir therapi target therapeut use not prophylaxi,0,0.809,0.19099999999999995
aspirin stroke multivari analysi use calcul odd ratio recurr stroke recurr stroke death aspirin treatment failur patient durat avail follow-up num month toast patient num2 month nind rt-pa trial patient,1,0.20109999999999995,0.7989
roxithromycin ten episod ten probabl drug roxithromycin induc,1,0.0,1.0
lopinavir/ritonavir oral glucos toler fast glucos insulin lipid lipoprotein profil oral glucos toler insulin secret insulin-medi glucos dispos hyperglycem clamp bodi composit dual energi x-ray absorptiometri determin lopinavir/ritonavir administr,0,0.7892,0.2108
pegyl interferon hiv/hepat c virus-coinfect treatment pegyl interferon plu ribavirin safe effect hiv/hepat c virus-coinfect patient,0,1.0,0.0
retinol carotenoid diet assess ffq n num4 blood collect analysi serum high-sensit c-reactiv protein hs-crp il-num serum amyloid e-selectin lipid profil dietari biomark carotenoid tocopherol retinol,0,1.0,0.0
dexrazoxan cardiotox suppress mitoxantron cardiotox multipl sclerosi patient dexrazoxan,0,1.0,0.0
cocain addict studi analyz suggest potenti role nac treatment addict especi cocain cannabi depend,1,0.3925,0.6075
glucos diabet fuzzi logic base closed-loop control system blood glucos level regul diabet,0,0.8094,0.1906
succinylcholin headach aim compar effect succinylcholin rocuronium-sugammadex develop myalgia headach electroconvuls therapi ect,0,0.8017,0.19830000000000006
calcium pancreat cancer no associ found pancreat cancer risk intak total fat satur fat cholesterol omega-num fatti acid vitamin c. unexpect invers associ calcium intak pancreat cancer risk data,0,0.8119,0.18810000000000004
indomethacin pancreat rectal indomethacin proven effect prevent post-ercp pancreat pep impact bleed biliari sphincterotomi babe cardiovascular mortal not extens studi,0,1.0,0.0
estrogen rhabdoid tumor estrogen receptor express estrogen receptor-independ cytotox effect tamoxifen malign rhabdoid tumor cell vitro,0,1.0,0.0
ceftriaxon mening furthermor ceftriaxon therapi mening induc strain rabbit model ineffect,0,0.8063,0.1937
thalidomid multipl myeloma recent thalidomid demonstr signific activ treatment multipl myeloma variou western studi,0,0.8265,0.1735
ramosetron abdomin pain ramosetron potent select serotonin num-ht num receptor antagonist shown affect abnorm colon function abdomin pain anim,1,0.1957,0.8043
num-fluorouracil tumor recombin human interferon alpha-2a increas num-fluorouracil efficaci elev fluorouridin concentr tumor tissu,0,1.0,0.0
adr/adriamycin cardiac toxic adriamycin adr potent anticanc drug known caus sever cardiac toxic,1,0.0,1.0
carbidopa parkinsonian open randomis cross-ov studi investig effect singl num3 mg oral dose entacapon novel catechol-o-methyltransferas comt inhibitor pharmacokinet metabol levodopa/carbidopa cardiovascular respons blood pressur puls rate variat standard stimuli eight parkinsonian patient,0,1.0,0.0
nicotin neurodegen disord latter observ coupl find nicotin protect against nigrostriat damag suggest alpha6 nachr may repres uniqu target neurodegen disord link nigrostriat system parkinson 's diseas,0,1.0,0.0
num-fu/num-fluorouracil thymidyl synthase/t thymidyl synthas ts regard paramet num-fluorouracil num-fu chemosensit colorect carcinoma,0,1.0,0.0
bortezomib pre explicit clinic imag featur case highlight need earli recognit pre clinic cours bortezomib therapi,0,0.6069,0.3931
glucos pleural thicken develop pleural thicken relat level pleural fluid glucos p numnum2,1,0.0,1.0
testosteron obes known bmi invers proport serum total testosteron concentr low serum shbg level obes contribut low serum total testosteron,0,1.0,0.0
famotidin reflux oesophag famotidin manag acid-reflux oesophag multicentr studi,0,1.0,0.0
apomorphin parkinson 's disease/pd non-ergot dopamin receptor agonist ropinirol pramipexol rotigotin apomorphin may allevi non-motor symptom parkinson 's diseas pd other may precipit,0,0.8095,0.1905
triacsin c. adrp addit triacsin c potent inhibitor acyl-coa synthas num h decreas amount tg vldl-induc foam cell oleic acid-tr liver cell decreas amount adrp protein parallel indic amount adrp reduc regress lipid-stor cell,0,0.7967,0.20330000000000004
dihydropyridin hypocalcem order studi role calcium ion pathogenesi vasoconstrict lesion caus acut smoke author studi peripher vascular effect calcium-channel antagonist nifedipin dihydropyridin deriv calcitonin hypocalcem hormon possess vasoact action num2 elderli regular smoker mean age num2num year,0,1.0,0.0
octreotid acromegali effect octreotid somatostatin analog sleep apnea patient acromegali,0,1.0,0.0
aspirin atherosclerosi subgroup analysi aspirin treatment failur not found associ recurr stroke combin endpoint stroke death among categori defin etiolog subtyp includ larg arteri atherosclerosi,0,1.0,0.0
phosphat tumor measur express level three differ reductas enzymes-dt-diaphoras nad p h inume. reduc nicotinamid adenin dinucleotid without phosphat quinon oxidoreductas nadph cytochrom p-num3 reductas nadh inume. reduc nicotinamid adenin dinucleotid cytochrome-b5 reductase- num2 cell line nation cancer institut nci human tumor cell panel see relationship could establish activ enzym cellular sensit bioreduct compound mitomycin c eo9,0,1.0,0.0
propofol ripc contrast ripc propofol anesthesia n num2 not alter ctni auc num3 num3 ng/ml num2 h vs. num3 num3 ng/ml num2 h n num2 p numnum3 peak postop ctni num2num num ng/ml vs. num2 num p numnum3,0,0.802,0.19799999999999995
creatin myocardi infarct measur creatin kinas ck mb level preoper entri intens care unit icu everi num2 h num2 h obtain serial num2-lead electrocardiogram ecg preoper num num num2 num2 num2 h icu admiss num num2 morn surgeri num min pre- postextub myocardi infarct identifi,0,1.0,0.0
vancomycin sevs/simul endocardi veget mutant jh1 select vitro mean pharmacokinetic/pharmacodynam pk/pd model simul endocardi veget sev exposur vancomycin laboratori growth medium,0,1.0,0.0
ssri major depress disorder/mdd open trial investig efficaci triiodothyronin num adjuv select serotonin reuptak inhibitor ssri subject major depress disord mdd resist ssri treatment,0,1.0,0.0
sunitinib tumor believ studi sunitinib octreotid neoadjuv intent prepar tumor resect warrant strategi improv cur manag neuroendocrin tumor,0,1.0,0.0
reboxetin anxieti irrit anxieti sleep disturb dri mouth common side effect reboxetin,1,0.0,1.0
cocain cannabi depend studi analyz suggest potenti role nac treatment addict especi cocain cannabi depend,0,1.0,0.0
bilirubin hepatocellular carcinoma higher bilirubin level refractori ascit presenc hepatocellular carcinoma predict paramet mortal num2 patient determin multivari analysi,0,1.0,0.0
adenosin psychiatr diseas recent data support evid adenosin a2 receptor properti may prove use futur drug develop select manipul receptor-associ biolog effect might relev treatment variou disord includ psychiatr diseas hypoxia/ischemia inflamm erythrocytosi,0,1.0,0.0
androgen t1d begin puberti t1d group higher level shbg pua=ua0numnum3 similar androgen level control group,0,1.0,0.0
panton-valentin leukocidin tissu infect studi investig outcom therapi without appropri antibiot among children ca-mrsa skin soft tissu infect ssti analyz outcom manag among children panton-valentin leukocidin pvl -posit strain pvl-neg strain,0,1.0,0.0
celecoxib analgesia clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,1.0,0.0
mangafodipir hepat lesion spio- mangafodipir-enhanc imag compar detect focal hepat lesion small hcc better detect spio-enhanc imag,0,1.0,0.0
estrogen labial adhes compar estrogen betamethason topic treatment labial adhes prepubert girl,0,1.0,0.0
everolimu tuber sclerosi brain subependym giant cell astrocytoma sega patient tuber sclerosi report respond everolimu,0,1.0,0.0
bortezomib/velcad escc investig therapeut potenti tumor necrosi factor-rel apoptosis-induc ligand trail/apo2l combin proteasom inhibitor bortezomib velcad human escc cell line,0,0.8367,0.1633
cholesterol hypertens although sirolimus-tr patient display compar lower platelet white blood cell count higher level serum cholesterol triglycerid sirolimu not augment nephrotox hypertens procliv cyclosporin,0,1.0,0.0
resveratrol tumor resveratrol phytoalexin found grape inhibit vitro growth multipl tumor cell type,0,0.7806,0.21940000000000004
num2-hydroxyvitamin d. vitamin defici object describ preval vitamin defici investig determin plasma num2-hydroxyvitamin num2-ohd concentr high northern latitud countri,0,1.0,0.0
num-methyladenine/num-ma ovarian cancer inhibit autophagi use num-methyladenin num-ma increas level intracellular misfold protein enhanc ovarian cancer apoptosi,0,0.8170000000000001,0.18299999999999994
glucos blood glucos effect konjac food blood glucos level patient diabet,0,1.0,0.0
suramin tumor suramin polysulphon naphthylurea inhibit activ sever growth factor vitro experi clinic respons report human solid tumor,0,1.0,0.0
aza toxic signific proport studi cohort rheumatolog patient aza drug-rel toxic result discontinu aza,1,0.2028,0.7972
ofloxacin bacteri kerat gatifloxacin moxifloxacin vitro suscept comparison levofloxacin ciprofloxacin ofloxacin use bacteri kerat isol,0,1.0,0.0
quinotrierixin endoplasm reticulum paradox quinotrierixin exacerb endoplasm reticulum stress-induc phosphoryl eif2 turn led decreas protein translat,1,0.3943,0.6057
hydroxychloroquin system lupu erythematosu therapi system lupu erythematosu antimalari drug chloroquin hydroxychloroquin quinacrin use long time,0,1.0,0.0
lamivudin hepat b. predict respons peginterferon alpha-2a lamivudin two combin hbeag-neg chronic hepat b,0,1.0,0.0
everolimu spinal cord metastasi respons subependym giant cell astrocytoma spinal cord metastasi everolimu,0,1.0,0.0
anum5 hypoglycemia human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0
propofol myocardi injuri specif hypothes ripc isofluran anesthesia attenu myocardi injuri patient undergo coronari arteri bypass graft cabg surgeri effect may differ propofol anesthesia,0,1.0,0.0
aspirin gastrointestin disord current frequenc gastrointestin disord among user low-dos aspirin unknown,0,1.0,0.0
glucos pain investig whether breast feed effect pain relief venepunctur term neonat compar effect oral glucos combin pacifi,0,1.0,0.0
metformin pco treatment insulin sensit metformin thiazolidinedion tzd improv metabol hormon pattern also improv ovul pco,0,1.0,0.0
restylan hypersensit no inflammatori hypersensit reaction restylan occur,0,0.8002,0.1998
adr/adriamycin gastric cancer investig role mdr1 knockdown drug resist revers knock mdr1 express use shrna drug resist gastric cancer cell examin consequ regard adriamycin adr accumul drug- sensit,0,1.0,0.0
tyrosin nsclc tyrosin kinas inhibitor tki epiderm growth factor receptor egfr erlotinib gefitinib activ agent treatment advanc nsclc,0,1.0,0.0
num-fu toxic none num2 patient treat outpati requir hospit due advers reaction result suggest s-num achiev similar respons infusion num-fu plu leucovorin show potenti anoth biochem modul easili manag toxic,0,0.7979,0.20209999999999995
pivampicillin bronchiti oral azithromycin regim effect treatment acut exacerb chronic bronchiti similar efficaci longer pivampicillin regim may offer superior patient complianc,0,1.0,0.0
dexamethason tumor studi regul gsh synthesi respons pro-inflammatori cytokin tumor necrosi factor-alpha tnf-alpha anti-inflammatori agent dexamethason human alveolar epitheli cell anum3,0,1.0,0.0
imatinib gastrointestin stromal tumor pubm search use phrase 'gastrointestin stromal tumor 'imatinib c-kit,0,1.0,0.0
ca4p prostat cancer dose-limit toxic effect dlt revers ataxia oculomotor nerv palsi occur two patient prostat cancer receiv weekli ca4p num2 mg/m2,0,1.0,0.0
methotrex dmard establish dmard sulfasalazin hydroxychloroquin also demonstr efficaci use togeth methotrex,0,1.0,0.0
srl hcv intent-to-treat analysi srl cohort significantli less advanc fibrosi stage num compar hcv control group year one num2num vs. num2num p numnum4 year two num2num vs. num2num p numnum3,0,0.8339,0.16610000000000005
triglycerid dyslipidemia p-om3 effect reduc triglycerid approxim num2 popul like combin drug enumg. statin treat combin dyslipidemia,0,1.0,0.0
ndma toxic result document abil rat pnum3 2e1 metabol ndma toxic reactiv intermedi demonstr cell line provid use model studi mechan metabolism-medi toxic carcinogenesi,0,0.8074,0.1926
iron oxid hepat lesion detect character focal hepat lesion mangafodipir vs. superparamagnet iron oxide-enhanc magnet reson imag,0,0.8089,0.19110000000000005
cholesterol mcd cell line ra num mcnum3 sigm aggreg patch insensit disrupt cholesterol-rich membran microdomain nystatin beta-mcd,0,1.0,0.0
vancomycin rp vitro antistaphylococc activ rp num5 new streptogramin compar vancomycin teicoplanin against staphylococcu aureu rp num5 activ agent against coagulase-neg staphylococci,0,1.0,0.0
cisplatin non-small-cel lung cancer cisplatin weekli docetaxel concurr thorac radiotherapi local advanc stage iii non-small-cel lung cancer,0,0.8299,0.17010000000000006
heparan sulphat harp harp found differ effect neutral anticoagul activ mimet heparan sulphat otrnum4 heparin purifi system human plasma,0,1.0,0.0
cytarabin acut myeloid leukaemia report favour outcom num2 paediatr apl patient treat accord consecut acut myeloid leukaemia-berlin/frankfurt/muenst aml-bfm trial -num2/-num2/-num4 anthracycline-cytarabin regimen combin all-trans-retinoid acid atra,0,1.0,0.0
dexamethason tumor stimul primari human corneal epitheli cell keratocyt retin endotheli cell num num2 ng/ml interleukin 1e_ il-1e_ result signific increas numer inflammatori cytokin includ il-num il-num tumor necrosi factor e tnf-e dexamethason abl significantli inhibit effect,0,1.0,0.0
steroid diseas diseas refractori high-dos glucocorticoid two cours steroid puls therapi addit cyclosporin num mg/kg/day,0,0.7982,0.2018
pcp nasal carcinoma although pcp not classifi human carcinogen epidemiolog observ suggest exposur chlorophenol gener pcp solut particular may result increas risk certain malign disord nasal carcinoma soft tissu sarcoma,1,0.0,1.0
paroxetin pruritu therefor identifi underli caus pruritu prime import order develop tailor treatment plan even palli care treatment focus toward symptom not necessarili underli disease.result show palli care patient pruritu differ natur treatment drug paroxetin select serotonin reuptak inhibitor may benefici,0,1.0,0.0
oxygen os aim studi respons lymphomonocyt os statu reactiv oxygen speci by-product oral unsatur fat load test oflt fh compar respons obtain normolipidem normoglycem subject,0,1.0,0.0
dcp hyperkalem twenty-four num2 particip hyperkalem period paralysi complet treatment phase num2 particip attack rate data treatment phase mean improv attack rate p numnum3 severity-weight attack rate p numnum2 dcp rel placebo signific,0,1.0,0.0
sunum4 tripl combin tripl combin use low-tox drug exposur pemetrex sunum4 result greater respons treatment alon combin two modal test endotheli tumor cell model,0,1.0,0.0
omega-num fatti acid cardiac diseas omega-num fatti acid shown reduc platelet endotheli activ patient risk cardiac diseas,0,0.8095,0.1905
naloxon respiratori depress patient experi opioid-rel toxic associ respiratori depress treat immedi opioid antagonist naloxon close monitor least num2 hour,0,1.0,0.0
mitomycin nsclc patient stage iiib iv nsclc random start treatment receiv either three six cours mitomycin num mg/m num cours num num num num vinblastin num mg/m num cisplatin num2 mg/m num mvp everi num2 day,0,1.0,0.0
betamethason rash howev dexchlorpheniramin betamethason alon seem better clear rash combin dexchlorpheniramin betamethason,0,1.0,0.0
thalidomid leprosi thalidomid recent shown consider promis treatment number condit leprosi cancer,0,1.0,0.0
sphingosin growth arrest inhibitor display k valu submicromolar rang sphingosin kinas cultur vascular smooth muscl cell decreas s1p level initi growth arrest,0,1.0,0.0
cilansetron abnorm defec ramosetron num num3 microg/kg pnumo found significantli suppress abnorm defec induc conditioned-fear stress cf restraint stress corticotropin releas factor crf num-ht rat mice effect potent alosetron cilansetron loperamid,0,1.0,0.0
axitinib palmar-plantar erythrodysaesthesia toler profil gener consist vegf receptor inhibitor axitinib associ numer lower incid palmar-plantar erythrodysaesthesia cutan toxic anaemia sorafenib phase iii trial,1,0.3993,0.6007
vancomycin vancomycin-intermedi s. aureus/visa use num vitro experiment system compar phenotyp genotyp chang accompani select mutant methicillin-resist staphylococcu aureu mrsa strain jh1 low-level vancomycin resist similar type found vancomycin-intermedi s. aureu visa,0,1.0,0.0
cisplatin toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.3855,0.6145
mtx toxic result suggest polymorph abcc4 abcc2 could novel marker mtx toxic pediatr,1,0.3973,0.6027
cocain hyperthermia lethal effect cocain uniqu among illicit drug cocain propens caus hyperthermia,1,0.2067,0.7933
anthracyclin breast cancer carboplatin gemcitabin cg combin activ unselect anthracycline/taxan pretreat metastat breast cancer patient carri out phase ii studi evalu activ cg combin pretreat metastat tnbc patient,0,1.0,0.0
amiodaron ild contrast cell observ two out num2 area lp-amr-ip patient one out num2 area ild patient not receiv amiodaron none num2 area amiodarone-tr patient without ild p numnum3 hp-amr-ip versu group,0,1.0,0.0
nitric oxid hyperoxia effect exogen nitric oxid hyperoxia lung fibroblast viabil dna fragment,0,1.0,0.0
heparin blood loss use heparin-co circuit reduc mean length stay hospit num +/- num num +/- num day p numnum3 postop ventil time num +/- num num +/- num h p numnum3 blood loss num h post surgeri num3 +/- num3 num3 +/- num3 ml p numnum3 individu periop chang haemoglobin loss p numnum3 leukocyt count p numnum3 creatinin elev p numnum3 proport patient expos allogen blood transfus num2num vs num2num p numnum3 postop coagul disturb num vs num p numnum3 postop deviat normal postop cours num2num vs num2num p numnum3 neurolog deviat num vs num p numnum3 atrial fibril num2num vs num2num p numnum3,0,1.0,0.0
triphosph cll major case num2 analogu triphosph present num2 hour infus indic prolong retent triphosph cll cell,0,1.0,0.0
carmustin ocular toxic articl discuss ocular toxic six patient advanc nonpretr colorect cancer receiv megados carmustin mitomycin support autolog bone marrow transplant,1,0.3884,0.6116
procarbazin rhabdomyosarcoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
vitamin d. breast cancer describ baselin healthi lifestyl behavior dietari calcium vitamin caffein alcohol intak smoke histori physic activ postmenopaus breast cancer survivor bc identifi relationship healthi lifestyl behavior bone miner densiti bmd forearm total hip spine l1-l4,0,1.0,0.0
yohimbin ptsd signific differ brain metabol respons yohimbin patient ptsd compar healthi subject prefront tempor pariet orbitofront cortex,0,1.0,0.0
ziprasidon multipl neurocognit domain robust find signific across multipl neurocognit domain adjac snp show evid associ rsnum5 ehf gene p-valu numnum2 num2 -num q-valu numnum3 mediat effect ziprasidon vigil rsnum5 slcnum2a9 p-valu num num2 -num q-valu numnum3 mediat effect olanzapin process speed rsnum5 il1a p-valu numnum2 num2 -num q-valu numnum3 mediat effect olanzapin work memori,0,1.0,0.0
dmso/dimethylsulfoxid acut myeloid leukemia atra all-tran retino acid dimethylsulfoxid dmso induc differenti hl-num2 nb4 two human acut myeloid leukemia cell line myelocyt lineag up-regul two enzym variou degre num num2 h treatment,0,0.8046,0.1954
methionin sclc summari bn analogu lack c-termin methionin may function use sclc bn receptor antagonist,0,1.0,0.0
glucos blood glucos studi examin efficaci biasp num2 evalu term glycaem control glycosyl haemoglobin hba 1c reduct proport patient achiev hba 1c target num num fast blood glucos blood glucos profil and/or prandial postprandi glucos increment,0,1.0,0.0
corticosteroid hepat b. report two hepat b viru hbv carrier liver failur withdraw corticosteroid steroid administ treatment seriou asthmat attack,0,1.0,0.0
axitinib death significantli axitinib sorafenib recipi achiev object respons axitinib therapi significantli prolong time deterior composit endpoint death diseas progress symptom worsen rel sorafenib therapi,0,1.0,0.0
cbz/carbamazepin pht pharmacoresist epilept patient may ascrib least two not mutual exclus mechan pharmacokinet mechan decreas sensit avail target antiepilept drug a i.e. carbamazepin phenytoin cbz pht,0,1.0,0.0
ginkgolid bleed complic inhibit platelet activ factor paf -induc aggreg human thrombocyt ginkgolid consider possibl bleed complic oral intak ginkgo biloba extract,1,0.1904,0.8096
steroid encephalomyel effect intraven immunoglobulin treatment adult patient steroid-resist monophas recurr acut dissemin encephalomyel,0,1.0,0.0
sertindol schizophren num2-day random placebo-control dose-rang multicent studi design assess effect sertindol previous neuroleptic-respons hospit schizophren patient n num3,0,1.0,0.0
camptothecin mix oligoastrocytoma determin efficaci toxic novel chemotherapeut approach topotecan camptothecin analog progress recur anaplast oligodendroglioma mix oligoastrocytomanumpati seven center recurr progress diseas treat topotecan num mg/m num intraven inumv num2 min dailyx5 day everi num week,0,0.7996,0.2004
paclitaxel tumor paclitaxel might thu effect elimin radioresist clone cervic tumor even absenc synergist interact therapeut modal,0,1.0,0.0
atp avb unusu behaviour could interpret abnorm suscept atp patient could consid 'atp-sensit avb,1,0.3702,0.6298
perindopril cardiac event european trial reduct cardiac event perindopril stabl coronari arteri diseas europa trial recent report,0,1.0,0.0
capecitabin breast cancer determin safeti inumv trastuzumab num mg/kg follow num mg/kg everi num week combin chemotherapeut agent administ num-weekli cours docetaxel vinorelbin capecitabin num2 patient her2-posit recurr locoregion and/or metastat breast cancer,0,1.0,0.0
aspirin hypercapnia therefor nonsteroid anti-inflammatori drug aspirin inhibit cyclooxygenas might expect reduc cerebr blood flow respons hypercapnia,0,1.0,0.0
sulfasalazin dmard establish dmard sulfasalazin hydroxychloroquin also demonstr efficaci use togeth methotrex,0,1.0,0.0
sodium nitroprussid toxic cyanid toxic complic sodium nitroprussid administr,1,0.0,1.0
amlodipin hypertens efficaci fixed-dos combin therapi treatment patient hypertens focu amlodipine/valsartan,0,0.8101,0.1899
lamotrigin nocturn myoclonu syndrome/nm lamotrigin treatment nocturn myoclonu syndrom nm two case report,0,1.0,0.0
ketotifen at twelv patient receiv ketotifen num2 olopatadin num2 at,0,1.0,0.0
oleic acid adrp induct adrp tg accumul also observ oleic acid-tr huh-num human liver cell,1,0.3688,0.6312
num num'-dideoxycytidin immunodefici novel mutat human immunodefici viru type num revers transcriptas gene encod cross-resist num num'-dideoxyinosin num num'-dideoxycytidin,0,1.0,0.0
epinephrin platelet aggreg cross-sect protocol platelet aggreg respons adp epinephrin von willebrand antigen vwf ag collagen-bind capac vwf cb obtain,0,0.7867,0.21330000000000005
"pentostatin chronic leukemia ten patient hairi cell leukemia hcl seven patient b-cell chronic leukemia bcl studi intracellular num num'-oligoadenyl synthetas num,5oa activ mononuclear cell num h num2 h num2 h pentostatin administr",0,1.0,0.0
ammonia impair ammonia detoxif therefor therapeut efficaci oral l-ornithine-l-aspart improv impair ammonia detoxif investig patient cirrhosi hyperammonemia stabl overt chronic hepat encephalopathi subclin hepat encephalopathi random double-blind placebo-control clinic trial,0,1.0,0.0
vinflunin neurotox articl provid overview incid characterist manag mti-associ neurotox known vinca alkaloid taxan well newer agent vinflunin ixabepilon,1,0.3726,0.6274
ethanol ap ethanol embol patient hcc sever ap efficaci safe may contribut prolong life span versu gelfoam embol,0,1.0,0.0
num2 -hete melanoma endogen releas num2 -hete/num2 -hete host organ may affect metastat potenti melanoma,1,0.3921,0.6079
cyclophosphamid breast cancer high-risk node-neg low-risk node-posit breast cancer patient receiv ac given arm concurr ac doxorubicin num2 mg/m2 cyclophosphamid num g/m2 intraven iv everi num week six cycl arm ii sequenc c doxorubicin num2num mg/m2 iv day num num everi num week four cycl follow cyclophosphamid num gm/m2 iv everi num week three cycl,0,1.0,0.0
nac addict behavior inclus criteria review clinic trial use nac treatment disord relat substanc use and/or addict behavior limit text english spanish french,0,1.0,0.0
methotrex rheumatoid arthriti evid radiograph benefit treatment infliximab plu methotrex rheumatoid arthriti patient no clinic improv detail subanalysi data anti-tumor necrosi factor trial rheumatoid arthriti concomit therapi studi,0,1.0,0.0
cyclosporin a/csa psoriasi studi conduct quantifi solubl il-num receptor sil-2r level sera num2 chronic plaqu psoriasi patient correl measur diseas activ number il-2r-posit cdnum2+ lymphocyt lesion biopsi num2 cyclosporin csa num2 psoralen plu ultraviolet radiat puva treat patient,0,0.7893,0.2107
dopamin hyperthermia urinari adrenalin concentr not elev hyperthermia case signific differ urinari dopamin da concentr two group,0,1.0,0.0
num-ht contract ketanserin-resist compon num-ht-induc contract found -log ecnum2 num f1 numnum2 num3 nm ketanserin -log ecnum2 num f1 numnum2 num4 nm ketanserin,1,0.2056,0.7944
cisplatin tumor preclin data indic cisplatin sensit suggest tumor may defect brca1 pathway,0,1.0,0.0
atg aplast anemia four not receiv atg/alg two aplast anemia two bone marrow suppress,0,0.8138,0.18620000000000006
piracetam aphasia electroencephalograph clinic effect piracetam post-strok aphasia evalu prospect random double-blind placebo-control trial,0,1.0,0.0
ethanol muscl atrophi present num alcohol myopathi past present futur timothi j. peter victor r. preedi num protein adduct type ii fiber-predomin muscl ethanol-f rat simon worral seppo parkkila onni niemela num hydroperoxid chang alcohol myopathi junko adachi migiwa asamo yasuhino ueno num close associ testicular atrophi muscl atrophi increas protein catabol chronic ethanol administr kunihiko takeda masayoshi yamauchi kazuhiko sakamoto masaru takagi hisato nakajima gotaro toda,1,0.0,1.0
num-methyladenine/num-ma death blockad autophagi matur autophagy-specif inhibitor num-methyladenin num-ma lysosome-neutr agent nh4cl num h as2o3 potenti as2o3-induc death hlnum2 cell,0,0.8203,0.17969999999999994
pegaptanib diabet macular edema diabet macular edema phase ii trial intravitr pegaptanib intravitr ranibizumab shown short-term benefit visual acuiti,0,1.0,0.0
sugammadex major depress rocuronium-sugammadex reduc myalgia headach electroconvuls therapi patient major depress,0,1.0,0.0
tesetaxel cancer data support continu clinic develop tesetaxel singl agent combin activ cancer therapeut,0,1.0,0.0
vancomycin visa mutant display reduc vancomycin daptomycin suscept phenotyp alter eg thicker cell wall abnorm autolysi typic vivo visa mutant,0,1.0,0.0
melatonin hcc/apoptosi hepatocellular carcinoma melatonin induc apoptosi hepatocellular carcinoma hcc experiment studi effect melatonin endoplasm reticulum er stress-induc apoptosi hcc not test,1,0.1964,0.8036
moxifloxacin bacteri kerat gatifloxacin moxifloxacin vitro suscept comparison levofloxacin ciprofloxacin ofloxacin use bacteri kerat isol,0,1.0,0.0
ketamin analgesia doubl blind cross studi design evalu effect ketamin spinal morphin analgesia termin cancer pain patient,0,0.7963,0.2037
calcium hypocalcem order studi role calcium ion pathogenesi vasoconstrict lesion caus acut smoke author studi peripher vascular effect calcium-channel antagonist nifedipin dihydropyridin deriv calcitonin hypocalcem hormon possess vasoact action num2 elderli regular smoker mean age num2num year,0,1.0,0.0
dcp paralysi twenty-four num2 particip hyperkalem period paralysi complet treatment phase num2 particip attack rate data treatment phase mean improv attack rate p numnum3 severity-weight attack rate p numnum2 dcp rel placebo signific,0,1.0,0.0
temozolomid glioblastoma phase ii studi temozolomid cisplatin primari treatment prior radiotherapi newli diagnos glioblastoma multiform patient measur diseas,0,1.0,0.0
nitric oxid inflamm exhal nitric oxid eno measur appear noninvas marker airway inflamm examin hypothesi eno would increas night,0,1.0,0.0
delta num -tetrahydrocannabinol/thc delta num -tetrahydrocannabinol/thc activ principl marijuana delta num -tetrahydrocannabinol thc shown wide therapeut applic number import medic condit includ pain anxieti glaucoma nausea emesi muscl spasm wast diseas,0,1.0,0.0
clopidogrel stroke commit trial demonstr clopidogrel produc num rel reduct death reinfarct stroke num vs. num2num num2 ci numnum2-numnum2 st-elev myocardi infarct stemi patient,0,1.0,0.0
warfarin stroke overal high-risk patient warfarin superior aspirin prevent stroke rel risk reduct num2,0,1.0,0.0
tau cytotox az combin tau inhibit melanin product tyrosinas activ bnum2fnum2 melanoma cell without signific cytotox,0,1.0,0.0
metformin type metformin use among individu risk type num diabet,0,1.0,0.0
clozapin death death common caus clozapin cessat,0,0.6094,0.3906
aldosteron primari aldosteron aldosteron synthas inhibit lcinum3 proof-of-concept studi patient primari aldosteron,0,0.7904,0.2096
abirateron ar/androgen receptor mini-review discuss gener mechan resist ar-direct therapi focu role androgen receptor splice variant new era treat advanc prostat cancer enzalutamid abirateron,0,1.0,0.0
glucos diabet clinic trial lower blood glucos disappoint probabl particip late natur histori diabet alreadi extens vascular diseas,0,0.7882,0.2118
doxorubicin os/overal surviv conduct phase iii random studi two adjuv treatment schedul doxorubicin cyclophosphamid c early-stag breast cancer determin administr sequenti singl agent -- c result superior disease-fre surviv df overal surviv os versu total dose given combin ac,0,0.601,0.39899999999999997
num-fluorouracil colorect cancer systems-level analysi correctli predict posit neg outcom num2 p=numnum3 colorect cancer patient receiv num-fluorouracil base chemotherapi significantli outperform common uni- multi-vari statist approach,0,0.7973,0.2027
aspirin atrial fibril final patient bother littl symptom atrial fibril cardiovers follow either aspirin warfarin without subsequ antiarrhythm therapi treatment choic,0,0.794,0.206
duloxetin asthenia gener duloxetin well toler num2 patient achiev maximum dose insomnia asthenia advers event report statist significantli p .num2 frequent duloxetine-tr patient compar placebo-tr patient,1,0.0,1.0
num-fu ts recent research indic chemosensit num-fu colorect carcinoma low express ts better tumor high express ts,0,0.8079999999999999,0.1920000000000001
amlodipin arteriosclerosi present studi evalu effect treatment calcium channel blocker amlodipin angiotensin i-convert enzym inhibitor perindopril vascular endotheli function arteriosclerosi patient essenti hypertens alreadi receiv angiotensin receptor blocker monotherapi,0,1.0,0.0
calcium vomit taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,1.0,0.0
clopidogrel death commit trial demonstr clopidogrel produc num rel reduct death reinfarct stroke num vs. num2num num2 ci numnum2-numnum2 st-elev myocardi infarct stemi patient,0,0.8001,0.1999
clonidin pmdd clonidin sexual abus pmdd women exhibit greater decreas rest stress-induc hr p numnum2 stress-induc systol bp p numnum2 non-abus pmdd women exhibit greater reduct plasma ne concentr p numnum2 greater increas beta2-ar respons p numnum2 abus pmdd women,0,1.0,0.0
betamethason labial adhes comparison estrogen betamethason topic treatment labial adhes prepubert girl,0,1.0,0.0
anum5 ra incub pmn rac ra num-num3 microm caus dose-depend inhibit upto num2 o2- product chemiluminesc induc phorbol myrist acet pma n-formyl-methionyl-leucyl-phenylanalin fmlp opson zymosan ionophor anum5,0,1.0,0.0
tyrosin detect mrd may predict outcom patient philadelphia chromosome-posit treat tyrosin kinas inhibitor plu chemotherapi,0,1.0,0.0
aspirin ischem stroke object determin aspirin treatment failur predict recurr ischem stroke and/or death,0,1.0,0.0
sfa lp lp lipopeptid contamin wide use reagent fatty-acid-fre bsa explain previous report stimul tlr2 tlr4 sfa,0,0.7874,0.2126
desmopressin diabet insipidu desmopressin synthet vasopressin analogu mainli use treatment diabet insipidu nocturia,0,1.0,0.0
auristatin pe wm auristatin pe dolastatin num2 ad triplic well cell count viabil assess num2 num2 num2 h. result show agent activ against wsu-wm abl induc complet growth inhibit num3 pg/ml,0,1.0,0.0
statin ckd observ studi found reduct risk contrast media induc nephropathi reduct risk hospit sepsi patient ckd treat statin,0,0.809,0.19099999999999995
topiram mood disord bing eat disord best evid mood disord cognitive-behavior therapi well topiram zonisamid select case select serotonin reuptak inhibitor,0,1.0,0.0
serotonin/num-ht abdomin pain ramosetron potent select serotonin num-ht num receptor antagonist shown affect abnorm colon function abdomin pain anim,0,0.6153,0.3847
adrenalin hyperthermia urinari adrenalin concentr not elev hyperthermia case signific differ urinari dopamin da concentr two group,0,1.0,0.0
glucos ischemia report downregul gaba receptor gaba r express affect mrna protein level gaba r subunit hippocamp neuron subject oxygen-glucos depriv ogd vitro model ischemia,0,0.8006,0.1994
steroid structur damag follow steroid hydroxyurea administr lesion mri disappear suggest pathogenet mechan revers not caus signific structur damag,0,1.0,0.0
num-fu cancer/colon cancer chloroquin potenti anti-canc effect num-fu colon cancer cell,0,1.0,0.0
barbitur hypothermia includ 'forc hyperventil paco2 num2 mmhg barbitur coma experiment protocol tri buffer indomethacin induc hypothermia,0,1.0,0.0
fluticason bronchiectasi cochran airway group rct regist cochran control clinic trial regist search use follow search term bronchiectasi corticosteroid* beclomethason budesonid fluticason triamcinolon flunisolid,0,1.0,0.0
calcium death cardiomyocyt calcium ca num+ load recogn major factor acut ischaemia-reperfus patholog promot cell death contractil dysfunct arrhythmogen activ,1,0.21419999999999995,0.7858
fludarabin phosphat hp aim identifi contribut hp engraft failur cbt follow prepar regimen contain fludarabin phosphat num3 patient median age num2 year rang num2-num2 year haematolog diseas,0,1.0,0.0
pilocarpin ocular hypertens compar addit intraocular pressure-low effect latanoprost numnum3 administ daili pilocarpin num administ three time daili patient primari open-angl glaucoma ocular hypertens current monotherapi timolol num twice daili,0,1.0,0.0
tamoxifen breast cancer random contro-l trial num3 chines women attend univers hospit hong kong requir adjuv tamoxifen breast cancer complet postop radiotherapi chemotherapi,0,1.0,0.0
berberin cancer berberin bbr isoquinolin deriv alkaloid isol chines herb long histori use treatment multipl diseas includ cancer,0,1.0,0.0
nh4cl death blockad autophagi matur autophagy-specif inhibitor num-methyladenin num-ma lysosome-neutr agent nh4cl num h as2o3 potenti as2o3-induc death hlnum2 cell,0,0.612,0.38799999999999996
clofarabin leukemia base mechanist similar fludarabin cladribin success analogu treatment chronic lymphocyt leukemia cll hypothes clofarabin would effect indol leukemia,0,1.0,0.0
adrenaline/epinephrin mw compar efficaci endoscop band ligat vs. hemoclip plu epinephrin adrenalin bleed mw,0,1.0,0.0
methamphetamin hiv-num neurodegener progress understand basal ganglia dysfunct common target methamphetamin abus hiv-num neurodegener,0,1.0,0.0
quinolon cancer escherichia coli resist quinolon comprehens cancer center,0,1.0,0.0
salicyl bronchial asthma drug choic patient not treat non-steroid anti-inflammatori drug nsaid peopl bronchial asthma peptic ulcer diseas hemophilia salicylate-sensit peopl children num2 year age pregnant breastfeed women,0,1.0,0.0
cis- rucl num nh num num cl mi mi human peripher blood lymphocyt cultur treat num num2 num3 num num3 microg ml -num cis- rucl num nh num num cl num num num num respect,0,1.0,0.0
tyrosin tumor northern western blot tyrosin phosphoryl analysi show hgf receptor overexpress function five tumor well two addit tumor,0,1.0,0.0
pravastatin hypercholesterolemia recent posit effect cholesterol-low drug pravastatin lovastatin npt observ middle-ag male chronic hypercholesterolemia,0,1.0,0.0
nedocromil sodium bronchospasm nedocromil sodium prevent exercise-induc bronchospasm athlet asthma,0,0.825,0.17500000000000004
enzalutamid ar/androgen receptor mini-review discuss gener mechan resist ar-direct therapi focu role androgen receptor splice variant new era treat advanc prostat cancer enzalutamid abirateron,0,1.0,0.0
polyethylen glycol ada deficiency/adenosin deaminase/ada describ effect polyethylen glycol-conjug adenosin deaminas ada replac therapi lymphocyt count activ apoptosi prolifer cytokin secret num2-month-old girl delayed-onset ada defici mark immunodysregul,0,1.0,0.0
prednison narcolepsi explor whether acut destruct hypocretin cell patient narcolepsi could detect cours diseas could revers alter use prednison immunosuppress,0,1.0,0.0
vitamin d. fractur result suggest system effect estrogen vitamin defici not crucial fractur heal mechan properti callu,0,1.0,0.0
glucos real-tim jdrf random clinic trial assess efficaci real-tim continu glucos monitor manag type num diabet research design method,0,1.0,0.0
naltrexon alcohol disulfiram naltrexon approv food drug administr fda treatment alcohol agent not rigor evalu dualli diagnos individu,0,1.0,0.0
verteporfin age-rel macular degener intravitr inject bevacizumab combin verteporfin photodynam therapi choroid neovascular age-rel macular degener,0,1.0,0.0
lenalidomid mm sinc introduct immunomodulatori deriv imid thalidomid lenalidomid therapeut armamentarium mm vte emerg one lead complic particular patient newli diagnos mm,0,0.8087,0.19130000000000005
olanzapin bodyweight gain quetiapin appear increas risk sedat bodyweight gain albeit less olanzapin,1,0.39299999999999996,0.607
asa ulcer usual low dose asa relat ulcer reason small asymptomat probabl heal period week month,1,0.0,1.0
adenosin ada deficiency/adenosin deaminase/ada describ effect polyethylen glycol-conjug adenosin deaminas ada replac therapi lymphocyt count activ apoptosi prolifer cytokin secret num2-month-old girl delayed-onset ada defici mark immunodysregul,0,1.0,0.0
amiodaron af amiodaron may use select patient symptomat life-threaten af refractori drug,0,1.0,0.0
carnitin total free carnitin contrari control patient pco character slightli lower level fast total free carnitin precursor deriv,0,1.0,0.0
quinin poison case ocular toxic vasospasm secondari quinin poison describ,0,0.6163,0.3837
strychnin convuls compound also report activ against convuls induc bicucullin picrotoxin strychnin,1,0.1966,0.8034
alcohol alcohol-impair alcohol-impair drive still major problem need continu attent,0,0.6051,0.3949
tamoxifen uterin cancer object studi determin percentag women develop uterin cancer num2 month discontinu tamoxifen past user compar clinic patholog featur women develop uterin cancer tamoxifen therapi within num2 month stop therapi recent user,1,0.389,0.611
salmeterol death imbal occur larg african-american subpopul respiratory-rel death life-threaten experi num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 combin asthma-rel death life-threaten experi num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 subject receiv salmeterol vs placebo,0,0.6008,0.3992
pyruv primari biliari cirrhosis/pbc understand primari biliari cirrhosi pbc significantli enhanc rigor dissect multilineag b cell respons against immunodomin mitochondri autoantigen e2 compon pyruv dehydrogenas complex pdc-e2,0,1.0,0.0
pimecrolimu atop dermat pimecrolimu cream num long-term manag adult atop dermat prevent flare progress,0,1.0,0.0
vardenafil ed/erectil dysfunct vardenafil report improv success rate mainten erect suffici complet intercours sep-num compar placebo erectil dysfunct ed patient attempt intercours earli num2 minut dose,0,1.0,0.0
olopatadin sac short-term studi select small studi popul sac ketotifen olopatadin diminish express cam inflammatori marker conjunctiv surfac cell effect,0,1.0,0.0
fentanyl analgesia transderm fentanyl initi base num2-hour opioid requir adequ analgesia achiev,0,0.8016,0.1984
thiobarbitur asthmat asthmat patient num2 num2 num2 mean num2 confid interv receiv thiobarbitur num2 num num2 receiv oxybarbitur none num num2 receiv propofol wheez intub,0,1.0,0.0
venlafaxin hypertens num2num patient develop hypertens start treatment venlafaxin,1,0.0,1.0
glucos glucos obes children adolesc classifi metabol syndrom met three follow criteria hypertriglyceridemia low level high-dens lipoprotein hdl high fast glucos obes hypertens,0,0.7989,0.20109999999999995
propionylcarnitin intermitt claudic effect propionylcarnitin chang endotheli function plasma level adhes molecul induc acut exercis patient intermitt claudic,0,1.0,0.0
irinotecan/snnum2 cancer five cancer cell line resist irinotecan snnum2 paclitaxel ptx etoposid vpnum2 oxaliplatin oxa gemcitabin gem respect establish parent gastric cancer cell line ocum-2m name ocum-2m/snnum2 ocum-2m/ptx ocum-2m/vpnum2 ocum-2m/oxa ocum-2m/gem,0,1.0,0.0
epothilon peripher neuropathi microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,1,0.3914,0.6086
warfarin postop complic three group continu cw discontinu dw case-match control c not warfarin therapi compar oper detail postop complic,0,1.0,0.0
n-acetylcystein toxicosi comparison n-acetylcystein methylen blue alon combin treatment acetaminophen toxicosi cat,0,1.0,0.0
sucros niddm rational combin insulin oral drug therapi deriv better understand pathophysiolog niddm mechan action oral drug avail num type num diabet patient insulin-defici insulin-resist thu requir quit high dose exogen insulin num peripher insulin deliveri lead hyperinsulinaemia could play role pathogenesi late diabet complic num sulphonylurea stimul insulin releas directli portal vein could also potenti peripher insulin action num metformin improv glucos metabol insulin sensit alpha-glucosidas inhibitor slow digest complex carbohydr sucros abl reduc amount insulin need control postprandi hyperglycaemia,0,1.0,0.0
corticosteroid bronchial asthma/ba aim studi test fluticason propion fp efficaci treatment patient bronchial asthma ba not control high dose num mg inhal corticosteroid,0,0.8156,0.1844
lidocain fibromyalgia studi investig effect intraven infus lidocain pain qualiti life patient fibromyalgia,0,1.0,0.0
bile acid esophag aim studi assess express bile acid receptor esophagu normal esophag barrett 's esophagu adenocarcinoma investig possibl function,0,1.0,0.0
glucos type num diabet jdrf random clinic trial assess efficaci real-tim continu glucos monitor manag type num diabet research design method,0,1.0,0.0
clopidogrel bleed howev clopidogrel-tr patient significantli lower rate bleed carrier num2num num3/num3 vs. num2num num3/num4 non-carri hr numnum2 num2 ci numnum2-numnum2 p numnum3 genotype/treat interact p-valu numnum3,0,1.0,0.0
pyrazinamid tuberculosi pyrazinamid suscept test mycobacterium tuberculosi systemat review meta-analys,0,1.0,0.0
sunitinib thymic carcinoid thymic carcinoid respond neoadjuv therapi sunitinib octreotid case report,0,1.0,0.0
creatinin type furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0
nevirapin hiv-infect examin antiretrovir resist among cohort num3 south african hiv-infect children num year old expos nevirapin prevent mother-to-child transmiss,0,0.8051,0.1949
pimecrolimu ad adult histori mild moder ad free activ skin lesion intervent pimecrolimu cream num first sign and/or symptom subsequ recurr reduc number flare requir tc use decreas number disease-rel offic visit,0,1.0,0.0
aflatoxin infecti hepat liver cancer one common cancer worldwid particularli asia africa infecti hepat aflatoxin exposur common,0,1.0,0.0
glatiram acet multipl sclerosi glatiram acet glat well toler safe immunomodulatori drug treatment relapsing-remit multipl sclerosi,0,1.0,0.0
morphin pain no differ pain intens initi assess morphin usag mood anxieti depress measur period,0,1.0,0.0
amifostin thyroid cancer assess effect amifostin salivari gland radioact iodine-tr differenti thyroid cancer,0,0.8072,0.1928
atp/adenosin triphosph atrioventricular block/avb sought investig patient syncop relationship document paroxysm atrioventricular block avb unknown mechan avb induc adenosin triphosph atp inject,1,0.1907,0.8093
imatinib myeloid disord imatinib mesyl gleevec small molecul inhibitor abl kit platelet-deriv growth factor receptor pdgfr tyrosin kinas report effect treatment hypereosinophil syndrom he rare eosinophilia-associ chronic myeloid disord eos-cmd character num num2 qnum2 pnum2 cytogenet abnorm,0,0.8232,0.17679999999999996
clonidin pmdd result suggest pmdd women without histori sexual abus respond differ clonidin challeng measur reflect autonom nervou system function indic abus may modifi presynapt alpha2-ar function pmdd,0,1.0,0.0
homovanil acid ocd ocd case analys csf num-hydroxyindoleacet acid homovanil acid concentr not significantli differ age-correct control,0,1.0,0.0
num-hc clonal abnorm data suggest clonal abnorm observ posttranspl best explain clinic relaps tumor ex vivo marrow purg num-hc not like induc clonal chromosom abnorm normal cell,0,1.0,0.0
ketamin termin cancer pain intrathec ketamin reduc morphin requir patient termin cancer pain,0,0.8082,0.1918
imatinib gist/gastrointestin stromal tumour although tyrosin kinas inhibitor imatinib shown activ agent patient gastrointestin stromal tumour gist complet remiss almost never seen patient final experi diseas progress cours treatment,0,0.6029,0.3971
acetazolamid cataract studi evalu effect acetazolamid latanoprost travoprost bimatoprost brimonidin brinzolamid timolol pain phacoemulsif cataract surgeri,0,1.0,0.0
epothilon neuropathi epothilon new class mti may associ grade num/num peripher neuropathi howev neuropathi associ ixabepilon novel epothilon b analog gener mild moder revers baselin grade num level,1,0.2024,0.7976
linol acid breast cancer conjug linol acid cla natur found dairi product rumin meat posit geometr isom tran ci c linol acid wide report possess anti-tumor activ against breast cancer vitro vivo,0,1.0,0.0
corticosteroid multipl cranial neuropathi report case ramsay hunt syndrom immun compromis patient classic facial nerv palsi ipsilater ear vesicl rapidli evolv involv multipl cranial neuropathi improv dramat antivir therapi corticosteroid,0,1.0,0.0
nmda pain mice enhanc function forebrain nmda receptor demonstr select enhanc persist pain allodynia,1,0.3995,0.6005
calcium vascular endotheli dysfunct conclus result suggest angiotensin i-convert enzym inhibitor perindopril superior calcium channel blocker amlodipin reduc vascular endotheli dysfunct co-administ angiotensin receptor blocker patient essenti hypertens,0,1.0,0.0
creatin myocardi tissu injuri creatin kinas activ cardiac troponin concentr use marker myocardi tissu injuri,0,1.0,0.0
"num num'-oligoadenyl chronic leukemia ten patient hairi cell leukemia hcl seven patient b-cell chronic leukemia bcl studi intracellular num num'-oligoadenyl synthetas num,5oa activ mononuclear cell num h num2 h num2 h pentostatin administr",0,1.0,0.0
atp neurodegen diseas addit atp synthesi mitochondria key regul calcium homeostasi free radic product steroid synthesi apoptosi factor could also associ essenti mechan involv neurodegen diseas,0,0.6139,0.3861
etoposid leukemia april num juli num num4 cancer leukemia group b calgb conduct phase ii studi etoposid carboplatin advanc ajc stage iiib-iv non-small-cel lung cancer nsclc patient whose perform statu ps num-num,0,1.0,0.0
vancomycin bacteremia identif tempor cluster risk factor bacteremia nosocomi vancomycin-resist enterococci,0,1.0,0.0
gemcitabin leukemia anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0
curcumin ag furthermor downregul rat sarcoma ra upregul extracellular-signal-regul kinas erk also observ ag cell treat curcumin western blot,0,1.0,0.0
androgen ar/androgen receptor drug design suppress androgen receptor ar signal restor follow first-lin androgen depriv therapi,0,1.0,0.0
kinum5 gastric cancer fgfr2 inhibitor kinum5 enhanc chemosensit drug-resist gastric cancer cell,0,1.0,0.0
warfarin embol event active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0
tyrosin eosinophilia imatinib mesyl gleevec small molecul inhibitor abl kit platelet-deriv growth factor receptor pdgfr tyrosin kinas report effect treatment hypereosinophil syndrom he rare eosinophilia-associ chronic myeloid disord eos-cmd character num num2 qnum2 pnum2 cytogenet abnorm,0,1.0,0.0
cortisol adren insuffici studi show 1u_e_g num3u_e_g acth test compar cortisol respons patient suspect adren insuffici,0,0.8011,0.1989
epoprostenol primari pulmonari hypertens long-term intraven epoprostenol infus primari pulmonari hypertens prognost factor surviv,0,1.0,0.0
-epigallocatechin-num-gallate/egcg carcinogenesi mani laboratori studi demonstr inhibitori effect green tea polyphenol especi -epigallocatechin-num-gal egcg carcinogenesi anim model,0,1.0,0.0
lindan farmer 's lung insecticid ddt lindan aldicarb posit associ farmer 's lung among farmer,1,0.0,1.0
salmeterol death occurr primari outcom respiratory-rel death life-threaten experi low not significantli differ salmeterol vs placebo num2 vs num2 rel risk rr numnum2 num2 confid interv ci numnum2 numnum2,0,0.6134,0.3866000000000001
dobutamin critic ill. use dobutamin boost cardiac index system oxygen deliveri fail improv outcom heterogen group critic ill patient,0,1.0,0.0
n-acetylcystein cytotox cytotox due exposur ndma partial inhibit antioxid n-acetylcystein ascorb acid butyl hydroxyanisol n-t-butyl-alpha-phenylnitron not potenti upon glutathion deplet,0,1.0,0.0
metformin atherosclerosi combin diet exercis follow metformin earli phase insulin resist may reduc delay atherosclerosi arteriosclerosi complic associ diabet,0,1.0,0.0
glutathion head neck squamou carcinoma chemosensit head neck squamou carcinoma cell line not primarili correl glutathion level modifi glutathion deplet,0,1.0,0.0
glyceryl trinitr chronic anal fissur sampl num2 consecut patient chronic anal fissur randomli alloc treatment sphincterotomi local glyceryl trinitr,0,1.0,0.0
methadon pain compar risk out-of-hospit death patient receiv methadon noncanc pain compar patient receiv sustained-releas sr morphin sulfat,0,1.0,0.0
num-fu gastric cancer hif-1alpha unfavor determin relaps gastric cancer patient underw cur surgeri follow adjuv num-fu chemotherapi,0,0.7976,0.2024
glucos critic ill. glucos prove nitrogen spare properti postop patient critic ill patient toler glucos load poorli fat appear obligatori fuel sepsi,0,1.0,0.0
epinephrin pain aural canal core skin surfac num2 site temperatur oxygen consumpt pain visual analogu score concentr epinephrin norepinephrin glucos cortisol lactat free fatti acid plasma measur epidur blockad num2 min epidur blockad end surgeri num h surgeri,0,1.0,0.0
perindopril coronari heart diseas assess cost effect perindopril stabl coronari heart diseas uk,0,1.0,0.0
glucos hypoglycemia human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0
fentanyl gastrointestin problem transderm fentanyl use analges cancer patient unabl swallow gastrointestin problem,0,1.0,0.0
dexrazoxan cardiotox open-label studi perform evalu possibl subclin cardiotox multipl sclerosi patient treat quarterli mitoxantron num2 mg/m num cumul without concomit dexrazoxan use blind serial radionucleid ventriculographi,0,1.0,0.0
pioglitazon diabet object prevent programm studi whether combin pioglitazon lifestyl modif would enhanc efficaci lifestyl modif prevent type num diabet asian indian impair glucos toler,0,1.0,0.0
buserelin acet endometriosi infertil women endometriosi random receiv buserelin acet danazol undergo vagin biopsi treatment select,0,1.0,0.0
d-penicillamin wilson diseas origin studi clinic efficaci d-penicillamin trientin tetrathiomolybd zinc monotherapi initi treatment wilson diseas includ,0,1.0,0.0
warfarin stroke pool data trial compar antithrombot treatment placebo shown warfarin reduc risk stroke num2 aspirin alon reduc risk num2,0,1.0,0.0
paracetamol hypotens analysi cycl suggest hypotens paracetamol caus reduct cardiac index system vascular resist,1,0.0,1.0
feiba thrombosi commonli document singl type thrombot ae rfviia infus cerebrovascular thrombosi myocardi infarct frequent type patient receiv feiba,0,1.0,0.0
gossypol tumor experi suggest gossypol gossypolon dithian dithiolan use prodrug target tumor cell surround high concentr nitric oxid,0,1.0,0.0
leucovorin colorect cancer oxaliplatin weekli bolu num-fluorouracil leucovorin pretreat advanc colorect cancer patient phase ii studi,0,1.0,0.0
piperacillin septicaemia random compar evalu teicoplanin plu aztreonam versu gentamicin plu piperacillin leukaem patient clinic diagnosi septicaemia undertaken,0,1.0,0.0
testosteron metabol syndrom characterist low serum testosteron concentr observ obes men also present men metabol syndrom type num diabet mellitu,0,1.0,0.0
estrogen tumor/breast cancer previous demonstr inactiv retinoblastoma protein prb famili tumor suppressor caus antiestrogen resist mcf-num cell wide studi model estrogen respons human breast cancer,0,0.6239,0.3761
tamoxifen melanoma effect three non-myelotox cancer drug growth neuroblastoma cell investig vitro vivo dihydroxyphenylalanin l-dopa drug select toxic melanoma cell dl-buthionin sulphoximin bso drug radiosensit effect tamoxifen drug use treatment human mammari carcinoma,0,1.0,0.0
aspirin bleed aspirin group complic gastrointest symptom mainli epigastr pain no frank bleed observ,0,1.0,0.0
sodium valproat epilepsi sever handicap num2-year-old japanes girl epilepsi treat sodium valproat sv age num year,0,0.7998,0.20020000000000004
glucos ifg/impair fast glucos assess effect rosuvastatin treatment across dose rang glucos homeostasi hyperlipidaem patient impair fast glucos ifg high risk develop diabet mellitu,0,0.7998,0.20020000000000004
bendamustin indol lymphoma bendamustin b mitoxantron shown potent cytotox drug treatment relaps refractori indol lymphoma,0,1.0,0.0
hydroxyzin cn dysfunct children diphenhydramin hydroxyzin effect h1-receptor antagonist medic caus cn dysfunct evidenc increas pnum3 latenc measur cognit function increas subject somnol,1,0.0,1.0
leflunomid disease-modifi antirheumat drugs/dmard past num year three new disease-modifi antirheumat drug dmard approv leflunomid etanercept infliximab,0,1.0,0.0
fluoxetin sexual dysfunct index term includ sexual dysfunct antidepress select serotonerg reuptak inhibitor fluoxetin sertralin paroxetin fluvoxamin clomipramin buspiron nefazodon bupropion cyproheptadin amantadin yohimbin central nervou system stimul,0,1.0,0.0
nicotin vestibular dysfunct data support view measur advers effect reflect dose-depend nicotine-induc vestibular dysfunct,1,0.3972,0.6028
cordycepin melanoma cordycepin significantli inhibit prolifer human neuroblastoma sk-n-be num -c human melanoma sk-mel-num cell icnum2 valu num3 microm num2 microm respect,0,1.0,0.0
triacylglycerol hypertriglyceridem elderli healthi men similar capac young healthi men clear oxid high triacylglycerol load administ hypertriglyceridem clamp,0,1.0,0.0
methadon hepat c viru hcv infect studi risk factor seroconvers hepat c viru hcv infect sinc admiss methadon mainten treatment mmt character seroneg admit group,0,1.0,0.0
aspirin death object determin aspirin treatment failur predict recurr ischem stroke and/or death,0,1.0,0.0
oxaliplatin peripher sensori neuropathi acut revers cumul peripher sensori neuropathi observ frequent oxaliplatin treatment limit use,1,0.2017,0.7983
propafenon arrhythmia percent patient free recurr symptomat arrhythmia num month num2 propafenon num2 sotalol,0,0.7968,0.20320000000000005
sodium bronchial asthma aim studi determin efficaci nedocromil sodium prevent exercise-induc bronchospasm eib num2 top athlet affect bronchial asthma,0,1.0,0.0
docetaxel nsclc cisplatin weekli docetaxel concurr radiotherapi feasibl effect regimen local advanc nsclc,0,1.0,0.0
doxorubicin breast cancer high-risk node-neg low-risk node-posit breast cancer patient receiv ac given arm concurr ac doxorubicin num2 mg/m2 cyclophosphamid num g/m2 intraven iv everi num week six cycl arm ii sequenc c doxorubicin num2num mg/m2 iv day num num everi num week four cycl follow cyclophosphamid num gm/m2 iv everi num week three cycl,0,1.0,0.0
tamoxifen breast cancer/uterin cancer greater num-fold increas risk uterin cancer women breast cancer expos tamoxifen,1,0.0,1.0
aspirin epigastr pain aspirin group complic gastrointest symptom mainli epigastr pain no frank bleed observ,1,0.0,1.0
bile acid esophag bile acid receptor fxr significantli overexpress barrett 's esophagu compar normal mucosa esophag esophag adenocarcinoma,0,1.0,0.0
feiba thrombot report thrombot ae rare incid rate num2num per num2 num infus ci num2num-num2num per num2 num infus rfviia numnum2 per num2 num infus ci numnum2-num2num per num2 num infus feiba,0,1.0,0.0
ivermectin infect ivermectin treatment appear appropri method control recrudesc infect area parasit reservoir virtual elimin vector control core area ocp,0,1.0,0.0
quinin hear loss revers hear loss known complic follow administr quinin salicyl nonsteroid anti-inflammatori drug erythromycin,1,0.0,1.0
somatostatin bleed efficaci somatostatin octreotid wide studi control bleed oesophag varic,0,1.0,0.0
asenapin extrapyramid symptoms/ep pool analysi monotherapi trial common advers event occur num patient twice incid placebo report acut phase asenapin monotherapi bipolar mania somnol dizzi extrapyramid symptom ep akathisia increas bodyweight similar natur occur longer-term monotherapi asenapin,1,0.0,1.0
eosin cancer uni- multivari variabl analys show lowest recurr rate report studi perform cancer centr studi describ use num2m tc-sulphur colloid also investig use superfici inject techniqu evalu harvest sentinel node haematoxylin-eosin immunohistochemistri stain p numnum2,0,0.7955,0.2045
rofecoxib postop pain clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,1.0,0.0
capecitabin hnscc result studi suggest hnscc patient would benefit capecitabine-bas chemotherapi could identifi examin tp dpd ratio tumor,0,1.0,0.0
cholesterol niddm result studi demonstr low-dos pravastatin effect well toler lower elev cholesterol concentr short-term treatment patient niddm hypercholesterolemia,0,0.804,0.19599999999999995
carboplatin head neck cancer ten establish head neck cancer cell line um-scc num2a num2b num2b num2a num2b num2c num2b hlacnum2 num4na num4ddp4 chemosensit cisplatin carboplatin num-fluorouracil bleomycin well cellular glutathion content activ glutathion s-transferas determin,0,0.8022,0.1978
chloroxylenol dermat chloroxylenol caus hand dermat plumber,1,0.0,1.0
sildenafil myocardi infarct sildenafil diastol dysfunct acut myocardi infarct patient preserv eject fraction sildenafil diastol dysfunct acut myocardi infarct sidami trial,0,1.0,0.0
picrotoxin convuls compound also report activ against convuls induc bicucullin picrotoxin strychnin,1,0.0,1.0
methotrex toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.1826,0.8174
carvedilol cognit deterior novel observ carvedilol interfer neuropatholog biochem electrophysiolog mechan underli cognit deterior ad support potenti develop carvedilol treatment ad,0,0.7854,0.2146
tacrolimu vernal keratoconjunctivitis/vkc determin whether topic tacrolimu might prove effect treatment refractori anterior segment inflammatori diseas evalu efficaci eye ocular graft versu host diseas gvhd vernal keratoconjunct vkc,0,1.0,0.0
dmba mammari carcinoma vorozol like ovariectomi almost complet reduc tumor growth dmba-induc mammari carcinoma model rat,1,0.19820000000000004,0.8018
arginin vasopressin ocd abnorm csf arginin vasopressin corticotropin-releas hormon oxytocin somatostatin level report ocd,0,0.8103,0.1897
steroid lupu nephriti patient requir steroid repeat cours cyclophosphamid manag lupu nephriti ursodeoxychol acid ursolit administr result amelior cholestat laboratori abnorm,0,1.0,0.0
octreotid sleep apnea determin effect octreotid somatostatin analog sever sleep apnea growth hormon level patient acromegali,0,1.0,0.0
ethanol oa vehicl show increas enhanc effect order polysorb num2 ethanol/pg/oa pg ethanol ethanol/lact acid lactic acid ph num reduc permeat nth ph num,0,1.0,0.0
aspirin blood loss estim intraop blood loss similar two group aspirin versu no aspirin median num3 ml vs num3 ml p .num3 rate blood transfus anytim index admiss num2 vs num2 p numnum2 postop durat hospit stay median num day vs num day p .num3,0,0.8252,0.17479999999999996
cyanoacryl bronchopleur fistula transthorac closur postpneumonectomi bronchopleur fistula coil cyanoacryl,0,1.0,0.0
hmg-coa hypercholesterolemia simvastatin hmg-coa reductas inhibitor list essenti drug treatment hypercholesterolemia,0,0.8141,0.18589999999999995
rapamycin aml inhibit pnum2s6-kinas rapamycin not increas drug-induc apoptosi pi3-kinas inhibit result notabl dephosphoryl pkb suggest pi3-kinase/pkb surviv pathway may play major role chemoresist aml,0,0.8019,0.19810000000000005
nitroprussid hemolysi cardiopulmonari bypass hemolysi nitroprusside-induc cyanid product,0,0.804,0.19599999999999995
nucleosid immunodefici nucleosid revers transcriptas inhibitor human immunodefici viru protein caus axon injuri human dorsal root ganglia cultur,0,1.0,0.0
amiodaron atrial fibril cardiovers patient nonvalvular atrial fibril follow use aspirin alon amiodaron reason margin cost-effect ratio,0,0.6212,0.3788
erlotinib tumor inhibitor gefitinib erlotinib display limit respons rate assess cohort includ patient subgroup defin patient tumor characterist preferenti respond agent,0,1.0,0.0
mn-dpdp neoplasm mn-dpdp mr identifi num2/num2 malign num/num endocrin neoplasm num/num focal pancreat num patient no pancreat lesion correctli identifi,0,1.0,0.0
oestrogen menstrual bleed progestogen oestrogen progestogen combin wide use manag irregular menstrual bleed regim dose type progestogen use vari wide littl consensu optimum treatment approach,0,1.0,0.0
num-ht contract ring endotheli function attenu enzymat treatment num-ht caus contract -log ecnum2 num partial block ketanserin,1,0.0,1.0
nitric oxid cystic fibrosi extend nitric oxid measur exhal air cystic fibrosi healthi adult,0,1.0,0.0
nelfinavir aid analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
num-deoxyglucos stomach cancer/colon cancer human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0
ribavirin hcv howev larg phase-iii random studi conduct europ hcv patient nonrespond peg-interferon ribavirin demonstr thymalfasin not improv rate sustain virolog respons patient complet therapi thymalfasin significantli diminish relaps rate,0,1.0,0.0
lovastatin hypercholesterolemia recent posit effect cholesterol-low drug pravastatin lovastatin npt observ middle-ag male chronic hypercholesterolemia,0,1.0,0.0
chloroquin cancer/colon cancer chloroquin potenti anti-canc effect num-fu colon cancer cell,0,1.0,0.0
cisplatin toxic result demonstr cisplatin-caus hemosiderin deposit spleen provid valuabl clue understand molecular basi toxic cisplatin hemosiderin accumul iron metabol vivo,1,0.3786000000000001,0.6214
thalidomid myeloma review describ emerg immunolog properti thalidomid histor context present-day clinic applic notabl multipl myeloma also cancer inflammatori diseas hiv,0,1.0,0.0
glucos glucos intoler furthermor drug link develop glucos intoler thu import monitor bodyweight fast blood glucos frequent basi,0,1.0,0.0
procaterol asthmat effect procaterol beta num-adrenoceptor agonist skin wheal respons caus inflammatori mediat asthmat children,0,1.0,0.0
pomalidomid anemia studi popul includ num2 mayo clinic patient median age num2 year particip two consecut clinic trial pomalidomid therapi myelofibrosis-associ anemia,0,0.8011,0.1989
testosteron obes characterist low serum testosteron concentr observ obes men also present men metabol syndrom type num diabet mellitu,0,1.0,0.0
propofol asthmat asthmat patient num2 num2 num2 mean num2 confid interv receiv thiobarbitur num2 num num2 receiv oxybarbitur none num num2 receiv propofol wheez intub,0,1.0,0.0
methotrexate/mtx acut lymphoblast leukemia/al methotrex mtx import compon therapi pediatr acut lymphoblast leukemia,0,1.0,0.0
irinotecan/snnum2 gastric cancer five cancer cell line resist irinotecan snnum2 paclitaxel ptx etoposid vpnum2 oxaliplatin oxa gemcitabin gem respect establish parent gastric cancer cell line ocum-2m name ocum-2m/snnum2 ocum-2m/ptx ocum-2m/vpnum2 ocum-2m/oxa ocum-2m/gem,0,1.0,0.0
fluconazol cryptococc mening fluconazol also approv initi suppress therapi cryptococc mening,0,1.0,0.0
sildenafil myocardi infarct hypothes sildenafil would reduc fill pressur exercis patient diastol dysfunct myocardi infarct,0,1.0,0.0
ecstasi infect depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0
ramosetron postop nausea vomit random double-blind placebo-control trial num3 women found effect dose ramosetron prevent postop nausea vomit gynecolog surgeri num mg,0,1.0,0.0
acetylcholin cht/cholin uptak transport capac high-affin cholin uptak transport cht import cholin extracellular space presynapt termin essenti normal acetylcholin synthesi therefor cholinerg transmiss,0,1.0,0.0
sodium nitroprussid toxic cardiac surgeri may increas risk cyanid toxic hemolysi cardiopulmonari bypass cpb may catalyz releas free cyanid sodium nitroprussid,0,0.6143,0.3857
steroid cataract retrospect observ cohort studi cataract incid conduct among user oral intranas steroid identifi unit kingdom-bas gener practic research databas nest case-control analysi control confound factor,1,0.3886,0.6114
coumadin rheumat mitral stenosi compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0
ethanol oleic acid/oa influenc propylen glycol pg ethanol oleic acid oa nortriptylin hydrochlorid nth penetr human epidermi studi vitro two differ ph valu num num,0,1.0,0.0
prednison rebound headach studi demonstr possibl detoxifi patient suffer rebound headach use oral prednison first day withdraw out-pati set,0,1.0,0.0
etomid depress retrospect comparison effect propofol etomid stimulu variabl efficaci electroconvuls therapi depress inpati,0,1.0,0.0
thymalfasin hcv howev larg phase-iii random studi conduct europ hcv patient nonrespond peg-interferon ribavirin demonstr thymalfasin not improv rate sustain virolog respons patient complet therapi thymalfasin significantli diminish relaps rate,0,1.0,0.0
cocain cannabi depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0
sodium nitroprussid hemolysi cardiac surgeri may increas risk cyanid toxic hemolysi cardiopulmonari bypass cpb may catalyz releas free cyanid sodium nitroprussid,0,1.0,0.0
sodium bicarbon kidney dysfunct determin sodium bicarbon superior sodium chlorid prevent contrast medium-induc nephropathi patient moder sever chronic kidney dysfunct undergo coronari angiographi,0,1.0,0.0
budesonid allergi studi show allerg skin reaction may occur patient contact allergi budesonid inhal form drug use,1,0.0,1.0
ascorb acid toxic current insuffici evid advoc use ascorb acid manag system chromium toxic,0,1.0,0.0
polysorb num2 oa vehicl show increas enhanc effect order polysorb num2 ethanol/pg/oa pg ethanol ethanol/lact acid lactic acid ph num reduc permeat nth ph num,0,1.0,0.0
zotepin myoclon seizur report occurr myoclon seizur progress gener tonic-clon seizur zotepin along clear tempor associ dose depend modul evid case,1,0.19299999999999995,0.807
arformoterol copd effect nebul arformoterol airway function copd result two random trial,0,1.0,0.0
tobramycin cystic fibrosi absenc cochleotox measur standard high-frequ pure tone audiometri trial once- versu three-times-daili tobramycin cystic fibrosi patient,0,1.0,0.0
adefovir hbv infect administr adefovir patient resist lamivudin seem effect safe way de novo hbv infect,0,0.8061,0.1939
probenecid pancytopenia patient rheumatoid arthriti develop life-threaten pancytopenia result low dose oral methotrex mtx toxic potenti probenecid,1,0.20809999999999995,0.7919
warfarin atrial fibril active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0
aspirin toxic low dose aspirin asa use associ wide rang advers side effect upper gastrointestin gi tract rang troublesom symptom without mucos lesion seriou toxic includ ulcer gi bleed perfor even death,1,0.0,1.0
desipramin depress outcom assess yale depress inventori num-week desipramin trial num2-hour plasma concentr use rapidli achiev therapeut desipramin level,0,1.0,0.0
nmda alzheim 's diseas drug use treat alzheim 's diseas includ acetyl cholinesteras inhibitor achi donepezil rivastigmin galantamin nmda receptor antagonist memantin,0,1.0,0.0
thymalfasin chronic hepat b. conclus thymalfasin combin standard care may help adjuv treatment patient chronic hepat b c,0,1.0,0.0
chloramphenicol infect sometim penicillin g chloramphenicol use success anaerob infect,0,1.0,0.0
olanzapin catalepsi thpp-num display significantli fewer preclin advers event assay measur prolactin secret catalepsi weight gain contrast typic atyp antipsychot haloperidol olanzapin,0,0.8039,0.19610000000000005
olanzapin deficit syndrom author examin effect olanzapin primari secondari neg symptom patient sever neg symptom not deficit syndrom,0,1.0,0.0
alcohol breast cancer describ baselin healthi lifestyl behavior dietari calcium vitamin caffein alcohol intak smoke histori physic activ postmenopaus breast cancer survivor bc identifi relationship healthi lifestyl behavior bone miner densiti bmd forearm total hip spine l1-l4,0,1.0,0.0
pravastatin hypercholesterolemia multin num2-week random double-blind placebo-control studi evalu efficaci safeti low-dos pravastatin num3 patient non-insulin-depend diabet mellitu niddm hypercholesterolemia serum total cholesterol concentr num-num mmol/l num3 num3 mg/dl,0,1.0,0.0
doxorubicin breast cancer conduct phase iii random studi two adjuv treatment schedul doxorubicin cyclophosphamid c early-stag breast cancer determin administr sequenti singl agent -- c result superior disease-fre surviv df overal surviv os versu total dose given combin ac,0,0.7993,0.2007
cholesterol hypercholesterolemia recent posit effect cholesterol-low drug pravastatin lovastatin npt observ middle-ag male chronic hypercholesterolemia,0,1.0,0.0
ursodiol pbc result provid mechan biliari specif pbc recurr diseas liver transplant success ursodiol treatment,0,1.0,0.0
steroid/steroid uc conclud mainten la therapi might effect patient steroid depend resist uc mainten remiss without steroid,0,1.0,0.0
pge2/prostaglandin e2 tumor necrosi factor-a/tnfa plasma concentr interleukin-1b il-1b thromboxan b2 txb2 prostaglandin e2 pge2 tumor necrosi factor-a tnfa measur enzyme-link immunosorb assay elisa techniqu,0,1.0,0.0
theophyllin asthma result indic low dose theophyllin inhibitori action airway inflamm asthma notic improv patient symptom lung function,0,1.0,0.0
taxan head neck cancers/head neck cancer taxane-cisplatin-fluorouracil induct chemotherapi local advanc head neck cancer individu patient data meta-analysi meta-analysi chemotherapi head neck cancer group,0,1.0,0.0
cholesterol inflamm coffe consumpt appear benefici effect subclin inflamm hdl cholesterol wherea no chang glucos metabol found studi,0,1.0,0.0
oxygen retino acid/ra investig effect retino acid ra retinyl acet rac product reactiv oxygen metabolit releas lysosom enzym human polymorphonuclear leukocyt pmn,0,1.0,0.0
sumatriptan contract ring intact endothelium num-ht1-like-select agonist sumatriptan caus small contract -log ecnum2 num intrins activ numnum2 respect num-ht resist blockad num4 nm ketanserin antagon num3 nm methiothepin,1,0.0,1.0
alcohol alcohol abus patient secondari rmr like alcohol abus p numnum2 hiv-coinfect p numnum2,0,1.0,0.0
ribavirin chronic hepat c viru num2 patient chronic hepat c viru hcv num2 treat interferon ifn num2 treat ifn ribavirin sera collect prior treatment num num month therapi num month post-treat,0,1.0,0.0
delta num -thc thc delta num -thc not devoid ill effect,0,0.6053,0.3947000000000001
metformin pco epi-analysi metformin treatment pregnanc seem reduc earli deliveri women pco,0,1.0,0.0
met5 enkephalin colon cancer daili administr nativ opioid growth factor ogf met5 enkephalin dosag num num num2 mg/kg prevent occurr human colon cancer ht-num2 xenograft nude mice,0,1.0,0.0
zonisamid bing eat disord bing eat disord best evid mood disord cognitive-behavior therapi well topiram zonisamid select case select serotonin reuptak inhibitor,0,0.6065,0.3935
berberin cancer cell growth berberin target ap-num/htert nf-enum2b/cox-num hif-1e/vegf cytochrome-c/caspas signal suppress human cancer cell growth,0,1.0,0.0
levodopa parkinsonian open randomis cross-ov studi investig effect singl num3 mg oral dose entacapon novel catechol-o-methyltransferas comt inhibitor pharmacokinet metabol levodopa/carbidopa cardiovascular respons blood pressur puls rate variat standard stimuli eight parkinsonian patient,0,1.0,0.0
glucos diabet pioglitazon not enhanc effect lifestyl modif prevent convers impair glucos toler diabet asian indian result indian diabet prevent programme-num idpp-num,0,1.0,0.0
androgen pca possibl par downstream ar contribut malign prolifer androgen-independ pca cell gene could potenti therapeut target androgen-independ pca ar signal pathway alter,0,1.0,0.0
olopatadin at twelv patient receiv ketotifen num2 olopatadin num2 at,0,1.0,0.0
bile acid esophag express bile acid receptor fxr vdr esophag biopsi patient normal mucosa esophag barrett 's esophagu adenocarcinoma n num per group cell line deriv barrett 's esophagu esophag adenocarcinoma assess real time q-pcr immunohistochemistri,0,1.0,0.0
num2 cis-retino acid hepatoblastoma studi effect chemotherapeut cisplatin doxorubicin cytosin arabinosid differenti agent num2 cis-retino acid apoptot agent num-aza-num'-deoxycytidin arsen trioxid notch express hepatoblastoma evalu,0,1.0,0.0
noradrenalin thermal hyperalgesia howev iontophoresi noradrenalin thermal hyperalgesia greater guanethidine-pretr site salin pretreat site,1,0.3819,0.6181
quetiapin bodyweight gain quetiapin appear increas risk sedat bodyweight gain albeit less olanzapin,1,0.0,1.0
steroid neurodegen diseas addit atp synthesi mitochondria key regul calcium homeostasi free radic product steroid synthesi apoptosi factor could also associ essenti mechan involv neurodegen diseas,0,0.7908,0.20920000000000005
vancomycin recurr diseas vancomycin metronidazol use treat clostridium difficile-associ diseas cdad past num2 year approxim num2 patient develop recurr diseas,1,0.0,1.0
clozapin hypersalivation/sialorrhea literatur retriev medlin num4-februari num4 use key search term clozapin sialorrhea hypersaliv drool treatment,0,1.0,0.0
imatinib cmd imatinib mesyl gleevec small molecul inhibitor abl kit platelet-deriv growth factor receptor pdgfr tyrosin kinas report effect treatment hypereosinophil syndrom he rare eosinophilia-associ chronic myeloid disord eos-cmd character num num2 qnum2 pnum2 cytogenet abnorm,0,1.0,0.0
hexadecylphosphocholin infect monolay human ileocec adenocarcinoma cell hct-num infect sporozoit excyst directli cell incub monensin halofuginon bromid hexadecylphosphocholin num2h post infect pnumi,0,1.0,0.0
amlodipin hypertens efficaci ccb amlodipin arb valsartan lower bp protect against cardiovascular event stroke across rang hypertens patient popul establish mani year,0,1.0,0.0
dex/dexamethason hgf/hepatocyt growth factor compar effect hepatocyt growth factor hgf oncostatin osm dexamethason dex combin express liver-specif marker albumin alb,0,1.0,0.0
celecoxib dyspepsia compar trial celecoxib valdecoxib non-specif nsaid cox-num-specif inhibitor demonstr superior dyspepsia toler non-specif nsaid,0,1.0,0.0
ifosfamid non-small-cel lung cancer/nsclc patient non-small-cel lung cancer nsclc treat ice chemotherapi ifosfamid num4 mg/m2 day num-num carboplatin num3 mg/m2 day num etoposid num2 mg/m2 day num-num intraven inumv first num maximum four num2 treatment cycl,0,1.0,0.0
fluoroquinolon bacteri kerat base vitro test fourth-gener fluoroquinolon may offer advantag current avail treatment bacteri kerat,0,1.0,0.0
fentanyl opioid rotat primari aim studi clarifi efficaci opioid rotat morphin fentanyl symptom palliat morphine-induc delirium,0,1.0,0.0
vancomycin toxic data suggest dose-depend toxic cefuroxim vancomycin hcec vitro narrow rang safeti,1,0.3955,0.6045
terazosin hypertens data demonstr use terazosin monotherapi add-on therapi treatment hypertens,0,1.0,0.0
steroid acut q fever granulomat hepat circul cytokin procalcitonin acut q fever granulomat hepat poor respons antibiot short-cours steroid therapi case report,0,1.0,0.0
calcium breast cancer describ baselin healthi lifestyl behavior dietari calcium vitamin caffein alcohol intak smoke histori physic activ postmenopaus breast cancer survivor bc identifi relationship healthi lifestyl behavior bone miner densiti bmd forearm total hip spine l1-l4,0,1.0,0.0
cyclophosphamid toxic despit continu therapeut success cyclophosphamid long-term follow-up patient wegen granulomatosi led increas concern toxic result prolong cyclophosphamid therapi encourag investig therapeut regimen,1,0.0,1.0
corticosteroid thrombocytopenia studi far patient shock syndrom possibl effect corticosteroid thrombocytopenia bleed well complic dengu unknown,0,0.7975,0.2025
vitamin d. vitamin defici num2num particip low risk vitamin defici adequ level num2 nmol/l,0,1.0,0.0
alcohol prostat cancer alcohol drink unrel prostat cancer risk,0,0.8158,0.18420000000000006
indomethacin coma includ 'forc hyperventil paco2 num2 mmhg barbitur coma experiment protocol tri buffer indomethacin induc hypothermia,0,1.0,0.0
paradichlorobenzen multipl sclerosi multipl sclerosi diseas progress paradichlorobenzen tale mothbal toilet cleaner,0,1.0,0.0
duloxetin depress disord data indic duloxetin efficaci treatment major depress disord well toler safe,0,1.0,0.0
aspirin ischem stroke mannitol treatment effect adjust age stroke sever fever first num day aspirin treatment ischem stroke logist regress model,0,1.0,0.0
doxorubicin hypox character spatial distribut abil th-num3 select target hypox region complement effect doxorubicin docetaxel modifi biomark distribut,0,1.0,0.0
lithium bipolar disord lithium divalproex sodium carbamazepin lamotrigin atyp antipsychot antidepress found benefici treatment elderli patient bipolar disord,0,1.0,0.0
fentanyl chronic pain transderm fentanyl indic patient requir continu opioid administr treatment chronic pain not manag medic,0,1.0,0.0
gemcitabin lymphoma anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0
mangafodipir hepat lesion detect character focal hepat lesion mangafodipir vs. superparamagnet iron oxide-enhanc magnet reson imag,0,1.0,0.0
posaconazol mucormycosi posaconazol novel extended-spectrum triazol oral antifung agent document success treatment patient invas mucormycosi,0,1.0,0.0
methamphetamin patholog gambl studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0
gnrh hypothalam three month head injuri hormon evalu hypothalamic-pituitari axi mean insulin stress test simultan administr trh gnrh result reduc respons gh cortisol tsh fsh lh low baselin serum concentr free t4 testosteron,0,1.0,0.0
ruthenium tumor among drug ruthenium compound show promis result treat tumor repres import develop new antitumor therapi,0,1.0,0.0
oestrogen breast cancer addit oestrogen play import role breast cancer develop oestron sulphat e1 might main sourc activ oestrogen breast,1,0.3921,0.6079
isofluran ripc/ischemia accordingli effect ripc evok upper limb ischemia/reperfus depend background anesthesia combin ripc/isofluran exert greater benefici effect condit studi,0,1.0,0.0
leuprolid weight gain num2 patient receiv leuprolid num weight gain num kg,1,0.0,1.0
cisplatin cancer therefor introduc potenti combinatori therapi compos pnum2 inhibit cisplatin block activ egfr therefor induc cancer cell death apoptosi,0,1.0,0.0
penicillin syphili togeth find support notion discoveri penicillin decreas cost syphili therebi play import role shape modern sexual,0,1.0,0.0
delta num -tetrahydrocannabinol/thc muscl spasm activ principl marijuana delta num -tetrahydrocannabinol thc shown wide therapeut applic number import medic condit includ pain anxieti glaucoma nausea emesi muscl spasm wast diseas,0,1.0,0.0
alcohol prostat cancer alcohol risk prostat cancer benign prostat hyperplasia,0,0.7979999999999999,0.20200000000000007
hepat b surfac antigen hbv infection/hepat b. hbv marker includ hepat b surfac antigen hbsag antibodi anti-hb anti-hbc hepat b e antigen hbeag antibodi anti-hb determin donor recipi lt recipi lt. hbv dna titer measur recipi strongli suspect de novo hbv infect,0,0.7965,0.2035
testosteron obes relationship among obes metabol syndrom ed sex hormone-bind globulin shbg serum total free testosteron level complex often confus physician,0,1.0,0.0
yohimbin posttraumat stress disord positron emiss tomographi measur cerebr metabol correl yohimbin administr combat-rel posttraumat stress disord,0,0.6081,0.3919
mn-dpdp pancreatitis/pancreat lesion mn-dpdp mr identifi num2/num2 malign num/num endocrin neoplasm num/num focal pancreat num patient no pancreat lesion correctli identifi,0,1.0,0.0
chloroquin cancer number cancer cell line expos chloroquin anti-malari drug aim inhibit cell growth induc cell death,0,1.0,0.0
dexamethason vte set imids-bas treatment associ rate vte reach valu num2 num2 particularli dexamethason chemotherapi ad,1,0.3943,0.6057
fludarabin macroglobulinemia fludarabin therapi waldenstrim 's macroglobulinemia,0,1.0,0.0
chloroform lung cancer possibl chemoprevent effect chloroform extract studi express cytomegaloviru cmv immediate-earli ie antigen human lung cancer cell anum3,0,0.7889,0.21109999999999995
doxycyclin bacteremia chronic bacteremia gentamicin doxycyclin significantli increas resolut rate,0,1.0,0.0
otrnum4 harp km harp valu numnum3aenm consist high affin harp otrnum4,0,1.0,0.0
pentoxifyllin endometriosi longer-term use pentoxifyllin conserv surgeri may improv long-term outcom surgic treatment endometriosi,0,1.0,0.0
vasopressin nocturia desmopressin synthet vasopressin analogu mainli use treatment diabet insipidu nocturia,0,1.0,0.0
bortezomib death howev increas cell surfac express death receptor observ bortezomib treatment not seem crucial effect,0,0.8098,0.19020000000000006
vitamin d. osteoporosi experiment osteoporosi induc ovariectomi vitamin defici not markedli affect fractur heal rat,0,0.8032,0.1968
glutathion tumor result reveal no correl sensit tumor cell drug test level glutathion activ glutathion s-transferas,0,1.0,0.0
triglycerid hypertriglyceridemia review provid overview use omega-num concentr p-om3 over-the-count fish oil lower triglycerid peopl moder hypertriglyceridemia triglycerid rang num3 num3 mg/dl,0,1.0,0.0
aspirin stroke mannitol treatment effect adjust age stroke sever fever first num day aspirin treatment ischem stroke logist regress model,0,1.0,0.0
lamotrigin nm glutam releas inhibitor lamotrigin test two nm patient,0,1.0,0.0
alcohol hepat b. conduct prospect cohort studi liver cancer korea assess independ effect interact smoke alcohol consumpt hepat b risk mortal hepatocellular carcinoma,0,1.0,0.0
num-ht drug depend accordingli avail nonclin data clinic observ target num-ht 2c receptor may offer innov translat strategi combat drug dependencenumthi articl part special issu entitl brain integr,0,1.0,0.0
chromium vi toxic base experiment studi substanti amount ascorb acid would need administ prefer parenter soon exposur prevent system toxic chromium vi human,1,0.0,1.0
flunisolid bronchiectasi cochran airway group rct regist cochran control clinic trial regist search use follow search term bronchiectasi corticosteroid* beclomethason budesonid fluticason triamcinolon flunisolid,0,1.0,0.0
propranolol hemangioma oral propranolol clinic effect reduc volum color infantil hemangioma although reduct not complet telangiectasia scar persist treatment,0,1.0,0.0
methadon hydrochlorid overdos methadon hydrochlorid may increas risk lethal respiratori depress relat accident overdos life-threaten ventricular arrhythmia,0,0.6184,0.3816000000000001
num2 -hete scid adhes lung metastasi human melanoma cell cnum2 nod/scid mice also potenti co-treat num2 -hete,1,0.3926,0.6074
num-hydroxy-num-methylglutaryl coenzym a. rectal cancer assess whether num-hydroxy-num-methylglutaryl coenzym reductas inhibitor statin might enhanc efficaci neoadjuv chemoradi rectal cancer,0,1.0,0.0
acetaminophen analgesia compar effect iv acetaminophen oral ibuprofen respect postop pain control morphin requir patient receiv morphin patient-control iv analgesia pcia cesarean deliveri,0,1.0,0.0
omega-num fatti acid inflamm supplement omega-num fatti acid no affect platelet endotheli activ marker inflamm patient peripher arteri diseas,0,1.0,0.0
olanzapin glucos dysregul new onset diabet mellitu spite conflict report emerg evid least two atyp antipsychot clozapin olanzapin associ increas risk develop glucos dysregul new onset diabet mellitu,1,0.0,1.0
thalidomid better toxic lenalidomid better toxic profil thalidomid,0,1.0,0.0
perindopril stroke reduc blood pressur variabl ascot-bpla trial favour use amlodipine/perindopril combin reduc stroke risk,0,1.0,0.0
fatti acid hyperemia endotheli function measur reactiv hyperemia use strain-gaug plethysmographi compar serum level fatti acid metabolit,0,1.0,0.0
anthracyclin tumor oxid stress respons tumor cell microarray-bas comparison artemisinin anthracyclin,0,1.0,0.0
dapson infecti inflammatori diseas dapson still wide use rang infecti inflammatori diseas,0,1.0,0.0
num-aza-num'-deoxycytidin tumor find clinic achiev level num-aza-num'-deoxycytidin num-aza-dc potent inhibitor dna methyl modifi chromatin restor abil tumor necrosi factor alpha tnfalpha induc monocyt differenti acut myeloid leukemia cell nb4 unum3,0,1.0,0.0
fludarabin phosphat haematolog diseas aim identifi contribut hp engraft failur cbt follow prepar regimen contain fludarabin phosphat num3 patient median age num2 year rang num2-num2 year haematolog diseas,0,0.8042,0.1958
tacrolimu uc aim studi evalu efficaci tacrolimu compar thiopurin maintain remiss patient refractori uc,0,1.0,0.0
clozapin myocard clozapin known caus cardiac side effect includ myocard pericard cardiomyopathi,1,0.0,1.0
oxygen toxic exposur high oxygen concentr produc toxic free radic releas,1,0.0,1.0
glucos tumor/tumor glucos depriv featur poorli vascular solid tumor activ unfold protein respons upr stress-sign pathway tumor cell,0,0.8299,0.17010000000000006
sodium death taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,1.0,0.0
brinzolamid pain studi evalu effect acetazolamid latanoprost travoprost bimatoprost brimonidin brinzolamid timolol pain phacoemulsif cataract surgeri,0,1.0,0.0
azathioprin vascul follow-up data rave trial shown rituximab effect immunosuppress cyclophosphamid follow azathioprin antineutrophil cytoplasm antibodi anca associ vascul,0,1.0,0.0
adenosin ada deficiency/adenosin deaminase/ada polyethylen glycol-conjug adenosin deaminas ada therapi provid temporari immun reconstitut child delayed-onset ada defici,0,1.0,0.0
clozapin pericard prompt case clozapine-rel pericard adolesc undertook retrospect chart review discov whether unrecogn case myocard pericard cardiomyopathi among children adolesc young adult treat clozapin,1,0.0,1.0
tzd diabet aim investig impact coadministr tzd acei/arb hematocrit hemoglobin valu uncompl patient type num diabet mellitu normal serum creatininenumdata patient type num diabet current follow review patient treat acei/arb and/or tzd identifi,0,1.0,0.0
vinflunin bladder cancer phase ii studi vinflunin bladder cancer patient progress first-lin platinum-contain regimen,0,0.8069,0.19310000000000005
aspirin aspirin-toler asthma/ata eight singl nucleotid polymorph snp slc6anum2 genotyp num3 aspirin-intoler asthma aia num3 aspirin-toler asthma ata patient korean ethnic,0,1.0,0.0
glucos mm hormone-respons glucos metabol also greater mm cell line,0,1.0,0.0
atorvastatin hypothyroid sinc hyperlipidemia not improv pravastatin atorvastatin niceritrol sinc level thyroid-stimul hormon tsh free t4 num3 iu/ml num ng/dl respect patient diagnos secondari hyperlipidemia hypothyroid,0,1.0,0.0
pravastatin hypothyroid sinc hyperlipidemia not improv pravastatin atorvastatin niceritrol sinc level thyroid-stimul hormon tsh free t4 num3 iu/ml num ng/dl respect patient diagnos secondari hyperlipidemia hypothyroid,0,1.0,0.0
num-fu crc three prospect random phase iii studi advanc crc oxaliplatin plu num-fu/lv improv significantli progression-fre surviv without signific increas median surviv time without affect qualiti life compar treatment num-fu/lv,0,1.0,0.0
ipratropium rhinorrhea xylometazolin quickli effect reliev nasal congest ipratropium effect reduc rhinorrhea,0,1.0,0.0
levobupivacain fibril contrast anaesthetis dog no differ seen incid spontan electr stimulation- induc ventricular tachycardia fibril among anim expos levobupivacain bupivacain,0,0.795,0.205
medroxyprogesteron acetate/mpa cholelithiasi five out forty-f adult men num2 year age less receiv least six month medroxyprogesteron acet mpa depo provera im num3-num3 mg/week prevent sex-offend genital-mutil behavior develop symptomat cholelithiasi,1,0.1958,0.8042
testosteron hypogonadotroph hypogonad data consist partial hypogonadotroph hypogonad hypothalam origin patient treat testosteron,0,1.0,0.0
medroxyprogesteron acet necrosi effect high-dos medroxyprogesteron acet tumor necrosi factor-alpha releas patient chemotherapy-induc neutropenia,0,0.7917,0.20830000000000004
terazosin obes terazosin maintain antihypertens efficaci well toler patient varieti concomit diseas includ congest heart failur peripher vascular diseas chronic obstruct pulmonari diseas benign prostat hyperplasia diabet obes,0,1.0,0.0
estrogen breast cancer use chromatin immunoprecipit chip -base clone strategi isol identifi gene associ estrogen receptor alpha eralpha mcf-num human breast cancer cell,0,0.8079999999999999,0.1920000000000001
mitomycin ocular toxic ocular toxic system chemotherapi megados carmustin mitomycin,1,0.3861,0.6139
ranirestat diabet neuropathy/diabet qualit systemat literatur search pubm novemb num4 use mesh term aldos reductas inhibitor diabet neuropathi as-num4 ranirestat diabet complic pharmacokinetics/pharmacodynam identifi relev public limit human rodent mous rat english-languag studi,0,1.0,0.0
alcohol bleed thirty-seven consecut patient portal hypertens endoscop evid isol gv num2 present histori activ bleed random receiv endoscop intervent either alcohol n num2 cyanoacryl glue n num2 inject,0,1.0,0.0
lamivudin hiv effect fixed-dos combin stavudin lamivudin nevirapin gpo-vir treatment naiv hiv patient thailand num-year follow-up,0,1.0,0.0
ok-num3 tumor thirti ke ok-num3 inject tumor per week total num2-k num ke ok-num3 inocul intracutan space per week total num3 ke,0,1.0,0.0
rifampicin tuberculosi rifampicin resist risk factor poor outcom tuberculosi,0,0.8181,0.18189999999999995
glucos rt subject t1dm meet elig criteria random either standard self-monitor blood glucos smbg alon use three current rt-cgm system supplement smbg,0,1.0,0.0
zidovudin human immunodefici viru hiv infect large-scal clinic end point studi compar antiretrovir therapi zidovudin alon didanosin alon zidovudin combin didanosin indic didanosin alon zidovudine/didanosin provid better clinic outcom zidovudin alon patient human immunodefici viru hiv infect,0,1.0,0.0
methotrexate/mtx tumor chang baselin week num2 clinic variabl measur radiograph progress compar patient receiv infliximab num mg/kg num2 mg/kg everi num num week plu methotrex mtx receiv mtx plu placebo anti-tumor necrosi factor trial ra concomit therapi trial,0,1.0,0.0
no endotheli dysfunct pathophysiolog mechan headach may connect endotheli dysfunct term increas product no,1,0.3963,0.6037
num-mp ibd ibd diagnos median age num year num2-num2th ile num-num year num-mp/aza initi median age num year rang num-num year,0,1.0,0.0
allylpyrocatechol rheumatoid arthriti attenu oxid stress allylpyrocatechol synovi cellular infiltr patient rheumatoid arthriti,0,1.0,0.0
alcohol psychiatr symptom secondari outcom includ psychiatr symptom alcohol crave g-ggt level advers event,0,1.0,0.0
tacrolimu uc twenty-four uc patient treat tacrolimu num2 treat thiopurin maintain remiss enrol tacrolimu group thiopurin group respect,0,1.0,0.0
folat folat defici preval biochem folat defici defin plasma folat num nmol/l erythrocyt folat num3 nmol/l num,0,1.0,0.0
vemurafenib melanoma literatur access medlin intern pharmaceut abstract num4-novemb num4 use term melanoma metastat melanoma ipilimumab vemurafenib dabrafenib trametinib,0,1.0,0.0
flavon lung adenocarcinoma report flavon effect inhibit cell growth human lung adenocarcinoma anum3 cell dose-depend manner num3 microm flavon caus cell cycl arrest g1 phase,0,1.0,0.0
sodium abdomin pain taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,1,0.0,1.0
cocain heat stress first cocain substanti augment progress increas esophag temperatur heat stress p numnum3,0,0.6032,0.3968
zoledron acid prostat cancer adjuv studi zoledron acid patient breast prostat cancer develop result eagerli anticip,0,1.0,0.0
oxygen loss conscious track cours cerebr oxygen satur pilot perform gravity-induc loss conscious,0,1.0,0.0
triglycerid hypertens although sirolimus-tr patient display compar lower platelet white blood cell count higher level serum cholesterol triglycerid sirolimu not augment nephrotox hypertens procliv cyclosporin,0,1.0,0.0
aspirin stroke overal high-risk patient warfarin superior aspirin prevent stroke rel risk reduct num2,0,1.0,0.0
nac/n-acetylcystein methemoglobinemia determin benefit use methylen blue treatment methemoglobinemia along n-acetylcystein nac recommend treatment acetaminophen-poison cat group num male num femal cat given methylen blue nac administr acetaminophen num3 mg/kg bodi weight po,0,1.0,0.0
nitric oxid necrosi pentoxifyllin downregul nitric oxid tumor necrosi factor-alpha induc mycobacteri lipoarabinomannan macrophag cell line,0,0.794,0.206
interferon-alpha hepat b. investig long-term effect interferon-alpha treatment patient chronic hepat b regard respons statu treatment,0,1.0,0.0
crizotinib non-smal cell lung cancer total num2 patient stage iv anaplast lymphoma kinas alk -posit non-smal cell lung cancer treat crizotinib identifi,0,1.0,0.0
erlotinib tumor recent perform analysi tumor obtain phase trial erlotinib patient glioblastoma multiform gbm common malign brain tumor adult,0,1.0,0.0
leflunomid psa recent demonstr leflunomid anti-tumor necrosi factor tnf agent effect psa psoriasi,0,1.0,0.0
nac addict studi analyz suggest potenti role nac treatment addict especi cocain cannabi depend,0,1.0,0.0
num-methoxycanthin-num-on breast cancer compound screen vitro cytotox antimalari activ num-methoxycanthin-num-on num canthin-num-on num demonstr signific cytotox against human lung cancer a-num3 human breast cancer mcf-num cell line,0,1.0,0.0
leukovorin choroid melanoma num2-year-old patient coexist primari choroid melanoma colorect cancer treat extern beam radiat ebr choroid melanoma system chemotherapi leukovorin/num fluorouracil fu treatment metastat colorect cancer,0,1.0,0.0
levonorgestrel breast cancer estim rate endometri patholog prophylact use levonorgestrel-releas intrauterin system women breast cancer treat tamoxifen,0,1.0,0.0
fluoroquinolon tendinopathi fluoroquinolon antibiot therapi recogn poorli understood caus achil tendinopathi,1,0.3931,0.6069
valsartan hypertens efficaci fixed-dos combin therapi treatment patient hypertens focu amlodipine/valsartan,0,1.0,0.0
phenytoin antiepilept drug pharmacoresist epilept patient may ascrib least two not mutual exclus mechan pharmacokinet mechan decreas sensit avail target antiepilept drug a i.e. carbamazepin phenytoin cbz pht,0,1.0,0.0
gemcitabin breast cancer carboplatin gemcitabin combin metastat triple-neg anthracycline- taxane-pretr breast cancer patient phase ii studi,0,1.0,0.0
lopinavir/ritonavir fast glucos fast glucos insulin lipid lipoprotein profil oral glucos toler insulin secret insulin-medi glucos dispos hyperglycem clamp bodi composit dual energi x-ray absorptiometri determin lopinavir/ritonavir administr,0,1.0,0.0
fludarabin macroglobulinemia twenty-eight patient waldenstrim 's macroglobulinemia num previous untreat receiv fludarabin dose num2 num2 mg/m2 intraven daili num day num2 patient num2 mg/m2 intraven daili num day num patient,0,1.0,0.0
imatinib cmd five patient he men median age num2 year num eos-cmd men age num2 num2 year treat imatinib start dose num3 num3 mg/day,0,1.0,0.0
alanin flatul among num num3 elig patient advers drug reaction observ num common abdomin distens flatul diarrhea increas alanin aminotransferas level,0,1.0,0.0
dexamethason necrosi studi regul gsh synthesi respons pro-inflammatori cytokin tumor necrosi factor-alpha tnf-alpha anti-inflammatori agent dexamethason human alveolar epitheli cell anum3,0,1.0,0.0
cidofovir/cdv adenoviru ad infect although current no fda approv antivir treatment adenoviru ad infect broad spectrum antivir cidofovir cdv demonstr potent inhibitori activ against mani ad serotyp vitro vivo ocular replic model,0,1.0,0.0
heparin osteoporosi fondaparinux not inhibit osteoblast prolifer vitro may reduc risk heparin-induc osteoporosi associ long-term heparin administr,1,0.0,1.0
clomiphen citrat polycyst ovari syndrom num3 patient clomiphen citrat resist polycyst ovari syndrom num2 alloc electrocauteri num2 alloc recombin follicl stimul hormon,0,1.0,0.0
dopamin tic disord addit psychosoci intervent alpha-num agonist dopamin antagonist constitut mainstay treatment approach treat tic disord,0,1.0,0.0
monensin infect monolay human ileocec adenocarcinoma cell hct-num infect sporozoit excyst directli cell incub monensin halofuginon bromid hexadecylphosphocholin num2h post infect pnumi,0,0.8018,0.19820000000000004
methicillin methicillin-resist genet relationship methicillin-sensit methicillin-resist staphylococcu aureu strain franc intern sourc delin genom group,0,1.0,0.0
pfoa hepatoblastoma present studi demonstr treatment human hepatoblastoma hepg2 cell pfoa induc apoptosi well perturb cell cycl,0,1.0,0.0
tsa cornea real-tim pcr immunocytochemistri studi show system administr tsa suppress inflamm fibrot respons stroma acceler epitheli heal alkali-burn mous cornea,0,1.0,0.0
nimodipin urticaria present studi aim test therapeut effect side effect nimodipin therapi new dihydropyridin anti-calcium deriv physic stimulus-induc urticaria comparison standard h1-antihistamin therapi,0,1.0,0.0
cisplatin glioblastoma phase ii studi temozolomid cisplatin primari treatment prior radiotherapi newli diagnos glioblastoma multiform patient measur diseas,0,1.0,0.0
chromium vi toxic system toxic may occur follow ingest chromium vi salt chromium vi -induc skin burn inhal chromium vi occur occup,1,0.0,1.0
adefovir hbv-infect two de novo hbv-infect patient ymdd mutat given adefovir combin lamivudin liver function gradual improv follow-up period,0,1.0,0.0
lidocain heat stress progress passiv heat stress particip receiv intranas cocain num mg/kg bodi weight placebo lidocain num mg/kg,0,0.8068,0.19320000000000004
auristatin pe tumor studi investig anti-tumor effect auristatin pe structur modif marin shell-less mollusk peptid constitu dolastatin num2,0,1.0,0.0
hva/homovanil acid schizophren homovanil acid hva oxid metabolit dopamin shown number studi reflect sever symptom predict respons neurolept treatment schizophren patient,0,1.0,0.0
gaba ischemia report downregul gaba receptor gaba r express affect mrna protein level gaba r subunit hippocamp neuron subject oxygen-glucos depriv ogd vitro model ischemia,0,1.0,0.0
steroid lupu studi need establish whether bindarit may function steroid spare drug human lupu,0,1.0,0.0
glatiram acet multipl sclerosi grow evid immunomodulatori treatment particular glatiram acet improv fatigu symptom patient multipl sclerosi,0,1.0,0.0
progesteron bca mono-lay cell cultur model pnum2-wild type estrogen receptor er -depend mcf-num bca cell pnum2-mut er-/progesteron receptor pr her2-regular triple-neg mda-mb-num3 bca expos pgg comprehens investig cellular consequ molecular targets/medi,0,1.0,0.0
magnesium sudden death epidemiolog clinic studi suggest magnesium may reduc frequenc sudden death sodium contribut occurr hypertens calcium may help prevent osteoporosi,0,1.0,0.0
naftidrofuryl optic nerv damag suggest naftidrofuryl might administ use complement convent hypotens therapi sinc act posit glaucomat optic nerv damag,0,1.0,0.0
paroxetin sexual dysfunct ssri-induc sexual dysfunct describ fluoxetin paroxetin sertralin fluvoxamin num-num2 week therapi,1,0.20940000000000006,0.7906
levofloxacin bacteri kerat gatifloxacin moxifloxacin vitro suscept comparison levofloxacin ciprofloxacin ofloxacin use bacteri kerat isol,0,1.0,0.0
fluticason propion bronchial asthma/ba aim studi test fluticason propion fp efficaci treatment patient bronchial asthma ba not control high dose num mg inhal corticosteroid,0,1.0,0.0
sorafenib ptc object present adolesc progress rai-resist ptc success treat sorafenib,0,1.0,0.0
indomethacin pancreat rectal indomethacin given prevent post-ercp pancreat increas bleed biliari endoscop sphincterotomi cardiovascular mortal,0,1.0,0.0
feiba thrombot commonli document singl type thrombot ae rfviia infus cerebrovascular thrombosi myocardi infarct frequent type patient receiv feiba,0,0.6123,0.3877
adr cardiac injuri result support major role free radic gener adr toxic well suggest mitochondria critic site cardiac injuri,0,0.7839,0.2161
olmesartan medoxomil hypertens result suggest olmesartan medoxomil combin amlodipin effect well toler reduc bp patient moder sever hypertens,0,1.0,0.0
ethanol aps/arterioport shunt evalu long-term effect ethanol embol treatment hepatocellular carcinoma hcc sever hepat arterioport shunt ap compar gelfoam embol,0,1.0,0.0
anthracyclin cardiotox acut promyelocyt leukaemia apl treatment often includ high cumul dose anthracyclin caus long-term cardiotox,1,0.0,1.0
glutamin tumor larg bodi evid vivo suggest supplement glutamin not make tumor grow fact result decreas growth stimul immun system,0,1.0,0.0
cisplatin malign tumor cisplatin one commonly-us chemotherapeut drug effici treat malign tumor clinic howev advers effect cisplatin nephrotox neurotox hemolyt urem syndrom often observ clinic dose approxim num2 mg/m num limit broader applic,0,1.0,0.0
temozolomid tumor due proxim tumor brainstem adjuv temozolomid chemotherapi administ rather first-lin radiotherapi,0,1.0,0.0
no migrain sinc calcineurin inhibitor known influenc renal metabol no key molecul tension-typ headach migrain interest whether calcineurin inhibitor might chang no metabol hbmec well,0,1.0,0.0
aspirin stemi addit clopidogrel aspirin given num year set stemi highli cost-effect strategi,0,1.0,0.0
perindopril hypertens present studi evalu effect treatment calcium channel blocker amlodipin angiotensin i-convert enzym inhibitor perindopril vascular endotheli function arteriosclerosi patient essenti hypertens alreadi receiv angiotensin receptor blocker monotherapi,0,1.0,0.0
estrogen stroke epht recruit num4-num4 women 's health initi whi usa decid stop estrogen-progestin trial mean num year juli num4 increas risk breast cancer later num4 estrogen-onli trial ht increas risk stroke decreas risk hip fractur not affect coronari heart diseas incid,1,0.0,1.0
piperacillin melioidosi role piperacillin/ tazobactam melioidosi remain undefin,0,1.0,0.0
formoterol copd studi could not show differ lung deposit formoterol inhal via turbuhal patient moder sever copd,0,1.0,0.0
androgen ar/androgen receptor among androgen receptor splice variant ar-v particularli variant num ar-v7 implic resist enzalutamid abirateron preclin studi not target current avail ar-direct drug,0,1.0,0.0
meropenem escherichia part meropenem yearli suscept test inform collection/usa surveil programm monitor occurr quinolon resist escherichia coli num2-year period,0,1.0,0.0
mn hypertens addit blood lead mercuri cadmium covari not affect associ blood mn preval hypertens,0,0.7997,0.20030000000000006
polyphenol carcinogenesi mani laboratori studi demonstr inhibitori effect green tea polyphenol especi -epigallocatechin-num-gal egcg carcinogenesi anim model,0,1.0,0.0
mannitol hyperosmolar first-tier option includ induc hypocapnea hyperventil paco2 num2 mmhg hyperosmolar therapi mannitol hyperton salin induc arteri hypertens cpp concept,0,1.0,0.0
epoprostenol primari pulmonari hypertension/pph sought determin factor associ long-term surviv patient primari pulmonari hypertens pph treat continu epoprostenol infus,0,1.0,0.0
n num fatti acid colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,1.0,0.0
num-fluorouracil colon carcinoma relat thymidyl synthas express surviv colon carcinoma determin appropri applic num-fluorouracil immunohistochem method,0,1.0,0.0
pomalidomid anemia circul level mcp-num sil-2r il-num2 il-num predict anemia respons pomalidomid therapi myelofibrosi,0,0.7949,0.20509999999999995
tunicamycin hypoglycemia human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0
somatostatin sleep apnea determin effect octreotid somatostatin analog sever sleep apnea growth hormon level patient acromegali,0,1.0,0.0
num-fu colorect carcinoma recent research indic chemosensit num-fu colorect carcinoma low express ts better tumor high express ts,0,1.0,0.0
toremifen breast cancer antiatherogen effect adjuv antiestrogen random trial compar effect tamoxifen toremifen plasma lipid level postmenopaus women node-posit breast cancer,0,1.0,0.0
hva drug action howev administr dopamin postsynapt antagonist expect increas synapt dopamin avail therebi increas hva concentr accord tradit model drug action,0,1.0,0.0
thalidomid mm immunomodulatori agent imid thalidomid lenalidomid chang landscap treatment patient mm newer imid pomalidomid show promis earli clinic trial,0,1.0,0.0
naftidrofuryl normal tension glaucoma double-blind studi treatment normal tension glaucoma naftidrofuryl,0,1.0,0.0
clomiphen citrat polycyst ovari syndrome/pco avail laparoscop ovarian cauteri resurg interest surgic treatment clomiphen citrate-resist polycyst ovari syndrom pco,0,1.0,0.0
statin claudic symptomat treatment claudic includ smoke cessat exercis cilostazol statin revascular percutan surgic therapi,0,1.0,0.0
vemurafenib melanoma treatment strategi chang patient advanc melanoma use ipilimumab vemurafenib first-lin agent,0,1.0,0.0
hbsag hepatocellular carcinoma no interact among smoke alcohol drink hbsag term hepatocellular carcinoma mortal,0,1.0,0.0
c/cyclophosphamid breast cancer conduct phase iii random studi two adjuv treatment schedul doxorubicin cyclophosphamid c early-stag breast cancer determin administr sequenti singl agent -- c result superior disease-fre surviv df overal surviv os versu total dose given combin ac,0,1.0,0.0
olanzapin schizophrenia thirty-nin outpati schizophrenia sever neg symptom assess presenc deficit syndrom enter num2-week open-label studi olanzapin,0,1.0,0.0
no dementia small molecul mimic biolog activ no no mimet bypass cholinerg receptor activ anticip provid multipl pathway treat circumv dementia alzheim 's diseas,0,1.0,0.0
n-butyl-num-cyanoacryl intraoss lesion patient embol fiber coil direct punctur coil place directli center intraoss lesion case conjunct polyvinyl alcohol foam n-butyl-num-cyanoacryl vascular access,0,1.0,0.0
aza ibd standard dose num-mp/aza may not adequ ibd patient num year age younger,0,1.0,0.0
gliclazid vascular diseas hemobiolog vascular diseas review potenti gliclazid influenc pathogenesi diabet vascular diseas,0,0.6228,0.3772
posaconazol gastric intrahepat mucormycosi knowledg first report case extens gastric intrahepat mucormycosi respond combin posaconazol lamb without surgic debrid,1,0.391,0.609
brimonidin pain studi evalu effect acetazolamid latanoprost travoprost bimatoprost brimonidin brinzolamid timolol pain phacoemulsif cataract surgeri,0,1.0,0.0
bupivacain cardiovascular central nervou system toxic levobupivacain new long-act local anesthet isol s-enantiom racem bupivacain less cardiovascular central nervou system toxic bupivacain,0,0.7942,0.2058
glucos obes mechan blood glucose-low effect num-day low calori diet vlcd num4 kj/d combin cessat blood glucose-low agent studi num2 num women num men obes bodi mass index num2num +/- num kg/m num mean +/- sem type num diabet patient age num2 +/- num year hba 1c num +/- num undergo insulin therapi,0,1.0,0.0
diltiazem af oral beta blocker verapamil diltiazem use person af fast ventricular rate occur rest exercis despit digoxin,0,1.0,0.0
ascorb acid acut oxal nephropathi howev ascorb acid metabol precursor oxal administr ascorb acid high dose could lead acut oxal nephropathi particularli presenc renal failur,1,0.0,1.0
vitamin d. ckd patient ckd may requir intraven oral activ vitamin d. investig effect lanthanum carbon sevelam carbon bioavail oral calcitriol,0,1.0,0.0
iron splenic increas splenic iron content erythrocyt injuri observ treatment low dose cisplatin,0,0.7999,0.20009999999999994
taxan tumor phase studi conduct primarili determin maximum toler dose mtd tesetaxel novel oral activ semisynthet microtubul inhibitor taxan class administ oral capecitabin patient advanc solid tumor,0,1.0,0.0
methicillin mrsa/methicillin-resist staphylococcu aureu methicillin-resist staphylococcu aureu mrsa well-recogn agent health care-associ infect long-term care facil data circul mrsa set itali avail,0,1.0,0.0
rasagilin pd rasagilin shown effect monotherapi earli pd adjunct dopaminerg therapi,0,1.0,0.0
okada acid okada acid/oa human num +/- num x num2 -num mu/num2 num sperm monkey num +/- num x num2 -num mu/num2 num sperm sonic contain activ tent identifi pp1 basi inhibit profil okada acid oa ca,0,1.0,0.0
heparin venou thromboembol prolong administr heparin prevent treatment venou thromboembol associ risk heparin-induc osteoporosi,0,1.0,0.0
risperidon hallucin studi suggest risperidon long-act inject paliperidon palmit long-act inject may use treatment dd patient specif nonpromin hallucin,0,1.0,0.0
indoxyl sulfat glomerular sclerosi conclus low-protein diet ast-num3 reduc serum urin level indoxyl sulfat stimul factor glomerular sclerosi urem rat undialyz urem patient,0,0.7904,0.2096
carbosilan hiv enhanc activ carbosilan dendrim against hiv combin revers transcriptas inhibitor drug search potent microbicid,0,1.0,0.0
procarbazin tumor cpt-num2 produc statist signific p numnum3 growth delay subcutan xenograft test includ resist busulfan cyclophosphamid procarbazin melphalan growth delay rang num2num day dnum3 med num2+ day sever tumor line,0,1.0,0.0
diltiazem hypertens relat rsnum5 statu num-month blood pressur reduct risk cardiovascular event num4 hypertens patient dbp num3 mmhg nordic diltiazem studi nordil random either e_-block and/or diuretic-bas treatment diltiazem-bas treatment,0,1.0,0.0
tamoxifen inflammatori result show tamoxifen raloxifen ici num3numnum3 induc anti-inflammatori respons acut model mous rat microgli cell,0,1.0,0.0
doxorubicin tumor e_h2ax express num2 min cleav caspase-num -num num2 hr doxorubicin docetaxel decreas increas distanc tumor blood vessel minim express hypox region maximum reduct kinum2 level observ region closest vasculatur num2 hr,0,1.0,0.0
alcohol hepat b. particip report smoke alcohol consumpt hepat b surfac antigen hbsag statu document num2num particip,0,1.0,0.0
methotrex urticari vascul num2-year-old woman num yr histori chronic recurr urticari vascul angioedema refractori convent treatment includ glucocorticosteroid h1 h2 blocker nonsteroid antiinflammatori agent methotrex hydroxychloroquin dapson azathioprin intraven gamma globulin plasma exchang success treat interferon alpha 2a,0,1.0,0.0
chloroquin cancer/colon cancer studi conduct investig anti-canc effect autophagi inhibit use chloroquin togeth num-fluorouracil num-fu colon cancer cell line,0,1.0,0.0
androgen ligand-bind domain/lbd prostat cancer pca therapi typic involv administr classic antiandrogen competit inhibitor androgen receptor ar ligand dihydrotestosteron dht testosteron te ligand-bind pocket lbp ligand-bind domain lbd ar,0,1.0,0.0
metformin gestat diabet no differ preval gestat diabet pre-eclampsia metformin placebo group,0,1.0,0.0
capsaicin thermal hyperalgesia investig effect guanethidin pretreat thermal hyperalgesia experiment site sensit heat topic applic num capsaicin,0,0.8179,0.18210000000000004
perfluorooctano acid hepatoma effect rodent peroxisom prolifer hepatocarcinogen perfluorooctano acid apoptosi human hepatoma hepg2 cell,0,1.0,0.0
ascorb acid poison administr exogen ascorb acid advoc therefor treatment system chromium poison chromium dermat enhanc extracellular reduct chromium vi less bioavail chromium iii,0,1.0,0.0
serotonin oral bleed complic purpos studi examin frequenc oral bleed complic invas dental procedur patient take select serotonin reuptak inhibitor ssri medic,0,0.62,0.38
mitoxantron cognit impair although patient initi stabil therapi corticosteroid plasma exchang mitoxantron sever cognit impair persist eventu die sequela diseas,0,1.0,0.0
warfarin red lesion median number red lesion combin group highest among four group significantli higher warfarin group,0,1.0,0.0
methotrex necrosi evid radiograph benefit treatment infliximab plu methotrex rheumatoid arthriti patient no clinic improv detail subanalysi data anti-tumor necrosi factor trial rheumatoid arthriti concomit therapi studi,0,1.0,0.0
ursodeoxychol acid/ursolit laboratori abnorm patient requir steroid repeat cours cyclophosphamid manag lupu nephriti ursodeoxychol acid ursolit administr result amelior cholestat laboratori abnorm,1,0.38799999999999996,0.612
ribavirin hepat c viru result suggest even fail erad hepat c viru convent interferon ribavirin therapi abl halt progress necroinflamm fibrosi,0,1.0,0.0
estrogen tumour estrogen progesteron receptor er pr immunocytochem analys mammari tumour cell obtain fine needl sampl num2 patient,0,1.0,0.0
ibuprofen pda cyclo-oxygenas inhibitor indomethacin ibuprofen remain mainstay medic therapi pda use prophylaxi well rescu therapi achiev pda closur,0,1.0,0.0
vorozol mammari carcinoma vorozol like ovariectomi almost complet reduc tumor growth dmba-induc mammari carcinoma model rat,0,1.0,0.0
epinephrin cardiac death epinephrin challeng power test establish electrocardiograph diagnosi silent lqt1 mutat carrier thu allow implement prophylact measur aim reduc sudden cardiac death,0,1.0,0.0
retinoid acut promyelocyt leukemia retinoid differenti leukem cell line vitro induc clinic complet remiss patient acut promyelocyt leukemia,0,1.0,0.0
doxorubicin tumor th-num3 given num hr doxorubicin docetaxel increas dna damag apoptosi throughout tumor compar chemotherapi alon,0,1.0,0.0
danazol endometriosi vagin mucosa undergo constant well-defin modif buserelin acet danazol treatment endometriosi,0,0.7945,0.2055
cisplatin primari tumor cisplatin-dna adduct format patient treat cisplatin-bas chemoradi lack correl normal tissu primari tumor,0,1.0,0.0
indomethacin stroke use doppler technolog determin cardiac output stroke volum total peripher resist three num2-mg dose indomethacin,0,0.7854,0.2146
nucleosid revers transcriptas hiv-num isol harbor multipl nucleosid revers transcriptas inhibitor nrti resist mutat suscept hypersuscept nonnucleosid revers transcriptas inhibitor nnrti isol lack nrti resist mutat report single-cycl replic phenotyp assay,0,0.7968,0.20320000000000005
pma aids/arc significantli reduc dna synthesi cdnum2 express observ aid arc upon stimul anti-cd3 pma,0,1.0,0.0
glucos vte increas glucos level total hip replac associ total vte adjust odd ratio highest versu lowest quartil num num2 confid interv ci num num,0,0.7876,0.21240000000000006
tau melanoma az combin tau inhibit melanin product tyrosinas activ bnum2fnum2 melanoma cell without signific cytotox,0,1.0,0.0
carbidopa parkinson 's observ suggest oral administr egcg may signific benefici effect parkinson 's patient treat l-dopa carbidopa exert modest inhibit l-dopa methyl plu strong neuroprotect against oxid damag degener,0,1.0,0.0
num-fu colorect cancer total num2 patient document num-fu-resist advanc colorect cancer enrol,0,1.0,0.0
androgen prostat cancer mini-review discuss gener mechan resist ar-direct therapi focu role androgen receptor splice variant new era treat advanc prostat cancer enzalutamid abirateron,0,1.0,0.0
guanethidin thermal hyperalgesia observ indic prolong deplet adrenerg store guanethidin induc adrenerg supersensit cutan vessel adrenerg supersensit enhanc thermal hyperalgesia presenc noradrenalin,1,0.0,1.0
clopidogrel cardiovascular diseas clinic trial establish valu clopidogrel therapi wide spectrum patient cardiovascular diseas,0,1.0,0.0
y-num5 metastasi find confirm import rho/pnum3rock signal pathway intrahepat metastasi human hcc indic y-num5 may use prevent intrahepat metastasi human hcc,0,1.0,0.0
nac copd copd patient underw num l/m oxygen num2 h nac num4 num4 mg/day placebo num2 h start oxygen administr,0,1.0,0.0
combretastatin-a4-phosph squamou cell carcinoma head neck phase ib trial radiotherapi combin combretastatin-a4-phosph patient non-small-cel lung cancer prostat adenocarcinoma squamou cell carcinoma head neck,0,1.0,0.0
sunum4 toxic tripl combin use low-tox drug exposur pemetrex sunum4 result greater respons treatment alon combin two modal test endotheli tumor cell model,0,0.8038,0.19620000000000004
tenofovir hiv-infect switch virolog suppress hiv-infect adult low bmd take rpi tenofovir raltegravir safe significantli improv hip spine bmd reduc marker bone turnov num2 week,0,1.0,0.0
propofol seizures/seizur propofol group shorter mean electroencephalogram etomid num2numnum2 num2numnum2 propofol num2numnum2 num2numnum2 p numnum3 seizur durat motor etomid num2numnum2 num2numnum2 propofol num2numnum2 numnum2 p numnum3 seizur durat higher mean number inadequ seizur etomid numnum2 numnum2 propofol numnum2 numnum2 p numnum3,0,0.7867,0.21330000000000005
furosemid thrombocytopenia num-year case furosemide-induc immun thrombocytopenia,1,0.3878,0.6122
androgen prostat cancer androgen affect growth prostat gland mani prostat cancer,1,0.1846,0.8154
num-aza-num'-deoxycytidin necrosi find clinic achiev level num-aza-num'-deoxycytidin num-aza-dc potent inhibitor dna methyl modifi chromatin restor abil tumor necrosi factor alpha tnfalpha induc monocyt differenti acut myeloid leukemia cell nb4 unum3,1,0.3979,0.6021
clopidogrel stemi long-term cost-effect clopidogrel stemi patient,0,1.0,0.0
pcp sarcoma although pcp not classifi human carcinogen epidemiolog observ suggest exposur chlorophenol gener pcp solut particular may result increas risk certain malign disord nasal carcinoma soft tissu sarcoma,1,0.0,1.0
alanin hepat c. includ requir improv enzymolog screen despit introduct test hepat c imbal popular unexplain chronic aminotransferas elev effort solv inher problem inadequ attempt use metabol chang hepatocyt improv diagnosi prognosi pathophysiolog understand viral liver diseas remark investig num'-num'-oligoadenyl synthetas better control interferon therapi chronic viral hepat use enzym marker etiolog particularli detect alcohol induc liver diseas continu prefer aminotransferas scenario although ratio aspart aminotransferas alanin aminotransferas mitochondri aspart aminotransferas total aspart aminotransferas activ larg depend sever intralobular local damag stage liver diseas,0,1.0,0.0
budesonid polyposi thirty-two patient nasal polyposi random unilater endoscop sinu surgeri pretreat oral prednisolon num2 day nasal budesonid bilater num month,0,1.0,0.0
thymidin head neck squamou cell carcinoma/hnscc evalu whether two molecular biomark thymidin phosphorylas tp dihydropyrimidin dehydrogenas dpd could clinic use predict improv chemotherapeut outcom oral fluoropyrimidin capecitabin num'-dfur xeloda treatment human head neck squamou cell carcinoma hnscc,0,1.0,0.0
ascorb acid melanoma investig surviv two kind human embryon cell clvnum3 lunum3 human melanoma cell mel8 expos exogen iron copper ion absenc presenc ascorb acid catalas superoxid dismutas,0,0.813,0.18700000000000008
dronedaron af primari composit endpoint num2num num2num dronedaron amiodaron respect num2 month hazard ratio hr numnum2 num2 confid interv ci numnum2-numnum2 p numnum4 mainli driven af recurr dronedaron compar amiodaron num2num vs num2num,0,0.6238,0.3762
aspirin respiratori diseas baselin feva lower lung function treatment clinic factor indic poor prognosi aspirin-exacerb respiratori diseas,1,0.2117,0.7883
cisplatin primari tumor studi format cisplatin-dna adduct concurr cisplatin-radi relationship adduct-form primari tumor tissu normal tissu investig,0,0.7895,0.2105
tpa skin carcinogenesi addit compound num num2 exhibit inhibitori effect skin-tumor promot vivo two-stag mous skin carcinogenesi test base num num2-dimethylbenz anthracen dmba initi tpa promot,0,0.8119,0.18810000000000004
cilostazol lymphedema studi investig whether cilostazol potenti prolifer lymphat vessel improv lymphat function use human lymphat endotheli cell lec mous lymphedema model,0,1.0,0.0
polyphenol cancer addit also propos tea polyphenol function cancer chemoprevent agent modul mitot signal transduct,0,0.8044,0.1956
aspirin stroke pool data trial compar antithrombot treatment placebo shown warfarin reduc risk stroke num2 aspirin alon reduc risk num2,0,1.0,0.0
glucos diabet object prevent programm studi whether combin pioglitazon lifestyl modif would enhanc efficaci lifestyl modif prevent type num diabet asian indian impair glucos toler,0,0.8009999999999999,0.19900000000000007
num-hc tumor data suggest clonal abnorm observ posttranspl best explain clinic relaps tumor ex vivo marrow purg num-hc not like induc clonal chromosom abnorm normal cell,0,1.0,0.0
methadon pain increas risk death observ patient receiv methadon retrospect cohort studi even low dose support recommend not drug first choic noncanc pain,0,0.7974,0.2026
bombesin tumor bombesin significantli stimul growth pt tumor day num2 mice sacrif day num2,1,0.0,1.0
methadon death increas risk death observ patient receiv methadon retrospect cohort studi even low dose support recommend not drug first choic noncanc pain,1,0.0,1.0
cisplatin hemolyt urem syndrom hemolyt urem syndrom may associ varieti etiolog chemotherapeut agent also report associ hemolyt urem syndrom includ mitomycin cisplatin bleomycin recent gemcitabin,1,0.17520000000000002,0.8248
paclitaxel tumor paclitaxel preferenti cytotox radioresist tumor clone level paclitaxel-induc cytotox significantli p numnum4 influenc raf-num kinas activ level,0,1.0,0.0
ofx/ofloxacin bacteri kerat compar vitro suscept pattern minimum inhibitori concentr mic gatifloxacin gat moxifloxacin mox fourth-gener fluoroquinolon ciprofloxacin cip ofloxacin ofx second-gener fluoroquinolon levofloxacin lev third-gener fluoroquinolon use bacteri kerat isol,0,1.0,0.0
alcohol hepat b. cigarett smoke alcohol drink hepat b risk hepatocellular carcinoma korea,0,1.0,0.0
trientin wilson diseas origin studi clinic efficaci d-penicillamin trientin tetrathiomolybd zinc monotherapi initi treatment wilson diseas includ,0,1.0,0.0
ketamin cancer pain hypothes intrathec ketamin would potenti effect intrathec morphin treatment cancer pain,0,1.0,0.0
morphin death methadon dose num2 mg/d less lowest dose quartil associ increas risk death hr ua1numnum2 num2 ci numnum2-numnum2 pua=uanumnum3 rel compar dose morphin sr num2 mg/d,0,0.8046,0.1954
oral contracept endogen pain influenc oral contracept endogen pain control healthi women,0,1.0,0.0
cobalt california regul howev accord california regul lithium batteri test classifi hazard due excess level cobalt averag num3 num3 mg/kg ia num2 num3 limit num4 copper averag num2 num3 mg/kg ia num2 num3 limit num4 nickel averag num4 mg/kg ia num2 num3 limit num4,0,0.8301,0.16990000000000005
resveratrol death show previous resveratrol induc autophag cell death ovarian cancer cell,0,0.8084,0.1916
roflumilast copd roflumilast treatment copd asian popul random double-blind parallel-group studi,0,1.0,0.0
pamidron breast cancer accord recent publish asco guidelin pamidron num2 mg inumv deliv num h everi num-num week recommend patient metastat breast cancer imag evid lytic destruct bone concurr receiv system therapi hormon therapi chemotherapi,0,1.0,0.0
nucleosid hiv-infect haart-rel long-term toxic mani ascrib mitochondri mt toxic nucleosid analogu increasingli report hiv-infect children,0,1.0,0.0
statin coronari arteri diseas effect tirofiban statin high-sensit c-reactiv protein interleukin-num solubl cdnum2 ligand follow percutan coronari intervent patient stabl coronari arteri diseas,0,1.0,0.0
ethanol hyperthermia suggest combin heat stress ethanol consumpt respons elev urinari na hyperthermia case reflect increas sympathet nervou system activ,0,0.8194,0.1806
heparin osteoporosi prolong administr heparin prevent treatment venou thromboembol associ risk heparin-induc osteoporosi,1,0.1919,0.8081
methotrex acceler nodulosi acceler nodulosi low dose methotrex therapi rheumatoid arthriti,1,0.1733,0.8267
argentatin a. cancer synthesi argentatin deriv growth inhibitor human cancer cell line vitro,0,1.0,0.0
dasatinib acut lymphoblast leukemia num4 num4 num3 patient newli diagnos philadelphia chromosome-posit acut lymphoblast leukemia treat chemotherapi imatinib n num2 dasatinib n num2,0,1.0,0.0
glucos diabet mellitu type studi closed-loop system control plasma glucos level patient diabet mellitu type num propos,0,1.0,0.0
metformin diabet metformin prevent develop diabet among patient impair fast glucos short term,0,1.0,0.0
saponin tumor saponin tumor therapi,0,1.0,0.0
corticosteroid crohn 's diseas corticosteroid therapi age infliximab acut num-year outcom newli diagnos children crohn 's diseas,0,1.0,0.0
num-anilinoacridin cytotox caspase-depend cell death mediat potent cytotox sulfid deriv num-anilinoacridin,1,0.3919,0.6081
ssri sexual dysfunct describ occurr manag sexual dysfunct induc select serotonin-reuptak inhibitor ssri provid overview sexual dysfunct report ssri-induc sexual dysfunct manag strategi,1,0.2006,0.7994
no neuroblastoma neuron no synthas nno overexpress neuroblastoma cell line expos differenti action retino acid no slow prolifer acceler differenti toward neuron phenotyp,0,1.0,0.0
vancomycin posttraumat endophthalm describ case posttraumat endophthalm unrespons system amoxicillin+clavulan acid piperacillin/tazobactam intra-ocular vancomycin topic ofloxacin tetracyclin sulfametoxazol antibiot therapi,0,1.0,0.0
sertindol schizophrenia random control dose-rang trial sertindol patient schizophrenia,0,0.8239,0.17610000000000006
aspirin death subgroup analysi aspirin treatment failur not found associ recurr stroke combin endpoint stroke death among categori defin etiolog subtyp includ larg arteri atherosclerosi,0,1.0,0.0
aspirin gastroduoden disord investig endoscop examin frequenc gastroduoden disord associ buffer enteric-co aspirin eca,1,0.18220000000000006,0.8178
cj-num5 tumor pge num inhibit lipopolysaccharid lp -induc product tumor necrosi factor alpha tnfalpha human whole blood hwb cj-num5 revers inhibitori effect pge num lps-induc tnfalpha product concentration-depend manner,0,1.0,0.0
n-methyl-d-aspart multipl sclerosi sever cognit impair associ intrathec antibodi nr1 subunit n-methyl-d-aspart receptor patient multipl sclerosi,0,1.0,0.0
aspirin stemi num2/num4 num2/num4 num2 num3 stemi patient random clopidogrel n=num2 num3 match placebo n=num2 num3 addit aspirin,0,1.0,0.0
oxamniquin acut schistosomiasi oxamniquin treatment acut schistosomiasi patient follow improv th1 respons vitro,0,1.0,0.0
doxorubicin diffus larg b-cell non-hodgkin lymphoma/dlbcl studi design assess activ safeti dose-adjust infusion cyclophosphamid doxorubicin vincristin prednison chemotherapi rituximab da-poch-r elderli patient poor-prognost untreat diffus larg b-cell non-hodgkin lymphoma dlbcl,0,1.0,0.0
glucos postprandi hyperlipidaemia studi efficaci evalu use plasma insulin glucos infus rate plasma c-peptid level mean serum fructosamin level postprandi hyperlipidaemia overal well-b treatment satisfact qualiti life,0,1.0,0.0
nitrogen sepsi glucos prove nitrogen spare properti postop patient critic ill patient toler glucos load poorli fat appear obligatori fuel sepsi,0,0.795,0.205
acarbos obes preliminari result suggest insulin-metformin obes present insulin-acarbos post-prandi hyperglycaemia occur combin might offer favour featur treatment niddm patient although therapeut approach still requir adequ evalu control studi,0,1.0,0.0
tamoxifen human mammari carcinoma effect three non-myelotox cancer drug growth neuroblastoma cell investig vitro vivo dihydroxyphenylalanin l-dopa drug select toxic melanoma cell dl-buthionin sulphoximin bso drug radiosensit effect tamoxifen drug use treatment human mammari carcinoma,0,1.0,0.0
steroid liver failur prompt readministr steroid indic evid liver failur develop,0,1.0,0.0
methotrex angioedema num2-year-old woman num yr histori chronic recurr urticari vascul angioedema refractori convent treatment includ glucocorticosteroid h1 h2 blocker nonsteroid antiinflammatori agent methotrex hydroxychloroquin dapson azathioprin intraven gamma globulin plasma exchang success treat interferon alpha 2a,0,0.8035,0.1965
gliclazid diabet vascular diseas hemobiolog vascular diseas review potenti gliclazid influenc pathogenesi diabet vascular diseas,1,0.3841,0.6159
nickel hypersensit result studi demonstr patient posit patch test nickel sulphat perpetu ra relat hypersensit ingest nickel salt independ local contact nickel,0,0.8077,0.19230000000000005
xylometazolin rhinorrhea xylometazolin quickli effect reliev nasal congest ipratropium effect reduc rhinorrhea,0,1.0,0.0
nifedipin hypocalcem order studi role calcium ion pathogenesi vasoconstrict lesion caus acut smoke author studi peripher vascular effect calcium-channel antagonist nifedipin dihydropyridin deriv calcitonin hypocalcem hormon possess vasoact action num2 elderli regular smoker mean age num2num year,0,1.0,0.0
corticosteroid ulcer colitis/uc prospect examin effect leukocytapheresi la mainten remiss num patient ulcer coliti uc initi refractori corticosteroid therapi steroid resist steroid depend,0,0.8101,0.1899
azithromycin chronic periodont azithromycin togeth monthli subgingiv debrid treatment case num sever chronic periodont poorli control diabet complic gingiv overgrowth relat medic calcium channel blocker,0,1.0,0.0
nickel eczema recent sever studi report patient affect cutan diseas i.e dermat eczema urticaria posit patch test nickel posit oral nickel challeng,0,0.8073,0.1927
ascorb acid poison therapeut review ascorb acid valu chromium poison chromium dermat,0,1.0,0.0
num-aminopyridin multipl sclerosi clinic studi suggest fampridin num-aminopyridin improv motor function peopl multipl sclerosi,0,1.0,0.0
acebutolol lupu syndrom literatur data along case suggest link acebutolol therapi onset lupu syndrom,1,0.0,1.0
fentanyl physic impair cognit physic impair confus abnorm co-ordin occur transderm fentanyl,1,0.0,1.0
steroid ulcer colitis/uc prospect examin effect leukocytapheresi la mainten remiss num patient ulcer coliti uc initi refractori corticosteroid therapi steroid resist steroid depend,0,1.0,0.0
lactic acid/lact inflammatori arthropathi concentr tumor necrosi factor alpha interleukin-num vascular endotheli growth factor lactic acid lactat dehydrogenas hmgb-num measur synovi fluid sf sampl patient inflammatori arthropathi rheumatoid arthriti pseudogout patient noninflammatori arthropathi osteoarthr,0,1.0,0.0
testosteron testosteron defici frequent strategi includ dietari chang vitamin modif routin rest exercis prescrib medic anemia vitamin b num2 defici testosteron defici,0,1.0,0.0
alcohol gastric cardia distal gastric adenocarcinoma sought determin role smoke alcohol use bodi size characterist etiolog esophag gastric cardia distal gastric adenocarcinoma,0,0.8002,0.1998
ethanol hcc ethanol embol patient hcc sever ap efficaci safe may contribut prolong life span versu gelfoam embol,0,1.0,0.0
ecstasi anxieti depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0
lithium depress avail option treatment bipolar disord includ mania hypomania depress mainten elderli includ lithium antiepilept antipsychot benzodiazepin antidepress electroconvuls therapi ect psychotherapi,0,1.0,0.0
aspirin red small eros lesion red small eros aspirin combin group tend exist proxim part small bowel,1,0.3944,0.6056
num- num-phosphonylmethoxyethyl -num num-diaminopurin human immunodefici viru hiv replic num- num-phosphonylmethoxyethyl -num num-diaminopurin pmedap potent inhibitor human immunodefici viru hiv replic evalu activ against human cytomegaloviru hcmv vitro murin cytomegaloviru mcmv rat cmv rcmv vivo,0,1.0,0.0
vancomycin infect order determin extent vancomycin resist enterococcu vre colonis within paediatr oncolog unit risk factor acquisit organ molecular epidemiolog isol impact infect control measur extens patient environment surveil undertaken identif antibiot suscept test pulsed-field gel electrophoresi pfge vre isol,0,0.8066,0.1934
dapson psoriasi describ num2-year-old chines woman develop dh num week dapson therapi pustular palmoplantar psoriasi,0,0.8219,0.17810000000000006
etoricoxib postop pain clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,1.0,0.0
polyvinyl alcohol intraoss lesion patient embol fiber coil direct punctur coil place directli center intraoss lesion case conjunct polyvinyl alcohol foam n-butyl-num-cyanoacryl vascular access,0,1.0,0.0
pioglitazon cardiac diseas pioglitazon group two death two non-fat hospitalis occur due cardiac problem placebo group two occurr cardiac diseas,0,0.6036,0.3964
atp hypoton challeng hypoton challeng not camp stimul found induc releas atp measur luciferin-luciferas assay murin mammari carcinoma cell line cnum3i cnum3 cell stabli transfect cdna human cystic fibrosi transmembran conduct regul cftr protein cnum3/cftr,0,0.8065,0.1935
asenapin mania num-week extens studi recruit complet monotherapi trial no signific differ asenapin olanzapin group term montgomery-iesberg depress rate scale madr score cgi-bp mania sever score ymr respons rate ymr remiss rate extens phase,0,1.0,0.0
duloxetin hydrochlorid major depress duloxetin hydrochlorid dual reuptak inhibitor serotonin norepinephrin evalu therapeut efficaci safety/toler treatment major depress,0,1.0,0.0
verteporfin amd/age-rel macular degener report outcom eye treat intravitr inject bevacizumab combin verteporfin photodynam therapi pdt choroid neovascular cnv age-rel macular degener amd,0,1.0,0.0
glucos stomach cancer/colon cancer human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0
loratadin ocular dryness loratadin cetirizin hydrochlorid induc sign symptom associ ocular dryness includ increas corneal conjunctiv stain decreas tfbut increas ocular discomfort healthi individu,1,0.0,1.0
naftidrofuryl normal tension glaucoma administr num x num3 mg/day naftidrofuryl num week num2 patient normal tension glaucoma shown improv visual acuiti visual field compar num-week period placebo administr double-blind studi method,0,1.0,0.0
creatinin ssc baselin subject stabl moder sever diffus ssc diseas durat num year modifi rodnan skin score num2 serum creatinin num mg/dl percentag forc vital capac fvc predict num2 dlco predict num2 not receiv concomit diseas modifi therapi,0,1.0,0.0
num-fluorouracil excess lacrim ocular side effect system num-fluorouracil therapi includ excess lacrim often resolv cessat therapi,1,0.0,1.0
glucos tumor examin effect vst upr induc glucos depriv stressor tumor growth vivo,0,1.0,0.0
androgen prostat cancer androgen ablat remain cornerston manag advanc prostat cancer,0,1.0,0.0
adrenaline/epinephrin bleed compar efficaci endoscop band ligat vs. hemoclip plu epinephrin adrenalin bleed mw,0,1.0,0.0
yohimbin ptsd metabol tend decreas patient ptsd increas healthi subject follow administr yohimbin,0,1.0,0.0
alcohol brain damag drink pattern includ period alcohol consumpt follow abstin bing drink may enhanc possibl brain damag,1,0.0,1.0
doxycyclin furcat defect regener degre ii furcat defect num doxycyclin hyclat bioabsorb barrier,0,0.6007,0.3993
quinin blind quinin ocular toxic treatment blind use therapi vasospasm,0,0.7906,0.20940000000000006
apomorphin parkinson iontophoret deliveri apomorphin in-vitro model parkinson patient,0,1.0,0.0
pamidron bone pain repeat pamidron infus exert clinic relev analges effect half patient metastat bone pain,0,0.8111,0.1889
glutathion cross-resist howev cisplatin-resist subpopul num4ddp4 show highest glutathion level mark cross-resist bleomycin,0,1.0,0.0
somatostatin neuroendocrin tumor treatment patient inoper metastas neuroendocrin tumor somatostatin analogu label radioisotop num3 num2 num3 lu use far,0,1.0,0.0
raloxifen inflammatori result show tamoxifen raloxifen ici num3numnum3 induc anti-inflammatori respons acut model mous rat microgli cell,0,1.0,0.0
num-fluorouracil adenocarcinoma colon capecitabin oral prodrug num-fluorouracil use treatment adenocarcinoma colon,0,1.0,0.0
aspirin bronchial hypersensit g allel ccr3 -num3t g associ persist bronchial hypersensit aspirin,1,0.1863,0.8137
corticosteroid dermat num patient dermat consecut patch test allerg one corticosteroid,0,1.0,0.0
y-num5 hepatocellular carcinoma inhibit intrahepat metastasi human hepatocellular carcinoma rho-associ protein kinas inhibitor y-num5,0,0.601,0.39899999999999997
steroid inflamm twenty-eight eye num2 patient anterior segment inflamm refractori steroid treatment treat numnum2 tacrolimu ointment samsung medic center seoul korea march num4 august num4,0,1.0,0.0
cbz/carbamazepin epilept pharmacoresist epilept patient may ascrib least two not mutual exclus mechan pharmacokinet mechan decreas sensit avail target antiepilept drug a i.e. carbamazepin phenytoin cbz pht,0,1.0,0.0
amifostin xerostomia no statist signific differ effect amifostin acid-stimul agent incid xerostomia rr numnum2 num2 ci numnum2 numnum2 decreas scintigraph measur uptak num2m tc parotid rr numnum2 num2 ci -numnum2 numnum2 submandibular gland rr numnum2 num2 ci -numnum2 numnum2 num2 month reduct blood pressur rr numnum2 num2 ci numnum2 num2numnum2,0,1.0,0.0
glutathion necrosi molecular mechan regul glutathion synthesi tumor necrosi factor-alpha dexamethason human alveolar epitheli cell,0,1.0,0.0
nac cannabi depend studi analyz suggest potenti role nac treatment addict especi cocain cannabi depend,0,1.0,0.0
corticosteroid colon diverticula underappreci relationship perfor colon diverticula corticosteroid therapi,0,0.7895,0.2105
corticosteroid cognit impair although patient initi stabil therapi corticosteroid plasma exchang mitoxantron sever cognit impair persist eventu die sequela diseas,0,0.7942,0.2058
itraconazol oral candidosi aim studi evalu efficaci side effect itraconazol treatment oral candidosi,0,1.0,0.0
aspart hepat c. includ requir improv enzymolog screen despit introduct test hepat c imbal popular unexplain chronic aminotransferas elev effort solv inher problem inadequ attempt use metabol chang hepatocyt improv diagnosi prognosi pathophysiolog understand viral liver diseas remark investig num'-num'-oligoadenyl synthetas better control interferon therapi chronic viral hepat use enzym marker etiolog particularli detect alcohol induc liver diseas continu prefer aminotransferas scenario although ratio aspart aminotransferas alanin aminotransferas mitochondri aspart aminotransferas total aspart aminotransferas activ larg depend sever intralobular local damag stage liver diseas,0,1.0,0.0
procaterol asthmat examin effect procaterol beta num-adrenoceptor agonist skin wheal respons histamin platelet-activ factor paf substanc p bradykinin eight asthmat children double-blind random cross-ov studi,0,1.0,0.0
bp bone diseas bp provid support care reduc rate skelet morbid evid not abolish criteria stop administr differ use classic antineoplast drug not stop metastat bone diseas progress,0,1.0,0.0
fluoroquinolone/fluoroquinolon bacteri kerat compar vitro suscept pattern minimum inhibitori concentr mic gatifloxacin gat moxifloxacin mox fourth-gener fluoroquinolon ciprofloxacin cip ofloxacin ofx second-gener fluoroquinolon levofloxacin lev third-gener fluoroquinolon use bacteri kerat isol,0,1.0,0.0
thalidomid lch conclus thalidomid monotherapi repres effect safe well-toler treatment option consid first-lin therapi mucocutan lch,0,1.0,0.0
estrogen hypopituitar effect oral transderm estrogen igf1 igfbp3 igfbp1 serum lipid glucos patient hypopituitar gh treatment random studi,0,0.8026,0.1974
num-fu neutropenia besid milder neutropenia observ give lipofufol anim transient partial dpd-defici compar standard num-fu,0,1.0,0.0
catecholamin adhd studi behavior physiolog action clinic behavior relev dose mph normal anim provid opportun explor role catecholamin transmitt prefront cortic function attent process relat normal oper brain circuit adhd patholog,0,0.6026,0.3974
lactic acid hypoxia sf sampl patient hmgb-num-associ inflammatori arthropathi inume. sampl hmgb-num level num sd mean level sampl patient noninflammatori arthropathi concentr hmgb-num significantli correl lactic acid marker tissu hypoxia,0,0.6084,0.3916
coumarin alveolar hemorrhag hypothes patient treat coumarin alveolar hemorrhag associ vitamin k epoxid reductas vkorc1 cytochrom pnum3 cyp 2c9 cyp2c9 variant allel,0,1.0,0.0
platinum cancer although higher level cmax may increas side-effect hypoton condit i.pl fluid increas auc plasma may escal accumul platinum i.pl cancer cell,0,1.0,0.0
flavon rb result suggest g1 phase arrest flavon due pnum2-independ transcript induct pnum2/waf1 gene subsequ dephosphoryl rb protein,0,1.0,0.0
tyrosin thyroid carcinoma tyrosin kinas inhibitor rel new target therapi drug use treatment metastat clear cell kidney carcinoma gastrointestin stromal tumour thyroid carcinoma pancreat neuroendocrin tumour progress diseas,0,1.0,0.0
dopamin drug action howev administr dopamin postsynapt antagonist expect increas synapt dopamin avail therebi increas hva concentr accord tradit model drug action,0,1.0,0.0
cyclophosphamid hc patient hc cyclophosphamid ifosfamid neg bacteri cultur studi bkv,1,0.3994,0.6006
medroxyprogesteron acet neutropenia effect high-dos medroxyprogesteron acet tumor necrosi factor-alpha releas patient chemotherapy-induc neutropenia,0,1.0,0.0
nucleosid human immunodefici viru object studi determin popul pharmacokinet paramet extent absorpt num num'-dideoxyinosin nucleosid analog activ against human immunodefici viru vitro vivo oral intraven administr use non-linear mix effect model,0,1.0,0.0
cadmium tumorigenesi find demonstr first time cell transform tumorigenesi induc cadmium due least part overexpress tef-num delta novel cadmium-respons proto-oncogen,1,0.2131,0.7869
arsen cytotox pretreat myeloid leukemia line hl-num2 all-tran retino acid atra up-regul aqp9 lead significantli increas arsen uptak as2o3-induc cytotox incub as2o3 might explain synerg atra as2o3,0,0.8011,0.1989
corticosteroid pneumocysti pneumonia clinic pictur consist pneumocysti pneumonia antibiot therapi corticosteroid initi,0,1.0,0.0
estrogen hypertens estrogen effect heart rate variabl hypertens postmenopaus women,0,0.799,0.201
losartan hypertens stroke comparison effect amlodipin losartan blood pressur diurnal variat hypertens stroke patient prospect random double-blind compar parallel studi,0,1.0,0.0
glucos hyperglycemia cessat blood glucose-low therapi combin num-day vlcd not lead hyperglycemia associ reduct basal egp,0,1.0,0.0
ropivacain postop pain thorac epidur numnum2 num ropivacain provid effect postop pain control combin fentanyl without motor block,0,0.7961,0.2039
glucos pain aural canal core skin surfac num2 site temperatur oxygen consumpt pain visual analogu score concentr epinephrin norepinephrin glucos cortisol lactat free fatti acid plasma measur epidur blockad num2 min epidur blockad end surgeri num h surgeri,0,1.0,0.0
pentoxifyllin endometriosi compar outcom conserv surgeri endometriosi without pentoxifyllin assess efficaci pentoxifyllin prevent recurr endometriosi conserv surgeri,0,1.0,0.0
amiodaron atrial fibril vernakal demonstr effect placebo amiodaron rapid convers atrial fibril without signific advers event,0,0.8044,0.1956
remifentanil hypotens episod hypotens transient reduct splanchnic perfus common patient treat remifentanil compar receiv fentanyl opioid regimen,1,0.0,1.0
num-fluorouracil rectal cancer patient histolog proven rectal cancer stage t2n+ t3 random receiv either scrt num2 gy five fraction num gy plu tme-surgeri within num day rct num2num gy num2 fraction num gy continu infus num-fluorouracil plu tme-surgeri num-num week later,0,1.0,0.0
tyrosin pancreat neuroendocrin tumours/gastrointestin stromal tumour tyrosin kinas inhibitor rel new target therapi drug use treatment metastat clear cell kidney carcinoma gastrointestin stromal tumour thyroid carcinoma pancreat neuroendocrin tumour progress diseas,0,1.0,0.0
nevirapine/nvp aid analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
curcumin ag studi morpholog observ indic curcumin inhibit prolifer ag cell dose-depend manner,0,0.7843,0.2157
ipratropium bromid rhinorrhea review assess two wide use intranas treatment nasal congest rhinorrhea common cold xylometazolin hydrochlorid ipratropium bromid,0,1.0,0.0
coumadin mitral stenosi compar studi efficaci coumadin aspirin primari cardioembol stroke prevent chronic rheumat heart diseas mitral stenosi atrial fibril conduct siriraj hospit mahidol univers bangkok thailand,0,1.0,0.0
capecitabin head neck cancer predict therapeut valu thymidin phosphorylas dihydropyrimidin dehydrogenas capecitabin xeloda -base chemotherapi head neck cancer,0,1.0,0.0
pimar acid/pima necrosi studi reveal pimar acid pima purifi aralia cordata inhibitori effect mmp-num product migrat human aortic smooth muscl cell hasmc induc tumor necrosi factor tnf -e. down-regul mmp-num mrna transcript detect pima-tr cell use rt-pcr luciferase-tag mmp-num promot assay,0,1.0,0.0
phosphat ckd consid treat ckd patient requir phosphat binder oral vitamin,0,1.0,0.0
mitomycin non-small-cel lung cancer durat chemotherapi advanc non-small-cel lung cancer random trial three versu six cours mitomycin vinblastin cisplatin,0,1.0,0.0
nimodipin vasospasm therapi vasospasm use nimodipin hypertens haemodilut hypervolaemia institut subsequ resolut symptom,0,1.0,0.0
quinotrierixin paradox paradox quinotrierixin exacerb endoplasm reticulum stress-induc phosphoryl eif2 turn led decreas protein translat,0,1.0,0.0
tobramycin cystic fibrosi undertook assess hear patient cystic fibrosi take part larg random control trial once- versu three-times-daili tobramycin pulmonari exacerb cystic fibrosi topic studi,0,1.0,0.0
caffein breast cancer describ baselin healthi lifestyl behavior dietari calcium vitamin caffein alcohol intak smoke histori physic activ postmenopaus breast cancer survivor bc identifi relationship healthi lifestyl behavior bone miner densiti bmd forearm total hip spine l1-l4,0,1.0,0.0
simvastatin hypercholesterolemia simvastatin hmg-coa reductas inhibitor list essenti drug treatment hypercholesterolemia,0,1.0,0.0
epinephrin prostat cancer recent report show stress inhibit apoptosi prostat cancer cell via epinephrine/beta2 adrenerg receptor/pka/bad pathway,0,1.0,0.0
copper cytotox real-tim monitor copper ions-induc cytotox ei cell chip,1,0.19900000000000007,0.8009999999999999
piperacillin septicaemia compar efficaci safeti studi teicoplanin plu aztreonam versu gentamicin plu piperacillin haematolog oncolog patient clinic diagnos septicaemia,0,1.0,0.0
steroid uc patient refractori uc remiss due la induct la combin steroid therapi,0,1.0,0.0
testosteron hypogonad osteoporosi testosteron replac therapi improv bone densiti men hypogonad osteoporosi particularli epiphys still open,0,1.0,0.0
capsaicin spinal nerv ligat erb-num3 allevi tactil hyperalgesia induc capsaicin revers tactil allodynia caus spinal nerv ligat variou chemic insult,0,1.0,0.0
sildenafil ed incid naion men receiv sildenafil treatment ed estim use pool safeti data global clinic trial european observ studi,0,1.0,0.0
tacrolimu ocular graft versu host disease/gvhd determin whether topic tacrolimu might prove effect treatment refractori anterior segment inflammatori diseas evalu efficaci eye ocular graft versu host diseas gvhd vernal keratoconjunct vkc,0,1.0,0.0
clindamycin hiv-infect hiv-infect man becam increasingli breathless cyanos receiv clindamycin primaquin treatment pneumocysti jirovecii pneumonia,0,1.0,0.0
ropinirol parkinson 's disease/pd non-ergot dopamin receptor agonist ropinirol pramipexol rotigotin apomorphin may allevi non-motor symptom parkinson 's diseas pd other may precipit,0,1.0,0.0
aspirin ischem stroke aspirin treatment failur risk recurr stroke death among patient ischem stroke,0,1.0,0.0
steroid infecti myeliti present five patient num affect classic dissemin encephalomyel num post infecti myeliti show good respons intraven immunoglobulin ivig steroid treatment failur,0,1.0,0.0
lamivudin hbv infect administr adefovir patient resist lamivudin seem effect safe way de novo hbv infect,0,1.0,0.0
leukovorin colorect cancer num2-year-old patient coexist primari choroid melanoma colorect cancer treat extern beam radiat ebr choroid melanoma system chemotherapi leukovorin/num fluorouracil fu treatment metastat colorect cancer,0,1.0,0.0
num-fluorouracil toxic feasibl toxic local respons rate intra-arteri chemotherapi num-fluorouracil epirubicin mitomycin patient num2 year local advanc breast cancer evalu,0,0.7948,0.20520000000000005
calcium abdomin pain taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.6036,0.3964
pregabalin dizzi pregabalin well toler common advers event dizzi somnol,1,0.19710000000000005,0.8029
metformin diabet howev littl known effect metformin no-reflow diabet patient,0,1.0,0.0
tegafur colorect carcinoma studi set out evalu patient metastat colorect carcinoma efficaci toxic s-num contain tegafur num-chloro-num num-dihydroxypyridin cdhp potassium oxon base biochem modul num-fluorouracil num-fu target inhibit dihydropyrimidin dehydrogenas dpd,0,0.6111,0.3889
ropivacain akinesia ropivacain use retrobulbar-peribulbar combin anesthesia vitreoretin surgeri show excel clinic efficaci regard analgesia muscl akinesia,0,1.0,0.0
terazosin diabet terazosin maintain antihypertens efficaci well toler patient varieti concomit diseas includ congest heart failur peripher vascular diseas chronic obstruct pulmonari diseas benign prostat hyperplasia diabet obes,0,1.0,0.0
lidocain fibromyalgia fibromyalgia impact questionnair fiq health assess questionnair visual analog scale va pain appli first lidocain infus immedi fifth infus num2 day fifth infus,0,1.0,0.0
atra/all-tran retino acid hl present studi demonstr bufalin enhanc all-tran retino acid atra induc differenti hl-num2 cell accompani up-regul cbl famili ubiquitin ligas,1,0.19900000000000007,0.8009999999999999
dopamin schizophrenia observ support idea d4 might serv target clozapin significantli modifi extend understand mechan underli atyp antipsychot treatment schizophrenia well dopamin hypothesi schizophrenia,0,1.0,0.0
alinidin sinu arrest atenolol alinidin significantli decreas basic heart rate without caus sinu arrest higher-degre atrioventricular block,0,1.0,0.0
dopamin attent deficit-hyperact disorder/adhd methylphenid mph -ritalin r compound block reuptak synapt releas norepinephrin ne dopamin da brain use num2 year low dose long-term regimen treat attent deficit-hyperact disord adhd juvenil adolesc adult,0,1.0,0.0
tzd type aim investig impact coadministr tzd acei/arb hematocrit hemoglobin valu uncompl patient type num diabet mellitu normal serum creatininenumdata patient type num diabet current follow review patient treat acei/arb and/or tzd identifi,0,1.0,0.0
thymidin head neck cancer predict therapeut valu thymidin phosphorylas dihydropyrimidin dehydrogenas capecitabin xeloda -base chemotherapi head neck cancer,0,1.0,0.0
glucos glucos intoler accumul data develop glucos intoler adult receiv clozapin closer monitor bodyweight fast blood glucos imper,0,1.0,0.0
prednison ra eleven ra patient mean age num2+/-num year diseas durat num+/-num year high diseas activ despit treatment stabl dose methotrex prednison or=num2 mg/d investig,0,1.0,0.0
alcohol cardiomyopathi moreov alcohol abus produc cardiac arrhythmia hypertens cardiomyopathi stroke even sudden death,1,0.0,1.0
polyethylen glycol critic ill. laxat critic ill patient lactulos polyethylen glycol two-cent random double-blind placebo-control trial,0,0.8108,0.18920000000000006
vemurafenib cancer new agent possess uniqu toxic profil includ immune-rel advers event ipilimumab secondari cutan cancer report vemurafenib use,1,0.0,1.0
aldicarb farmer 's lung insecticid ddt lindan aldicarb posit associ farmer 's lung among farmer,1,0.0,1.0
ramipril adpkd prospect random double-blind studi perform compar renal cardiac effect ace inhibitor ramipril beta-block metoprolol first line therapi adpkd patient hypertens,0,1.0,0.0
fluoxetin depress one hundr patient major depress discontinu fluoxetin side effect enrol multicent open num-week studi sertralin,0,0.7864,0.2136
etomid seizures/seizur propofol group shorter mean electroencephalogram etomid num2numnum2 num2numnum2 propofol num2numnum2 num2numnum2 p numnum3 seizur durat motor etomid num2numnum2 num2numnum2 propofol num2numnum2 numnum2 p numnum3 seizur durat higher mean number inadequ seizur etomid numnum2 numnum2 propofol numnum2 numnum2 p numnum3,0,0.7989,0.20109999999999995
docetaxel hypox character spatial distribut abil th-num3 select target hypox region complement effect doxorubicin docetaxel modifi biomark distribut,0,1.0,0.0
bortezomib escc thu bortezomib could sensit escc trail apoptosi multipl molecular mechan action,0,0.8213,0.17869999999999994
roxithromycin advers drug reaction/ten/tox epiderm necrolysi case report highlight rare advers drug reaction oral roxithromycin caus toxic epiderm necrolysi ten,1,0.20540000000000005,0.7946
tyrosin chronic myeloid leukemia mechan novel approach overrid tyrosin kinas inhibitor resist chronic myeloid leukemia,0,1.0,0.0
fatti acid colorect cancer vitamin miner essenti fatti acid colorect cancer risk unit kingdom dietari cohort consortium,0,1.0,0.0
lamotrigin bipolar disord lithium divalproex sodium carbamazepin lamotrigin atyp antipsychot antidepress found benefici treatment elderli patient bipolar disord,0,1.0,0.0
mpa mpa median mpa concentr num num microg/ml patient within c2 rang respect p numnum2,0,1.0,0.0
cholesterol hypertens hypertens patient microalbuminuria manifest greater level blood pressur particularli night higher serum level cholesterol triglycerid uric acid patient normal uae,0,1.0,0.0
thymalfasin hepat b. thymalfasin treatment hepat b c. thymalfasin exhibit immunomodulatori direct antivir mechan action,0,1.0,0.0
cyanoacryl arrest acut gv bleed cyanoacryl glue inject could achiev arrest acut gv bleed often alcohol num2 vs num2 need rescu surgeri less differ howev not signific,1,0.1828,0.8172
silicon granulomat inflamm lung biopsi demonstr numer spheroid silicon particl within lung interstitium small pulmonari vessel surround foreign bodi giant cell nonnecrot granulomat inflamm,0,0.7964,0.2036
bisphosphon cancer bisphosphon cancer patient,0,1.0,0.0
lidocain pain fibromyalgia impact questionnair fiq health assess questionnair visual analog scale va pain appli first lidocain infus immedi fifth infus num2 day fifth infus,0,0.6101,0.3899
tsa inflamm effect tsa express inflammation-rel growth factor collagen examin real-tim rt-pcr immunoassay mous macrophag human subconjunctiv fibroblast,0,0.8024,0.1976
sodium bicarbon renal failur sodium bicarbon suggest possibl strategi prevent contrast medium-induc nephropathi common caus renal failur associ prolong hospit increas health care cost substanti morbid mortal,0,1.0,0.0
methylprednisolon leukem differenti arsen trioxid methylprednisolon use differ signal transduct pathway leukem differenti,0,0.7902,0.2098
oxygen bronchopulmonari dysplasia multipl regress analysi explain bronchopulmonari dysplasia use gestat age inspir oxygen day num-num protein carbonyl day num independ variabl protein carbonyl remain signific,0,1.0,0.0
cyclophosphamid medulloblastoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
somatostatin obes clarifi pathogenesi underli alter six obes patient num male num femal age num2-num2 yr bmi num2num +/- num unrestrict diet studi effect num day ghrh pretreat num micrograms/kg iv day acut somatotrop respons neurohormon administ alon combin arginin arg num g/kg iv infus num num2 min like inhibit releas hypothalam somatostatin,0,0.7956,0.20440000000000005
sodium bicarbon nephropathi sodium bicarbon vs sodium chlorid prevent contrast medium-induc nephropathi patient undergo coronari angiographi random trial,0,0.8186,0.1814
fludarabin graft-versus-host diseas multi-institut studi post-transplant cyclophosphamid single-ag graft-versus-host diseas prophylaxi allogen bone marrow transplant use myeloabl busulfan fludarabin condit,0,0.7904,0.2096
androgen prostat cancer/pca prostat cancer pca therapi typic involv administr classic antiandrogen competit inhibitor androgen receptor ar ligand dihydrotestosteron dht testosteron te ligand-bind pocket lbp ligand-bind domain lbd ar,0,1.0,0.0
oxygen hypertens review focus vascular action reactiv oxygen speci role oxid stress vascular damag hypertens therapeut potenti modul oxygen radic bioavail hypertens,0,1.0,0.0
erythromycin rash small good qualiti trial num2 peopl compar oral erythromycin placebo found erythromycin effect placebo term rash improv rate trialist two week rr num2numnum2 num2 ci numnum2 num2numnum2,0,1.0,0.0
melphalan ependymoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
enalapril congest heart failur outcom patient congest heart failur treat standard versu high dose enalapril multicent studi,0,1.0,0.0
creatinin type aim investig impact coadministr tzd acei/arb hematocrit hemoglobin valu uncompl patient type num diabet mellitu normal serum creatininenumdata patient type num diabet current follow review patient treat acei/arb and/or tzd identifi,0,1.0,0.0
nimodipin hypertens therapi vasospasm use nimodipin hypertens haemodilut hypervolaemia institut subsequ resolut symptom,0,0.7937,0.20630000000000004
ethanol toxic inhibitor pnum3 2e1 activ ethanol num-methylpyrazol isoniazid caus num2 decreas methyl cellular macromolecul also complet protect cell against ndma-medi toxic,0,1.0,0.0
mtx toxic slco1b1 transport involv mtx elimin polymorph gene pathway could also role mtx toxic,1,0.19610000000000005,0.8039
ramosetron postop nausea vomit ramosetron prevent postop nausea vomit women undergo gynecolog surgeri,0,1.0,0.0
irbesartan atrial fibril active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0
vitamin e. cataract prior vitamin e supplement may protect vecat particip develop least earli cortic cataract,0,1.0,0.0
aspirin cardiac embol studi not support use aspirin primari prevent cardiac embol chronic rheumat heart diseas,0,1.0,0.0
corticosteroid local system corticosteroid patient receiv no treatment short-term a_1 year treatment includ local system corticosteroid long-term num year treatment includ system corticosteroid second-lin immunosuppress agent,0,1.0,0.0
calcium urticaria present studi aim test therapeut effect side effect nimodipin therapi new dihydropyridin anti-calcium deriv physic stimulus-induc urticaria comparison standard h1-antihistamin therapi,0,1.0,0.0
etoposide/vpnum2 cancer five cancer cell line resist irinotecan snnum2 paclitaxel ptx etoposid vpnum2 oxaliplatin oxa gemcitabin gem respect establish parent gastric cancer cell line ocum-2m name ocum-2m/snnum2 ocum-2m/ptx ocum-2m/vpnum2 ocum-2m/oxa ocum-2m/gem,0,1.0,0.0
bortezomib death escc bortezomib treatment result effici recruit caspase-num fas-associ death domain death-induc signal complex,0,1.0,0.0
silicon hiv-num-infect specul hiv-num-infect patient may risk chronic progress granulomat pneumon due silicon inject year procedur owe shift level cell-medi immun,0,0.8343,0.16569999999999996
fentanyl hypoventil contraind manag acut postop pain pain may decreas rapidli circumst fentanyl blood level adjust lead develop life-threaten hypoventil,1,0.1939,0.8061
prednison daili headach studi aim analys possibl use short cours oral prednison detoxifi patient chronic daili headach due medic overus out-pati set,0,0.8079999999999999,0.1920000000000001
piperacillin posttraumat endophthalm describ case posttraumat endophthalm unrespons system amoxicillin+clavulan acid piperacillin/tazobactam intra-ocular vancomycin topic ofloxacin tetracyclin sulfametoxazol antibiot therapi,0,1.0,0.0
clopidogrel atrial fibril active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0
magnesium colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,1.0,0.0
quinin vasospasm quinin ocular toxic treatment blind use therapi vasospasm,0,1.0,0.0
bortezomib escc escc bortezomib treatment result effici recruit caspase-num fas-associ death domain death-induc signal complex,0,1.0,0.0
atp dlbcl herein assess role syk-depend tonic bcr surviv signal dlbcl cell line primari tumor evalu efficaci atp-competit inhibitor syk rnum3 vitro,0,1.0,0.0
glucos hypopituitar effect oral transderm estrogen igf1 igfbp3 igfbp1 serum lipid glucos patient hypopituitar gh treatment random studi,0,1.0,0.0
gemcitabin refractori hodgkin 's diseas gemcitabin treatment relaps refractori hodgkin 's diseas,0,1.0,0.0
simvastatin multipl sclerosi aim investig use oral simvastatin num2 mg num2 individu relapsing-remit multipl sclerosi,0,1.0,0.0
isoquinolin cancer berberin bbr isoquinolin deriv alkaloid isol chines herb long histori use treatment multipl diseas includ cancer,0,1.0,0.0
mitoxantron cardiotox suppress mitoxantron cardiotox multipl sclerosi patient dexrazoxan,0,0.7876,0.21240000000000006
glucos type conclus rosiglitazon direct protect effect glucos uptak wild-typ human podocyt,0,1.0,0.0
imatinib cml observ recent trial imatinib combin insight provid increas understand molecular mechan resist establish rational strategi avoid overcom imatinib resist manag cml patient,0,1.0,0.0
tryptophan bipolar affect disord clinic neurochem effect acut tryptophan deplet unaffect rel patient bipolar affect disord,0,1.0,0.0
l-ornithine-l-aspart hyperammonemia therefor therapeut efficaci oral l-ornithine-l-aspart improv impair ammonia detoxif investig patient cirrhosi hyperammonemia stabl overt chronic hepat encephalopathi subclin hepat encephalopathi random double-blind placebo-control clinic trial,0,1.0,0.0
calcium hypertens epidemiolog clinic studi suggest magnesium may reduc frequenc sudden death sodium contribut occurr hypertens calcium may help prevent osteoporosi,0,1.0,0.0
clozapin attrit clozapin uniqu effect refractori schizophrenia treatment attrit high,1,0.3919,0.6081
ecstasi depress depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0
telmisartan cardiovascular diseas present studi suggest due delta lock structur telmisartan may superior arb halt cardiovascular diseas patient hypertens,0,1.0,0.0
vitamin d. op therefor studi issu vitamin d-deplet ovariectom ovx rat op model previous shown induc weaken femor neck thu thought closer human condit classic ovx rat model,0,1.0,0.0
vigabatrin seizur vigabatrin anti-epilept drug particularli use drug-resist partial seizur infantil spasm,0,0.7957,0.20430000000000004
nitric oxide/no tumor ep shown decreas express variou pro-inflammatori mediat includ nitric oxid no* tumor necrosi factor tnf cyclooxygenase-num interleukin il -num varieti vitro vivo model system,0,1.0,0.0
apomorphin parkinson interest rout control deliveri apomorphin transderm iontophoresi could enabl parkinson patient directli control need amount apomorphin increas decreas drug input order achiev optim drug therapi 'on-demand minimum toxic side effect,0,1.0,0.0
vinca alkaloid neurotox articl provid overview incid characterist manag mti-associ neurotox known vinca alkaloid taxan well newer agent vinflunin ixabepilon,0,1.0,0.0
ammonia hepat encephalopathi therefor therapeut efficaci oral l-ornithine-l-aspart improv impair ammonia detoxif investig patient cirrhosi hyperammonemia stabl overt chronic hepat encephalopathi subclin hepat encephalopathi random double-blind placebo-control clinic trial,0,1.0,0.0
quinin ocular toxic quinin ocular toxic treatment blind use therapi vasospasm,1,0.3738,0.6262
methamphetamin addict studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,1,0.21040000000000006,0.7896
ibandron bone pain patient ibandron num mg also experienc decreas bone pain score analges use,0,0.7933,0.2067
testosteron head injuri three month head injuri hormon evalu hypothalamic-pituitari axi mean insulin stress test simultan administr trh gnrh result reduc respons gh cortisol tsh fsh lh low baselin serum concentr free t4 testosteron,0,1.0,0.0
methicillin infect methicillin-resist staphylococcu aureu mrsa well-recogn agent health care-associ infect long-term care facil data circul mrsa set itali avail,0,0.789,0.211
propranolol hemangioma assess theaesafeti effect oral propranolola op treatment infantil hemangioma,0,1.0,0.0
prostacyclin neutropenia effect prostacyclin bronchoconstrict neutropenia induc inhal platelet-activ factor man,0,1.0,0.0
manidipin headach two case delapril group withdrawn studi intoler cough one case manidipin group intoler dizzi headach,1,0.21519999999999995,0.7848
salbutamol breathless respons regular inhal fenoterol ipratropium bromid meter dose inhal mdi larg volum spacer regular nebul salbutamol ipratropium bromid assess home peak flow record spirometri two subject score rate breathless simpl four-point scale b activ score st georg 's respiratori questionnair,0,1.0,0.0
calcium respiratori distress taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.8097,0.1903
l-ornithine-l-aspart cirrhosi oral l-ornithine-l-aspart safe well-toler treatment good complianc rate benefici therapeut effect patient cirrhosi stabl overt chronic hepat encephalopathi,0,1.0,0.0
vardenafil dm vardenafil improv success intercours rate compar placebo japanes dm patient insert earli num2 minut num3 minut dose,0,1.0,0.0
heparin thromboembol retrospect evalu effect heparin use thromboembol bleed complic implant heartmat ii left ventricular assist devic lvad,0,0.8156,0.1844
testosteron osteoporosi effect testosteron osteoporosi men,0,0.8008,0.19920000000000004
paclitaxel head neck cancer purpos cisplatin plu fluorouracil pf induct chemotherapi compar taxan docetaxel paclitaxel cisplatin fluorouracil tax-pf random trial locoregion advanc head neck cancer lahnc,0,1.0,0.0
silic lung diseas hypothesi lung diseas silic inhal caus oxid gener,1,0.385,0.615
tyrosin adenocarcinoma aim determin whether receptor tyrosin kinas rtk array could use select effect therapeut strategi molecularli heterogen oesophago-gastr adenocarcinoma,0,1.0,0.0
progesteron gallbladd diseas find consist increas incid gallbladd diseas relat high-progesteron state suggest mpa may caus agent cholelithiasi,1,0.20130000000000006,0.7987
atp avb patient atp induc long ventricular paus relat avb mean durat num2num rang num num2,1,0.3986,0.6014
azathioprin urticari vascul num2-year-old woman num yr histori chronic recurr urticari vascul angioedema refractori convent treatment includ glucocorticosteroid h1 h2 blocker nonsteroid antiinflammatori agent methotrex hydroxychloroquin dapson azathioprin intraven gamma globulin plasma exchang success treat interferon alpha 2a,0,0.7941,0.2059
cd fetal death anim experi high-dos exposur cd induc sever testicular interstiti hemorrhag edema increas incid fetal death placent necrosi,1,0.3955,0.6045
lutein melanoma purpos effect lutein express mmp inhibitor timp tissu inhibitor metalloproteinas dermal fibroblast intrins age melanoma cell examin,0,1.0,0.0
prasugrel myocardi infarct data num3 patient undergo isol coronari arteri bypass graft trial assess improv therapeut outcom optim platelet inhibit prasugrel thrombolysi myocardi infarct num2 analyz retrospect,0,1.0,0.0
histamin sleep cognit disord antagon histamine-h num receptor one tactic explor increas wake treatment disord excess daytim sleepi ed well sleep cognit disord,0,0.8109999999999999,0.18900000000000008
capecitabin hnscc effect tp transgen express alter tp dpd ratio henc optim therapeut outcom capecitabin treatment evalu murin model human hnscc use immunohistochemistri detect tp dpd express vivo,0,1.0,0.0
fludarabin graft-versus-host disease/gvhd clinic safeti efficaci intraven busulfan fludarabin iv bu/flu myeloabl condit well graft-versus-host diseas gvhd prophylaxi high-dos post-transplant cyclophosphamid ptci demonstr independ sever single-institut studi,0,1.0,0.0
pentoxifylline/ptx tumor pentoxifyllin ptx phosphodiesteras inhibitor known downregul tumor necrosi factor-alpha tnf-alpha secret induc lipopolysacchrid lp gamma interferon ifn-gamma,0,1.0,0.0
sorafenib ptc num2-year-old girl progress lung metastas ptc despit previou therapi almost num3 mci num3 i. sorafenib initi start dose num3 mg twice daili decreas mainten dose num3 mg daili due side effect develop within num week treatment,0,1.0,0.0
tetracain ear infect use extemporan compound num tetracain improv adher clotrimazol num topic solut treatment ear infect case report,0,1.0,0.0
octreotid sleep apnea improv indic sleep apnea sever occur associ octreotid treatment patient sleep apnea acromegali,0,0.8059,0.19410000000000005
ammonia hyperammonemia therefor therapeut efficaci oral l-ornithine-l-aspart improv impair ammonia detoxif investig patient cirrhosi hyperammonemia stabl overt chronic hepat encephalopathi subclin hepat encephalopathi random double-blind placebo-control clinic trial,0,1.0,0.0
bp myeloma/multipl myeloma even better result achiev patient multipl myeloma gener consensu bp start soon diagnosi lytic diseas made myeloma patient,0,1.0,0.0
num-ht contract ring intact endothelium num-ht1-like-select agonist sumatriptan caus small contract -log ecnum2 num intrins activ numnum2 respect num-ht resist blockad num4 nm ketanserin antagon num3 nm methiothepin,0,1.0,0.0
dexrazoxan multipl sclerosi result support cardioprotect effect dexrazoxan mitoxantron treat multipl sclerosi patient,0,1.0,0.0
testosteron metabol syndrom relationship among obes metabol syndrom ed sex hormone-bind globulin shbg serum total free testosteron level complex often confus physician,0,0.8324,0.16759999999999994
glucos ovarian cancer show epitheli ovarian cancer cell highli sensit glucose-deprivation-induc cell death like resveratrol glucos depriv induc caspase-independ cell death hallmark autophagi,0,0.7981,0.2019
aldosteron diseas blockad renin-angiotensin-aldosteron system proven effect retard progress renal diseas remnant kidney model well experiment diseas importantli rang progress human renal diseas,0,1.0,0.0
valsartan hypertens efficaci ccb amlodipin arb valsartan lower bp protect against cardiovascular event stroke across rang hypertens patient popul establish mani year,0,1.0,0.0
oxygen sah continu monitor arteri blood pressur abp icp cerebr perfus pressur cpp brain tissu oxygen pbo2 middl cerebr arteri flow veloc fv microdialysi perform num2 poor grade sah patient,0,1.0,0.0
manidipin diabet studi design investig effect delapril ace inhibitor manidipin long action calcium antagonist persist microalbuminuria normotens type num diabet patient,0,1.0,0.0
perindopril arteriosclerosi present studi evalu effect treatment calcium channel blocker amlodipin angiotensin i-convert enzym inhibitor perindopril vascular endotheli function arteriosclerosi patient essenti hypertens alreadi receiv angiotensin receptor blocker monotherapi,0,1.0,0.0
salicyl hear loss revers hear loss known complic follow administr quinin salicyl nonsteroid anti-inflammatori drug erythromycin,1,0.0,1.0
catecholamin tumor necrosi factor alpha/tnfa aim studi determin effect exogen catecholamin tumor necrosi factor alpha tnfa interleukin-num il-num interleukin-num2 il-num2 beta beta -endorphin level patient sever trauma first num2 h injuri,0,1.0,0.0
cisplatin non-small-cel lung cancer/nsclc object assess efficaci toxic concurr chemoradiotherapi cisplatin weekli divided-dos docetaxel patient stage iii non-small-cel lung cancer nsclc,0,1.0,0.0
alcohol arrest acut gv bleed cyanoacryl glue inject could achiev arrest acut gv bleed often alcohol num2 vs num2 need rescu surgeri less differ howev not signific,0,0.7912,0.2088
propofol asthmat wherea thiopent contract human isol bronchi propofol etomid reduc histamine-induc contract human isol airway smooth muscl either not sensit passiv sensit asthmat serum,0,1.0,0.0
iodin thyroid cancer result two random control clinic trial suggest amifostin no signific radioprotect effect salivari gland radioact iodin treatment differenti thyroid cancer,0,1.0,0.0
corticosteroid colon diverticula report describ cours three patient develop perfor colon diverticula tempor relat corticosteroid use,1,0.0,1.0
furosemid decreas blood viscos furosemid administr mean arteri blood pressur decreas blood viscos carotid systol shear stress increas group,1,0.3959,0.6041
asenapin manic symptom num2-week trial asenapin adjunct therapi lithium valproat asenapin effect placebo improv manic symptom base differ group ymr total score week num primari endpoint,0,1.0,0.0
jte-num3 allerg use highli specif neutral anti-s1p antibodi mab sphingosine-num-phosph receptor num s1pr2 antagonist jte-num3 studi signal contribut s1p s1pr2 mc- ige-depend airway allerg respons mice within minut antigen challeng,0,1.0,0.0
cisplatin head neck cancer purpos cisplatin plu fluorouracil pf induct chemotherapi compar taxan docetaxel paclitaxel cisplatin fluorouracil tax-pf random trial locoregion advanc head neck cancer lahnc,0,1.0,0.0
celecoxib hepatoma furthermor down-regul cox-num express use cox-num inhibitor celecoxib increas tunicamycin-induc apoptosi concomit up-regul pro-apoptot transcript factor chop gaddnum3 down-regul b-cell lymphoma num/bcl-num-associ x protein bcl-num/bax ratio suggest inhibit cox-num sensit human hepatoma cell er stress-induc apoptosi,0,1.0,0.0
androgen pca/prost cancer undertook present analysi evalu effect nht patholog stage pca resect limit statu patient prostat cancer treat total androgen ablat either three six month rp,0,1.0,0.0
isofluran ischem protect remot ischem precondit coronari arteri bypass graft surgeri isofluran not propofol clinic trial,0,1.0,0.0
aspirin death post-hoc analysi num random ischem stroke trial aspirin treatment failur not found associ increas risk recurr stroke death,0,1.0,0.0
thienopyridin small bowel injuri combin low-dos aspirin thienopyridin exacerb small bowel injuri,1,0.0,1.0
perindopril effect stroke reduct lower within-individu visit-to-visit variabl blood pressur read amlodipine/perindopril combin treatment arm ascot studi shown account effect stroke reduct rate combin compar atenolol diuretic-bas therapi despit overal similar blood pressur lower,1,0.17679999999999996,0.8232
pyridostigmin autoimmun gastrointestin dysmotil autoimmun gastrointestin dysmotil treat success pyridostigmin,0,1.0,0.0
topotecan leukemia anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0
mpag ggt high csa c2 associ elev ggt probabl cholestat effect explain increas mpag-to-mpa ratio,0,0.7992,0.2008
fluoxetin mdd somat symptom depress found associ delay onset antidepress respons fluoxetin mdd,0,1.0,0.0
estrogen inflammatori seem respons not estrogen receptor-medi probabl attribut serm-induc modul lps-activ pro-inflammatori signal cascad,0,1.0,0.0
ethanol oa result cell viabil indict no notabl differ oa ethanol extract pv lung adenocarcinoma spc-a-num cell measur mtt assay,0,1.0,0.0
capecitabin breast cancer continu trastuzumab plu capecitabin xh show significantli improv overal respons rate time progress compar capecitabin x alon women her2-posit breast cancer progress trastuzumab treatment,0,1.0,0.0
quercetin tumor quercetin dose-depend inhibit vitro lipopolysaccharide-induc tumor necrosi factor-alpha product blood healthi volunt,0,1.0,0.0
docetaxel hypox given doxorubicin docetaxel th-num3 complement enhanc anticanc effect perivascular hypox region also increas toxic,0,1.0,0.0
eicosanoid inflamm aim studi determin quantiti produc mediat inflamm cytokin eicosanoid carotid endarterectomi cea factor ischem damag brain,0,0.6004,0.3996
floxuridin tumour effect aberr hepat arteri anatomi tumour respons hepat arteri infus floxuridin colorect liver metastas,0,1.0,0.0
aviptadil lung diseas aviptadil inhal tend improv oxygen patient signific lung diseas,0,1.0,0.0
otrnum4 harp interestingli intraperiton administ harp decreas anticoagul activ heparin otrnum4 mice,0,1.0,0.0
pazopanib aggress pediatr solid tumor metronom oral topotecan pazopanib activ antiangiogen regimen mous model aggress pediatr solid tumor,0,0.802,0.19799999999999995
sodium poison taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.6281,0.3719
aspirin atrial fibril compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0
axitinib renal cell carcinoma axitinib advanc treatment-experienc renal cell carcinoma,0,1.0,0.0
bupivacain pain evalu efficaci intraop infus bupivacain solut relief pain oper gynecolog laparoscopi,0,1.0,0.0
bucindolol hf potenti pathophysiolog correl assess placebo-control trial bucindolol num num3 hf patient,0,1.0,0.0
calcium hypertens effect calcium-entri blocker nicardipin intraren hemodynam studi essenti hypertens,0,0.8089,0.19110000000000005
ropivacain analgesia comparison three differ concentr ropivacain postop patient-control thorac epidur analgesia upper abdomin surgeri,0,0.804,0.19599999999999995
glucos breast feed median pain score interquartil rang breast feed held mother 's arm placebo num2 glucos plu pacifi group num num-num num2 num-num2 num2 num-num2 num num-num douleur aiguic nouveau-ni scale num numnum2-num num2 num2num-num2 num2 num-num2 num num-num prematur infant pain profil scale,0,1.0,0.0
num-fluorouracil head neck cancer ten establish head neck cancer cell line um-scc num2a num2b num2b num2a num2b num2c num2b hlacnum2 num4na num4ddp4 chemosensit cisplatin carboplatin num-fluorouracil bleomycin well cellular glutathion content activ glutathion s-transferas determin,0,1.0,0.0
num- num num-dimethylthiazol-num-yl -num num-diphenyltetrazolium bromid cytotox cytotox test num- num num-dimethylthiazol-num-yl -num num-diphenyltetrazolium bromid mtt test perform,0,1.0,0.0
desipramin desipramine-refractori depress characterist desipramine-refractori depress,0,0.7865,0.2135
nac depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,0.8096,0.1904
carbon disulfid neuropathi increas rate tubulin polymer acrylamid carbon disulfid treatment may alter rate transport axon constitu includ neurofila contribut toward accumul focal swell observ neuropathi,0,0.7961,0.2039
olopatadin at express rate cam inflammatori marker conjunctiv surfac cell significantli reduc ketotifen olopatadin compar at,0,1.0,0.0
calcium hypertens present studi evalu effect treatment calcium channel blocker amlodipin angiotensin i-convert enzym inhibitor perindopril vascular endotheli function arteriosclerosi patient essenti hypertens alreadi receiv angiotensin receptor blocker monotherapi,0,1.0,0.0
aspirin crc aspirin metformin activ ampk increas inhibit mtor akt well autophagi crc cell,0,0.7907,0.20930000000000004
daptomycin visa mutant display reduc vancomycin daptomycin suscept phenotyp alter eg thicker cell wall abnorm autolysi typic vivo visa mutant,0,1.0,0.0
creatin angina patient angina pectori num2 h. maxim creatin kinas increas num3 +/- num3 u/lit rang num3 num num3 num2num +/- num h rang num num2,0,1.0,0.0
glucos niddm rational combin insulin oral drug therapi deriv better understand pathophysiolog niddm mechan action oral drug avail num type num diabet patient insulin-defici insulin-resist thu requir quit high dose exogen insulin num peripher insulin deliveri lead hyperinsulinaemia could play role pathogenesi late diabet complic num sulphonylurea stimul insulin releas directli portal vein could also potenti peripher insulin action num metformin improv glucos metabol insulin sensit alpha-glucosidas inhibitor slow digest complex carbohydr sucros abl reduc amount insulin need control postprandi hyperglycaemia,0,0.7975,0.2025
amantadin sexual dysfunct index term includ sexual dysfunct antidepress select serotonerg reuptak inhibitor fluoxetin sertralin paroxetin fluvoxamin clomipramin buspiron nefazodon bupropion cyproheptadin amantadin yohimbin central nervou system stimul,0,1.0,0.0
ramosetron colon pain moreov ramosetron num num microg/kg p significantli suppress restraint stress-induc decreas colon pain threshold effect not observ loperamid,0,1.0,0.0
imatinib eosinophil disord imatinib therapi hypereosinophil syndrom eosinophil disord,0,1.0,0.0
nicotin dizzi nicotin wellknown unpleas side effect e.g. transient dizzi nausea nicotine-induc nystagmu nin,1,0.0,1.0
n-acetylcystein radiocontrast nephropathi review contemporari prevent strategi radiocontrast nephropathi focu fenoldopam n-acetylcystein,0,1.0,0.0
glutathion cytotox cytotox due exposur ndma partial inhibit antioxid n-acetylcystein ascorb acid butyl hydroxyanisol n-t-butyl-alpha-phenylnitron not potenti upon glutathion deplet,0,1.0,0.0
pioglitazon obes free carnitin acylcarnitin inaeobes patient polycyst ovari syndrom effect ofaepioglitazon treatment,0,0.8026,0.1974
dopamin parkinson 's disease/pd non-ergot dopamin receptor agonist ropinirol pramipexol rotigotin apomorphin may allevi non-motor symptom parkinson 's diseas pd other may precipit,0,1.0,0.0
methylprednisolon apl/acut promyelocyt leukemia high dose methylprednisolon treatment shown induc vivo vitro differenti myeloid leukemia cell matur granulocyt patient acut promyelocyt leukemia apl subtyp acut myeloid leukemia aml,0,1.0,0.0
acebutolol cutan lupu erythematosu acebutolol-induc subacut cutan lupu erythematosu,1,0.1875,0.8125
ethanol hepat failur procedure-rel hepat failur not occur ethanol group,0,1.0,0.0
steroid vestibular neuriti diagnos vestibular neuriti steroid therapi initi,0,1.0,0.0
h2o2 patholog lesion patholog lesion deposit igg c3 mpo found immun rat perfus mpo h2o2 without neutral proteas mpo alon rat strain day num day num2,1,0.3861,0.6139
chloramphenicol cataract main aim studi assess whether omit prophylact postop topic antibiot chloramphenicol influenc risk develop endophthalm cataract surgeri,0,0.7923,0.2077
irinotecan rectal cancer design studi local advanc rectal cancer determin patholog respons toxic disease-fre surviv df induct capecitabin plu irinotecan follow capecitabine-bas chemoradiotherapi crt analyz gene express enzym involv metabol capecitabin irinotecan associ respons toxic,0,1.0,0.0
fludarabin cll/chronic lymphocyt leukemia base mechanist similar fludarabin cladribin success analogu treatment chronic lymphocyt leukemia cll hypothes clofarabin would effect indol leukemia,0,1.0,0.0
nitric oxid tumor pentoxifyllin downregul nitric oxid tumor necrosi factor-alpha induc mycobacteri lipoarabinomannan macrophag cell line,0,1.0,0.0
aspirin rheumat mitral stenosi compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0
vinblastin nsclc patient stage iiib iv nsclc random start treatment receiv either three six cours mitomycin num mg/m num cours num num num num vinblastin num mg/m num cisplatin num2 mg/m num mvp everi num2 day,0,1.0,0.0
methadon cancer cohort includ patient receiv morphin sr methadon age num2 num2 year not cancer anoth life-threaten ill not hospit nurs home,0,1.0,0.0
dexrazoxan multipl sclerosi open-label studi perform evalu possibl subclin cardiotox multipl sclerosi patient treat quarterli mitoxantron num2 mg/m num cumul without concomit dexrazoxan use blind serial radionucleid ventriculographi,0,1.0,0.0
fentanyl hypoventil transderm fentanyl administ cautious patient pre-exist condit emphysema may predispos develop hypoventil,1,0.39799999999999996,0.602
methamphetamin cannabi depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0
ondansetron postop vomit postop vomit occur num2num children no statist signific differ group num group receiv ondansetron combin dexamethason num2num placebo group num2 group receiv dexamethason alon p numnum2,0,0.6112,0.3888
alfuzosin benign prostat hyperplasia evalu effect alfuzosin num2 mg daili administ num year progress event men lower urinari tract symptoms/benign prostat hyperplasia luts/bph,0,1.0,0.0
capecitabin tumor result studi suggest hnscc patient would benefit capecitabine-bas chemotherapi could identifi examin tp dpd ratio tumor,0,1.0,0.0
fatti acid colorect cancer risk colorect cancer may influenc dietari intak variou vitamin miner essenti fatti acid,1,0.1955,0.8045
progesteron ht articl review properti discuss evid suggest ht reconsid progesteron given attent potent neurotroph agent may play import role reduc prevent motor cognit sensori impair accompani senesc male femal,0,0.7978,0.20220000000000005
leflunomid necrosi recent demonstr leflunomid anti-tumor necrosi factor tnf agent effect psa psoriasi,0,1.0,0.0
atorvastatin diabet atorvastatin exert benefici vascular effect diabet underli mechan yet elucid,0,1.0,0.0
reboxetin dri mouth irrit anxieti sleep disturb dri mouth common side effect reboxetin,1,0.0,1.0
simvastatin multipl sclerosi oral simvastatin might inhibit inflammatori compon multipl sclerosi lead neurolog disabl,0,1.0,0.0
corticosteroid ba result demonstr improv efficaci fp vs high dose inhal corticosteroid treatment moder persist sever form ba,0,1.0,0.0
cisplatin death meta-analysi earli trial adjuv chemotherapi non-smal cell lung cancer collabor group show chemotherapi alkyl agent also detriment chemotherapi cisplatin-bas adjuv chemotherapi associ improv hazard ratio death hr numnum2 equat num percent surviv benefit num year,0,0.6154,0.3846000000000001
acetylcholin spasm major complic spasm provoc test intracoronari inject acetylcholin,1,0.1905,0.8095
azdnum4 crc test done cell line xenograft k-ra mutant crc human explant model develop predict genom classifi azdnum4,0,1.0,0.0
etoposid non-small-cel lung cancer/nsclc april num juli num num4 cancer leukemia group b calgb conduct phase ii studi etoposid carboplatin advanc ajc stage iiib-iv non-small-cel lung cancer nsclc patient whose perform statu ps num-num,0,1.0,0.0
sulfamethoxazol wegen 's granulomatosi report experi long-term sulfamethoxazole-trimethoprim therapi patient wegen 's granulomatosi,0,1.0,0.0
atp primari tumor herein assess role syk-depend tonic bcr surviv signal dlbcl cell line primari tumor evalu efficaci atp-competit inhibitor syk rnum3 vitro,0,1.0,0.0
calcium arteriosclerosi present studi evalu effect treatment calcium channel blocker amlodipin angiotensin i-convert enzym inhibitor perindopril vascular endotheli function arteriosclerosi patient essenti hypertens alreadi receiv angiotensin receptor blocker monotherapi,0,1.0,0.0
amiodaron af short-term studi dronedaron less effect amiodaron decreas af recurr better safeti profil specif regard thyroid neurolog event lack interact oral anticoagul,0,1.0,0.0
atorvastatin acut coronari syndrom comparison clinic benefit clopidogrel therapi patient acut coronari syndrom take atorvastatin versu statin therapi,0,1.0,0.0
doxorubicin hepatoblastoma studi effect chemotherapeut cisplatin doxorubicin cytosin arabinosid differenti agent num2 cis-retino acid apoptot agent num-aza-num'-deoxycytidin arsen trioxid notch express hepatoblastoma evalu,0,1.0,0.0
furosemid bronchopulmonari dysplasia addit metolazon overcom toler furosemid infant bronchopulmonari dysplasia,0,1.0,0.0
alinidin atrial fibril preval atrial fibril alinidin patient lower atenolol patient p .num3 not lower placebo patient p .num2,0,0.6027,0.3973
acetazolamid pain median visual analog pain-scal score acetazolamid latanoprost travoprost brinzolamid timolol group num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 respect,1,0.3955,0.6045
propranolol hemangioma conduct prospect studi infantil hemangiomasa ih treat oral propranolol octob num4 march num4,0,1.0,0.0
erlotinib pancreat cancer erlotinib epiderm growth factor receptor tyrosin kinas inhibitor egfr-tki recent approv pancreat cancer treatment no reliabl predictor patient respons,0,1.0,0.0
oxygen pain aural canal core skin surfac num2 site temperatur oxygen consumpt pain visual analogu score concentr epinephrin norepinephrin glucos cortisol lactat free fatti acid plasma measur epidur blockad num2 min epidur blockad end surgeri num h surgeri,0,1.0,0.0
bombesin cancer variou studi suggest bombesin gastrin-releas peptid act autocrin growth factor may play role initi progress cancer includ breast,1,0.0,1.0
r -methanandamid carcinoma use human cervic carcinoma cell hela studi investig role cyclooxygenase-num cox-num apoptosi elicit endocannabinoid analog r -methanandamid,0,0.7937,0.20630000000000004
glucos glucos intoler broad-rang effect fxe may due uniqu composit profil could use prevent metabol syndrom character obes insulin resist glucos intoler hypertriglyceridemia elev blood pressur,0,0.8205,0.1795
busulfan medulloblastoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
num-fu toxic issu drug-resist drug-rel toxic address use stealth liposom formul modul num-fu,0,0.794,0.206
retino acid hepatoblastoma use retino acid control minim residu diseas hepatoblastoma discuss,0,0.8111,0.1889
creatinin anemia furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0
thiazid diastol dysfunct calcium channel blocker ccb attract altern thiazid patient uncontrol intoler thiazid specif indic agent eg angina sever diastol dysfunct,0,1.0,0.0
tryptophan bad num hour aa drink ingest rel placebo atd result num2 num2 decreas total plasma tryptophan concentr control subject rel patient bad respect,0,1.0,0.0
paclitaxel cytotox paclitaxel preferenti cytotox radioresist tumor clone level paclitaxel-induc cytotox significantli p numnum4 influenc raf-num kinas activ level,1,0.0,1.0
midazolam gcse midazolam particularli use treat acut gcse imidazol ring open low ph allow dissolv aqueou solut intramuscular inject close physiolog ph increas lipophil render good intramuscular absorpt brain penetr fast onset action,0,1.0,0.0
cholin cht/cholin uptak transport capac high-affin cholin uptak transport cht import cholin extracellular space presynapt termin essenti normal acetylcholin synthesi therefor cholinerg transmiss,0,1.0,0.0
rocuronium myalgia rocuronium-sugammadex reduc myalgia headach electroconvuls therapi patient major depress,0,1.0,0.0
donepezil ad benefit well simpl once-daili dose regimen make donepezil viabl therapeut option ad patient,0,1.0,0.0
propofol depress compar effect propofol etomid stimulu variabl efficaci electroconvuls therapi ect depress inpati,0,1.0,0.0
nucleotid crc aspirin chang nucleotid ratio activ ampk crc cell mtor still inhibit aspirin crc cell sirna knockdown ampk indic ampk-depend ampk-independ mechan aspirin-induc inhibit mtor,0,1.0,0.0
desmopressin multipl sclerosi examin safeti efficaci desmopressin three dose given women multipl sclerosi treat nocturia without enuresi,0,1.0,0.0
sorbitol turp syndrom report case hyperglycaemia lactic acidosi complic turp syndrom caus massiv absorpt approxim num2 litr sorbitol- mannitol irrig solut,1,0.0,1.0
ascorb acid renal failur howev ascorb acid metabol precursor oxal administr ascorb acid high dose could lead acut oxal nephropathi particularli presenc renal failur,0,0.6043,0.3957000000000001
alcohol alcohol-impair alcohol-impair drive consequ unit state past num2 year,0,0.6021,0.3979
polychlorin biphenyls/pcb nafld/non-alcohol fatti liver diseas polychlorin biphenyl pcb persist environment toxic present num3 ofaeunum adult dose-depend associ obes non-alcohol fatti liver diseas nafld,1,0.0,1.0
thiazolidinediones/tzd pco treatment insulin sensit metformin thiazolidinedion tzd improv metabol hormon pattern also improv ovul pco,0,1.0,0.0
fluorescein cytotox cytotox remain whether cell treat anginex num degre c num2 degre c. low temperatur fluorescein-conjug anginex accumul endotheli surfac not reach cytoplasm indic cell membran primari target peptid,0,1.0,0.0
alcohol diabet rel risk num2 confid interv ci mortal hepatocellular carcinoma calcul use proport hazard model adjust age alcohol drink diabet hbsag statu,0,1.0,0.0
dht prostat cancer hormon therapi therefor design lower tissu level dht prevent bind receptor prostat cancer cell,0,0.8029999999999999,0.19700000000000006
nifedipin hypertens controlled-releas nifedipin candesartan low-dos combin therapi patient essenti hypertens nice combi nifedipin candesartan combin studi,0,1.0,0.0
o2 ra incub pmn rac ra num-num3 microm caus dose-depend inhibit upto num2 o2- product chemiluminesc induc phorbol myrist acet pma n-formyl-methionyl-leucyl-phenylanalin fmlp opson zymosan ionophor anum5,0,1.0,0.0
lactat claudic peak exercis no differ observ heart rate blood pressur ga exchang data time onset claudic peak exercis lactat num num diphosphoglycer level,0,1.0,0.0
flavonoid carcinogenesi studi suggest chemoprevent effect flavonoid carcinogenesi,0,1.0,0.0
dihydroxyphenylalanin melanoma effect three non-myelotox cancer drug growth neuroblastoma cell investig vitro vivo dihydroxyphenylalanin l-dopa drug select toxic melanoma cell dl-buthionin sulphoximin bso drug radiosensit effect tamoxifen drug use treatment human mammari carcinoma,0,0.8046,0.1954
digoxin af oral beta blocker verapamil diltiazem use person af fast ventricular rate occur rest exercis despit digoxin,0,1.0,0.0
imatinib cml/chronic myelogen leukemia imatinib molecularli target therapi inhibit oncogen fusion protein bcr-abl tyrosin kinas involv pathogenesi chronic myelogen leukemia cml,0,1.0,0.0
angiotensin ii heart failur double-blind placebo-control studi investig whether num2 week treatment angiotensin ii receptor blocker losartan influenc n-termin proanf plasma level num3 chronic heart failur patient,0,1.0,0.0
fluoroquinolon ototox suggest criteria includ use patient would otherwis candid oral fluoroquinolon therapi publish criteria exist not use oral rout administr due gastrointestin condit predispos malabsorpt unavail oral rout sever infect due gram-neg pathogen replac aminoglycosid ototox nephrotox substanti risk target resist pathogen i.e. not empir therapi target therapeut use not prophylaxi,0,1.0,0.0
camptothecin carcinoma lung camptothecin deriv irinotecan cpt-num2 shown possess antitumor activ phase ii trial patient carcinoma lung cervix ovari colon rectum patient non-hodgkin 's lymphoma,0,1.0,0.0
clozapin sialorrhea current treatment strategi clozapine-induc sialorrhea,1,0.3843,0.6157
bp prostat cancer hand data scanti prostat cancer large-scal trial potent bp ongo plan patient,0,1.0,0.0
dexrazoxan cardiotox explor potenti dexrazoxan suppress subclin cardiotox ms patient receiv mitoxantron,0,1.0,0.0
donepezil hci donepezil hci repres new chemic class ach inhibitor piperidin,0,1.0,0.0
num-aza-num'-deoxycytidin acut myeloid leukemia find clinic achiev level num-aza-num'-deoxycytidin num-aza-dc potent inhibitor dna methyl modifi chromatin restor abil tumor necrosi factor alpha tnfalpha induc monocyt differenti acut myeloid leukemia cell nb4 unum3,0,0.8283,0.17169999999999996
creatinin diabet aim investig impact coadministr tzd acei/arb hematocrit hemoglobin valu uncompl patient type num diabet mellitu normal serum creatininenumdata patient type num diabet current follow review patient treat acei/arb and/or tzd identifi,0,1.0,0.0
resveratrol ovarian cancer inhibit glycolysi ovarian cancer resveratrol compound may effect therapi ovarian cancer,0,1.0,0.0
octreotid chylou ascit chylou ascit living-donor liver graft effect treat child octreotid,0,1.0,0.0
nicotin dizzi investig factor influenc effect address three question num intens dizzi nausea nin unsteadi depend nicotin dosag,0,0.6094,0.3906
amino acid cirrhosi control studi perform num2 viral cirrhosi patient evalu whether immun function indic natur killer nk cell activ improv branched-chain amino acid-enrich nutrient mixtur nutrient-mixtur aminoleban en,0,1.0,0.0
tfa coronari heart diseas although increas report effect diet contain tfa risk factor metabol syndrom diabet mellitu coronari heart diseas observ recent year influenc intestin inflamm remain unknown,1,0.0,1.0
tyrosin clear cell kidney carcinoma tyrosin kinas inhibitor rel new target therapi drug use treatment metastat clear cell kidney carcinoma gastrointestin stromal tumour thyroid carcinoma pancreat neuroendocrin tumour progress diseas,0,1.0,0.0
ketanserin contract ring endotheli function attenu enzymat treatment num-ht caus contract -log ecnum2 num partial block ketanserin,0,1.0,0.0
glatiram acet ms. glatiram acet drug recent approv treatment ms. therefor investig effect glatiram acet rant express glial cell vitro,0,1.0,0.0
acetylcholin spasm spasm provoc test use acetylcholin perform care although consid safe reliabl method,1,0.0,1.0
vincristin local diseas seven patient local diseas stage i/ii six surviv patient receiv chemotherapi vincristin actinomycin no patient receiv radiotherapi,0,1.0,0.0
tyrosin cancer studi s- nonphosphorylat point mutant suggest site coordin upregul fak ynum3 tyrosin phosphoryl convent initi fak activ mediat pressure-induc cancer cell adhes,0,0.6312,0.3688
vitamin e. cataract vitamin e cataract prevent studi vecat clinic trial current progress design assess affect vitamin e supplement develop progress cataract age-rel macular degener,0,1.0,0.0
probenecid rheumatoid arthriti patient rheumatoid arthriti develop life-threaten pancytopenia result low dose oral methotrex mtx toxic potenti probenecid,0,0.6151,0.3849
mibg pulmonari hypertens num3 i-mibg also use potenti marker pulmonari endotheli cell function may relat pulmonari hypertens,1,0.0,1.0
clopidogrel st-elev myocardi infarction/stemi present single-cent longitudin cohort studi includ num num3 consecut patient st-elev myocardi infarct stemi undergo ppci pretreat num3 mg aspirin num3 mg clopidogrel,0,0.8211,0.17889999999999995
cyclosporin mycophenol acid/mpa therapeut drug monitor mycophenol acid mpa combin cyclosporin num-h concentr csa c2 n num2 tacrolimu trough concentr n num2 investig repeat measur mpa mpa-glucuronid mpag trough concentr renal allograft recipi first num month post-transpl,0,1.0,0.0
nicotin nausea degre nicotine-induc nausea significantli correl postur imbal,1,0.0,1.0
mesna malign paper review current approach use ifosfamide/mesna alon combin agent modal treatment pediatr malign,0,1.0,0.0
camp hypoton challeng hypoton challeng not camp stimul found induc releas atp measur luciferin-luciferas assay murin mammari carcinoma cell line cnum3i cnum3 cell stabli transfect cdna human cystic fibrosi transmembran conduct regul cftr protein cnum3/cftr,0,1.0,0.0
epirubicin hcc howev dose schedul epirubicin modest activ against hcc,0,1.0,0.0
fructos num num-diphosph peripher vascular diseas effect fructos num num-diphosph exercis capac patient peripher vascular diseas,0,1.0,0.0
alcohol alcohol depend two-hundr fifty-four patient axi psychiatr disord comorbid alcohol depend treat num2 week outpati medic studi conduct three veteran administr outpati clinic,0,0.7945,0.2055
diltiazem cardiovascular diseas function nedd4l rsnum5 polymorph influenc efficaci e_-block and/or diuretic-bas antihypertens treatment term blood pressur reduct cardiovascular diseas protect wherea diltiazem-bas antihypertens treatment efficaci not influenc nedd4l polymorph,0,1.0,0.0
clopidogrel st-elev myocardi infarction/stemi commit trial demonstr clopidogrel produc num rel reduct death reinfarct stroke num vs. num2num num2 ci numnum2-numnum2 st-elev myocardi infarct stemi patient,0,1.0,0.0
creatinin blood loss analysis-of-vari model repeat measur appli compar creatinin level statin user nonus adjust clamp time blood loss,0,1.0,0.0
morphin cancer opioid rotat morphin fentanyl may effect allevi delirium pain cancer patient morphine-induc delirium,0,1.0,0.0
ethanol hyperthermia except one hyperthermia victim influenc ethanol,1,0.21640000000000004,0.7836
gemcitabin refractori hodgkin 's diseas treat num2 patient relaps refractori hodgkin 's diseas gemcitabin,0,1.0,0.0
ximelagatran embol event ximelagatran oral direct thrombin inhibitor found effici vitamin k antagonist drug prevent embol event recent withdrawn abnorm liver function test,0,1.0,0.0
triamcinolon macular oedema intravitr triamcinolon adjunct treatment laser panretin photocoagul concomit prolif diabet retinopathi clinic signific macular oedema,0,1.0,0.0
metformin niddm preliminari result suggest insulin-metformin obes present insulin-acarbos post-prandi hyperglycaemia occur combin might offer favour featur treatment niddm patient although therapeut approach still requir adequ evalu control studi,0,1.0,0.0
pantoprazol ulcer bleed pantoprazol infus adjuv therapi endoscop treatment patient peptic ulcer bleed prospect random control trial,0,1.0,0.0
terfenadin urticaria nimodipin versu terfenadin treatment physic stimulus-induc urticaria,0,1.0,0.0
amifostin xerostomia nine patient num2num develop grade num acut xerostomia num grade num-num xerostomia num start amifostine/pilocarpin,0,1.0,0.0
rimonab obes rimonab compound group along pathway approv select cb num cannabinoid receptor subtyp num antagonist invers agonist european union india regulatori review unit state treatment obes associ cardiometabol risk,0,1.0,0.0
quinon tumor measur express level three differ reductas enzymes-dt-diaphoras nad p h inume. reduc nicotinamid adenin dinucleotid without phosphat quinon oxidoreductas nadph cytochrom p-num3 reductas nadh inume. reduc nicotinamid adenin dinucleotid cytochrome-b5 reductase- num2 cell line nation cancer institut nci human tumor cell panel see relationship could establish activ enzym cellular sensit bioreduct compound mitomycin c eo9,0,0.7989,0.20109999999999995
alcohol alcohol abus moreov alcohol abus produc cardiac arrhythmia hypertens cardiomyopathi stroke even sudden death,0,1.0,0.0
indomethacin pruritu patient suffer pruritu associ hiv infect indomethacin describ effect drug although evid weak,0,1.0,0.0
erlotinib pancreat cancer effect rna inhibit erbb3 sensit erlotinib treatment evalu aspc-num pancreat cancer cell,0,1.0,0.0
dopamin tic disord alpha-num agonist dopamin antagonist constitut mainstay pharmacolog agent tic disord advanc neurobiolog psychopharmacolog discov newer avenu treatment tic disord,0,0.8341,0.16590000000000005
oxaliplatin rectal cancer neoadjuv capecitabin oxaliplatin chemoradiotherapi total mesorect excis mri-defin poor-risk rectal cancer phase num trial,0,1.0,0.0
salmeterol asthma small statist signific increas respiratory-rel asthma-rel death combin asthma-rel death life-threaten experi total popul receiv salmeterol,1,0.0,1.0
cd hemorrhag anim experi high-dos exposur cd induc sever testicular interstiti hemorrhag edema increas incid fetal death placent necrosi,1,0.0,1.0
clozapin sialorrhea sialorrhea common disabl advers effect clozapin use,1,0.19330000000000006,0.8067
platinum hypoton although higher level cmax may increas side-effect hypoton condit i.pl fluid increas auc plasma may escal accumul platinum i.pl cancer cell,0,1.0,0.0
propofol ripc/ischemia random single-blind placebo-control prospect studi serum troponin concentr ctni baselin num num num2 num2 num2 num2 h postop measur isoflurane/sufentanil propofol/sufentanil anesthesia without ripc three num-min period intermitt left upper arm ischemia num min reperfus non-diabet patient n num2 three-vessel coronari arteri diseas clinicaltrialsnumgov nctnum5,0,1.0,0.0
mitoxantron diseas although patient initi stabil therapi corticosteroid plasma exchang mitoxantron sever cognit impair persist eventu die sequela diseas,0,1.0,0.0
levocabastin season allerg rhiniti levocabastin select topic h1 antagonist effect treatment season allerg rhiniti conjunct,0,1.0,0.0
bilirubin hyperthyroid patient 's jaundic promptli resolv therapi hyperthyroid thyroid storm bilirubin level decreas num2 mg/dl normal num-num mg/dl num mg/dl,0,0.804,0.19599999999999995
levodopa anxieti investig effect levodopa mood anxieti eight parkinson 's diseas patient motor fluctuat,0,1.0,0.0
azithromycin gingiv overgrowth azithromycin togeth monthli subgingiv debrid treatment case num sever chronic periodont poorli control diabet complic gingiv overgrowth relat medic calcium channel blocker,0,0.8245,0.1755
thalidomid cancer thalidomid recent shown consider promis treatment number condit leprosi cancer,0,1.0,0.0
arsen trioxid apl salvag treatment effect num/num patient num2 relaps apl long-term survivor second line combin treatment arsen trioxid num/num patient stem cell transplant num/num patient,0,1.0,0.0
epinephrin bleed endoscop band ligat could decreas recurr bleed mallory-weiss syndrom compar haemostasi hemoclip plu epinephrin,0,1.0,0.0
num-fu cancer result suggest chloroquin may potenti anti-canc effect num-fu via cell cycl inhibit,0,1.0,0.0
terazosin hypertens purpos studi evalu effect alpha num-block agent terazosin blood pressur bp blood lipid larg variant popul patient hypertens,0,1.0,0.0
thienopyridin small bowel injuri combin low-dos aspirin therapi thienopyridin may exacerb small bowel injuri prevent strategi establish,1,0.0,1.0
nscnum5 ovarian cancer nscnum5 induc apoptosi exert synergist effect cisplatin inhibit hypoxia-stabil hif-1alpha protein human ovarian cancer cell,0,0.8126,0.1874
ca crf parent educ programm address crf practices/percept tailor parent group improv ca intak earli adolesc children,0,1.0,0.0
verapamil hypertens once-daili fix dose combin verapamil trandolapril black patient mild moder hypertens new choic first line treatment,0,1.0,0.0
porphyrin pdt/photodynam therapi light-bas treatment photodynam therapi pdt use topic precursor porphyrin off-label altern treatment acn vulgari advantag disadvantag,0,1.0,0.0
coumadin thromboembol compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0
aspirin stroke subgroup analysi aspirin treatment failur not found associ recurr stroke combin endpoint stroke death among categori defin etiolog subtyp includ larg arteri atherosclerosi,0,1.0,0.0
dihydrotestosterone/dht prostat cancer/pca prostat cancer pca therapi typic involv administr classic antiandrogen competit inhibitor androgen receptor ar ligand dihydrotestosteron dht testosteron te ligand-bind pocket lbp ligand-bind domain lbd ar,0,0.8034,0.1966
cisplatin nsclc three trial ialt jbr num2 anita util cisplatin-bas doublet show significantli posit surviv benefit adjuv chemotherapi patient stage ii-iiia nsclc,0,1.0,0.0
aza ibd clinic data collect retrospect ibd patient num year age younger treat num-mp/aza children 's hospit philadelphia,0,1.0,0.0
cyclosporin hypertens although sirolimus-tr patient display compar lower platelet white blood cell count higher level serum cholesterol triglycerid sirolimu not augment nephrotox hypertens procliv cyclosporin,0,0.7947,0.20530000000000004
aldosteron renal diseas aldosteron progress renal diseas,0,0.8083,0.1917
nmda brain damag therapeut adjunct treat ethanol withdraw includ nmda calcium glucocorticoid antagonist may eventu prove use prevent brain damag alcohol,0,1.0,0.0
tyrosin hematopoiesi retrospect studi conduct quantit plasma level num cytokin regul hematopoiesi name num stimulatori fms-like tyrosin kinas flt3-l stem cell factor scf num inhibitori growth factor tumor necrosi factor-alpha tnfalpha tumor growth factor-beta macrophag inflammatori protein mip-1alpha immunoassay num2 patient enrol clinic trial garden state cancer center bellevil new jersey,0,1.0,0.0
caffein hypoventil time-cours analys show vmca num follow triphas pattern increas baselin hypoventil regardless caffein condit num slow baselin hyperventil degre slow attenu caffein num increas baselin cognit activ rang num-num,0,1.0,0.0
pinocembrin hyperlipidemia combin simvastatin pinocembrin synergist inhibit atherosclerot lesion develop apoe-/- mice hyperlipidemia partial depend protect vascular endothelium,0,1.0,0.0
ibuprofen analgesia compar effect iv acetaminophen oral ibuprofen respect postop pain control morphin requir patient receiv morphin patient-control iv analgesia pcia cesarean deliveri,0,1.0,0.0
glutathion tumor basi interact endogen synthet substanc glutathion key enzym conjug glutathion s-transferas appear critic determin tumor cell resist sever antineoplast drug e.g platinum analog,0,1.0,0.0
levothyroxin hypothyroid effect levothyroxin total lipid profil assess analyt capillari isotachophoresi patient hypothyroid,0,1.0,0.0
paracetamol postop pain prospect random double-blind studi compar analges efficaci oral diclofenac resin num mgnumkg -num paracetamol num2 mg/kg -num control postop pain paediatr patient outpati bilater myringotomi tube insert,0,1.0,0.0
num-mp ibd clinic data collect retrospect ibd patient num year age younger treat num-mp/aza children 's hospit philadelphia,0,0.8059999999999999,0.19400000000000006
glucos impair glucos toler pioglitazon not enhanc effect lifestyl modif prevent convers impair glucos toler diabet asian indian result indian diabet prevent programme-num idpp-num,0,1.0,0.0
sunum4 tumor combin folat antimetabolit pemetrex sunum4 receptor tyrosin kinas inhibitor vegfr2 irradi investig human endotheli cell tumor cell line,0,1.0,0.0
glucos diabet mellitu cross-sect analysi data num4 particip gubbio popul studi num3 men num3 women age num2 num2 year without macroalbuminuria without diabet mellitu fast plasma glucos level less num mmol/l num3 mg/ dl,0,1.0,0.0
fludarabin leukemia base mechanist similar fludarabin cladribin success analogu treatment chronic lymphocyt leukemia cll hypothes clofarabin would effect indol leukemia,0,1.0,0.0
nickel toxic environment impact associ resourc deplet human toxic mainli associ cobalt copper nickel thallium silver wherea ecotox potenti primarili associ cobalt copper nickel thallium silver,1,0.1955,0.8045
potassium colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.8079999999999999,0.1920000000000001
valdecoxib dyspepsia compar trial celecoxib valdecoxib non-specif nsaid cox-num-specif inhibitor demonstr superior dyspepsia toler non-specif nsaid,0,1.0,0.0
rifampicin tuberculosi molecular characteris rifampicin-resist mycobacterium tuberculosi strain morocco,0,1.0,0.0
iron lung diseas inhal silic dust may caus lung diseas surfac coordin iron subsequ oxid gener via fenton reaction,1,0.2097,0.7903
aminoglycosid endocard mortal due left-sid endocard caus pseudomona aeruginosa remain high despit therapeut regimen high dose aminoglycosid plu beta-lactam antibiot,0,1.0,0.0
ceftazidim neutropenia risk factor vre colon paediatr oncolog patient includ durat neutropenia durat antibiot therapi exposur ceftazidim amikacin teicoplanin number antibiot use,0,0.8108,0.18920000000000006
oestrogen anovulatori cycl anovulatori cycl may prolong oestrogen stimul endometrium without progesteron withdraw cycl irregular bleed may heavi,0,0.7908,0.20920000000000005
curcumin ag meanwhil activ caspase-num -num -num also enhanc curcumin-tr ag cell,0,1.0,0.0
acetylcholin parkinson 's diseas striatal alpha6* nicotin acetylcholin receptor potenti target parkinson 's diseas therapi,0,1.0,0.0
glucos blood glucos furthermor drug link develop glucos intoler thu import monitor bodyweight fast blood glucos frequent basi,0,0.8093,0.1907
serotonin oral bleed complic select serotonin reuptak inhibitor oral bleed complic invas dental treatment,0,1.0,0.0
cyclosporin a. psoriasi effect cyclosporin immun activ marker patient activ psoriasi,0,1.0,0.0
thalidomid vte sinc introduct immunomodulatori deriv imid thalidomid lenalidomid therapeut armamentarium mm vte emerg one lead complic particular patient newli diagnos mm,1,0.0,1.0
somatostatin acromegali effect octreotid somatostatin analog sleep apnea patient acromegali,0,1.0,0.0
cholesterol obes curcumin reduc serum glucos cholesterol triglycerid low densiti lipoprotein level high-fat-diet-induc obes rat,0,1.0,0.0
sirolimu hepat c. limit hepat c viru progress liver transplant recipi use sirolimus-bas immunosuppress,0,1.0,0.0
corticosteroid allerg rhiniti efficaci nasal corticosteroid alon combin antihistamin montelukast treatment allerg rhiniti,0,1.0,0.0
calcium oxal acidosi ingest ethylen glycol either accident suicid attempt character sever acidosi calcium oxal crystal format deposit wide varieti end organ effect may fatal,0,1.0,0.0
glucos vte influenc glucos adjust bodi mass index age gender diabet mellitu vte assess logist regress analys,0,1.0,0.0
bombesin breast cancer femal athym nude mice bear xenograft mcf-num miii human breast cancer cell line treat num week bombesin/gastrin-releas peptid antagonist d-tpi6 leunum2 psi ch2nh -leunum2 bombesin num-num2 rc-num4 inject subcutan daili dose num2 microgram lutein hormone-releas hormon antagonist sb-num2 cetrorelix administ biweekli form microgranul releas num2 micrograms/day,0,1.0,0.0
dopamin schizophrenia review role dopamin d4 receptor schizophrenia antipsychot action,0,1.0,0.0
histamin asthmat examin effect procaterol beta num-adrenoceptor agonist skin wheal respons histamin platelet-activ factor paf substanc p bradykinin eight asthmat children double-blind random cross-ov studi,0,1.0,0.0
oxygen copd conclus stabl state iii copd patient present unstabl redox balanc long term low flow oxygen administr induc system oxid stress prevent nac treatment,0,1.0,0.0
fluoroquinolon infect suggest criteria includ use patient would otherwis candid oral fluoroquinolon therapi publish criteria exist not use oral rout administr due gastrointestin condit predispos malabsorpt unavail oral rout sever infect due gram-neg pathogen replac aminoglycosid ototox nephrotox substanti risk target resist pathogen i.e. not empir therapi target therapeut use not prophylaxi,0,0.8129,0.18710000000000004
praziquantel schistosoma report studi among num2 schoolchildren area highli endem schistosoma mansoni hookworm infect place particular emphasi effect praziquantel preval intens hookworm infect,0,1.0,0.0
fatti acid death clear studi other multipl pathway fatti acid palmit lead beta-cel dysfunct death,1,0.3784,0.6216
tamoxifen breast cancer forty-nin postmenopaus patient node-posit breast cancer random trial compar effect tamoxifen toremifen serum lipoprotein,0,1.0,0.0
paclitaxel tumor paclitaxel preferenti cytotox human cervic tumor cell low raf-num kinas activ implic paclitaxel-bas chemoradi regimen,0,0.7981,0.2019
pamidron cancer hypercalcemia bp standard treatment cancer hypercalcemia dose num2 mg pamidron num4 mg clodron recommend former compound potent longer last effect,0,1.0,0.0
num num'-dideoxyinosin human immunodefici viru object studi determin popul pharmacokinet paramet extent absorpt num num'-dideoxyinosin nucleosid analog activ against human immunodefici viru vitro vivo oral intraven administr use non-linear mix effect model,0,1.0,0.0
serotonin/num-ht/num-hydroxytryptamin drug depend present review provid overview serotonin num-hydroxytryptamin num-ht 2c receptor relationship drug depend,1,0.3982,0.6018
fructosamin plasma glucos no signific chang fast plasma glucos hba1c serum fructosamin creatinin potassium lipid profil num2 week treatment group,0,1.0,0.0
timolol ocular hypertens compar addit intraocular pressure-low effect latanoprost numnum3 administ daili pilocarpin num administ three time daili patient primari open-angl glaucoma ocular hypertens current monotherapi timolol num twice daili,0,1.0,0.0
danazol infertil infertil women endometriosi random receiv buserelin acet danazol undergo vagin biopsi treatment select,0,1.0,0.0
lamivudin hbv-infect two de novo hbv-infect patient ymdd mutat given adefovir combin lamivudin liver function gradual improv follow-up period,0,1.0,0.0
deoxyadenosin melanoma studi effect cordycepin num'-deoxyadenosin major compon cordycep militari ingredi tradit chines medicin investig first time apoptotsi human neuroblastoma sk-n-be num -c melanoma sk-mel-num cell,0,1.0,0.0
dexamethason necrosi stimul primari human corneal epitheli cell keratocyt retin endotheli cell num num2 ng/ml interleukin 1e_ il-1e_ result signific increas numer inflammatori cytokin includ il-num il-num tumor necrosi factor e tnf-e dexamethason abl significantli inhibit effect,0,1.0,0.0
ascorb acid dermat sever case report suggest topic ascorb acid effect manag chromium dermat not confirm control clinic trial moreov practic difficulti frequent applic like limit use,0,1.0,0.0
nicotin nin investig factor influenc effect address three question num intens dizzi nausea nin unsteadi depend nicotin dosag,0,1.0,0.0
sphingosine-num-phosph allerg sphingosine-num-phosphate/sphingosine-num-phosph receptor num axi regul earli airway t-cell infiltr murin mast cell-depend acut allerg respons,0,1.0,0.0
corticosteroid atop dermat number patient atop dermat refus use topic corticosteroid person fear seem increas,0,1.0,0.0
lorazepam catatonia although lorazepam help treat catatonia may not suffic case present,0,1.0,0.0
roxithromycin advers drug reaction/ten naranjo advers drug reaction probabl scale suggest likelihood oral administr roxithromycin respons ten 'probabl,1,0.0,1.0
pristinamycin cancer pristinamycin-resist strain seven isol isol five patient haematolog cancer bone marrow transplant centr tunisia num4,0,1.0,0.0
pravastatin non-insulin-depend diabet mellitus/niddm multin num2-week random double-blind placebo-control studi evalu efficaci safeti low-dos pravastatin num3 patient non-insulin-depend diabet mellitu niddm hypercholesterolemia serum total cholesterol concentr num-num mmol/l num3 num3 mg/dl,0,1.0,0.0
calcium osteoporosi age character besid chang progress increas calcium content arteri wall enhanc diabet mellitu osteoporosi arteri hypertens tabag,0,1.0,0.0
norepinephrin attent deficit-hyperact disorder/adhd methylphenid mph -ritalin r compound block reuptak synapt releas norepinephrin ne dopamin da brain use num2 year low dose long-term regimen treat attent deficit-hyperact disord adhd juvenil adolesc adult,0,1.0,0.0
auristatin pe waldenstrom 's macroglobulinemia new tubulin polymer inhibitor auristatin pe induc tumor regress human waldenstrom 's macroglobulinemia xenograft model,0,0.8138,0.18620000000000006
busulfan anll anll patient receiv busulfan cytoxan other receiv cytoxan total bodi irradi prepar regimen transplant,0,1.0,0.0
morphin postop pain compar effect iv acetaminophen oral ibuprofen respect postop pain control morphin requir patient receiv morphin patient-control iv analgesia pcia cesarean deliveri,0,1.0,0.0
nitric oxid alzheim 's diseas nitric oxid mimet molecul therapeut agent alzheim 's diseas,0,1.0,0.0
aspirin respiratori diseas clinic cours patient aspirin-exacerb respiratori diseas predict prognosi,1,0.0,1.0
amphotericin b. nausea analyz daili basi mean chill score meperidin dosag puls rise also higher addit nausea vomit num num2 patient receiv rapid infus versu num num patient receiv slow infus p less numnum2 appear common receiv amphotericin b rapidli,1,0.0,1.0
sorafenib infect manag strategi base prevent measur reduc develop cutan ae includ pain risk infect patient discomfort avoid discontinu reduct sorafenib dosag,0,0.7924,0.2076
sodium chlorid death patient random receiv sodium bicarbon vs sodium chlorid rate death dialysi myocardi infarct cerebrovascular event not differ significantli num2 day num vs num num vs num num vs num num vs num respect num2 day num month num vs num num vs num num vs num num vs num respect p .num2,0,0.8042,0.1958
oxa/oxaliplatin cancer five cancer cell line resist irinotecan snnum2 paclitaxel ptx etoposid vpnum2 oxaliplatin oxa gemcitabin gem respect establish parent gastric cancer cell line ocum-2m name ocum-2m/snnum2 ocum-2m/ptx ocum-2m/vpnum2 ocum-2m/oxa ocum-2m/gem,0,1.0,0.0
androgen prostat cancer effect total androgen ablat patholog stage resect limit statu prostat cancer,0,1.0,0.0
calcium angina calcium channel blocker ccb attract altern thiazid patient uncontrol intoler thiazid specif indic agent eg angina sever diastol dysfunct,0,1.0,0.0
simvastatin multipl sclerosi oral simvastatin treatment relapsing-remit multipl sclerosi,0,1.0,0.0
steroid endometri cancer investig whether variant sex steroid hormon metabol gene modifi effect hormon therapi ht endometri cancer risk postmenopaus non-hispan white women,0,1.0,0.0
oxygen chronic obstruct pulmonari disease/copd aim studi whether stabl chronic obstruct pulmonari diseas copd patient present unbal blood redox statu effect oxygen administr blood redox balanc efficaci n-acetyl-cystein nac treatment against oxid stress-induc oxygen administr whether dose-rel,0,1.0,0.0
gsh necrosi studi regul gsh synthesi respons pro-inflammatori cytokin tumor necrosi factor-alpha tnf-alpha anti-inflammatori agent dexamethason human alveolar epitheli cell anum3,0,0.7996,0.2004
clonidin pmdd twelv women meet prospect dsm-iv criteria pmdd five histori sexual abus particip random placebo-control double-blind cross-ov design studi compar num month oral clonidin num mg/day num month activ placebo,0,1.0,0.0
alcohol psychiatr preced num2 month respond screen posit mdq greater use psychiatr hospit emerg depart urgent care center also outpati visit primari care physician psychiatrist alcohol treatment center screen neg,0,1.0,0.0
simvastatin atherosclerosi inhibitori effect combin therapi simvastatin pinocembrin atherosclerosi apoe-defici mice,0,1.0,0.0
iron tuberculosi increas incid tuberculosi observ among silic worker could explain accumul iron complex dust particl lung made avail dormant mycobacteria virul factor,1,0.0,1.0
methylphenid juvenil huntington diseas juvenil huntington diseas exacerb methylphenid case report,1,0.2098,0.7902
progesteron ht part almost work ht estrogen given primari focu despit fact progesteron import properti enhanc repair neurodegen traumat injuri central nervou system,0,1.0,0.0
glucos ovarian cancer resveratrol inhibit glucos metabol human ovarian cancer cell,0,1.0,0.0
paclitaxel breast cancer importantli cellular respons grnnum3l significantli augment effect microtubul stabil paclitaxel mda-mb-num3 breast cancer cell growth vitro vivo compar paclitaxel alon mismatch control oligonucleotid plu paclitaxel,0,1.0,0.0
cocain addict studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0
dihydrotestosterone/dht prostat cancer although androgen effect prostat cell believ dihydrotestosteron dht activ metabolit primarili util prostat cancer cell growth divis,1,0.0,1.0
ranirestat diabet object evalu summar provid expert opinion statu ranirestat emphasi pharmacokinet context potenti effect prevent/treat diabet complic,0,0.7877,0.21230000000000004
pentoxifyllin diseas pentoxifyllin analogu may lower toxic pentoxifyllin may therefor use futur treatment diseas induc endotox substanc,0,1.0,0.0
vitamin e. cataract examin associ prior supplement vitamin e earli cataract chang volunt current enrol cross-sect vecat studi,0,1.0,0.0
num2 -hete adhes enhanc adher elicit num2 -hete bnum2fnum2 cell could antagonis focal adhes kinas fak inhibitor num2 fak inhibitor pdnum5 extracellular signal-regul kinas erk inhibitor,0,0.8007,0.19930000000000006
carnitin obes free carnitin acylcarnitin inaeobes patient polycyst ovari syndrom effect ofaepioglitazon treatment,0,1.0,0.0
rifampicin/rmp tuberculosi mutat rpob gene associ rifampicin rmp resist studi num2 rmp-resist num3 rmp-suscept clinic strain mycobacterium tuberculosi morocco use probe-bas assay dna sequenc,0,1.0,0.0
pioglitazon impair glucos toler community-bas placebo-control num year prospect studi num3 particip impair glucos toler mean age num2num +/- num year mean bmi num2num +/- num kg/m num sequenti group receiv either lifestyl modif plu pioglitazon num2 mg n num3 lifestyl modif plu placebo n num3,0,1.0,0.0
argon choroid neovascular choroid neovascular treat argon laser photocoagul,0,1.0,0.0
tyrosin tumor review consid data support exploit differ target pancreat net includ peptid receptor receptor tyrosin kinas involv tumor angiogenesi directli support tumor growth intracellular target mammalian target rapamycin mtor central role regul cell growth metabol apoptosi,0,0.6057,0.3943
metformin diabet metformin use among individu risk type num diabet,0,1.0,0.0
glutathion tumor molecular mechan regul glutathion synthesi tumor necrosi factor-alpha dexamethason human alveolar epitheli cell,0,1.0,0.0
dopamin parkinson 's diseas dopamin receptor agonist sleep disturb parkinson 's diseas,0,1.0,0.0
quinotrierixin endoplasm reticulum xbp1 mrna splice express endoplasm reticulum stress respons gene determin cell expos thapsigargin presenc absenc quinotrierixin,0,1.0,0.0
cbnum4 breast cancer result indic cbnum4 potenti respons breast cancer cell tnfalpha suggest ceramid and/or cpla num might involv downstream effector vitamin d-mediat caspase-independ cell death,1,0.3691,0.6309
sodium hypertens epidemiolog clinic studi suggest magnesium may reduc frequenc sudden death sodium contribut occurr hypertens calcium may help prevent osteoporosi,1,0.0,1.0
capecitabin tumour/breast cancer present studi investig therapeut valu singl use capecitabin solid tumour tissu vitro use breast cancer cell line refer,0,1.0,0.0
cddp tumor tumor sensit measur icnum2 drug concentr produc num2 growth inhibit vari larg drug rang larger num x num2 num ng/ml num-fu larger num x num2 num ng/ml mmc num2 ng/ml num x num2 num ng/ml adm num2 ng/ml num x num2 num ng/ml cddp,0,1.0,0.0
bile acid intestin atrophi dietari bile acid inhibit potenti element diet-induc small intestin atrophi rat,0,0.6082,0.3918
nac addict studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0
fentanyl confus cognit physic impair confus abnorm co-ordin occur transderm fentanyl,1,0.0,1.0
l-ornithine-l-aspart hepat encephalopathi therefor therapeut efficaci oral l-ornithine-l-aspart improv impair ammonia detoxif investig patient cirrhosi hyperammonemia stabl overt chronic hepat encephalopathi subclin hepat encephalopathi random double-blind placebo-control clinic trial,0,1.0,0.0
corticosteroid/corticosteroid cataract oral corticosteroid user increas risk cataract risk among intranas corticosteroid user unknown,1,0.0,1.0
calcium chlorid clonic-ton convuls effect calcium chlorid inject cerebr ventricl group-hous unanaesthet cat upon vocal rage hiss snarl fight attack paw claw defens paw claw bite mydriasi tremor clonic-ton convuls produc carbachol eserin inject similarli investig,1,0.0,1.0
aspirin ischem stroke post-hoc analysi num random ischem stroke trial aspirin treatment failur not found associ increas risk recurr stroke death,0,1.0,0.0
nitroglycerin acut coronari syndrom current guidelin call nitroglycerin prescrib patient coronari heart diseas includ stabl angina recov acut coronari syndrom myocardi infarct,0,1.0,0.0
bupivacain pain efficaci bupivacain post-tonsillectomi pain studi intra-individu design,0,1.0,0.0
brilliant blue epiretin membranes/erm evalu feasibl safeti dye solubl lutein/zeaxanthin lz num brilliant blue bb numnum3 improv remov vitreou epiretin membran erm intern limit membran ilm human,0,1.0,0.0
glucos inflamm aim investig effect daili coffe consumpt biomark coffe intak subclin inflamm oxid stress glucos lipid metabol,0,1.0,0.0
ndma cytotox cytotox due exposur ndma partial inhibit antioxid n-acetylcystein ascorb acid butyl hydroxyanisol n-t-butyl-alpha-phenylnitron not potenti upon glutathion deplet,1,0.17820000000000005,0.8218
bps/bisphosphon tumor/breast cancer/canc bisphosphon bp potent inhibitor osteoclast-medi bone resorpt well accept tumor cell bone especi breast cancer myeloma cell stimul osteoclast format activ lead releas growth factor cytokin stimul cancer cell growth secret osteolyt factor,0,0.6285,0.3715000000000001
8ohdg cancer normal healthi individu found excret num2num +/- num nmol 8ohdg/num2 h numnum2 +/- numnum2 mumol 8ohdg per mol creatinin urin wherea increas level 8ohdg found num2 h collect varieti cancer patient sampl taken onset oncolog therapi numnum2 +/- numnum2 mumol/mol creatinin p numnum2 versu healthi individu therapi onset numnum2 +/- numnum2 mumol/mol creatinin p numnum3 versu healthi individu,0,1.0,0.0
clozapin pericard chart review potenti featur myocard pericard cardiomyopathi children adolesc treat clozapin,1,0.17520000000000002,0.8248
glucos weight gain ahrq systemat review indic premix insulin analogu effect long-act insulin analogu lower postprandi glucos hemoglobin a1c howev comparison premix analogu associ higher rate hypoglycemia weight gain,0,0.7911,0.2089
camp asthma varieti drug known act via increas intracellular camp use treatment asthma,0,1.0,0.0
pcb nafld pcb predict interact receptor previous implic xenobiotic/energi metabol nafld,0,0.7974,0.2026
sodium hyaluronate/sh cornea aim present studi quantifi man distribut clearanc two aqueou sodium hyaluron sh solut numnum3 numnum3 administr num2 microlit onto cornea,0,1.0,0.0
ramosetron ib pharmacolog profil ramosetron novel therapeut agent ib,0,1.0,0.0
nitric oxid toxic addit low toxic gossypol thioderiv revers nitric oxid donor physiolog media,0,0.7969,0.20309999999999995
camp pulmonari thromboembol compound 7e compar level txa2 synthas icnum2 num microm human platelet camp pde icnum2 num microm inhibitori activ found oral bioavail long durat action offer effect protect against mortal collagen-epinephrine-induc pulmonari thromboembol model mice,0,1.0,0.0
chloroquin cancer result suggest chloroquin may potenti anti-canc effect num-fu via cell cycl inhibit,0,1.0,0.0
gastrin sclc/small cell lung cancer abil reduc peptid bond analogu gastrin releas peptid grp antagon small cell lung cancer sclc grp receptor investig,0,0.8167,0.1833
tamoxifen breast carcinoma iodine-label tamoxifen uptak primari human breast carcinoma,0,1.0,0.0
anthracyclin cardiotox anthracyclin cardiotox close correl cumul dose great variabl individu suscept dramat increas advanc age,1,0.3908,0.6092
acyclovir varicella pneumonia/varicella adult complic varicella usual symptomat varicella pneumonia receiv intraven acyclovir,0,1.0,0.0
oleic acid adrp addit triacsin c potent inhibitor acyl-coa synthas num h decreas amount tg vldl-induc foam cell oleic acid-tr liver cell decreas amount adrp protein parallel indic amount adrp reduc regress lipid-stor cell,0,1.0,0.0
levonorgestrel endometri polyp levonorgestrel-releas intrauterin system significantli reduc de novo endometri polyp hazard ratio numnum2 num2 confid interv numnum2-numnum2 cours num year intention-to-treat basi,0,1.0,0.0
pristinamycin staphylococcu epidermidi report analysi genet determin confer resist pristinamycin staphylococcu epidermidi strain epidemiolog type strain pulsed-field gel electrophoresi,0,0.8055,0.1945
warfarin thromboembol patient receiv heartmat ii lvad directli transit warfarin aspirin therapi without intraven heparin no short-term increas risk thrombot thromboembol event bleed requir transfus significantli reduc,0,0.7956,0.20440000000000005
mg. sac mg load test urinari fecal mg excret also greater shk uhk group sac uac group,0,1.0,0.0
cyproteron acet prostat cancer systemat overview meta-analysi randomis evid maximum androgen blockad mab advanc prostat cancer identifi num2 trial compar convent castrat surgic medic versu mab castrat plu prolong use antiandrogen flutamid cyproteron acet nilutamid,0,1.0,0.0
taxan breast cancer trastuzumab repeatedli shown result signific clinic benefit subsequ accept treatment choic her2-posit advanc breast cancer particularli first-lin treatment combin taxan monotherapi second-lin third-lin set,0,1.0,0.0
testosteron diabet ed common symptom patient type num diabet also low testosteron level,0,0.8119,0.18810000000000004
cda/num-chloro-num'-deoxyadenosin chronic lymphocyt leukemia num-chloro-num'-deoxyadenosin cda nucleosid analogu activ b-cell chronic lymphocyt leukemia b-cll,0,1.0,0.0
folat folat defici preval biochem folat defici new zealand adult low,0,1.0,0.0
statin ischem stroke although statin use secondari prevent ischem stroke recent experiment data shown new pleiotrop effect drug respons role neuroprotect,0,1.0,0.0
morphin opioid rotat twenty-on consecut cancer patient morphine-induc delirium underw opioid rotat fentanyl,1,0.2166,0.7834
gemcitabin breast cancer carboplatin gemcitabin cg combin activ unselect anthracycline/taxan pretreat metastat breast cancer patient carri out phase ii studi evalu activ cg combin pretreat metastat tnbc patient,0,0.8036,0.1964
testosteron hypothalam three month head injuri hormon evalu hypothalamic-pituitari axi mean insulin stress test simultan administr trh gnrh result reduc respons gh cortisol tsh fsh lh low baselin serum concentr free t4 testosteron,0,1.0,0.0
topiram bing eat disord bing eat disord best evid mood disord cognitive-behavior therapi well topiram zonisamid select case select serotonin reuptak inhibitor,0,0.7991,0.2009
nickel cancer/nas cancer aim determin whether occup exposur receiv manufactur nickel alloy lead increas risk cancer particular nasal cancer lung cancer,1,0.0,1.0
aldosteron primari aldosteron conclus administr lcinum3 num mg bid effect safe inhibit aldosteron synthas patient primari aldosteron,0,0.8041,0.1959
aspirin claudic antithrombot therapi aspirin clopidogrel import reduc cardiovascular event not affect symptom claudic,0,1.0,0.0
nmda alcohol therapeut adjunct treat ethanol withdraw includ nmda calcium glucocorticoid antagonist may eventu prove use prevent brain damag alcohol,0,1.0,0.0
steroid edema addit trend toward less ecchymosi less intranas edema less discomfort patient receiv steroid note,0,0.8117,0.1883
nitroglycerin coronari heart diseas current guidelin call nitroglycerin prescrib patient coronari heart diseas includ stabl angina recov acut coronari syndrom myocardi infarct,0,1.0,0.0
octreotid manag neuroendocrin tumor believ studi sunitinib octreotid neoadjuv intent prepar tumor resect warrant strategi improv cur manag neuroendocrin tumor,0,1.0,0.0
capecitabin tumor/tumour/breast cancer capecitabin demonstr similar inhibitori effect vinorelbin breast cancer cell line solid tumour tissu decreas cell prolifer metabol well decreas express metabol protein tumor suppressor gene,0,1.0,0.0
ecstasi memori problem depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0
sorbitol turp syndrom anoth featur turp syndrom hyperglycaemia lactic acidosi caus massiv absorpt sorbitol,1,0.1994,0.8006
bortezomib relaps diseas bortezomib thalidomid lenalidomid improv therapeut armentarium patient refractori relaps diseas often use combin dexamethason chemotherapeut agent,0,1.0,0.0
salicyl ulcer diseas drug choic patient not treat non-steroid anti-inflammatori drug nsaid peopl bronchial asthma peptic ulcer diseas hemophilia salicylate-sensit peopl children num2 year age pregnant breastfeed women,0,1.0,0.0
digoxin atrial fibril data indic patient develop spontan postop atrial fibril treat digoxin num week follow oper drug therapi may discontinu indefinit,0,1.0,0.0
mpa ggt high csa c2 associ elev ggt probabl cholestat effect explain increas mpag-to-mpa ratio,0,1.0,0.0
dexamethason prophylaxi postop vomit dexamethason versu ondansetron combin dexamethason prophylaxi postop vomit pediatr outpati double-blind random placebo-control clinic trial,0,1.0,0.0
oestrogen breast cancer effect transform growth factor beta num oestrogen metabol mcf-num breast cancer cell line,0,0.7983,0.2017
statin renal dysfunct aim present studi assess effect statin renal function patient high risk renal dysfunct underw supraren aortic cross clamping-declamp,0,1.0,0.0
midazolam statu epilepticu midazolam treatment acut refractori statu epilepticu,0,1.0,0.0
fdp peripher vascular diseas contrast previou studi perform among patient peripher vascular diseas studi use sever hypox condit fdp not affect respiratori ga exchang exercis capac patient exert claudic,0,1.0,0.0
fluoxetin neuropeptid abnorm long-term treatment high-dos clomipramin fluvoxamin fluoxetin tend correct neuropeptid abnorm,0,1.0,0.0
silicon pneumon silicon commonli use cosmet procedur owe presum inert yield seriou sequela includ acut embol pneumon,1,0.0,1.0
perindopril cardiovascular event cost effect perindopril reduc cardiovascular event patient stabl coronari arteri diseas use data europa studi,0,1.0,0.0
rtv aid compar efv adjust hazard ratio hr aids/death numnum2 num2 confid interv ci numnum2-numnum2 nvp numnum2 num2 ci numnum2-numnum2 rtv numnum2 num2 ci numnum2-numnum2 rtv-boost pi,0,1.0,0.0
gadolinium ms. four double-blind trial relapsing-remit ms demonstr ivig may reduc relaps rate progress number gadolinium-enhanc lesion,0,1.0,0.0
theophyllin asthmat nineteen asthmat subject given num3 mg sustained-releas theophyllin prepar twice daili num week,0,1.0,0.0
l-ornithine-l-aspart chronic hepat encephalopathi oral l-ornithine-l-aspart therapi chronic hepat encephalopathi result placebo-control double-blind studi,0,1.0,0.0
ethanol obes therefor attenu activ ec system would therapeut benefit treat disord might compon excess appetit drive over-act endocannabinoid system obes ethanol drug abus varieti central nervou system disord,0,1.0,0.0
leuprolid prostat hyperplasia lutein hormon releas hormon agonist leuprolid investig double-blind random placebo-control studi compris num2 evalu patient moder sever symptom result benign prostat hyperplasia,0,1.0,0.0
chloroform necrosi babior davidson note first drug implic hepat necrosi -- presum except chloroform -- first report appear num4,0,0.7771,0.2229
ciprofloxacin cholera conduct random double-blind clinic trial compar ciprofloxacin num3 mg day num day tetracyclin num3 mg four time day num day term efficaci safeti treatment moderate-to-sever cholera peruvian adult,0,1.0,0.0
glucos plasma glucos no signific chang fast plasma glucos hba1c serum fructosamin creatinin potassium lipid profil num2 week treatment group,0,1.0,0.0
medroxyprogesteron acet tumor effect high-dos medroxyprogesteron acet tumor necrosi factor-alpha releas patient chemotherapy-induc neutropenia,0,0.8324,0.16759999999999994
monomethoxypolyethylen glycol renal cell carcinoma recombin interleukin-num ril-num modifi monomethoxypolyethylen glycol peg il-num util patient metastat renal cell carcinoma two separ multi-institut trial,0,1.0,0.0
ca4p oculomotor nerv palsi dose-limit toxic effect dlt revers ataxia oculomotor nerv palsi occur two patient prostat cancer receiv weekli ca4p num2 mg/m2,1,0.0,1.0
corticosteroid cataract incid rate cataract num/num4 person-year among user intranas corticosteroid similar incid rate among nonus,0,0.8256,0.1744
poly-sno-hsa cancer thu polyethylen glycol-poly-sno-hsa dimer seem appeal safe no carrier therebi strong candid antitumor drug futur develop cancer therapeut,0,1.0,0.0
epinephrin mallory-weiss syndrom endoscop band ligat could decreas recurr bleed mallory-weiss syndrom compar haemostasi hemoclip plu epinephrin,0,1.0,0.0
arsen trioxid death dynam effect autophagi arsen trioxide-induc death human leukemia cell line hlnum2 cell,1,0.0,1.0
mpd pd mechan mpd action patient advanc pd discuss,0,1.0,0.0
sorafenib renal cell carcinoma pivot phase iii trial patient advanc renal cell carcinoma progress despit first-lin therapi axitinib 5uamg twice daili significantli prolong median progression-fre surviv primari endpoint compar sorafenib num3uamg twice daili,0,1.0,0.0
vinca alkaloid breast cancer microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,0,1.0,0.0
num-fluorouracil stenosi sever stenosi puncta canaliculi may associ prolong system num-fluorouracil therapi,1,0.0,1.0
cyclophosphamid glioma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
platinum metastat diseas patient tumour fail progress first-lin platinum-contain regimen advanc metastat diseas progress diseas platinum-contain chemotherapi given adjuv neoadjuv intent,0,1.0,0.0
arsen myeloid leukemia pretreat myeloid leukemia line hl-num2 all-tran retino acid atra up-regul aqp9 lead significantli increas arsen uptak as2o3-induc cytotox incub as2o3 might explain synerg atra as2o3,0,1.0,0.0
asenapin bipolar disorder/mania asenapin review use manag mania adult bipolar disord,0,1.0,0.0
num-fu dpd-defici besid milder neutropenia observ give lipofufol anim transient partial dpd-defici compar standard num-fu,0,1.0,0.0
fentanyl cancer transderm fentanyl use analges cancer patient unabl swallow gastrointestin problem,0,1.0,0.0
sorafenib ptc rare case pediatr patient progress rai-refractori ptc no good system therapi exist sorafenib may play import role manag diseas,0,1.0,0.0
ixabepilon peripher neuropathi epothilon new class mti may associ grade num/num peripher neuropathi howev neuropathi associ ixabepilon novel epothilon b analog gener mild moder revers baselin grade num level,1,0.18010000000000004,0.8199
methotrex histoplasmosi present rare case isol granulomat hepat due histoplasmosi num2-year-old femal dermatomyos receiv low-dos prednison methotrex,0,0.8144,0.1856
androgen prostat carcinoma demonstr molecular mechan inhibitori action apigenin androgen-refractori human prostat carcinoma dunum3 cell mutat tumor suppressor gene pnum2 prb,0,0.6011,0.3989
glucos blood glucos clinic trial lower blood glucos disappoint probabl particip late natur histori diabet alreadi extens vascular diseas,0,1.0,0.0
nilutamid prostat cancer systemat overview meta-analysi randomis evid maximum androgen blockad mab advanc prostat cancer identifi num2 trial compar convent castrat surgic medic versu mab castrat plu prolong use antiandrogen flutamid cyproteron acet nilutamid,0,1.0,0.0
aviptadil pah total num2 patient ph pah nine ph lung diseas eight chronic thromboembol ph three inhal singl num3-microg dose aviptadil right-heart catheteris,0,1.0,0.0
ribavirin hiv/hepat c virus-coinfect introduct pegyl interferon/ribavirin combin therapi significantli improv treatment option hiv/hepat c virus-coinfect patient becom avail lead sustain virolog respons rate num2,0,1.0,0.0
vigabatrin vfc summari half children treat vigabatrin demonstr vfc abnorm ocular electrophysiolog studi,1,0.17859999999999998,0.8214
duloxetin depress analysi suggest escitalopram effect term qalw less costli duloxetin treatment depress,0,1.0,0.0
levothyroxin hyperlipidemia citp analysi abl obtain inform coronari risk factor may clinic use evalu effect treatment levothyroxin patient hypothyroid secondari hyperlipidemia,0,1.0,0.0
estrogen hypopituitar find patient hypopituitar impact respons treatment gh sinc patient receiv oral estrogen requir increas gh dosag,0,0.7987,0.20130000000000006
ropivacain tn six lidocain patient report tn num2 compar no patient receiv ropivacain num p=numnum3,0,1.0,0.0
cyclosporin a. psoriasi solubl il-num receptor cdnum2 cell psoriasi effect cyclosporin puva therapi,0,0.7933,0.2067
sodium chlorid nephropathi sodium bicarbon vs sodium chlorid prevent contrast medium-induc nephropathi patient undergo coronari angiographi random trial,0,1.0,0.0
pimecrolimu ad evalu effect pimecrolimu cream num prevent flare progress adult ad,0,1.0,0.0
imatinib hypereosinophil syndrom imatinib therapi hypereosinophil syndrom eosinophil disord,0,1.0,0.0
gemcitabin hemolyt urem syndrom num2-year-old caucasian male treat four cycl gemcitabin num num3 mg/m2 develop clinic laboratori find compat hemolyt urem syndrom,1,0.20330000000000004,0.7967
propofol ischem protect remot ischem precondit coronari arteri bypass graft surgeri isofluran not propofol clinic trial,0,1.0,0.0
dihydroergotamin headach data suggest iv dihydroergotamin given num day produc improv headach disabl patient migrain shorter cours,0,0.7941,0.2059
methotrex rheumatoid arthriti radiograph evid progress bone loss inabl elimin synovi prolifer methotrex becam appar therapi rheumatoid arthriti need advanc,0,0.804,0.19599999999999995
cephalosporin tubular marker protein order assess nephrotox potenti antibiot variou aminoglycosid cephalosporin test potenc alter excret tubular marker protein brush border antigen chang normal pattern serumproteinuria analyz sd polyacrylamidgel gradient electrophoresi,0,0.7959,0.20409999999999995
testosteron osteoporosi although pathogenesi osteoporosi men multi-factori testosteron known play import role mainten male skeleton,0,0.7987,0.20130000000000006
probenecid toxic patient rheumatoid arthriti develop life-threaten pancytopenia result low dose oral methotrex mtx toxic potenti probenecid,1,0.0,1.0
oxygen hypertens particular follow topic highlight chemistri sourc reactiv oxygen speci antioxid defens mechan signal event mediat reactiv oxygen speci role reactiv oxygen speci hypertens put therapeut role antioxid cardiovascular diseas,0,0.7886,0.21140000000000006
furazolidon aid investig chang morpholog development stage enterocytozoon bieneusi symptomat relief observ aid patient treatment furazolidon,0,1.0,0.0
yohimbin ptsd yohimbin result signific increas anxieti patient ptsd not healthi subject,0,0.6319,0.3681
stavudin hiv effect fixed-dos combin stavudin lamivudin nevirapin gpo-vir treatment naiv hiv patient thailand num-year follow-up,0,1.0,0.0
calcium diabet mellitu age character besid chang progress increas calcium content arteri wall enhanc diabet mellitu osteoporosi arteri hypertens tabag,0,0.8374,0.16259999999999994
pioglitazon type object prevent programm studi whether combin pioglitazon lifestyl modif would enhanc efficaci lifestyl modif prevent type num diabet asian indian impair glucos toler,0,1.0,0.0
flavonoid breast cancer present studi suggest intak flavonol flavon not flavonoid subclass total flavonoid associ decreas risk breast cancer especi among post-menopaus women,0,0.8104,0.1896
iron rt two studi use supplement iron rt plu epo group not rt alon group,0,1.0,0.0
ranirestat diabet neuropathi evalu ranirestat treatment diabet neuropathi,0,1.0,0.0
lutein melanoma regul extracellular matrix remodel lutein dermal fibroblast melanoma cell ultraviolet radiat expos fibroblast,0,1.0,0.0
polyethylen glycol intestin pseudoobstruct patient receiv polyethylen glycol slightli lower incid acut intestin pseudoobstruct wherea length stay shorter lactulose-tr patient,0,0.8003,0.1997
chloramphenicol endophthalm endophthalm follow cataract surgeri role prophylact postop chloramphenicol eye drop,0,1.0,0.0
chloroquin cutan vascul describ case steroid resist cutan vascul success treat chloroquin addit corticosteroid subsequ relaps chloroquin alon,0,1.0,0.0
nucleosid chronic lymphocyt leukemia num-chloro-num'-deoxyadenosin cda nucleosid analogu activ b-cell chronic lymphocyt leukemia b-cll,0,0.7973,0.2027
fludarabin cll/chronic lymphocyt leukemia past year effect therapi emerg treatment chronic lymphocyt leukemia cll mainli combin immunotherapi fludarabine-bas regimen,0,1.0,0.0
glutamin cachexia tumor act glutamin trap deplet host glutamin store result cachexia,0,0.6202,0.3798
cyclophosphamid lupu nephriti patient requir steroid repeat cours cyclophosphamid manag lupu nephriti ursodeoxychol acid ursolit administr result amelior cholestat laboratori abnorm,0,1.0,0.0
l-dopa pd studi demonstr low dose mpd may improv gait especi freez patient sever pd without need exogen l-dopa,0,1.0,0.0
oxygen cytotox primari cultur normal human lung fibroblast expos num h room air ra num2 oxygen no either num2 num2 ppm blend ra no blend num2 num incub num2 num2 h. cell viabil determin fluoresc viability/cytotox assay dna fragment tunel assay,0,1.0,0.0
sirolimu hcv review num4 liver recipi num4 num4 identifi cohort hcv recipi expos sirolimu primari immunosuppress srl cohort hcv control group recipi never receiv sirolimu,0,1.0,0.0
sorafenib anaemia toler profil gener consist vegf receptor inhibitor axitinib associ numer lower incid palmar-plantar erythrodysaesthesia cutan toxic anaemia sorafenib phase iii trial,0,1.0,0.0
polyethylen glycol ada deficiency/adenosin deaminase/ada polyethylen glycol-conjug adenosin deaminas ada therapi provid temporari immun reconstitut child delayed-onset ada defici,0,1.0,0.0
imiquimod basal cell carcinoma induct member notch pathway superfici basal cell carcinoma treat imiquimod,0,1.0,0.0
no pseudomona aeruginosa infect pulmonari no exchang not differ significantli subgroup cf patient without chronic pseudomona aeruginosa infect,0,1.0,0.0
alcohol hepatocellular carcinoma heavi alcohol drink associ hepatocellular carcinoma mortal risk subgroup men test hbsag rr =num num2 ci num num,1,0.1927,0.8073
leflunomid rheumatoid nodul antirheumat drug methotrex leflunomid lef infliximab etanercept known risk factor develop rheumatoid nodul,1,0.0,1.0
asa gi complic death worst outcom gi complic low dose asa user data aspect scarc,1,0.392,0.608
dihydroergotamin headach intraven dihydroergotamin inpati manag refractori primari headach,0,1.0,0.0
rasagilin parkinson 's diseas rasagilin parkinson 's diseas,0,1.0,0.0
schiff base hepat carcinoma studi determin cytotox cyto-select mutagen potenti novel quinolinon schiff base ligand correspond copper ii complex human-deriv hepat carcinoma cell hep-g2 non-malign human-deriv hepat cell chang,0,1.0,0.0
num2-o-tetradecanoylphorbol-num2-acetate/tpa tumor studi use num2-o-tetradecanoylphorbol-num2-acet tpa ultraviolet uv radiat tumor promot found anticarcinogen effect caus green tea polyphenol,0,0.7967,0.20330000000000004
feiba thrombot contrast ae report pattern rfviia feiba may contribut observ differ thrombot event incid,0,0.7964,0.2036
cisplatin tumor day num2 num2 tumor inocul tumor volum group treat rh2 significantli less ethanol-tr control group also cisplatin treat group,0,0.8103,0.1897
ether glioma effect structur modif ether lipid antiprolif activ against human glioma cell line,0,1.0,0.0
glucos ovarian cancer ovarian cancer cell incub normal media media contain resveratrol glucos free media media lack amino acid,0,1.0,0.0
thalidomid relaps diseas bortezomib thalidomid lenalidomid improv therapeut armentarium patient refractori relaps diseas often use combin dexamethason chemotherapeut agent,0,0.8306,0.1694
ramosetron ib result indic ramosetron produc benefici clinic effect ib symptom,0,1.0,0.0
oxygen diabet foot ulcer aim studi evalu effect hyperbar oxygen therapi hbot manag chronic diabet foot ulcer,0,1.0,0.0
oxygen oxygen-glucos deprivation/ogd report downregul gaba receptor gaba r express affect mrna protein level gaba r subunit hippocamp neuron subject oxygen-glucos depriv ogd vitro model ischemia,0,1.0,0.0
sildenafil diastol dysfunct hypothes sildenafil would reduc fill pressur exercis patient diastol dysfunct myocardi infarct,0,1.0,0.0
angiotensin chf angiotensin-convert enzym ace inhibitor produc hemodynam symptomat benefit patient chf still controversi optim dose clinic set,0,1.0,0.0
cocain depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,1,0.21900000000000008,0.7809999999999999
aspirin cardiovascular complic aspirin group slightli increas rate cardiovascular complic num2num vs num pae=aenumnum3 like reflect increas cardiovascular comorbid led physician recommend aspirin therapi,1,0.1975,0.8025
iodin conscious conscious recov gradual concomit decreas plasma iodin level,0,0.6114,0.3886
testosteron ed/erectil dysfunct clinic report patient erectil dysfunct ed combin hypogonad receiv testosteron therapi inconsist result,0,0.7879,0.2121
metformin acut myocardi infarct chronic pretreat metformin associ reduct no-reflow phenomenon patient diabet mellitu primari angioplasti acut myocardi infarct,0,1.0,0.0
caffein tumorigenesi caffein tea also import tea prevent tumorigenesi,0,1.0,0.0
fenoldopam rcn antihypertens agent fenoldopam shown canin model well small retrospect prospect random human evalu effect prevent rcn,0,1.0,0.0
fentanyl constip compar oral opioid advantag transderm fentanyl includ lower incid impact advers effect constip nausea vomit daytim drowsi higher degre patient satisfact improv qualiti life improv conveni complianc result administr everi num2 hour decreas use rescu medic,0,0.8066,0.1934
nelfinavir death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
cyclophosphamid tumor tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
bp cancer hypercalcemia bp standard treatment cancer hypercalcemia dose num2 mg pamidron num4 mg clodron recommend former compound potent longer last effect,0,1.0,0.0
creatin acut myocardi infarct latter complex creatin kinas cardiac troponin measur peripher venou blood sampl serial drawn num2 patient acut myocardi infarct,0,1.0,0.0
calcium pyrophosph dihydr arthropathi best knowledg no case calcium pyrophosph dihydr arthropathi total knee arthroplasti report previous,0,1.0,0.0
cyclophosphamid diffus larg b-cell non-hodgkin lymphoma/dlbcl studi design assess activ safeti dose-adjust infusion cyclophosphamid doxorubicin vincristin prednison chemotherapi rituximab da-poch-r elderli patient poor-prognost untreat diffus larg b-cell non-hodgkin lymphoma dlbcl,0,1.0,0.0
paracetamol rheumatoid arthriti addit effect combin naproxen paracetamol rheumatoid arthriti,0,0.7929999999999999,0.20700000000000007
naloxon trachea naloxon prevent inhibit endomorphin-num -num guinea-pig human trachea suggest peptid inhibit cholinerg parasympathet neurotransmiss airway via activ classic opioid receptor,0,1.0,0.0
mannitol acut stroke base result studi no recommend made use mannitol acut stroke properli random control trial perform come final conclus,0,1.0,0.0
vitamin d. vitamin defici vitamin defici recent implic possibl risk factor etiolog numer diseas includ nonskelet condit,0,1.0,0.0
sodium coma taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.6094,0.3906
metformin niddm rational combin insulin oral drug therapi deriv better understand pathophysiolog niddm mechan action oral drug avail num type num diabet patient insulin-defici insulin-resist thu requir quit high dose exogen insulin num peripher insulin deliveri lead hyperinsulinaemia could play role pathogenesi late diabet complic num sulphonylurea stimul insulin releas directli portal vein could also potenti peripher insulin action num metformin improv glucos metabol insulin sensit alpha-glucosidas inhibitor slow digest complex carbohydr sucros abl reduc amount insulin need control postprandi hyperglycaemia,0,1.0,0.0
glucos inflamm coffe consumpt appear benefici effect subclin inflamm hdl cholesterol wherea no chang glucos metabol found studi,0,1.0,0.0
triacylglycerol hypertriglyceridem ten healthi elderli men num2-num2 age bodi mass index num2-num2 kg/m num num2 healthi young men num2-num2 age bodi mass index num2-num2 kg/m num studi hypertriglyceridem clamp prime infus long-chain triacylglycerol emuls reach stabil triacylglycerol concentr num mmol/l num3 min,0,1.0,0.0
tfa inflamm review describ pro-inflammatori effect tfa diari diet variou system disord also discuss possibl role tfa gut inflamm,1,0.1957,0.8043
aminoglycosid toxic haemofiltr indic particularli aminoglycosid toxic,1,0.3692,0.6308
rosiglitazon type conclus rosiglitazon direct protect effect glucos uptak wild-typ human podocyt,0,1.0,0.0
bortezomib aml taken togeth data support liposom bortezomib singl agent erad mll ptd/wt flt3 itd/wt aml mous may repres power potenti cur approach high-risk human diseas,0,1.0,0.0
carbidopa parkinson 's diseas combin levodopa l-dopa carbidopa commonly-us treatment symptom manag parkinson 's diseas,0,1.0,0.0
thromboxan b2/txb2 tumor necrosi factor-a/tnfa plasma concentr interleukin-1b il-1b thromboxan b2 txb2 prostaglandin e2 pge2 tumor necrosi factor-a tnfa measur enzyme-link immunosorb assay elisa techniqu,0,1.0,0.0
nicotin motion sick addit motion stimul aggrav dizzi nausea i.e. nicotin increas sensit motion sick,1,0.0,1.0
prednison inflamm num patient activ inflamm receiv prednison num mg. kg-num d-num num week follow numnum2 mg. kg-num d-num num month azathioprin num mg. kg-num d-num num month addit convent drug therapi heart failur,0,1.0,0.0
calcium colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.8125,0.1875
flavonoid breast cancer aim examin associ flavonoid flavonoid subclass except isoflavon risk breast cancer conduct meta-analysi,0,0.8154,0.1846
alcohol drug depend current inject drug use odd ratio numnum2 num2 ci numnum2-numnum2 past current treatment drug depend numnum2 num2 ci numnum2-numnum2 numnum2 num2 ci numnum2-numnum2 respect alcohol use num2 g/day numnum2 num2 ci numnum2-numnum2 independ predictor deferr treatment,0,1.0,0.0
no stroke articl review develop no-rel therapeut treatment stroke particular emphasi compound clinic research develop pipelin,0,1.0,0.0
num alpha-dihydrotestosteron prostat cancer examin effect num alpha-dihydrotestosteron dht testosteron egf egf-alpha cell prolifer 3h-thymidin incorpor androgen-depend human prostat cancer cell line alvanum3 serum-fre medium,0,1.0,0.0
voriconazol valv endocard describ diabet patient lecythophora mutabili prosthet valv endocard treat surgic well amphotericin b lipid complex voriconazol subsequ follow prolong voriconazol suppress therapi,0,1.0,0.0
aspirin mitral stenosi compar studi efficaci coumadin aspirin primari cardioembol stroke prevent chronic rheumat heart diseas mitral stenosi atrial fibril conduct siriraj hospit mahidol univers bangkok thailand,0,1.0,0.0
acetylcholin analgesia neostigmin given intrathec inhibit breakdown endogen spinal neurotransmitt acetylcholin therebi induc analgesia,0,0.8122,0.1878
haloperidol neurolept syndrom patient suffer rare enzym defici develop malign neurolept syndrom treat one singl dose haloperidol,1,0.0,1.0
zaleplon reduct sleep latenc result phase ii/iii studi suggest zaleplon num num2 mg produc dose-depend reduct sleep latenc patient suffer primari insomnia,1,0.0,1.0
methacholin asthmat ten asthmat subject studi three occas bronchial challeng aerosol paf methacholin isoton salin,0,1.0,0.0
alanin diarrhea among num num3 elig patient advers drug reaction observ num common abdomin distens flatul diarrhea increas alanin aminotransferas level,0,0.8082,0.1918
sulfasalazine/ssz psa methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0
quinin toxic although quinin load dose may effect uniform dose rapid fever clearanc also appear associ higher toxic,1,0.0,1.0
danazol angioedema danazol treatment reliev symptom angioedema increas c1 inh activ concentr normal chnum2 c1q c4 level,0,1.0,0.0
ondansetron ill assess hypothesi ondansetron administr children type num diabet mellitu t1dm present emerg depart ed care intercurr ill vomit improv clinic outcom reduc hospit rate primari length ed stay intraven fluid ivf administr revisit secondari outcom,0,1.0,0.0
zanamivir ili uncontrol open-label multicentr studi evalu antivir activ safeti inhal zanamivir rotadisk via diskhal devic num2 mg administ twice daili num day subject num2 year old ili,0,1.0,0.0
efavirenz rt nevirapin efavirenz suscept test compar control wild-typ viru rt,0,1.0,0.0
yohimbin anxieti yohimbin result signific increas anxieti patient ptsd not healthi subject,1,0.0,1.0
ceftriaxon mening recent manag infant mening caus streptococcu pneumonia ceftriaxon fail steril cerebrospin fluid num day therapi,0,1.0,0.0
ondansetron t1dm time along increas ondansetron use reduct admiss length stay ivf administr children t1dm,0,1.0,0.0
aspirin small bowel injuri combin low-dos aspirin thienopyridin exacerb small bowel injuri,1,0.1926,0.8074
glatiram acet diseas result suggest glatiram acet may inhibit il-1beta-stimul rant express human glial cell block nf-kappab activ thu identifi part molecular basi anti-inflammatori immunosuppress effect demyelin diseas,0,0.812,0.18799999999999994
indoxyl sulfat renal failur indoxyl sulfat progress renal failur effect low-protein diet oral sorbent indoxyl sulfat product urem rat undialyz urem patient,0,0.6076,0.3924
ramipril adpkd forty-six hypertens adpkd patient random either ramipril n num2 metoprolol n num2,0,1.0,0.0
phosphat ckd/chronic kidney diseas lanthanum carbon sevelam carbon non-calcium-bas phosphat binder use manag hyperphosphataemia patient chronic kidney diseas ckd,0,1.0,0.0
l-ornithine-l-aspart chronic hepat encephalopathi therefor therapeut efficaci oral l-ornithine-l-aspart improv impair ammonia detoxif investig patient cirrhosi hyperammonemia stabl overt chronic hepat encephalopathi subclin hepat encephalopathi random double-blind placebo-control clinic trial,0,1.0,0.0
cyclosporin toxic relationship drug transport function endogen melanogen toxic assess treat cell cyclosporin analog psc-num3 assess vacuol format cell growth inhibit,0,1.0,0.0
amino acid alcohol abus proteom analysi show therapi downregul enzym involv amino acid metabol glycolysis/gluconeogenesi alcohol catabol take place latter probabl due cessat alcohol abus,0,1.0,0.0
bleomycin head neck cancer ten establish head neck cancer cell line um-scc num2a num2b num2b num2a num2b num2c num2b hlacnum2 num4na num4ddp4 chemosensit cisplatin carboplatin num-fluorouracil bleomycin well cellular glutathion content activ glutathion s-transferas determin,0,1.0,0.0
cholesterol atherosclerosi macrophag cholesterol homeostasi key process involv initi progress atherosclerosi,0,0.6185,0.3815
cidofovir hematuria one patient treat intraven cidofovir resolut bk viruria hematuria,0,1.0,0.0
magnesium muscl damag thu magnesium supplement magnesium-replet subject not enhanc perform increas resist muscl damag race rate recoveri muscl function follow race,0,1.0,0.0
clopidogrel acut coronari syndrom clinic practic found no signific differ atorvastatin therapi statin therapi clinic outcom patient acut coronari syndrom receiv clopidogrel therapi,0,1.0,0.0
steroid encephalomyel present five patient num affect classic dissemin encephalomyel num post infecti myeliti show good respons intraven immunoglobulin ivig steroid treatment failur,0,1.0,0.0
epirubicin chf actuari estim num2 patient experienc num2 rel reduct lvef num year num3-num4 mg/m2 epirubicin num2 deterior chf,0,0.612,0.38799999999999996
oleic acid adrp jnum3 murin macrophag incub either vldl oleic acid content adrp triacylglycerol tg increas num- num-fold,1,0.2065,0.7935
formoterol fumar asthmat ten asthmat patient enrol studi effect dri powder formoterol fumar,0,1.0,0.0
hydroxyurea structur damag follow steroid hydroxyurea administr lesion mri disappear suggest pathogenet mechan revers not caus signific structur damag,0,1.0,0.0
no neuroblastoma studi regulatori function no neuroblastoma cell line sk-n-be primari cerebellar granul cell cultur,0,0.7928,0.20720000000000005
cholesterol atherosclerosi peroxisom proliferator-activ receptor ppar regul transcript gene involv cholesterol homeostasi thu repres import therapeut target term reduc atherosclerosi,1,0.3781,0.6219
bn sclc summari bn analogu lack c-termin methionin may function use sclc bn receptor antagonist,0,0.7925,0.2075
bile acid barrett 's esophagu aim studi assess express bile acid receptor esophagu normal esophag barrett 's esophagu adenocarcinoma investig possibl function,0,1.0,0.0
otrnum4 harp harp found differ effect neutral anticoagul activ mimet heparan sulphat otrnum4 heparin purifi system human plasma,0,1.0,0.0
artemisinin cardiotox contrast artemisinin not reveal cardiotox,0,1.0,0.0
nicotin lewi bodi diseas anti-fibrillogen fibril-destabil activ nicotin vitro implic prevent therapeut lewi bodi diseas,0,1.0,0.0
doxorubicin hypox given doxorubicin docetaxel th-num3 complement enhanc anticanc effect perivascular hypox region also increas toxic,0,1.0,0.0
estrogen breast cancer estrogen receptor alpha regul express breast cancer num associ ring domain num bard1 gene intron dna sequenc,0,0.7978,0.20220000000000005
terazosin chronic obstruct pulmonari diseas terazosin maintain antihypertens efficaci well toler patient varieti concomit diseas includ congest heart failur peripher vascular diseas chronic obstruct pulmonari diseas benign prostat hyperplasia diabet obes,0,1.0,0.0
telmisartan hypertens recent meta-analysi demonstr possibl telmisartan strongest arb reduct bp patient essenti hypertens,0,1.0,0.0
propofol asthmat asthmat nonasthmat patient receiv thiobarbitur induct greater incid wheez patient receiv propofol,0,1.0,0.0
corticosteroid interstiti lung diseas except acut eosinophil pneumonia respond well corticosteroid therapi role corticosteroid immune-suppress treatment manag smoking-rel interstiti lung diseas not entir clear probabl limit util particularli absenc smoke cessat,0,1.0,0.0
clindamycin pneumocysti hiv-infect man becam increasingli breathless cyanos receiv clindamycin primaquin treatment pneumocysti jirovecii pneumonia,0,0.7849,0.2151
testosteron erectil dysfunct obes low testosteron level erectil dysfunct,0,1.0,0.0
glucos oral glucos toler fast glucos insulin lipid lipoprotein profil oral glucos toler insulin secret insulin-medi glucos dispos hyperglycem clamp bodi composit dual energi x-ray absorptiometri determin lopinavir/ritonavir administr,0,0.799,0.201
num2 -hete melanoma adhes lung metastasi human melanoma cell cnum2 nod/scid mice also potenti co-treat num2 -hete,1,0.3867,0.6133
glatiram acet multipl sclerosis/m howev trial smaller pivot trial interferon-beta glatiram acet therefor perform meta-analysi four trial order provid overal assess benefit ivig relapsing-remit multipl sclerosi comparison drug current avail treatment diseas activ ms,0,1.0,0.0
nelfinavir cancer nelfinavir viracepta hiv proteas inhibitor shown induc endoplasm reticulum er stress reaction human cancer cell,0,1.0,0.0
cefixim gonorrhea single-dos oral treatment cefixim suprax quinolon appear effect safe practic patient uncompl gonorrhea,0,1.0,0.0
fentanyl nausea compar oral opioid advantag transderm fentanyl includ lower incid impact advers effect constip nausea vomit daytim drowsi higher degre patient satisfact improv qualiti life improv conveni complianc result administr everi num2 hour decreas use rescu medic,0,1.0,0.0
imatinib eosinophilia imatinib mesyl gleevec small molecul inhibitor abl kit platelet-deriv growth factor receptor pdgfr tyrosin kinas report effect treatment hypereosinophil syndrom he rare eosinophilia-associ chronic myeloid disord eos-cmd character num num2 qnum2 pnum2 cytogenet abnorm,0,1.0,0.0
aluminum toxic howev rel contribut aluminum lithium human toxic ecotox could not estim due insuffici toxic data model,0,0.6184,0.3816000000000001
pyridoxin seizur long-term follow-up two sibl pyridoxine-depend seizur associ novel aldh7a1 mutat,0,0.6099,0.3901
pimecrolimu skin lesion adult histori mild moder ad free activ skin lesion intervent pimecrolimu cream num first sign and/or symptom subsequ recurr reduc number flare requir tc use decreas number disease-rel offic visit,0,1.0,0.0
pyridoxin seizur pyridoxine-depend seizur pd rare disord character seizur resist anticonvuls control daili pharmacolog dose pyridoxin,0,0.6009,0.3991
tzd type num diabet mellitu aim investig impact coadministr tzd acei/arb hematocrit hemoglobin valu uncompl patient type num diabet mellitu normal serum creatininenumdata patient type num diabet current follow review patient treat acei/arb and/or tzd identifi,0,1.0,0.0
zonisamid mood disord bing eat disord best evid mood disord cognitive-behavior therapi well topiram zonisamid select case select serotonin reuptak inhibitor,0,1.0,0.0
serotonin mood disord bing eat disord best evid mood disord cognitive-behavior therapi well topiram zonisamid select case select serotonin reuptak inhibitor,0,1.0,0.0
dopamin neuroblastoma tumour growth neuroblastoma tumour inhibit differ mechan l-dopa metabolit dopamin reduc activ tyrosinas bso reduc glutathion level l-dopa tamoxifen rais camp concentr,0,1.0,0.0
silicon myopia investig efficaci safeti stabil correct achiev silicon posterior chamber intraocular len use correct high myopia phakic eye,0,1.0,0.0
titanium perin hernia repair describ applic titanium mesh perin hernia repair,0,1.0,0.0
nickel hypersensit claim high correl posit histori nickel hypersensit patch-test result test unnecessari histori hypersensit,1,0.2009,0.7991
dichlorphenamide/dcp paralysi one studi dichlorphenamid dcp vs placebo test two group particip num2 hypokalem period paralysi hypopp num2 hyperkalem period paralysi hyperpp base clinic criteria,0,1.0,0.0
amphotericin b. candidemia compar trial amphotericin b vs. fluconazol treatment candidemia nonneutropen patient data manag intravascular cathet collect,0,1.0,0.0
anthracyclin cardiotox anthracyclin import anticanc drug use limit acut chronic cardiotox,0,0.6106,0.3894
acetaminophen methemoglobinemia acetaminophen-poison cat develop methemoglobinemia sometim hepat failur,1,0.0,1.0
ketotifen at express rate cam inflammatori marker conjunctiv surfac cell significantli reduc ketotifen olopatadin compar at,0,1.0,0.0
calcium coach healthcar provid must incorpor appropri teach strategi intens counsel coach along support mechan enabl bc understand import healthi diet calcium vitamin supplement regular strength/weight program integr daili lifestyl,0,1.0,0.0
desipramin major depress determin predictor desipramine-refractori depress author examin outcom patient major depress admit gener hospit treat desipramin adjust adequ blood level,0,1.0,0.0
levobupivacain death awak sheep exampl almost num2 levobupivacain requir caus death,1,0.3965,0.6035
"pentostatin hcl/hairi cell leukemia ten patient hairi cell leukemia hcl seven patient b-cell chronic leukemia bcl studi intracellular num num'-oligoadenyl synthetas num,5oa activ mononuclear cell num h num2 h num2 h pentostatin administr",0,1.0,0.0
ketotifen fumar at patient sac includ studi randomli assign num num group topic ketotifen fumar numnum3 ophthalm solut topic olopatadin hcl num ophthalm solut at control group,0,1.0,0.0
idarubicin abl elucid role dna repair phenomenon examin capac murin baf3 lymphoid cell tel/abl-transform counterpart repair dna lesion caus gamma- uv-radi anti-canc drug idarubicin,0,0.8075,0.1925
simvastatin peripher arteri diseas high-dos atorvastatin superior moderate-dos simvastatin prevent peripher arteri diseas,0,1.0,0.0
glucos death show epitheli ovarian cancer cell highli sensit glucose-deprivation-induc cell death like resveratrol glucos depriv induc caspase-independ cell death hallmark autophagi,0,1.0,0.0
n-acetyl-cysteine/nac chronic obstruct pulmonari disease/copd aim studi whether stabl chronic obstruct pulmonari diseas copd patient present unbal blood redox statu effect oxygen administr blood redox balanc efficaci n-acetyl-cystein nac treatment against oxid stress-induc oxygen administr whether dose-rel,0,0.8285,0.1715
alcohol gv thirty-seven consecut patient portal hypertens endoscop evid isol gv num2 present histori activ bleed random receiv endoscop intervent either alcohol n num2 cyanoacryl glue n num2 inject,0,0.6314,0.3686
terazosin hypertens alpha num-blockad treatment hypertens megastudi terazosin num4 clinic practic set,0,0.8372,0.16279999999999994
dihydroergotamin primari headach disord determin dose side effect dihydroergotamin affect outcom primari headach disord,1,0.3961,0.6039
aspirin small bowel injuri recent studi small bowel injuri enteropathi associ low-dos aspirin increasingli recogn,1,0.0,1.0
pramipexol parkinson 's disease/pd non-ergot dopamin receptor agonist ropinirol pramipexol rotigotin apomorphin may allevi non-motor symptom parkinson 's diseas pd other may precipit,0,0.8088,0.19120000000000004
dcp weak hypokalem largest includ studi met inclus criteria suggest dcp effect prevent episod weak hypokalem hyperkalem period paralys,0,1.0,0.0
n- num-hydroxyphenyl retinamid breast cancer report her2/neu reduc sensit breast cancer cell n- num-hydroxyphenyl retinamid num-hpr suppress nitric oxid product,0,0.6045,0.3955
testosteron obes obes low testosteron level erectil dysfunct,0,1.0,0.0
chloramphenicol endophthalm main aim studi assess whether omit prophylact postop topic antibiot chloramphenicol influenc risk develop endophthalm cataract surgeri,0,0.8089,0.19110000000000005
midazolam gcse refractori gcse continu inumv midazolam infus num-num mg/kg/hr num mg/kg inumv bolu effect advantag tradit therapi induc less hypotens cardiorespiratori depress easili titrat,0,1.0,0.0
praziquantel hookworm infection/hookworm infect report studi among num2 schoolchildren area highli endem schistosoma mansoni hookworm infect place particular emphasi effect praziquantel preval intens hookworm infect,0,0.607,0.39299999999999996
hbeag proteinuria one reduct proteinuria remain hbeag posit,0,1.0,0.0
gemcitabin toxic newer combin gemcitabin plu cisplatin gc demonstr compar surviv improv toxic profil von der maas et al,0,1.0,0.0
thiopent asthmat wherea thiopent contract human isol bronchi propofol etomid reduc histamine-induc contract human isol airway smooth muscl either not sensit passiv sensit asthmat serum,0,1.0,0.0
androgen bph invers relationship bph may relat hormon correl ie lower androgen level heavi alcohol drinker,0,0.795,0.205
morphin analgesia doubl blind cross studi design evalu effect ketamin spinal morphin analgesia termin cancer pain patient,1,0.384,0.616
ddt farmer 's lung insecticid ddt lindan aldicarb posit associ farmer 's lung among farmer,1,0.0,1.0
etoposid cancer april num juli num num4 cancer leukemia group b calgb conduct phase ii studi etoposid carboplatin advanc ajc stage iiib-iv non-small-cel lung cancer nsclc patient whose perform statu ps num-num,0,1.0,0.0
levothyroxin hypothyroid one pregnant patient take levothyroxin hypothyroid,0,1.0,0.0
sirolimu hypertens although sirolimus-tr patient display compar lower platelet white blood cell count higher level serum cholesterol triglycerid sirolimu not augment nephrotox hypertens procliv cyclosporin,0,1.0,0.0
histamin daytim sleepi antagon histamine-h num receptor one tactic explor increas wake treatment disord excess daytim sleepi ed well sleep cognit disord,0,0.8111,0.1889
triacylglycerol adrp jnum3 murin macrophag incub either vldl oleic acid content adrp triacylglycerol tg increas num- num-fold,0,1.0,0.0
diphenhydramin toxic dose-depend toxic diphenhydramin overdos,1,0.0,1.0
corticosteroid bronchiectasi bronchiectasi regular use inhal corticosteroid may improv lung function,0,1.0,0.0
iron toxic result demonstr cisplatin-caus hemosiderin deposit spleen provid valuabl clue understand molecular basi toxic cisplatin hemosiderin accumul iron metabol vivo,0,1.0,0.0
aspirin cardioembol stroke compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,0.7976,0.2024
pah cancer polycycl aromat hydrocarbon pah ubiquit environment pollut toxic focu establish cancer risk human,1,0.2088,0.7912
carboplatin tnbc carboplatin gemcitabin cg combin activ unselect anthracycline/taxan pretreat metastat breast cancer patient carri out phase ii studi evalu activ cg combin pretreat metastat tnbc patient,0,1.0,0.0
ketanserin contract ketanserin num2-num4 nm antagon part num-ht-induc contract,0,0.8188,0.18120000000000006
clozapin myocard chart review potenti featur myocard pericard cardiomyopathi children adolesc treat clozapin,1,0.19530000000000006,0.8047
tyrosin lung cancer role tyrosin kinase-independ phosphoryl egfr activ mutat cisplatin-tr lung cancer cell,0,1.0,0.0
artesun malaria malaria treatment recommend world health organ involv medicin deriv artemisinin activ compound extract plant artemisia annua deriv artesun,0,1.0,0.0
metolazon bronchopulmonari dysplasia addit metolazon overcom toler furosemid infant bronchopulmonari dysplasia,0,0.8087,0.19130000000000005
oxygen diabet hyperbar oxygen therapi facilit heal chronic foot ulcer patient diabet,0,1.0,0.0
clofarabin chronic lymphocyt leukemia clinic pharmacokinet studi clofarabin chronic lymphocyt leukemia strategi treatment,0,1.0,0.0
serotonin pruritu therefor identifi underli caus pruritu prime import order develop tailor treatment plan even palli care treatment focus toward symptom not necessarili underli disease.result show palli care patient pruritu differ natur treatment drug paroxetin select serotonin reuptak inhibitor may benefici,0,1.0,0.0
warfarin bleed patient receiv heartmat ii lvad directli transit warfarin aspirin therapi without intraven heparin no short-term increas risk thrombot thromboembol event bleed requir transfus significantli reduc,0,0.8121,0.1879
paclitaxel tumor/breast cancer activ rnum5 paclitaxel alon combin studi human breast cancer cell line bt-num3 overexpress her2/neu mda-mb-num3 low her2/neu cell viabil biomark farnesyl hdj-num rho b tumor growth raf/mek/erk surviv pi3k/akt angiogenesi vegf fgf-num mmp-num mmp-num mmp-num endpoint,0,1.0,0.0
norepinephrin asystol num2-year-old male experienc postexercis bradycardia asystol higher basal plasma norepinephrin num3 versu num2 +/- num pg/ml epinephrin num2 versu less num2 pg/ml similar vagal tone vagal tone index numnum2 versu numnum2 +/- numnum2 u compar num close match subject underw unev stress test,1,0.3971,0.6029
aldosteron renal diseas blockad renin-angiotensin-aldosteron system proven effect retard progress renal diseas remnant kidney model well experiment diseas importantli rang progress human renal diseas,0,0.8162,0.1838
fluoxetin depress outpati receiv fluoxetin switch sertralin therapi without loss control depress without substanti advers effect,0,1.0,0.0
oleic acid oleic acid/oa anion lipid nanoparticl consist monostearin ms differ content oleic acid oa prepar,0,1.0,0.0
sugammadex headach rocuronium-sugammadex reduc myalgia headach electroconvuls therapi patient major depress,0,1.0,0.0
aspirin fever mannitol treatment effect adjust age stroke sever fever first num day aspirin treatment ischem stroke logist regress model,0,1.0,0.0
permethrin dermanyssu gallina infest dermanyssu gallina infest unusu caus scalp pruritu treat permethrin shampoo,0,1.0,0.0
cyproheptadin sexual dysfunct index term includ sexual dysfunct antidepress select serotonerg reuptak inhibitor fluoxetin sertralin paroxetin fluvoxamin clomipramin buspiron nefazodon bupropion cyproheptadin amantadin yohimbin central nervou system stimul,0,1.0,0.0
allylpyrocatechol rheumatoid arthriti taken togeth ex vivo studi establish allylpyrocatechol potent scaveng activ could consid add-on therapi treatment inflammation-associ disord like rheumatoid arthriti,0,1.0,0.0
sugammadex myalgia rocuronium-sugammadex reduc myalgia headach electroconvuls therapi patient major depress,0,1.0,0.0
fentanyl pain addit compar analges effect incid motor block opioid-rel side effect three differ ropivacaine/fentanyl solut also evalu workload pain staff,0,1.0,0.0
sildenafil ed data cite herein not suggest increas incid naion men took sildenafil ed,0,1.0,0.0
chromium cytotox chromium-releas assay common method assess cytotox immun effector flow cytometri increasingli use relationship either assay clonogen readout remain unknown,0,1.0,0.0
nitroglycerin myocardi infarct current guidelin call nitroglycerin prescrib patient coronari heart diseas includ stabl angina recov acut coronari syndrom myocardi infarct,0,1.0,0.0
fluoxetin compuls behavior disord seven num2 subject compuls behavior disord respond favor fluoxetin treatment none comparison subject respond favor medic,0,1.0,0.0
celecoxib b-cell lymphoma furthermor down-regul cox-num express use cox-num inhibitor celecoxib increas tunicamycin-induc apoptosi concomit up-regul pro-apoptot transcript factor chop gaddnum3 down-regul b-cell lymphoma num/bcl-num-associ x protein bcl-num/bax ratio suggest inhibit cox-num sensit human hepatoma cell er stress-induc apoptosi,0,1.0,0.0
capecitabin toxic neurotox infrequ report toxic capecitabin,1,0.2007,0.7993
taxan peripher neuropathi microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,1,0.1974,0.8026
amlodipin stroke efficaci ccb amlodipin arb valsartan lower bp protect against cardiovascular event stroke across rang hypertens patient popul establish mani year,0,1.0,0.0
heparin harp harp found differ effect neutral anticoagul activ mimet heparan sulphat otrnum4 heparin purifi system human plasma,0,1.0,0.0
ceftriaxon neutropen even combin aminoglycosid ceftriaxon would not good choic neutropen patient,0,1.0,0.0
androgen breast cancer find indic caus profound suppress adren steroid product addit suppress ovarian secret androgen postmenopaus breast cancer patient,0,1.0,0.0
dopamin sleep disturb dopamin receptor agonist sleep disturb parkinson 's diseas,0,1.0,0.0
amlodipin hypertens conclus result suggest angiotensin i-convert enzym inhibitor perindopril superior calcium channel blocker amlodipin reduc vascular endotheli dysfunct co-administ angiotensin receptor blocker patient essenti hypertens,0,1.0,0.0
lidocain fibromyalgia intraven lidocain infus safe effect manag fibromyalgia,0,1.0,0.0
sodium cardiovascular diseas diuret e_-block inhibit renal sodium reabsorpt renin releas respect hypothes e_-block diuretic-induc blood pressur reduct prevent cardiovascular diseas would greater patient highest enac express rsnum5 g-allel wherea would no genet mediat differ treatment efficaci among patient treat vasodil diltiazem,0,1.0,0.0
prostaglandin e num breast cancer apoptosi induc num-hpr cox-num inhibitor combin although unaffect anti-her2/neu antibodi revers cox-num product prostaglandin e num indic cox-num major mechan her2/neu suppress num-hpr apoptosi breast cancer cell,0,1.0,0.0
trametinib melanoma literatur access medlin intern pharmaceut abstract num4-novemb num4 use term melanoma metastat melanoma ipilimumab vemurafenib dabrafenib trametinib,0,1.0,0.0
warfarin atrial fibril final patient bother littl symptom atrial fibril cardiovers follow either aspirin warfarin without subsequ antiarrhythm therapi treatment choic,0,1.0,0.0
norepinephrin pain recoveri no differ two group norepinephrin concentr plasma bodi weight-adjust oxygen consumpt pain visual analogu score metabolit,0,1.0,0.0
otrnum4 harp harp shown compet antithrombin thrombin bind heparin otrnum4 respect,0,1.0,0.0
curcumin gastric carcinoma howev underli mechan curcumin gastric carcinoma cell still need investig,0,1.0,0.0
azdnum4 crc baselin gene array data crc cell line xenograft use develop k-top score pair k-tsp classifi predict num2 accuraci test set patient-deriv k-ra mutant crc explant would respond azdnum4 provid basi patient-select clinic trial,0,1.0,0.0
metformin diabet mellitu chronic pretreat metformin associ reduct no-reflow phenomenon patient diabet mellitu primari angioplasti acut myocardi infarct,0,1.0,0.0
corticosteroid facial nerv palsi report case ramsay hunt syndrom immun compromis patient classic facial nerv palsi ipsilater ear vesicl rapidli evolv involv multipl cranial neuropathi improv dramat antivir therapi corticosteroid,0,0.8005,0.1995
saquinavir death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
vitamin k. embol event ximelagatran oral direct thrombin inhibitor found effici vitamin k antagonist drug prevent embol event recent withdrawn abnorm liver function test,0,1.0,0.0
ribavirin diabet mellitu perform proteom analysi liver specimen num2-year-old woman affect hepat c genotyp 1a alcohol diabet mellitu type num antivir treatment pegyl interferon alpha 2b ribavirin,0,1.0,0.0
metformin ami/acut myocardi infarct studi investig retrospect whether chronic pretreat metformin associ no-reflow diabet patient underw primari coronari intervent acut myocardi infarct ami,0,0.8205,0.1795
nmda allodynia mice enhanc function forebrain nmda receptor demonstr select enhanc persist pain allodynia,1,0.1989,0.8011
nscnum5 hypoxia addit nscnum5 significantli antagon accumul hif-1alpha stabil hypoxia hypoxia-mimet agent,0,0.7878,0.21220000000000008
sorafenib palmar-plantar erythrodysaesthesia toler profil gener consist vegf receptor inhibitor axitinib associ numer lower incid palmar-plantar erythrodysaesthesia cutan toxic anaemia sorafenib phase iii trial,0,0.7951,0.2049
corticosteroid dengu infect previou studi children effect corticosteroid treatment adult dengu infect not evalu,0,1.0,0.0
bupivacain ventricular tachycardia contrast anaesthetis dog no differ seen incid spontan electr stimulation- induc ventricular tachycardia fibril among anim expos levobupivacain bupivacain,0,0.7936,0.20640000000000006
reboxetin adhd reboxetin could use toler effect treatment adult adhd,0,1.0,0.0
testosteron type ed common symptom patient type num diabet also low testosteron level,0,0.8241,0.17589999999999995
amlodipin acut stroke studi conduct compar bp-lower diurnal bp variat effect amlodipin losartan acut stroke patient,0,0.8121,0.1879
tsa cornea histolog real-tim rt-pcr investig evalu effect tsa heal process cornea,0,1.0,0.0
divalproex sodium bipolar disord lithium divalproex sodium carbamazepin lamotrigin atyp antipsychot antidepress found benefici treatment elderli patient bipolar disord,0,1.0,0.0
prostacyclin pph due complic natur therapi inhal sc oral prostacyclin also evalu treatment pph,0,1.0,0.0
pravastatin hyperlipidemia sinc hyperlipidemia not improv pravastatin atorvastatin niceritrol sinc level thyroid-stimul hormon tsh free t4 num3 iu/ml num ng/dl respect patient diagnos secondari hyperlipidemia hypothyroid,0,0.8245,0.1755
y-num5 tumor primari tumor volum site inject smaller y-num5-treat group compar control group differ not statist signific,0,1.0,0.0
levodopa parkinson 's diseas investig effect levodopa mood anxieti eight parkinson 's diseas patient motor fluctuat,0,1.0,0.0
terbinafin tinea pedi effect treatment sever tinea pedi num terbinafin cream member japanes self-defens forc,0,1.0,0.0
bile acid adenocarcinoma aim studi assess express bile acid receptor esophagu normal esophag barrett 's esophagu adenocarcinoma investig possibl function,0,1.0,0.0
mg. hypokinet prehypokinet hypokinet period excret mg fece urin concentr mg serum mg balanc measur,0,1.0,0.0
anthracyclin acut promyelocyt leukaemia favour outcom patient childhood acut promyelocyt leukaemia treatment reduc cumul anthracyclin dose,0,1.0,0.0
acebutolol hypertens one month ago patient start treatment oral acebutolol cure hypertens num-year evolut,0,1.0,0.0
thalidomid multipl myeloma although multipl myeloma remain incur diseas date present avail thalidomid base combin chemotherapi repres activ induct regimen improv outcom achiev eventu cure,0,0.8002,0.1998
calcium sudden death epidemiolog clinic studi suggest magnesium may reduc frequenc sudden death sodium contribut occurr hypertens calcium may help prevent osteoporosi,0,1.0,0.0
rnum5 tumor/breast cancer activ rnum5 paclitaxel alon combin studi human breast cancer cell line bt-num3 overexpress her2/neu mda-mb-num3 low her2/neu cell viabil biomark farnesyl hdj-num rho b tumor growth raf/mek/erk surviv pi3k/akt angiogenesi vegf fgf-num mmp-num mmp-num mmp-num endpoint,0,1.0,0.0
apigenin prostat carcinoma molecular mechan apigenin-induc cell-cycl arrest apoptosi hormon refractori human prostat carcinoma dunum3 cell,0,1.0,0.0
curcumin cancer achiev effect cancer prevent curcumin need find new method enhanc effect curcumin diet,0,1.0,0.0
azt infect interestingli surviv prolong greater treatment start five two year infect no strike increas surviv time dose azt inhibit num2 hiv prolifer use instead lower one induc num2 inhibit,0,1.0,0.0
pomalidomid mm immunomodulatori agent imid thalidomid lenalidomid chang landscap treatment patient mm newer imid pomalidomid show promis earli clinic trial,0,1.0,0.0
fingolimod neurolog condit report case woman multipl sclerosi develop sever neurolog condit follow natalizumab nzb withdraw soon fingolimod fti initi,1,0.0,1.0
asenapin manic/bipolar disord asenapin atyp antipsychot agent avail sublingu formul num num2 mg indic us saphri acut treatment monotherapi adjunct therapi manic mix episod eu sycrest treatment moder sever manic episod adult patient bipolar disord,0,1.0,0.0
adriamycin gastric cancer knockdown mdr1 increas sensit adriamycin drug resist gastric cancer cell,0,1.0,0.0
clonidin stress heart rate hr blood pressur result reveal comparison placebo clonidin significantli reduc plasma norepinephrin concentr increas beta1- beta2-ar respons reduc rest stress heart rate hr blood pressur bp p numnum2 pmdd women,0,1.0,0.0
corticosteroid dengu infect possibl benefici effect corticosteroid variou manifest dengu infect need evalu adequ power well design randomis control trial,0,1.0,0.0
serotonin obsessive-compuls disord role serotonin obsessive-compuls disord,0,0.6084,0.3916
barbitur gcse refractori gcse often difficult treat tradit therapi barbitur induc hypotens respiratori depress prolong recoveri,0,1.0,0.0
amiodaron atrial fibrillation/af compar efficaci safeti amiodaron dronedaron patient persist atrial fibril af,0,1.0,0.0
mg. hk conclud signific loss mg occur presenc neg mg balanc mg defici endurance-train subject prolong exposur hk daili mg supplement mg load test,0,0.8207,0.1793
adr mitochondri damag electron microscopi reveal dose-depend ultrastructur alter mark mitochondri damag nontransgen mice treat adr not transgen litterm,1,0.3876,0.6124
pomalidomid myelofibrosi studi popul includ num2 mayo clinic patient median age num2 year particip two consecut clinic trial pomalidomid therapi myelofibrosis-associ anemia,0,1.0,0.0
corticosteroid ipsilater ear vesicl report case ramsay hunt syndrom immun compromis patient classic facial nerv palsi ipsilater ear vesicl rapidli evolv involv multipl cranial neuropathi improv dramat antivir therapi corticosteroid,0,1.0,0.0
methotrex tumor evid radiograph benefit treatment infliximab plu methotrex rheumatoid arthriti patient no clinic improv detail subanalysi data anti-tumor necrosi factor trial rheumatoid arthriti concomit therapi studi,0,1.0,0.0
hbeag liver diseas aim investig relationship serum leptin concentr sever liver diseas cohort subject hbeag neg chronic hepat b chb c chc analyz effect bodi composit leptin system insulin resist togeth viral factor virolog respons antivir treatment,0,0.8048,0.19520000000000004
olmesartan mbp amlodipine-olmesartan combin therapi bedtim administr reduc better mbp correct nocturn bp fall improv urinari albumin excret,0,1.0,0.0
silicon dyspnea receiv silicon inject buttock patient develop rapid onset dyspnea pleurit chest pain fever chill,1,0.0,1.0
bombesin gastrinoma demonstr first time bombesin trophic hormon gastrinoma,1,0.387,0.613
vitamin a. defici iron vitamin defici impact anemia immun system,0,1.0,0.0
dopamin parkinson 's diseas apomorphin mix dopamin d1/d2 receptor agonist potenti use treatment parkinson 's diseas,0,1.0,0.0
metformin obes preliminari result suggest insulin-metformin obes present insulin-acarbos post-prandi hyperglycaemia occur combin might offer favour featur treatment niddm patient although therapeut approach still requir adequ evalu control studi,0,1.0,0.0
levodopa anxieti dose-respons relationship levodopa mood anxieti fluctuat parkinson 's diseas double-blind placebo-control studi,1,0.3899,0.6101
tyrosin philadelphia detect mrd may predict outcom patient philadelphia chromosome-posit treat tyrosin kinas inhibitor plu chemotherapi,0,1.0,0.0
irbesartan marfan syndrom prospect random placebo-control double-blind multicent studi effect irbesartan aortic dilat marfan syndrom aim trial studi protocol,0,0.8008,0.19920000000000004
anthracyclin acut promyelocyt leukaemia/apl acut promyelocyt leukaemia apl treatment often includ high cumul dose anthracyclin caus long-term cardiotox,0,1.0,0.0
apixaban death aristotl apixaban result num2 reduct stroke num2 reduct major bleed num2 reduct death,0,1.0,0.0
gemcitabin hemolyt urem syndrom hemolyt urem syndrom may associ varieti etiolog chemotherapeut agent also report associ hemolyt urem syndrom includ mitomycin cisplatin bleomycin recent gemcitabin,1,0.1925,0.8075
desmopressin enuresi examin safeti efficaci desmopressin three dose given women multipl sclerosi treat nocturia without enuresi,0,1.0,0.0
atra/all-tran retino acid cytotox pretreat myeloid leukemia line hl-num2 all-tran retino acid atra up-regul aqp9 lead significantli increas arsen uptak as2o3-induc cytotox incub as2o3 might explain synerg atra as2o3,0,0.7897,0.21030000000000004
aza toxic averag initi dose aza prescrib num3anum2 mg. num2 develop aza relat toxic,1,0.0,1.0
lithium toxic howev rel contribut aluminum lithium human toxic ecotox could not estim due insuffici toxic data model,1,0.3787,0.6213
alendron sodium fractur postmenopaus women low bmd assign treatment num mg/d alendron sodium fractur intervent trial complet num year bmd monitor adher studi medic n num4 postmenopaus women osteoporosi assign treatment num2 num3 mg/d raloxifen hydrochlorid multipl outcom raloxifen evalu trial similarli complet num year monitor adher studi medic n num4,0,1.0,0.0
quinin vasospasm case ocular toxic vasospasm secondari quinin poison describ,1,0.1967,0.8033
tetracyclin posttraumat endophthalm describ case posttraumat endophthalm unrespons system amoxicillin+clavulan acid piperacillin/tazobactam intra-ocular vancomycin topic ofloxacin tetracyclin sulfametoxazol antibiot therapi,0,1.0,0.0
berberin multipl diseas berberin bbr isoquinolin deriv alkaloid isol chines herb long histori use treatment multipl diseas includ cancer,0,0.8255,0.1745
marinomycin a. cancer room light marinomycin slowli isomer geometr isom marinomycin b c. marinomycin a-d show signific antimicrobi activ against drug resist bacteri pathogen demonstr impress select cancer cell cytotox against six eight melanoma cell line nation cancer institut 's num2 cell line panel,0,1.0,0.0
azithromycin bronchiti oral azithromycin regim effect treatment acut exacerb chronic bronchiti similar efficaci longer pivampicillin regim may offer superior patient complianc,0,1.0,0.0
glucos t1d outcom includ percentag sensor glucos valu within num2-num3 mg/dl rang score questionnair assess impact rt-cgm live t1d cost-effect rt-cgm,0,1.0,0.0
aspirin respiratori diseas studi aim identifi prognost factor aspirin-exacerb respiratori diseas compar clinic genet data clinic cours,0,0.6079,0.3921
glutamin cancer glutamin cancer therapi,0,1.0,0.0
aza laboratori abnorm no patient discontinu num-mp/aza laboratori abnorm improv spontan dose reduct,0,0.805,0.19499999999999995
penicillin neuropsychiatr symptom neuropsychiatr symptom recov gradual penicillin treatment two month later,0,1.0,0.0
itraconazol pediatr cancer itraconazol treatment oral candidosi pediatr cancer patient,0,1.0,0.0
paclitaxel tumor vitro data indic mark complet opposit raf-num kinas depend radiat paclitaxel cytotox cervic tumor cell,0,0.7893,0.2107
sugammadex seizur sugammadex num mg/kg iv administ group r motor seizur,0,1.0,0.0
morphin anxieti no differ pain intens initi assess morphin usag mood anxieti depress measur period,0,1.0,0.0
chloroform mdr mous lymphoma two chloroform extract enhanc antiprolif effect doxorubicin mdr mous lymphoma cell,0,1.0,0.0
salmeterol death small signific increas respiratory-rel death num2 vs num2 rr numnum2 num2 ci numnum2 numnum2 asthma-rel death num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 combin asthma-rel death life-threaten experi num2 vs num2 rr numnum2 num2 ci numnum2 numnum2 subject receiv salmeterol vs placebo,1,0.3805,0.6195
vitamin d. vitamin defici recommend num num3-num num3 iu vitamin per day pregnant lactat women vitamin defici,0,0.7975,0.2025
estrogen breast cancer epht recruit num4-num4 women 's health initi whi usa decid stop estrogen-progestin trial mean num year juli num4 increas risk breast cancer later num4 estrogen-onli trial ht increas risk stroke decreas risk hip fractur not affect coronari heart diseas incid,1,0.3819,0.6181
steroid death steroid readministr intens therapi liver failur not prevent death,0,1.0,0.0
atp carcinoma hypoton challeng not camp stimul found induc releas atp measur luciferin-luciferas assay murin mammari carcinoma cell line cnum3i cnum3 cell stabli transfect cdna human cystic fibrosi transmembran conduct regul cftr protein cnum3/cftr,0,1.0,0.0
enzalutamid ar/androgen receptor among androgen receptor splice variant ar-v particularli variant num ar-v7 implic resist enzalutamid abirateron preclin studi not target current avail ar-direct drug,0,1.0,0.0
aspirin pain describ patient suffer split-thick leg burn appli self-inflict mixtur consist white vinegar aspirin prepar knee pain,0,1.0,0.0
salmeterol asthma imbal occur larg african-american subpopul respiratory-rel death life-threaten experi num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 combin asthma-rel death life-threaten experi num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 subject receiv salmeterol vs placebo,1,0.0,1.0
isoflavon breast cancer aim examin associ flavonoid flavonoid subclass except isoflavon risk breast cancer conduct meta-analysi,0,1.0,0.0
epirubicin hcc/hepatocellular carcinoma pharmacokinet clinic activ epirubicin investig num2 patient hepatocellular carcinoma hcc receiv epirubicin num2 mg/m2 drug given intraven num patient via hepat arteri num patient num also underw embolis,0,1.0,0.0
steroid edema mani facial plastic surgeon use periop steroid reduc postop edema morbid,0,1.0,0.0
telithromycin/hmr num4 cap/community-acquir pneumonia open multin studi examin efficaci toler telithromycin hmr num4 first ketolid antibacteri agent oral dose num3 mg daili seven ten day valid use pharmacokinet analysi empir therapi adult mild moder community-acquir pneumonia cap,0,1.0,0.0
indomethacin periventricular leukomalacia antenat indomethacin associ increas risk periventricular leukomalacia odd ratio num num2 confid interv ci num-num,1,0.0,1.0
platinum tcc vinflunin activ agent treatment platinum-pretr bladder cancer result warrant investig phase iii trial either monotherapi combin agent treatment advanced/metastat tcc bladder,0,1.0,0.0
raloxifen bmd data suggest women lose bmd first year treatment alendron raloxifen gain bmd treatment continu second year,0,0.789,0.211
prednison diffus larg b-cell non-hodgkin lymphoma activ safeti dose-adjust infusion cyclophosphamid doxorubicin vincristin prednison chemotherapi rituximab elderli patient poor-prognost untreat diffus larg b-cell non-hodgkin lymphoma,0,1.0,0.0
oxaliplatin crc/colorect cancer oxaliplatin platinum compound character diaminocyclohexan dach platinum carrier ligand proven efficaci first- second-lin advanc colorect cancer crc treatment,0,1.0,0.0
pioglitazon diabet result varianc studi show signific rel risk reduct convers diabet pioglitazon american igt,0,1.0,0.0
mtx toxic treatment mtx often caus toxic necessit dose reduct treatment cessat,1,0.0,1.0
l-ornithine-l-aspart hepat encephalopathi analys base total studi sampl num2 placebo- num2 l-ornithine-l-aspartate-tr patient well subgroup sampl overt num2 placebo- num2 l-ornithine-l-aspartate-tr subclin hepat encephalopathi num2 placebo- num2 l-ornithine-l-aspartate-tr patient,0,1.0,0.0
docetaxel hypox e_h2ax express num2 min cleav caspase-num -num num2 hr doxorubicin docetaxel decreas increas distanc tumor blood vessel minim express hypox region maximum reduct kinum2 level observ region closest vasculatur num2 hr,0,1.0,0.0
oxygen vascular diseas accumul evid demonstr epc therapeut potenti reactiv oxygen speci ro -mediat vascular diseas,0,1.0,0.0
artesun cytotox consid lack data regard genotox effect compound human cell object studi evalu cytotox genotox express casp3 sod1 gene cultur human hepatocellular liver carcinoma cell line hepg2 cell treat artemisinin artesun,0,1.0,0.0
glucos hypertriglyceridemia broad-rang effect fxe may due uniqu composit profil could use prevent metabol syndrom character obes insulin resist glucos intoler hypertriglyceridemia elev blood pressur,0,1.0,0.0
sirolimu fibrosi first studi among liver transplant recipi recurr hcv describ posit impact sirolimu respect reduc fibrosi extent rate progress,0,1.0,0.0
flavonoid chlamydia pneumonia studi design screen antichlamydi activ natur flavonoid natur structur similar synthet compound against chlamydia pneumonia human cell line hl,0,1.0,0.0
acetylcholin trachea modul acetylcholin releas parasympathet nerv innerv guinea-pig human trachea endomorphin-num -num,0,1.0,0.0
ascorb acid poison addit no confirm clinic evid administr ascorb acid lessen morbid mortal system chromium poison,0,1.0,0.0
alcohol tb standard questionnair use collect basic demograph data region birth histori tb hiv-coinfect alcohol use antituberculosi treatment,0,1.0,0.0
praziquantel hookworm coexist area schistosom hookworm coexist praziquantel recommend schistosomiasi control large-scal applic drug might also reduc burden hookworm,0,1.0,0.0
nystatin mcd howev case lipid raft inhibitor nystatin beta-mcd disrupt patch,0,1.0,0.0
nitric oxid breast cancer report her2/neu reduc sensit breast cancer cell n- num-hydroxyphenyl retinamid num-hpr suppress nitric oxid product,0,0.6042,0.3958
tianeptin cardiac toxic present studi suggest tianeptin tricycl antidepress endow less cardiac toxic classic tricycl antidepress,1,0.3835,0.6165
methotrex ra eleven ra patient mean age num2+/-num year diseas durat num+/-num year high diseas activ despit treatment stabl dose methotrex or=num2 mg/wk prednison or=num2 mg/d investig,0,1.0,0.0
serotonin ventricular tachycardia serotonin catecholaminerg polymorph ventricular tachycardia possibl therapeut role ssri,0,1.0,0.0
oxygen ischemia report downregul gaba receptor gaba r express affect mrna protein level gaba r subunit hippocamp neuron subject oxygen-glucos depriv ogd vitro model ischemia,0,1.0,0.0
ptx gastric cancer fgfr2 inhibitor kinum5 might therapeut promis treat drug-resist gastric cancer cell especi use combin snnum2 ptx vpnum2,0,1.0,0.0
isofluran diabet random single-blind placebo-control prospect studi serum troponin concentr ctni baselin num num num2 num2 num2 num2 h postop measur isoflurane/sufentanil propofol/sufentanil anesthesia without ripc three num-min period intermitt left upper arm ischemia num min reperfus non-diabet patient n num2 three-vessel coronari arteri diseas clinicaltrialsnumgov nctnum5,0,1.0,0.0
iron athlet athlet whose iron intak suffici num2num mg princip caus iron defici blood loss due menstruat,0,1.0,0.0
num num2-dihydroxyvitamin d3 leukemia investig preclin studi potenti anti-leukemia use plant-deriv polyphenol silibinin sil combin num num2-dihydroxyvitamin d3 num num2d,0,0.8182,0.1818
amp rb/retinoblastoma effect lactoferrin adipogenesi studi express differ lipogen marker amp-activ protein kinas ampk activ retinoblastoma rb activ oil red stain 3t3-l1 cell,0,0.8037,0.19630000000000006
corticosteroid asthmat report two hepat b viru hbv carrier liver failur withdraw corticosteroid steroid administ treatment seriou asthmat attack,0,1.0,0.0
fentanyl chronic pain benefit-risk assess transderm fentanyl treatment chronic pain,0,1.0,0.0
oestrogen anovul no randomis trial identifi compar progestogen oestrogen progestogen placebo manag irregular bleed associ oligo/anovul,0,1.0,0.0
nitric oxide/no necrosi ep shown decreas express variou pro-inflammatori mediat includ nitric oxid no* tumor necrosi factor tnf cyclooxygenase-num interleukin il -num varieti vitro vivo model system,0,1.0,0.0
buserelin acet endometriosi evalu histolog ultrastructur chang vagin mucosa patient given buserelin acet danazol treatment endometriosi,0,1.0,0.0
glucos sepsi glucos prove nitrogen spare properti postop patient critic ill patient toler glucos load poorli fat appear obligatori fuel sepsi,0,0.8263,0.17369999999999994
corticosteroid cataract use intranas corticosteroid not associ increas risk cataract studi popul,0,1.0,0.0
buserelin acet infertil infertil women endometriosi random receiv buserelin acet danazol undergo vagin biopsi treatment select,0,0.8078,0.19220000000000004
aminoglycosid intraabdomin infect effect periton fluid ph outcom aminoglycosid treatment intraabdomin infect,0,1.0,0.0
arachidon acid diabet vascular diseas increas oxid stress due excess free-rad activ may central diabet vascular diseas endotheli cell damag lipoprotein oxid modif platelet reactiv arachidon acid cascad properti free radic reaction product lipid peroxid,0,0.8225,0.1775
gnrh head injuri three month head injuri hormon evalu hypothalamic-pituitari axi mean insulin stress test simultan administr trh gnrh result reduc respons gh cortisol tsh fsh lh low baselin serum concentr free t4 testosteron,0,1.0,0.0
thiazid hypertensive/hypertens thiazid diuret remain drug first choic treat hypertens african-american hypertens,0,1.0,0.0
cp-num4 lymphoma anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0
corticosteroid cataract cataract risk not increas number prior prescript intranas corticosteroid,0,1.0,0.0
testosteron prostat cancer potenti risk clinic use testosteron therapi individu care consid close monitor especi patient possibl occult prostat cancer larg benign prostat hyperplasia,0,0.6242,0.3758
creatinin atrial fibril use heparin-co circuit reduc mean length stay hospit num +/- num num +/- num day p numnum3 postop ventil time num +/- num num +/- num h p numnum3 blood loss num h post surgeri num3 +/- num3 num3 +/- num3 ml p numnum3 individu periop chang haemoglobin loss p numnum3 leukocyt count p numnum3 creatinin elev p numnum3 proport patient expos allogen blood transfus num2num vs num2num p numnum3 postop coagul disturb num vs num p numnum3 postop deviat normal postop cours num2num vs num2num p numnum3 neurolog deviat num vs num p numnum3 atrial fibril num2num vs num2num p numnum3,0,1.0,0.0
mycophenol mofetil st. investig vitro monokin respons num3 patient long-term stabl kidney graft function st patient n=num2 non-mycophenol mofetil mmf n=num2 mmf num2 patient chronic renal transplant reject cr patient non-mmf,0,1.0,0.0
verapamil hypertens double-blind placebo-control clinic trial conduct num2 hypertens postmenopaus women receiv num3 mg/day verapamil,0,1.0,0.0
amlodipin mbp amlodipine-olmesartan combin therapi bedtim administr reduc better mbp correct nocturn bp fall improv urinari albumin excret,0,1.0,0.0
capecitabin tumour/breast cancer effect capecitabin vinorelbin cell prolifer metabol cox2 pnum2 express breast cancer cell line solid tumour tissu,0,0.6017,0.3983
resveratrol death show epitheli ovarian cancer cell highli sensit glucose-deprivation-induc cell death like resveratrol glucos depriv induc caspase-independ cell death hallmark autophagi,0,1.0,0.0
arformoterol copd trial copd subject administ nebul arformoterol demonstr signific sustain improv lung function num2 week,0,1.0,0.0
alcohol vascular diseas contrast moder alcohol use produc chang overal favor effect atherosclerotic-rel vascular diseas,0,1.0,0.0
isofluran ripc thu ripc isofluran not propofol anesthesia decreas myocardi damag patient undergo cabg surgeri,0,0.805,0.19499999999999995
cidofovir hc cidofovir may benefici certain patient bk viruria hc howev definit data requir clinic trial,0,1.0,0.0
calcium arteri hypertens age character besid chang progress increas calcium content arteri wall enhanc diabet mellitu osteoporosi arteri hypertens tabag,0,1.0,0.0
medroxyprogesteron acetate/mpa necrosi aim studi investig effect high-dos medroxyprogesteron acet mpa tumor necrosi factor-alpha tnf-alpha releas patient chemotherapy-induc neutropenia,0,1.0,0.0
carboplatin breast cancer carboplatin gemcitabin cg combin activ unselect anthracycline/taxan pretreat metastat breast cancer patient carri out phase ii studi evalu activ cg combin pretreat metastat tnbc patient,0,0.7948,0.20520000000000005
zinc ad addit zinc tacrin treatment ad patient high dosag long term may effect process amyloidogensi,0,1.0,0.0
sunum4 tumor tripl combin use low-tox drug exposur pemetrex sunum4 result greater respons treatment alon combin two modal test endotheli tumor cell model,0,0.8143,0.1857
paracetamol analgesia twenti per cent diclofenac group num2 paracetamol group requir rescu analgesia not statist signific,0,1.0,0.0
oxygen bronchiti single-blind double-dummi multicentr studi compar oral azithromycin administ tablet num3 mg daili num day versu oral pivampicillin num3 mg twice daili num2 day adult acut exacerb chronic bronchiti not need parenter antibiot therapi hospit oxygen support,0,0.8068,0.19320000000000004
zaleplon primari insomnia result phase ii/iii studi suggest zaleplon num num2 mg produc dose-depend reduct sleep latenc patient suffer primari insomnia,0,0.8125,0.1875
carvedilol chronic heart failure/chf aim studi determin effect carvedilol cost relat treatment sever chronic heart failur chf,0,0.8218,0.17820000000000005
oxygen stun myocardium stun myocardium syndrom revers myocardi dysfunct may mediat oxygen-deriv free radic,0,1.0,0.0
methylphenid parkinson 's diseas low dose methylphenid improv freez advanc parkinson 's diseas off-stat,0,1.0,0.0
ethanol brain damag therapeut adjunct treat ethanol withdraw includ nmda calcium glucocorticoid antagonist may eventu prove use prevent brain damag alcohol,0,0.7844,0.2156
voriconazol diabet describ diabet patient lecythophora mutabili prosthet valv endocard treat surgic well amphotericin b lipid complex voriconazol subsequ follow prolong voriconazol suppress therapi,0,1.0,0.0
oxytocin ocd abnorm csf arginin vasopressin corticotropin-releas hormon oxytocin somatostatin level report ocd,0,1.0,0.0
octreotid acromegali determin effect octreotid somatostatin analog sever sleep apnea growth hormon level patient acromegali,0,1.0,0.0
ammonium citrat hepatocellular carcinoma human hepatocellular carcinoma cell line hep3b hepg2 combin lsnum3 ferric ammonium citrat lsnum3/feac inhibit hif-1 protein express not inhibit hif-1 mrna express,0,1.0,0.0
cisplatin hepatoblastoma cisplatin main chemotherapeut agent treatment shown chang gene express level notch signal pathway hepatoblastoma,0,0.8117,0.1883
num-fu/num-fluorouracil colorect carcinoma studi set out evalu patient metastat colorect carcinoma efficaci toxic s-num contain tegafur num-chloro-num num-dihydroxypyridin cdhp potassium oxon base biochem modul num-fluorouracil num-fu target inhibit dihydropyrimidin dehydrogenas dpd,0,1.0,0.0
desmopressin nocturia open in-pati increment safeti efficaci studi desmopressin women multipl sclerosi nocturia,0,0.8042,0.1958
triazolam drug abus clinic efficaci zaleplon persist least four week dose num2 mg num2 mg. studi patient histori drug abus suggest abus potenti zaleplon dose therapeut dose rang similar seen benzodiazepin triazolam,0,0.8178,0.18220000000000006
pah toxic oral ingest pah also caus toxic even affect pharmacokinet behavior therapeut agent,1,0.0,1.0
axitinib toxic toler profil gener consist vegf receptor inhibitor axitinib associ numer lower incid palmar-plantar erythrodysaesthesia cutan toxic anaemia sorafenib phase iii trial,1,0.1978,0.8022
pcb cancer present review address addit scientif data becam avail atsdr num4 num4 evalu magnitud offset weight evid numer epidemiolog studi exposur pcb not causal associ human cancer conclus num year later meaning evid pcb pose carcinogen risk human,1,0.19220000000000004,0.8078
methotrex rheumatoid arthriti acceler nodulosi low dose methotrex therapi rheumatoid arthriti,0,1.0,0.0
carbohydr diabet rational combin insulin oral drug therapi deriv better understand pathophysiolog niddm mechan action oral drug avail num type num diabet patient insulin-defici insulin-resist thu requir quit high dose exogen insulin num peripher insulin deliveri lead hyperinsulinaemia could play role pathogenesi late diabet complic num sulphonylurea stimul insulin releas directli portal vein could also potenti peripher insulin action num metformin improv glucos metabol insulin sensit alpha-glucosidas inhibitor slow digest complex carbohydr sucros abl reduc amount insulin need control postprandi hyperglycaemia,0,0.7879999999999999,0.21200000000000008
olanzapin mania olanzapin like risperidon also associ onset mania adult,1,0.0,1.0
poly-sno-hsa tumor observ pegyl enhanc stabil poly-sno-hsa vitro vivo dimer poly-sno-hsa enhanc antitumor activ via effici deliveri no colon num2 tumor-bear mice,0,1.0,0.0
carbamazepin bipolar disord lithium divalproex sodium carbamazepin lamotrigin atyp antipsychot antidepress found benefici treatment elderli patient bipolar disord,0,1.0,0.0
triiodothyronin major depress disord open studi triiodothyronin augment select serotonin reuptak inhibitor treatment-resist major depress disord,0,1.0,0.0
acebutolol lupu erythematosu although first report acebutolol-induc scle awar occurr avoid acebutolol recommend patient stigmata lupu erythematosu,0,0.8011,0.1989
naproxen rheumatoid arthriti addit effect combin naproxen paracetamol rheumatoid arthriti,0,0.626,0.374
vinblastin toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.3955,0.6045
ruboxistaurin protein kinas c. ruboxistaurin protein kinas c beta inhibitor emerg treatment diabet microvascular complic,0,1.0,0.0
nucleosid axon injuri nucleosid revers transcriptas inhibitor human immunodefici viru protein caus axon injuri human dorsal root ganglia cultur,1,0.2049,0.7951
lactulos bacteri overgrowth good clinic respons normal lactulos breath test achiev prokinet agent may use stimul phase iii interdigest motil delay relaps bacteri overgrowth,0,1.0,0.0
triamcinolon acetonid macular oedema evalu effect intravitr inject triamcinolon acetonid ivta combin panretin photocoagul prp visual acuiti va foveal thick patient concomit high-risk prolif diabet retinopathi pdr clinic signific macular oedema csmo,0,1.0,0.0
linol acid breast cancer conjug linol acid cla natur found dairi product rumin meat posit geometr isom tran ci c linol acid wide report possess anti-tumor activ against breast cancer vitro vivo,0,1.0,0.0
metformin pre-eclampsia no differ preval gestat diabet pre-eclampsia metformin placebo group,0,1.0,0.0
metformin preterm deliveri aim re-evalu whether metformin may reduc late miscarriage/preterm deliveri pre-eclampsia gestat diabet women polycyst ovari syndrom pco,0,1.0,0.0
zanamivir influenza-lik illness/ili first multicent clinic studi china investig zanamivir use among chines adolesc adult influenza-lik ill ili sinc num4 inhal zanamivir relenza market china,0,1.0,0.0
deferipron beta-thalassem examin num2 beta-thalassem patient undergo deferoxamin dfo num/num2 combin therapi dfo deferipron l1 num2/num2 two abdomin mri studi use t1-w/pd-w/t2*-wgre t1-wtse sequenc,0,0.8009999999999999,0.19900000000000007
dopamin widespread diseas past num2 year endur explan schizophrenia dopamin hypothesi propos dopaminerg system overact widespread diseas,0,0.6062,0.3938
num-quinolinol cytotox lanthanid complex num-num exhibit significantli enhanc cytotox vs. free substitut num-quinolinol,0,1.0,0.0
valdecoxib postop pain clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,1.0,0.0
morphin ponv num2 hour immedi total knee replac combin continu femor sciatic nerv block improv analgesia decreas morphin consumpt ponv,0,1.0,0.0
valsartan hypertens once-daili amlodipine/valsartan ration conveni treatment option effect manag patient hypertens improv adher antihypertens medic protect against cardiovascular renal morbid mortal,0,1.0,0.0
clopidogrel bleed rate ischaem bleed event compar carrier non-carri loss-of-funct gain-of-funct allel patient random clopidogrel vs. placebo,0,0.6067,0.3933
combretastatin-a4-phosph non-small-cel lung cancer phase ib trial radiotherapi combin combretastatin-a4-phosph patient non-small-cel lung cancer prostat adenocarcinoma squamou cell carcinoma head neck,0,1.0,0.0
lsnum3 hepatocellular carcinoma human hepatocellular carcinoma cell line hep3b hepg2 combin lsnum3 ferric ammonium citrat lsnum3/feac inhibit hif-1 protein express not inhibit hif-1 mrna express,0,1.0,0.0
nicotin nausea dizzi nausea nin unsteadi also depend nicotin dosag p numnum2 .nicotin blood concentr better predictor tempor depend nystagmu nicotin dosag,1,0.2231,0.7769
ramipril adpkd studi popul hypertens adpkd patient no differ renal function urinari albumin excret lvmi detect treat ramipril metoprolol respect num year follow-up,0,1.0,0.0
simvastatin myocardi infarct increment decreas end point aggress lipid lower trial num4 post-myocardi infarct patient randomis high-dos usual-dos statin therapi atorvastatin num2uemg/day vs simvastatin num2-num2uemg/day,0,1.0,0.0
flavonoid diabet mellitu artifici neural network-bas drug design diabet mellitu use flavonoid,0,1.0,0.0
naproxen ra clinic effect plasma naproxen level studi num2 patient ra receiv three dose naproxen two naproxen dose combin paracetamol acetaminophen random double-blind comparison five num-wk treatment period,0,1.0,0.0
lactat pain aural canal core skin surfac num2 site temperatur oxygen consumpt pain visual analogu score concentr epinephrin norepinephrin glucos cortisol lactat free fatti acid plasma measur epidur blockad num2 min epidur blockad end surgeri num h surgeri,0,1.0,0.0
polyphenol tumor like relat mechan biochem action tea polyphenol includ antioxid activ modul xenobiot metabolit enzym inhibit tumor promot,0,0.6086,0.3914
cladribin leukemia base mechanist similar fludarabin cladribin success analogu treatment chronic lymphocyt leukemia cll hypothes clofarabin would effect indol leukemia,0,1.0,0.0
ketotifen artifici tear substitut comparison effect ketotifen fumar numnum3 olopatadin hcl num ophthalm solut season allerg conjunct num2-day random double-mask artifici tear substitute-control trial,0,1.0,0.0
arsen cytotox knum3 egfp-aqp9 transfect accumul significantli higher level intracellular arsen control knum3 egfp incub as2o3 result significantli increas as2o3-induc cytotox,1,0.3926,0.6074
nicardipin hypertens effect calcium-entri blocker nicardipin intraren hemodynam essenti hypertens,0,0.7898,0.21020000000000005
catecholamin intra aortic balloon counterpuls immedi percutan translumin coronari angioplasti intra aortic balloon counterpuls catecholamin therapi fail stabilis haemodynam,0,1.0,0.0
nickel hyperlipidemia accord multivari analysi signific predictor cr-isr refer vessel diamet p=.num4 follow nickel-posit p=.num4 hyperlipidemia p=.num4,0,1.0,0.0
linol acid atherosclerosi conjug linol acid atherosclerosi no effect molecular marker cholesterol homeostasi thp-num macrophag,0,1.0,0.0
thymalfasin chronic hepat c. studi chronic hepat c patient would indic thymalfasin combin standard pegyl interferon ribavirin may improv respons rate hepat c viru hcv naiv nonrespond patient,0,1.0,0.0
polyphenol skin tumor major studi conduct mous skin tumor model tea polyphenol use either oral feed drink water direct local applic,0,0.8133,0.1867
dobutamin myocardi infarct dobutamin respons myocardi infarct transmur function improv coronari arteri bypass graft -- initi experi,0,1.0,0.0
cyclophosphamid vascul follow-up data rave trial shown rituximab effect immunosuppress cyclophosphamid follow azathioprin antineutrophil cytoplasm antibodi anca associ vascul,0,1.0,0.0
melatonin tumor therefor conclud direct inhibit action tumor cell not gener physiolog role melatonin oppos umo5r,0,1.0,0.0
poly-sno-hsa tumor previous demonstr poly-nitr oxid no conjug human serum albumin poly-sno-hsa potenti dd carrier capabl accumul no tumor,0,0.8024,0.1976
sunitinib renal cell carcinoma cost-effect evalu sunitinib first-lin target therapi metastat renal cell carcinoma spain,0,1.0,0.0
no headach pathophysiolog mechan headach may connect endotheli dysfunct term increas product no,1,0.3793,0.6207
tyrosin hematopoiet malign recent shown abl-fus oncogen tyrosin kinas bcr/abl tel/abl specif hematopoiet malign induc resist dna-damag agent,0,1.0,0.0
carnitin polycyst ovari syndrom free carnitin acylcarnitin inaeobes patient polycyst ovari syndrom effect ofaepioglitazon treatment,0,1.0,0.0
pentoxifyllin endometriosi use pentoxifyllin conserv surgeri endometriosi result improv va score num num month procedur compar patient conserv surgeri,0,1.0,0.0
tenofovir hiv g3-snum2 g2-nfnum2 dendrim show synergist addit activ profil zidovudin efavirenz tenofovir major combin test against x4 r5 tropic hiv-num cell line well human primari cell,0,1.0,0.0
steroid sd steroid treatment num2 recurr occur correspond mean numnum2 numnum2 sd relaps per year,0,0.7954,0.2046
oestrogen bleed progestogen without oestrogen irregular uterin bleed associ anovul,0,1.0,0.0
retino acid neuroblastoma studi mir-num3 brain-enrich microrna retino acid-differenti neuroblastoma cell found microrna up-regul treat cell down-modul express two protein involv migratori potenti neural cell reelin dcx,0,1.0,0.0
no cytotox primari cultur normal human lung fibroblast expos num h room air ra num2 oxygen no either num2 num2 ppm blend ra no blend num2 num incub num2 num2 h. cell viabil determin fluoresc viability/cytotox assay dna fragment tunel assay,0,1.0,0.0
ribavirin hiv/hepat c virus-coinfect treatment pegyl interferon plu ribavirin safe effect hiv/hepat c virus-coinfect patient,0,1.0,0.0
ritonavir/rtv aid analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
silicon granulomat pneumon progress granulomat pneumon respons cosmet subcutan silicon inject patient hiv-num infect case report review literatur,1,0.1903,0.8097
gabapentin pruritu patient suffer chronic kidney disease-associ pruritu gabapentin may option,0,1.0,0.0
rasagilin pd given demonstr benefit rasagilin along safeti toler profil import role play pd therapi,0,1.0,0.0
cyclophosphamid graft-versus-host diseas multi-institut studi post-transplant cyclophosphamid single-ag graft-versus-host diseas prophylaxi allogen bone marrow transplant use myeloabl busulfan fludarabin condit,0,1.0,0.0
flavonoid breast cancer flavonoid flavonoid subclass breast cancer risk meta-analysi epidemiolog studi,0,0.7872,0.2128
curcumin obes curcumin reduc serum glucos cholesterol triglycerid low densiti lipoprotein level high-fat-diet-induc obes rat,0,1.0,0.0
fluoxetin depress disord num-week multicent double-blind placebo-control studi num3 patient age num2-num2 year dsm-iv major depress disord randomli alloc receiv placebo n num2 duloxetin n num2 fluoxetin num2 mg qnumd,0,0.8002,0.1998
capsaicin tactil hyperalgesia/allodynia erb-num3 allevi tactil hyperalgesia induc capsaicin revers tactil allodynia caus spinal nerv ligat variou chemic insult,1,0.20409999999999995,0.7959
roxithromycin toxic epiderm necrolysi roxithromycin-induc toxic epiderm necrolysi,1,0.0,1.0
penicillin syphili not num4 amid world war penicillin found effect treatment syphili,0,1.0,0.0
sildenafil myocardi infarct sildenafil not decreas fill pressur rest exercis post-myocardi infarct patient diastol dysfunct,0,0.8154,0.1846
num-hc clonal chromosom abnorm data suggest clonal abnorm observ posttranspl best explain clinic relaps tumor ex vivo marrow purg num-hc not like induc clonal chromosom abnorm normal cell,0,1.0,0.0
doxorubicin toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.2097,0.7903
atorvastatin diabet result studi demonstr vascular antioxid effect atorvastatin diabet mediat inhibit rac-num via reduct ggpp,0,1.0,0.0
donepezil ad clinic trial donepezil shown improv significantli cognit global function patient mild moder sever ad demonstr excel toler safeti profil,0,1.0,0.0
estrogen bca mono-lay cell cultur model pnum2-wild type estrogen receptor er -depend mcf-num bca cell pnum2-mut er-/progesteron receptor pr her2-regular triple-neg mda-mb-num3 bca expos pgg comprehens investig cellular consequ molecular targets/medi,0,1.0,0.0
num-fu ts ts may prognost factor colon carcinoma num-fu adjuv chemotherapi may appropri colon carcinoma high express ts,0,1.0,0.0
sb-num2 tumor num week treatment signific inhibit tumor volum observ group treat rc-num4 alon combin sb-num2 not treat sb-num2 singl agent,0,1.0,0.0
carbosilan hiv therebi new nanosystem carbosilan dendrim shown safe effect compound against hiv great potenti topic microbicid,0,1.0,0.0
mangafodipir hepat lesion compar mangafodipir-enhanc magnet reson mr superparamagnet iron oxid spio -enhanc imag abil detect character focal hepat lesion,0,1.0,0.0
ixabepilon neurotox articl provid overview incid characterist manag mti-associ neurotox known vinca alkaloid taxan well newer agent vinflunin ixabepilon,1,0.3988,0.6012
bradykinin sindbi viru infect bradykinin enhanc sindbi viru infect human brain microvascular endotheli cell,1,0.3906,0.6094
carmustin ocular toxic ocular toxic system chemotherapi megados carmustin mitomycin,1,0.3791,0.6209
cyclophosphamid ependymoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
polyethylen glycol cancer thu polyethylen glycol-poly-sno-hsa dimer seem appeal safe no carrier therebi strong candid antitumor drug futur develop cancer therapeut,0,1.0,0.0
cisplatin/cddp ovarian cancer present studi investig potenti anti-human ovarian cancer effect nscnum5 novel rare studi camptothecin analog combin cisplatin cddp,0,1.0,0.0
bortezomib esophag squamou cell carcinoma bortezomib sensit human esophag squamou cell carcinoma cell trail-medi apoptosi via activ extrins intrins apoptosi pathway,0,0.815,0.18500000000000005
mitomycin c. tumor reductas enzym express across nation cancer institut tumor cell line panel correl sensit mitomycin c eo9,0,1.0,0.0
epoprostenol pph epoprostenol improv surviv patient pph new york heart associ nyha function class iii iv,0,1.0,0.0
terfenadin urticaria studi done num2 outpati physic stimulus-induc urticaria num2 patient receiv nimodipin three time day daili dose num3 mg num2 patient treat terfenadin dose num3 mg,0,0.8075,0.1925
olmesartan medoxomil hypertens efficaci toler olmesartan medoxomil combin amlodipin patient moder sever hypertens amlodipin monotherapi random double-blind parallel-group multicentr studi,0,1.0,0.0
trimethoprim wegen 's granulomatosi sinc num4 number report highlight effect short cours sulfamethoxazole-trimethoprim adjuv immunosuppress drug treatment wegen 's granulomatosi,0,1.0,0.0
cisplatin cancer although individu target erk1/num akt pathway report sensit cancer cell therapi effect concurr block two pathway sensit lung cancer cell cisplatin not investig,0,1.0,0.0
tetracyclin cholera conduct random double-blind clinic trial compar ciprofloxacin num3 mg day num day tetracyclin num3 mg four time day num day term efficaci safeti treatment moderate-to-sever cholera peruvian adult,0,1.0,0.0
cordycepin neuroblastoma cordycepin significantli inhibit prolifer human neuroblastoma sk-n-be num -c human melanoma sk-mel-num cell icnum2 valu num3 microm num2 microm respect,0,0.8136,0.1864
erlotinib nsclc tyrosin kinas inhibitor tki epiderm growth factor receptor egfr erlotinib gefitinib activ agent treatment advanc nsclc,0,1.0,0.0
indomethacin stroke although blood pressur not chang peripher resist rose stroke volum fell follow indomethacin administr,0,0.7922,0.2078
curcumin gastric carcinoma ras/erk signal pathway involv curcumin-induc cell cycl arrest apoptosi human gastric carcinoma ag cell,0,1.0,0.0
dopamin schizophren homovanil acid hva oxid metabolit dopamin shown number studi reflect sever symptom predict respons neurolept treatment schizophren patient,0,0.8017,0.19830000000000006
satur fatti acids/sfa atherosclerosi propos dietari satur fatti acid sfa may also serv endogen ligand tlr2 tlr4 therebi promot diseas associ inflamm dyslipidemia includ atherosclerosi insulin resist,1,0.20640000000000006,0.7936
acetaminophen toxicosi male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.0,1.0
abacavir aid analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
praziquantel schistosomiasi reduct preval intens hookworm infect praziquantel treatment schistosomiasi infect,0,1.0,0.0
testosteron testosteron defici testosteron defici menopaus women common appreci particularli patient hormon replac surgic menopaus,0,1.0,0.0
oxygen aggress contrari might expect result suggest case aggress effort increas oxygen consumpt may detriment,0,1.0,0.0
gssg copd num2 stabl state iii copd patient recruit reduc glutathion gsh oxidis glutathion gssg erythrocyt thiol protein p-sh carbonyl protein pc erythrocyt plasma evalu,0,1.0,0.0
haloperidol schizophren verbal work memori num2 treatment-resist schizophren patient assess part random double-blind comparison treatment risperidon haloperidol,0,1.0,0.0
silver acet cytotox novel benzyl-substitut n-heterocycl carbene-silv acet complex synthesi cytotox antibacteri studi,0,1.0,0.0
pregabalin neuropath pain aim studi evalu toler safeti efficaci pregabalin indian patient peripher neuropath pain,0,1.0,0.0
yohimbin ptsd use positron emiss tomographi fludeoxyglucos f num2 measur brain metabol vietnam combat veteran ptsd n num2 healthi age-match control subject n num2 follow administr yohimbin num mg/kg placebo random double-blind fashion,0,1.0,0.0
selenium hiv diseas progress observ studi adequ selenium statu associ better pregnanc outcom slow hiv diseas progress,0,1.0,0.0
num num-dihydroxybenzaldehyd cancer concentr num3 microm num num-dihydroxybenzaldehyd caus num2 growth inhibit human cancer cell unum3,0,1.0,0.0
steroid liver failur report two hepat b viru hbv carrier liver failur withdraw corticosteroid steroid administ treatment seriou asthmat attack,1,0.3888,0.6112
amphotericin b. valv endocard describ diabet patient lecythophora mutabili prosthet valv endocard treat surgic well amphotericin b lipid complex voriconazol subsequ follow prolong voriconazol suppress therapi,0,1.0,0.0
lorazepam cognit impair relationship plasma baselin pre-drug gaba concentr cognit impair induc acut oral dose lorazepam num num mg investig num2 healthi elderli individu,1,0.0,1.0
asenapin metabol abnorm meantim asenapin option manag manic and/or mix symptom patient bipolar disord may particular valu patient high risk metabol abnorm,0,1.0,0.0
propofol trachea effect propofol etomid also studi ca2+ increas measur microspectrofluorimetri isol myocyt isometr contract rat trachea,0,1.0,0.0
verteporfin choroid neovascularization/cnv report outcom eye treat intravitr inject bevacizumab combin verteporfin photodynam therapi pdt choroid neovascular cnv age-rel macular degener amd,0,1.0,0.0
nac/n-acetylcystein addict behavior conduct first systemat literatur review clinic trial n-acetylcystein nac treatment substanc abus disord addict behavior,0,1.0,0.0
cisplatin head neck cancer ten establish head neck cancer cell line um-scc num2a num2b num2b num2a num2b num2c num2b hlacnum2 num4na num4ddp4 chemosensit cisplatin carboplatin num-fluorouracil bleomycin well cellular glutathion content activ glutathion s-transferas determin,0,1.0,0.0
nicotin dizzi addit motion stimul aggrav dizzi nausea i.e. nicotin increas sensit motion sick,1,0.1974,0.8026
mtx result suggest polymorph abcc4 abcc2 could novel marker mtx toxic pediatr,0,0.7879999999999999,0.21200000000000008
fluorouracil choroid melanoma num2-year-old patient coexist primari choroid melanoma colorect cancer treat extern beam radiat ebr choroid melanoma system chemotherapi leukovorin/num fluorouracil fu treatment metastat colorect cancer,0,1.0,0.0
mannitol acut stroke mannitol use worldwid treat acut stroke although efficaci safeti not proven random trial,0,1.0,0.0
atorvastatin hyperlipidemia sinc hyperlipidemia not improv pravastatin atorvastatin niceritrol sinc level thyroid-stimul hormon tsh free t4 num3 iu/ml num ng/dl respect patient diagnos secondari hyperlipidemia hypothyroid,0,1.0,0.0
progesteron tumour estrogen progesteron receptor er pr immunocytochem analys mammari tumour cell obtain fine needl sampl num2 patient,0,1.0,0.0
fludarabin macroglobulinemia fludarabin effect salvag agent treatment patient resist waldenstrim 's macroglobulinemia,0,1.0,0.0
glucos impair glucos toler object prevent programm studi whether combin pioglitazon lifestyl modif would enhanc efficaci lifestyl modif prevent type num diabet asian indian impair glucos toler,0,1.0,0.0
selenium hiv diseas progression/hiv-infect among hiv-infect women dar es salaam tanzania selenium supplement given pregnanc not improv hiv diseas progress pregnanc outcom may improv child surviv,0,1.0,0.0
imiquimod tumor way imiquimod may act stimul notch pathway sbcc tumor cell up-regul protein express notch ligand jagged1,0,1.0,0.0
clozapin blood glucos accumul data develop glucos intoler adult receiv clozapin closer monitor bodyweight fast blood glucos imper,0,0.8041,0.1959
amlodipin cardiovascular event efficaci ccb amlodipin arb valsartan lower bp protect against cardiovascular event stroke across rang hypertens patient popul establish mani year,0,1.0,0.0
steroid laboratori abnorm patient requir steroid repeat cours cyclophosphamid manag lupu nephriti ursodeoxychol acid ursolit administr result amelior cholestat laboratori abnorm,0,1.0,0.0
paracetamol critic ill. hypotens intraven paracetamol critic ill patient caus reduct cardiac output system vascular resist,0,1.0,0.0
quinin falciparum malaria uniform dose quinin may prescrib sever falciparum malaria view better safeti profil,0,1.0,0.0
phenytoin pht pharmacoresist epilept patient may ascrib least two not mutual exclus mechan pharmacokinet mechan decreas sensit avail target antiepilept drug a i.e. carbamazepin phenytoin cbz pht,0,1.0,0.0
methylprednisolon leukem differenti contrast methylprednisolon no effect phosphatas inhibitor num num -induc leukem differenti,0,1.0,0.0
h num num inflamm evalu inflamm bak caus ocular surfac enzym link immunosorb assay elisa util quantifi level inflammatori biomark respons bak and/or h num num,0,0.7997,0.20030000000000006
nevirapine/nvp hiv gener fix dose combin stavudin d4t lamivudin 3tc nevirapin nvp name gpo-vir recommend hiv treatment guidelin thailand,0,1.0,0.0
feiba thrombot thrombot ae significantli frequent rfviia feiba recipi incid rate ratio numnum2 ci numnum2-numnum2,0,1.0,0.0
olanzapin diabet view uncertainti size mechan link olanzapin diabet discuss issu surround routin clinic manag monitor patient antipsychot clinic implic,0,0.6075,0.3925
catecholamin trauma aim studi determin effect exogen catecholamin tumor necrosi factor alpha tnfa interleukin-num il-num interleukin-num2 il-num2 beta beta -endorphin level patient sever trauma first num2 h injuri,0,1.0,0.0
brimonidin cataract studi evalu effect acetazolamid latanoprost travoprost bimatoprost brimonidin brinzolamid timolol pain phacoemulsif cataract surgeri,0,1.0,0.0
mitoxantron ms. explor potenti dexrazoxan suppress subclin cardiotox ms patient receiv mitoxantron,0,1.0,0.0
dexchlorpheniramin rash howev dexchlorpheniramin betamethason alon seem better clear rash combin dexchlorpheniramin betamethason,0,1.0,0.0
methotrex dmard result combin studi clearli demonstr clinic respons meaning improv new exist dmard ad methotrex,0,1.0,0.0
cephalosporin tubular marker protein excret tubular marker protein enhanc combin administr cephalosporin aminoglycosid mainli due aminoglycosid compon,0,0.7893,0.2107
clozapin schizophrenia furthermor no associ evid polymorph form d4 suscept schizophrenia variabl clozapin respons,0,0.8209,0.17910000000000004
pentoxifyllin endotox pentoxifyllin analogu may lower toxic pentoxifyllin may therefor use futur treatment diseas induc endotox substanc,0,1.0,0.0
tunicamycin fibrosarcoma human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0
docetaxel tumor e_h2ax express num2 min cleav caspase-num -num num2 hr doxorubicin docetaxel decreas increas distanc tumor blood vessel minim express hypox region maximum reduct kinum2 level observ region closest vasculatur num2 hr,0,1.0,0.0
l-thyroxin ch one-third patient ch eutop thyroid gland need continu l-thyroxin therapi re-evalu,0,1.0,0.0
alanin hepat b. post-treat respons defin alanin aminotransferas alt normalis hepat b viru hbv dna level num2 num3 copies/ml,0,1.0,0.0
num-hydroxydeoxyguanosin cancer determin urinari num-hydroxydeoxyguanosin autom coupled-column high perform liquid chromatographi power techniqu assay vivo oxid dna damag cancer patient,0,1.0,0.0
selenium fetal death selenium margin associ reduc risk low birth weight rel risk rr numnum2 num2 ci numnum2 numnum2 p numnum2 increas risk fetal death rr numnum2 num2 ci numnum2 numnum2 p numnum2 no effect risk prematur small-for-gest age birth,1,0.0,1.0
tyrosin tumor inhibitor tyrosin kinas activ associ receptor approv treatment chemotherapy-refractori nonsmal cell lung cancer clinic trial addit tumor type,0,0.8029,0.19710000000000005
acetylcholin trachea endomorphin-num -num also inhibit electrically-evok acetylcholin releas cholinerg nerv innerv guinea-pig num microm num2num +/- num2num num microm num2num +/- num respect human trachea num2 microm num2num +/- num2num num2num +/- num2num respect,0,1.0,0.0
polyphenol carcinogenesi inhibitori effect tea against carcinogenesi attribut biolog activ polyphenol fraction tea,0,0.7879,0.2121
corticosteroid melasma use broad-spectrum sunscreen import lighten agent like retino acid tretinoin azela acid combin therapi contain hydroquinon tretinoin corticosteroid use treatment melasma thought increas efficaci compar monotherapi,0,1.0,0.0
mpa mpa high csa c2 lower acut reject rate plasma mpa,0,1.0,0.0
cpt-num2 tumor cpt-num2 produc statist signific p numnum3 growth delay subcutan xenograft test includ resist busulfan cyclophosphamid procarbazin melphalan growth delay rang num2num day dnum3 med num2+ day sever tumor line,0,1.0,0.0
polysorb num2 oa consid result obtain ph num maximum enhanc ratio found polysorb num2 combin ethanol/pg/oa num2numnum2 numnum2,0,1.0,0.0
fentanyl delirium although recent studi suggest opioid rotat could effect treatment strategi morphine-induc delirium no prospect studi investig treatment effect opioid rotat use fentanyl,0,1.0,0.0
efv/efavirenz death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0
clonidin sexual abus result suggest pmdd women without histori sexual abus respond differ clonidin challeng measur reflect autonom nervou system function indic abus may modifi presynapt alpha2-ar function pmdd,0,1.0,0.0
bupivacain avp intraperiton bupivacain administr immedi placement trocar end surgeri found effect reduc intens avp not reduc stp app postop analgesia consumpt nonadvanc gynecolog laparoscop procedur,0,1.0,0.0
ramosetron corticotropin releas factor/crf ramosetron num num3 microg/kg pnumo found significantli suppress abnorm defec induc conditioned-fear stress cf restraint stress corticotropin releas factor crf num-ht rat mice effect potent alosetron cilansetron loperamid,0,0.6029,0.3971
corticosteroid prostat cancer comprehens review peer review literatur perform topic secondari hormon therapi includ oral antiandrogen adren androgen inhibitor corticosteroid estrogen compound gonadotropin-releas hormon antagonist altern hormon therapi advanc prostat cancer,0,1.0,0.0
capecitabin rectal cancer neoadjuv capecitabin oxaliplatin chemoradiotherapi total mesorect excis mri-defin poor-risk rectal cancer phase num trial,0,0.8045,0.1955
simvastatin pad median follow-up num8ueyear num2 patient num receiv atorvastatin num3 patient num receiv simvastatin develop pad hr=numnum2 num2 ci numnum2 numnum2 p=numnum3,1,0.0,1.0
capecitabin tumor phase studi conduct primarili determin maximum toler dose mtd tesetaxel novel oral activ semisynthet microtubul inhibitor taxan class administ oral capecitabin patient advanc solid tumor,0,1.0,0.0
fentanyl deliri cancer opioid rotat morphin fentanyl deliri cancer patient open-label trial,0,1.0,0.0
tamoxifen breast cancer eighty-eight women present local advanc metastat breast cancer treat tamoxifen alon,0,1.0,0.0
doxorubicin mdr mous lymphoma two chloroform extract enhanc antiprolif effect doxorubicin mdr mous lymphoma cell,0,1.0,0.0
oxaliplatin colorect cancer purpos studi determin efficaci toxic oxaliplatin combin weekli bolu num-fluorouracil num-fu leucovorin lv patient num-fu-pretr advanc colorect cancer,0,1.0,0.0
androgen ar/androgen receptor mini-review discuss gener mechan resist ar-direct therapi focu role androgen receptor splice variant new era treat advanc prostat cancer enzalutamid abirateron,0,1.0,0.0
chromium vi dermat repeat topic exposur chromium vi may caus allerg contact dermat format chrome ulcer,1,0.0,1.0
sodium chlorid nephropathi determin sodium bicarbon superior sodium chlorid prevent contrast medium-induc nephropathi patient moder sever chronic kidney dysfunct undergo coronari angiographi,0,1.0,0.0
clindamycin pneumonia hiv-infect man becam increasingli breathless cyanos receiv clindamycin primaquin treatment pneumocysti jirovecii pneumonia,0,0.8042,0.1958
gnrh submucos myoma spontan expuls submucos myoma might occur administr gnrh agonist henc may accept altern symptomat femal without sexual exposur,1,0.3869,0.6131
cephalosporin neutropen third-gener cephalosporin import part therapeut armamentarium empir manag neutropen patient,0,1.0,0.0
naproxen ra result show clinic effect naproxen ra may significantli increas concomit paracetamol administr,0,1.0,0.0
glucos diabet mechan blood glucose-low effect num-day low calori diet vlcd num4 kj/d combin cessat blood glucose-low agent studi num2 num women num men obes bodi mass index num2num +/- num kg/m num mean +/- sem type num diabet patient age num2 +/- num year hba 1c num +/- num undergo insulin therapi,0,1.0,0.0
auristatin pe tumor new tubulin polymer inhibitor auristatin pe induc tumor regress human waldenstrom 's macroglobulinemia xenograft model,0,0.7976,0.2024
clonidin sinus group num2 patient undergo fess chronic sinus polyp remov enrol randomli assign receiv either oral clonidin midazolam preoper premed,0,1.0,0.0
simvastatin hyperlipidemia combin simvastatin pinocembrin synergist inhibit atherosclerot lesion develop apoe-/- mice hyperlipidemia partial depend protect vascular endothelium,0,1.0,0.0
ropivacain pain addit compar analges effect incid motor block opioid-rel side effect three differ ropivacaine/fentanyl solut also evalu workload pain staff,0,1.0,0.0
testosteron obes review describ relationship low serum testosteron concentr ed obes patient metabol syndrom type num diabet mellitu,0,1.0,0.0
apigenin tumor demonstr molecular mechan inhibitori action apigenin androgen-refractori human prostat carcinoma dunum3 cell mutat tumor suppressor gene pnum2 prb,0,1.0,0.0
pima atherosclerot result suggest pima potent anti-atherosclerot activ inhibitori action mmp-num product cell migrat tnf-e-induc hasmc,0,1.0,0.0
paclitaxel cytotox vitro data indic mark complet opposit raf-num kinas depend radiat paclitaxel cytotox cervic tumor cell,0,0.7975,0.2025
remifentanil reduct splanchnic perfus episod hypotens transient reduct splanchnic perfus common patient treat remifentanil compar receiv fentanyl opioid regimen,1,0.0,1.0
dabrafenib melanoma literatur access medlin intern pharmaceut abstract num4-novemb num4 use term melanoma metastat melanoma ipilimumab vemurafenib dabrafenib trametinib,0,1.0,0.0
atracurium depress adductor pollici respons return normal valu singl intub dose atracurium vecuronium risk residu depress th geniohyoid muscl one princip muscl contribut airway patenc appear unlik,0,1.0,0.0
cocain hyperthermia howev cocaine-induc hyperthermia occur primarili hot weather hypothes cocain also impair thermoregulatori adjust mediat heat dissip,1,0.0,1.0
mpag mpa high csa c2 associ elev ggt probabl cholestat effect explain increas mpag-to-mpa ratio,0,1.0,0.0
fatti acid hcv infect real time data confirm vivo human hcv infect pathway relat fatti acid glucos metabol free radic scaveng inhibit,0,0.7917,0.20830000000000004
isofluran ripc/ischemia random single-blind placebo-control prospect studi serum troponin concentr ctni baselin num num num2 num2 num2 num2 h postop measur isoflurane/sufentanil propofol/sufentanil anesthesia without ripc three num-min period intermitt left upper arm ischemia num min reperfus non-diabet patient n num2 three-vessel coronari arteri diseas clinicaltrialsnumgov nctnum5,0,1.0,0.0
morphin analgesia num2 hour immedi total knee replac combin continu femor sciatic nerv block improv analgesia decreas morphin consumpt ponv,0,1.0,0.0
vitamin b6 colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.8117,0.1883
pregabalin neuropath pain prospect multicent non-compar open-label studi patient peripher neuropath pain n num3 receiv pregabalin dose rang num2 num3 mg twice daili num week,0,1.0,0.0
phentolamin tachycardia despit tachycardia sympathet activ snp phentolamin lf variabl rr msna bp increas snp decreas phentolamin snp rr +num2 +/- num msna +num +/- num systol bp +num +/- num diastol bp +num +/- num phentolamin rr -num +/- num msna -num2 +/- num systol bp -num2 +/- num diastol bp -num2 +/- num p numnum2 except systol bp p numnum2,0,0.7769,0.2231
cisplatin nsclc patient stage iiib iv nsclc random start treatment receiv either three six cours mitomycin num mg/m num cours num num num num vinblastin num mg/m num cisplatin num2 mg/m num mvp everi num2 day,0,1.0,0.0
diclofenac analgesia diclofenac paracetamol analgesia paediatr myringotomi outpati,0,0.8038,0.19620000000000004
etomid trachea effect propofol etomid also studi ca2+ increas measur microspectrofluorimetri isol myocyt isometr contract rat trachea,0,1.0,0.0
cadmium hypertens addit blood lead mercuri cadmium covari not affect associ blood mn preval hypertens,0,1.0,0.0
nevirapin hiv effect fixed-dos combin stavudin lamivudin nevirapin gpo-vir treatment naiv hiv patient thailand num-year follow-up,0,1.0,0.0
dopamin dystonia suggest tardiv cervic dystonia may clinic indistinguish idiopath form diagnosi rest sole document exposur dopamin antagonist medic,0,1.0,0.0
ofloxacin posttraumat endophthalm describ case posttraumat endophthalm unrespons system amoxicillin+clavulan acid piperacillin/tazobactam intra-ocular vancomycin topic ofloxacin tetracyclin sulfametoxazol antibiot therapi,0,1.0,0.0
leuprolid prostat hyperplasia safeti side effect patient accept lutein hormon releas hormon agonist leuprolid treatment benign prostat hyperplasia,0,0.8288,0.17120000000000002
rocuronium major depress rocuronium-sugammadex reduc myalgia headach electroconvuls therapi patient major depress,0,1.0,0.0
tfa metabol syndrom although increas report effect diet contain tfa risk factor metabol syndrom diabet mellitu coronari heart diseas observ recent year influenc intestin inflamm remain unknown,1,0.1969,0.8031
nefazodon sexual dysfunct index term includ sexual dysfunct antidepress select serotonerg reuptak inhibitor fluoxetin sertralin paroxetin fluvoxamin clomipramin buspiron nefazodon bupropion cyproheptadin amantadin yohimbin central nervou system stimul,0,0.7897,0.21030000000000004
formoterol fumar asthmat bronchodilat effect dri powder formoterol fumar asthmat patient,0,0.8270000000000001,0.17299999999999993
ibandron skelet complic intraven ibandron reduc incid skelet complic patient breast cancer bone metastas,0,1.0,0.0
suramin infect suramin consid treatment case human t. evansi infect occur,0,1.0,0.0
sulfamethoxazol wegen 's granulomatosi sinc num4 number report highlight effect short cours sulfamethoxazole-trimethoprim adjuv immunosuppress drug treatment wegen 's granulomatosi,0,1.0,0.0
tazobactam posttraumat endophthalm describ case posttraumat endophthalm unrespons system amoxicillin+clavulan acid piperacillin/tazobactam intra-ocular vancomycin topic ofloxacin tetracyclin sulfametoxazol antibiot therapi,0,1.0,0.0
methotrexate/mtx acut lymphoblast leukemia polymorph methotrex transport pathway new tool mtx plasma level predict pediatr acut lymphoblast leukemia,0,1.0,0.0
calcitriol ckd patient ckd may requir intraven oral activ vitamin d. investig effect lanthanum carbon sevelam carbon bioavail oral calcitriol,0,1.0,0.0
resazurin cytotox test concentr num num num num2 num2 e_g/ml substanc resazurin cytotox assay concentr use genotox experi num num num2 e_g/ml gene express analysi num e_g/ml determin,0,0.608,0.392
prednisolon polyposi thirty-two patient nasal polyposi random unilater endoscop sinu surgeri pretreat oral prednisolon num2 day nasal budesonid bilater num month,0,0.7965,0.2035
num-ht corticotropin releas factor/crf ramosetron num num3 microg/kg pnumo found significantli suppress abnorm defec induc conditioned-fear stress cf restraint stress corticotropin releas factor crf num-ht rat mice effect potent alosetron cilansetron loperamid,0,1.0,0.0
niceritrol hyperlipidemia sinc hyperlipidemia not improv pravastatin atorvastatin niceritrol sinc level thyroid-stimul hormon tsh free t4 num3 iu/ml num ng/dl respect patient diagnos secondari hyperlipidemia hypothyroid,0,1.0,0.0
cisplatin cytotox strikingli concurr inhibit p-erk1/num p-akt significantli potenti cisplatin cytotox vitro vivo,0,0.61,0.39
n-methyl-d-aspart enceph thorough reevalu age num2 year analysi current store cerebrospin fluid serum sampl demonstr intrathec synthesi igg antibodi nr1 subunit n-methyl-d-aspart receptor characterist laboratori find anti-n-methyl-d-aspart receptor enceph,0,1.0,0.0
dapson angioedema num2-year-old woman num yr histori chronic recurr urticari vascul angioedema refractori convent treatment includ glucocorticosteroid h1 h2 blocker nonsteroid antiinflammatori agent methotrex hydroxychloroquin dapson azathioprin intraven gamma globulin plasma exchang success treat interferon alpha 2a,0,1.0,0.0
rocuronium myalgia aim compar effect succinylcholin rocuronium-sugammadex develop myalgia headach electroconvuls therapi ect,0,1.0,0.0
nevirapine/nvp immunodefici impact nevirapin nvp plasma concentr select resist viru mother receiv single-dos nvp prevent perinat human immunodefici viru type num transmiss persist resist viru infect children,0,1.0,0.0
quinin falciparum malaria efficaci safeti quinin load dose patient sever falciparum malaria tertiari care hospit pakistan,0,1.0,0.0
cisplatin neuroblastoma mir-num3 novel predictor outcom neuroblastoma function least part increas sensit cisplatin direct target downregul anti-apoptot bcl2 mir-num3 also target full-length ntrk2 potent oncogen involv chemotherapi drug resist neuroblastoma,0,1.0,0.0
diphenhydramin allerg rhiniti fifteen subject allerg rhiniti test num-num h administr diphenhydramin hydroxyzin placebo double-blind single-dos three-way crossov studi,0,0.8026,0.1974
mth-num2/h aggress neuroectoderm neoplasm report administr mth-num2/h patient glioblastoma multiform common aggress neuroectoderm neoplasm poor prognosi averag six month year,0,1.0,0.0
capecitabin rectal cancer design studi local advanc rectal cancer determin patholog respons toxic disease-fre surviv df induct capecitabin plu irinotecan follow capecitabine-bas chemoradiotherapi crt analyz gene express enzym involv metabol capecitabin irinotecan associ respons toxic,0,1.0,0.0
tac anaplast larg cell lymphoma num2-year-old japanes man weigh num2 kg anaplast larg cell lymphoma receiv continu iv administr tac post-transplant prophylaxi against graft-versus-host diseas gvhd allogen bone marrow transplant bmt,0,1.0,0.0
levodopa osteoporot fractur calcif tissu int num2 num3-num2 num4 levodopa intak associ increas homocysteinemia known link poorer bone qualiti consequ osteoporot fractur,1,0.0,1.0
gaba ischemia gaba receptor dephosphoryl follow intern coupl neuron death vitro ischemia,0,0.8175,0.1825
bortezomib escc therefor combin bortezomib trail might novel therapeut strategi escc patient fail respond standard chemoradiotherapi predominantli target mitochondri apoptot pathway,0,1.0,0.0
ibandron bone diseas phase iii studi compar efficaci new potent bisphosphon ibandron placebo intraven i.v therapi metastat bone diseas due breast cancer,0,1.0,0.0
zinc wilson diseas origin studi clinic efficaci d-penicillamin trientin tetrathiomolybd zinc monotherapi initi treatment wilson diseas includ,0,1.0,0.0
mannitol acut stroke mannitol use acut stroke case fatal num2 day num year,0,1.0,0.0
tegafur toxic studi set out evalu patient metastat colorect carcinoma efficaci toxic s-num contain tegafur num-chloro-num num-dihydroxypyridin cdhp potassium oxon base biochem modul num-fluorouracil num-fu target inhibit dihydropyrimidin dehydrogenas dpd,0,1.0,0.0
alcohol stroke moreov alcohol abus produc cardiac arrhythmia hypertens cardiomyopathi stroke even sudden death,1,0.0,1.0
sucros diabet rational combin insulin oral drug therapi deriv better understand pathophysiolog niddm mechan action oral drug avail num type num diabet patient insulin-defici insulin-resist thu requir quit high dose exogen insulin num peripher insulin deliveri lead hyperinsulinaemia could play role pathogenesi late diabet complic num sulphonylurea stimul insulin releas directli portal vein could also potenti peripher insulin action num metformin improv glucos metabol insulin sensit alpha-glucosidas inhibitor slow digest complex carbohydr sucros abl reduc amount insulin need control postprandi hyperglycaemia,0,1.0,0.0
primaquin pneumonia hiv-infect man becam increasingli breathless cyanos receiv clindamycin primaquin treatment pneumocysti jirovecii pneumonia,0,1.0,0.0
vorozol tumor vorozol like ovariectomi almost complet reduc tumor growth dmba-induc mammari carcinoma model rat,0,1.0,0.0
terazosin peripher vascular diseas terazosin maintain antihypertens efficaci well toler patient varieti concomit diseas includ congest heart failur peripher vascular diseas chronic obstruct pulmonari diseas benign prostat hyperplasia diabet obes,0,1.0,0.0
testosteron prostat cancer examin effect num alpha-dihydrotestosteron dht testosteron egf egf-alpha cell prolifer 3h-thymidin incorpor androgen-depend human prostat cancer cell line alvanum3 serum-fre medium,0,1.0,0.0
etoposid testicular cancer evalu etoposid part standard treatment testicular cancer potenti caus atherogenesi experiment model,0,1.0,0.0
ginsenosid rh2 ovarian cancer inhibitori effect oral administr ginsenosid rh2 growth human ovarian cancer cell nude mice,0,1.0,0.0
h2o2 toxic report h2o2-induc cellular toxic act prdx6 hyperoxid,1,0.0,1.0
glucos fast glucos fast glucos insulin lipid lipoprotein profil oral glucos toler insulin secret insulin-medi glucos dispos hyperglycem clamp bodi composit dual energi x-ray absorptiometri determin lopinavir/ritonavir administr,0,0.794,0.206
sodium valproat tubulo-interstiti nephriti tubulo-interstiti nephriti caus sodium valproat,1,0.0,1.0
simvastatin pad pad patient major coronari event occur fewer patient atorvastatin group num2num simvastatin group num2num differ not reach statist signific,0,1.0,0.0
bps/bisphosphon myeloma bisphosphon bp potent inhibitor osteoclast-medi bone resorpt well accept tumor cell bone especi breast cancer myeloma cell stimul osteoclast format activ lead releas growth factor cytokin stimul cancer cell growth secret osteolyt factor,0,0.8062,0.1938
guanethidin thermal hyperalgesia investig effect guanethidin pretreat thermal hyperalgesia experiment site sensit heat topic applic num capsaicin,0,1.0,0.0
capecitabin adenocarcinoma colon capecitabin oral prodrug num-fluorouracil use treatment adenocarcinoma colon,0,1.0,0.0
paclitaxel breast cancer data support rational potenti combin grnnum3l paclitaxel treatment breast cancer clinic set,0,1.0,0.0
copper cytotox result indic complex quinolinon schiff base copper serv significantli enhanc cytotox,1,0.3927000000000001,0.6073
cisplatin cytotox sensit anum3 cell cisplatin cytotox induc p-akt inhibit mediat upregul puma wherea induc p-erk1/num inhibit occur bcl-num downregul,1,0.39399999999999996,0.606
dihydroergotamin migrain data suggest iv dihydroergotamin given num day produc improv headach disabl patient migrain shorter cours,0,1.0,0.0
folat tumor combin folat antimetabolit pemetrex sunum4 receptor tyrosin kinas inhibitor vegfr2 irradi investig human endotheli cell tumor cell line,0,1.0,0.0
oxygen cardiovascular diseas particular follow topic highlight chemistri sourc reactiv oxygen speci antioxid defens mechan signal event mediat reactiv oxygen speci role reactiv oxygen speci hypertens put therapeut role antioxid cardiovascular diseas,0,1.0,0.0
vigabatrin epilepsi visual impair children epilepsi treat vigabatrin,0,0.7928,0.20720000000000005
piracetam stroke restitut alpha-topographi piracetam post-strok aphasia,0,1.0,0.0
sevofluran unconsci author record num2-channel electroencephalogram healthi human particip conscious sevoflurane-induc unconsci recoveri n num2 n num suitabl analysi,1,0.3894,0.6106
chloramphenicol typhoid fever num2 children bacteriolog and/or serolog diagnos typhoid fever treat kem hospit bombay num4 initi one three recommend drug viz chloramphenicol amoxycillin co-trimoxazol given num day defervesc occur,0,1.0,0.0
steroid myopathi steroid-respons myopathi defici chondroitin sulfat c skelet muscl connect tissu,0,1.0,0.0
dronedaron af short-term studi dronedaron less effect amiodaron decreas af recurr better safeti profil specif regard thyroid neurolog event lack interact oral anticoagul,0,1.0,0.0
tobramycin auditori deficit conclud singl num2-day cours tobramycin treatment patient cystic fibrosi no preexisit auditori deficit no measur effect hear appar either once- three-times-daili treatment,0,1.0,0.0
bicucullin convuls compound also report activ against convuls induc bicucullin picrotoxin strychnin,1,0.0,1.0
epinephrin asystol num2-year-old male experienc postexercis bradycardia asystol higher basal plasma norepinephrin num3 versu num2 +/- num pg/ml epinephrin num2 versu less num2 pg/ml similar vagal tone vagal tone index numnum2 versu numnum2 +/- numnum2 u compar num close match subject underw unev stress test,0,0.7838,0.21619999999999995
estrogen fractur result suggest system effect estrogen vitamin defici not crucial fractur heal mechan properti callu,0,1.0,0.0
steroid liver failur excess immun respons provok steroid withdraw decreas reserv capac due underli chronic liver diseas thought factor liver failur,0,0.6153,0.3847
benzodiazepin drug abus clinic efficaci zaleplon persist least four week dose num2 mg num2 mg. studi patient histori drug abus suggest abus potenti zaleplon dose therapeut dose rang similar seen benzodiazepin triazolam,0,0.6286,0.3714
methotrexate/mtx rheumatoid arthritis/ra obtain inform occurr acceler nodulosi methotrex mtx rheumatoid arthriti ra local size presenc heart lung nodul predispos factor relationship extraarticular manifest eam histolog featur,0,1.0,0.0
celecoxib postop pain clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,1.0,0.0
acebutolol scle present herein first case scle induc acebutolol,1,0.18320000000000006,0.8168
aspirin rheumat heart diseas compar studi efficaci coumadin aspirin primari cardioembol stroke prevent chronic rheumat heart diseas mitral stenosi atrial fibril conduct siriraj hospit mahidol univers bangkok thailand,0,1.0,0.0
cyclosporin ibd four case nhl ibd cohort sir num2num num2 ci num-num2 p=numnum4 receiv immunosuppress therapi azathioprin n=num methotrex n=num methotrex cyclosporin n=num,0,0.8062,0.1938
aldosteron pa. hypothes measur nt-probnp could improv diagnost evalu pa. enrol num3 hypertens patient underw aldosteron renin ratio arr screen num2 underw intraven salin load test ivslt high arr,0,1.0,0.0
lutein epiretin membranes/erm evalu feasibl safeti dye solubl lutein/zeaxanthin lz num brilliant blue bb numnum3 improv remov vitreou epiretin membran erm intern limit membran ilm human,0,1.0,0.0
acetaminophen methemoglobinemia determin benefit use methylen blue treatment methemoglobinemia along n-acetylcystein nac recommend treatment acetaminophen-poison cat group num male num femal cat given methylen blue nac administr acetaminophen num3 mg/kg bodi weight po,0,1.0,0.0
oxygen chronic lung diseas studi pulmonari protein oxid associ develop chronic lung diseas num2 newborn infant mean gestat age num2num +/- num rang num2-num2 week requir intens care oxygen therapi,0,1.0,0.0
adriamycin acut cardiac toxic protect role manganes superoxid dismutas against adriamycin-induc acut cardiac toxic transgen mice,1,0.0,1.0
theophyllin asthmat use theophyllin sputum eosinophil eg2+ eosinophil ecp asthmat group much higher healthi group,0,1.0,0.0
cefotaxim sodium infect dissemin infect fatal hospit treatment intraven antibiot ceftriaxon sodium rocephin cefotaxim sodium claforan requir,0,1.0,0.0
vitamin a. rural south determin vitamin intak children age num-num year rural south african commun one year implement home-bas food product programm target beta-carotene-rich fruit veget,0,1.0,0.0
capecitabin rectal cancer patient t3/t4 node posit rectal cancer treat capecitabin num num3 mg/m num twice daili bid day num-num2 irinotecan num3 mg/m num day num everi num2 day num cycl follow capecitabin num3 mg/m num bid day num-num per week concurr radiotherapi num2num gy num2 fraction,0,1.0,0.0
glucos diabet process vascular damag acceler diabet often due co-exist diseas age although not clear improv long-term glycem control lower blood glucos level near nondiabet state reduc develop small larg vessel diseas,0,1.0,0.0
ketanserin contract ketanserin-resist compon num-ht-induc contract found -log ecnum2 num f1 numnum2 num3 nm ketanserin -log ecnum2 num f1 numnum2 num4 nm ketanserin,0,0.6231,0.3769
bupivacain pain median num2th num2th centil visual analog scale pain score associ drain remov bupivacain entonox morphin group num mm num num2 mm num2num mm num2 num2 mm num2num mm num num2 mm respect,0,0.8058,0.19420000000000004
barbitur coma includ 'forc hyperventil paco2 num2 mmhg barbitur coma experiment protocol tri buffer indomethacin induc hypothermia,1,0.3799,0.6201
warfarin thrombot patient receiv heartmat ii lvad directli transit warfarin aspirin therapi without intraven heparin no short-term increas risk thrombot thromboembol event bleed requir transfus significantli reduc,0,1.0,0.0
zeaxanthin epiretin membranes/erm evalu feasibl safeti dye solubl lutein/zeaxanthin lz num brilliant blue bb numnum3 improv remov vitreou epiretin membran erm intern limit membran ilm human,0,1.0,0.0
morphin pain pain score higher entonox group compar bupivacain group p=numnum3 morphin group p=numnum3,0,0.8048,0.19520000000000004
sotalol atrial fibril one hundr nine patient recurr episod symptomat atrial fibril flutter fail one five previou antiarrhythm drug trial treat propafenon subsequ sotalol atrial fibril recur,0,1.0,0.0
aspirin bleed first studi report aspirin therapi not associ increas rate periop bleed transfus requir major procedur relat complic elect pancreat surgeri,0,1.0,0.0
busulfan glioma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
methanol glycoprotein mous lymphoma present work extract num2 select herb prepar methanol chloroform ethyl acet water effect multidrug resist mdr p-glycoprotein mous lymphoma cell transfect human mdr1 gene human lung alveolar epitheli cell line investig,0,1.0,0.0
aspirin thromboembol compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0
risperidon schizophren verbal work memori num2 treatment-resist schizophren patient assess part random double-blind comparison treatment risperidon haloperidol,0,1.0,0.0
angiotensin hypertens present studi evalu effect treatment calcium channel blocker amlodipin angiotensin i-convert enzym inhibitor perindopril vascular endotheli function arteriosclerosi patient essenti hypertens alreadi receiv angiotensin receptor blocker monotherapi,0,1.0,0.0
mph adhd studi behavior physiolog action clinic behavior relev dose mph normal anim provid opportun explor role catecholamin transmitt prefront cortic function attent process relat normal oper brain circuit adhd patholog,0,1.0,0.0
num- num num-dimethylthiazol-num-yl -num num-diphenyl tetrazolium bromid crc stnum2-overexpress stnum2-knockdown crc cell construct respect lentivir transduct follow num- num num-dimethylthiazol-num-yl -num num-diphenyl tetrazolium bromid mtt assay plate coloni format cell-cycl analysi migrat assay evalu influenc stnum2 prolifer migrat vitro,0,1.0,0.0
alcohol death cardiovascular diseas due atherosclerosi lead caus death western societi desir effect alcohol use outweigh detriment action result favor find popul studi,0,0.8170000000000001,0.18299999999999994
clozapin anxiety/depress new num-factor model neg symptom realiti distort disorgan anxiety/depress better fit data set two commonli use factor model also fit better post-clozapin,0,0.6059,0.3941
mpa mpa conclus csa may confound relationship mpa incid reject contribut difficulti obtain therapeut rang mpa clinic practic,0,1.0,0.0
loperamid abnorm defec ramosetron num num3 microg/kg pnumo found significantli suppress abnorm defec induc conditioned-fear stress cf restraint stress corticotropin releas factor crf num-ht rat mice effect potent alosetron cilansetron loperamid,0,1.0,0.0
abirateron ar/androgen receptor among androgen receptor splice variant ar-v particularli variant num ar-v7 implic resist enzalutamid abirateron preclin studi not target current avail ar-direct drug,0,1.0,0.0
progesteron sensori impair articl review properti discuss evid suggest ht reconsid progesteron given attent potent neurotroph agent may play import role reduc prevent motor cognit sensori impair accompani senesc male femal,0,1.0,0.0
amino acid liver cirrhosi result suggest branched-chain amino acid-enrich nutrient mixtur increas nk cell activ moder patient compens liver cirrhosi show lower valu baselin nk cell activ,0,1.0,0.0
pioglitazon impair glucos toler object prevent programm studi whether combin pioglitazon lifestyl modif would enhanc efficaci lifestyl modif prevent type num diabet asian indian impair glucos toler,0,1.0,0.0
pentostatin hairi cell leukemia similar interferon alpha pentostatin highli effect hairi cell leukemia moder activ chronic lymphoid malign,0,0.7932,0.2068
methan constip presenc methan lactulos breath test associ constipation-predomin ib,1,0.0,1.0
dioc7 tumor biomark drug effect includ e_h2ax marker dna damag cleav caspase-num -num marker apoptosi reduct ki-num2 marker cell prolifer quantifi tumor section relat function blood vessel recogn dioc7 hypoxia recogn ef5 use immunohistochemistri,0,1.0,0.0
aspirin atrial fibril active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,0.8140000000000001,0.18599999999999994
neopterin aid pretreat characterist independ predict poor surviv determin use multivari proport hazard model diagnosi aid v aid relat complex age num2 year logarithm serum neopterin concentr,0,1.0,0.0
vinorelbin breast cancer data compar use vinorelbin convent appli drug advanc breast cancer patient,0,1.0,0.0
glucos diabet rational combin insulin oral drug therapi deriv better understand pathophysiolog niddm mechan action oral drug avail num type num diabet patient insulin-defici insulin-resist thu requir quit high dose exogen insulin num peripher insulin deliveri lead hyperinsulinaemia could play role pathogenesi late diabet complic num sulphonylurea stimul insulin releas directli portal vein could also potenti peripher insulin action num metformin improv glucos metabol insulin sensit alpha-glucosidas inhibitor slow digest complex carbohydr sucros abl reduc amount insulin need control postprandi hyperglycaemia,0,1.0,0.0
nickel respiratori cancer excess risk respiratori cancer demonstr group nickel-expos worker,1,0.0,1.0
corticosteroid eosinophil infiltr myocardi biopsi reveal eosinophil infiltr degranul cardiogen shock revers prompt institut corticosteroid therapi,0,1.0,0.0
clozapin schizophrenia clozapin uniqu effect refractori schizophrenia treatment attrit high,0,1.0,0.0
estrogen atherosclerosi observ studi includ postmenopaus women particip estrogen prevent atherosclerosi trial,0,1.0,0.0
tamoxifen tumor premenopaus women receptor neg tumor receiv tamoxifen chemotherapi,0,1.0,0.0
no cf median j no br significantli lower cf adult healthi control numnum2 nl/ rang numnum2-numnum2 vs. numnum2 nl/ numnum2-numnum2 p numnum3 median c alv similar group num ppb num-num vs. num num-num,0,1.0,0.0
pyridoxin pyridoxine-depend seizures/pd pyridoxine-depend seizur pd rare disord character seizur resist anticonvuls control daili pharmacolog dose pyridoxin,0,0.7914,0.2086
midazolam less hypotens refractori gcse continu inumv midazolam infus num-num mg/kg/hr num mg/kg inumv bolu effect advantag tradit therapi induc less hypotens cardiorespiratori depress easili titrat,1,0.2015,0.7985
lamotrigin mental disord evalu patient age num2 diagnost statist manual mental disord fourth edit text revis dsm-iv-tr bipolar disord outpati clinic treat lamotrigin use clinic global impress cgi scale,0,1.0,0.0
clotrimazol ear infect use extemporan compound num tetracain improv adher clotrimazol num topic solut treatment ear infect case report,0,1.0,0.0
polyethylen glycol critic ill. studi whether lactulos polyethylen glycol effect promot defec critic ill patient whether either two superior whether use enter lax relat clinic outcom,0,1.0,0.0
chromium dermat therapeut review ascorb acid valu chromium poison chromium dermat,0,1.0,0.0
irbesartan aortic dilat prospect random placebo-control double-blind multicent studi effect irbesartan aortic dilat marfan syndrom aim trial studi protocol,0,1.0,0.0
bupivacain pain bupivacain morphin unlik entonox produc lower pain score associ drain remov,0,0.7944,0.2056
valdecoxib analgesia clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,0.7998,0.20020000000000004
rp num5 rp vitro antistaphylococc activ rp num5 new streptogramin compar vancomycin teicoplanin against staphylococcu aureu rp num5 activ agent against coagulase-neg staphylococci,0,1.0,0.0
curcumin gastric carcinoma result suggest curcumin inhibit growth ag cell induc apoptosi activ ras/erk signal pathway downstream caspas cascad curcumin might potenti target treatment gastric carcinoma,0,0.7812,0.2188
h. daytim sleepi antagon histamine-h num receptor one tactic explor increas wake treatment disord excess daytim sleepi ed well sleep cognit disord,0,0.8129,0.18710000000000004
num-fluorouracil ocular toxic import oncologist ophthalmologist awar potenti ocular toxic num-fluorouracil,1,0.0,1.0
busulfan tumor cpt-num2 produc statist signific p numnum3 growth delay subcutan xenograft test includ resist busulfan cyclophosphamid procarbazin melphalan growth delay rang num2num day dnum3 med num2+ day sever tumor line,0,1.0,0.0
nitric oxid asthma circadian variat exhal nitric oxid nocturn asthma,0,1.0,0.0
linol acid tumor littl num dietari conjug linol acid inhibit develop rat mammari tumor independ amount type fat diet,0,0.8198,0.18020000000000005
busulfan graft-versus-host disease/gvhd clinic safeti efficaci intraven busulfan fludarabin iv bu/flu myeloabl condit well graft-versus-host diseas gvhd prophylaxi high-dos post-transplant cyclophosphamid ptci demonstr independ sever single-institut studi,0,0.7946,0.20540000000000005
sufentanil coronari arteri diseas random single-blind placebo-control prospect studi serum troponin concentr ctni baselin num num num2 num2 num2 num2 h postop measur isoflurane/sufentanil propofol/sufentanil anesthesia without ripc three num-min period intermitt left upper arm ischemia num min reperfus non-diabet patient n num2 three-vessel coronari arteri diseas clinicaltrialsnumgov nctnum5,0,1.0,0.0
taurolidin necrosi taurolidin inhibit immunoglobulin il -num il-num tumor necrosi factor-alpha express dose dependent-fashion pediatr oncolog patient healthi control,0,1.0,0.0
mannitol ischem stroke mannitol treatment effect adjust age stroke sever fever first num day aspirin treatment ischem stroke logist regress model,0,1.0,0.0
zidovudin aid surrog marker surviv patient aid aid relat complex treat zidovudin,0,1.0,0.0
dihydroxyphenylalanin human mammari carcinoma effect three non-myelotox cancer drug growth neuroblastoma cell investig vitro vivo dihydroxyphenylalanin l-dopa drug select toxic melanoma cell dl-buthionin sulphoximin bso drug radiosensit effect tamoxifen drug use treatment human mammari carcinoma,0,1.0,0.0
idarubicin abl also examin capabl bcr/abl-fus modul repair oxid lesion consid major side effect variou anti-canc drug includ idarubicin radiat,0,0.8008,0.19920000000000004
quinacrin system lupu erythematosu therapi system lupu erythematosu antimalari drug chloroquin hydroxychloroquin quinacrin use long time,0,1.0,0.0
borrelidin angiogenesi borrelidin also inhibit spontan lung metastasi bnum2-bl6 melanoma dose inhibit angiogenesi,0,0.7891,0.2109
gsh tumor studi regul gsh synthesi respons pro-inflammatori cytokin tumor necrosi factor-alpha tnf-alpha anti-inflammatori agent dexamethason human alveolar epitheli cell anum3,0,0.8302,0.16979999999999995
vinorelbin breast cancer determin safeti inumv trastuzumab num mg/kg follow num mg/kg everi num week combin chemotherapeut agent administ num-weekli cours docetaxel vinorelbin capecitabin num2 patient her2-posit recurr locoregion and/or metastat breast cancer,0,1.0,0.0
cholesterol iddm aim studi examin effect max epa commerci avail fish oil prepar serum cholesterol lipoprotein apolipoprotein insulin-depend diabet iddm men dosag like accept patient,0,1.0,0.0
clozapin hypersalivation/sialorrhea botulinum toxin also significantli improv sialorrhea case report double-blind studi although trial includ hypersaliv etiolog addit clozapin,0,0.6001,0.3999
csa/cyclosporin arthriti methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0
ketotifen sac aim studi compar clinic efficaci topic ketotifen olopatadin eye drop determin effect num drug express cell adhes molecul cam inflammatori marker conjunctiv surfac cell patient sac,0,1.0,0.0
dopamin impuls control disord riski busi dopamin agonist parkinson diseas impuls control disord,0,0.804,0.19599999999999995
dfo beta-thalassem combin therapi effect dfo remov prevent liver spleen bone marrow iron accumul beta-thalassem patient,0,1.0,0.0
glutamin tumor data varieti investig studi glutamin 's interact tumor-bear host receiv radiat chemotherapi compil summar,0,1.0,0.0
amiodaron pneumonia vivo probe-bas confoc laser endomicroscopi amiodarone-rel pneumonia,1,0.0,1.0
megestrol acet breast cancer profound suppress plasma estrogen megestrol acet postmenopaus breast cancer patient,0,1.0,0.0
tyrosin renal carcinoma introduct sunitinib oral multitarget receptor tyrosin kinas inhibitor delay diseas progress median overal surviv os num year improv qualiti life becom first-lin standard care metastat renal carcinoma mrcc,0,1.0,0.0
levobupivacain cardiotox revers levobupivacaine-induc cardiotox also assess,1,0.0,1.0
risperidon mania risperidone-induc mania report adult therefor increas caution use decid treat children adolesc risperidon particularli predisposit toward mania,1,0.0,1.0
metformin gestat diabet aim re-evalu whether metformin may reduc late miscarriage/preterm deliveri pre-eclampsia gestat diabet women polycyst ovari syndrom pco,0,0.8028,0.19720000000000004
titanium hernia sac hernia sac isol dissect titanium mesh mold place ischium coccyx support pelvic floor,0,1.0,0.0
aspirin embol event active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0
morphin ponv combin femor sciatic block decreas morphin consumpt num2 significantli decreas occurr ponv,0,0.8122,0.1878
dexamethason alveolar nerv solut dexamethason num mg/num ml drawn syring pour directli distal segment expos inferior alveolar nerv split num ml pour nerv immedi start fixat,0,1.0,0.0
ribavirin hepat c virus/hcv studi chronic hepat c patient would indic thymalfasin combin standard pegyl interferon ribavirin may improv respons rate hepat c viru hcv naiv nonrespond patient,0,0.7912,0.2088
curcumin gastric carcinoma curcumin biolog activ compound rhizom curcuma longa could inhibit cell growth induc apoptosi gastric carcinoma,0,0.6214,0.3786000000000001
catecholamin hyperthermia urinari catecholamin hyperthermia-rel death,0,0.6057,0.3943
batimastat malign ascit phase i/ii trial patient malign ascit batimastat well toler preliminari sign efficaci,0,1.0,0.0
vancomycin corynebacterium falsenii bacteremia give first detail descript clinic signific corynebacterium falsenii bacteremia occur infant vancomycin therapi,1,0.0,1.0
pinocembrin atherosclerosi inhibitori effect combin therapi simvastatin pinocembrin atherosclerosi apoe-defici mice,0,1.0,0.0
chromium vi ulcer repeat topic exposur chromium vi may caus allerg contact dermat format chrome ulcer,1,0.0,1.0
cyclosporin headach singl case cyclosporine-induc headach report,1,0.20330000000000004,0.7967
estrogen breast cancer reduct plasma estrogen compar valu obtain commonli use aromatas inhibitor may respons antitumor effect breast cancer,0,1.0,0.0
bp lytic diseas even better result achiev patient multipl myeloma gener consensu bp start soon diagnosi lytic diseas made myeloma patient,0,1.0,0.0
sevofluran unconsci furthermor revers disrupt anterior-posterior phase relationship alpha bandwidth identifi correl sevoflurane-induc unconsci,1,0.3945,0.6055
isofluran ripc specif hypothes ripc isofluran anesthesia attenu myocardi injuri patient undergo coronari arteri bypass graft cabg surgeri effect may differ propofol anesthesia,0,1.0,0.0
asenapin bipolar disorder/mania two larg n num3 well design num-week trial adult patient bipolar disord asenapin monotherapi significantli effect placebo improv mania symptom assess use young mania rate scale total score ymr primari endpoint signific differ asenapin placebo group occur num day treatment,0,1.0,0.0
oxygen loss conscious aim studi track cours cerebr tissu oxygen satur rso2 pilot perform episod gravity-induc loss conscious gloc,0,1.0,0.0
testosteron ed ed common symptom patient type num diabet also low testosteron level,1,0.3922,0.6078
angiotensin i. chronic heart failur combin angiotensin i-convert enzym inhibitor angiotensin receptor blocker shown effect individu drug alon treatment chronic kidney diseas chronic heart failur,0,1.0,0.0
potassium citrat bone loss studi explor whether combin treatment potassium citrat calcium citrat effect either agent alon inhibit bone loss,0,1.0,0.0
artemisinin malaria malaria treatment recommend world health organ involv medicin deriv artemisinin activ compound extract plant artemisia annua deriv artesun,0,1.0,0.0
acetaminophen postop pain compar effect iv acetaminophen oral ibuprofen respect postop pain control morphin requir patient receiv morphin patient-control iv analgesia pcia cesarean deliveri,0,1.0,0.0
praziquantel schistosomiasi area schistosom hookworm coexist praziquantel recommend schistosomiasi control large-scal applic drug might also reduc burden hookworm,0,1.0,0.0
mesyl pkc/protein kinas c. review current clinic data regard pharmacolog action ruboxistaurin lynum5 mesyl inhibitor protein kinas c pkc beta role potenti reduc develop and/or progress diabet microvascular complic,0,0.7979999999999999,0.20200000000000007
glucos oral glucos toler no chang first-phas insulin secret numnum2 +/- numnum2 versu numnum2 +/- numnum2 nmol/l p numnum2 well fast insulin glucos level oral glucos toler insulin-medi glucos dispos num week administr lopinavir/ritonavir,0,1.0,0.0
gaba ischem express phospho-mimet mutant gaba r e_3 subunit prevent receptor intern protect hippocamp neuron ischem cell death,0,1.0,0.0
streptozotocin diabet express pancreat islet mhc class insulin ica num3 tyrosin phosphatas low-dos streptozotocin-induc diabet mice,1,0.1946,0.8054
mitoxantron multipl sclerosi suppress mitoxantron cardiotox multipl sclerosi patient dexrazoxan,0,0.8073,0.1927
cisplatin apoptot cytotox lung cancer cell knockdown rip1 substanti increas cisplatin-induc apoptot cytotox associ robust jnk activ,1,0.18620000000000006,0.8138
vitamin d. ckd consid treat ckd patient requir phosphat binder oral vitamin,0,1.0,0.0
serotonin serotonin reuptak inhibitors/sri grow number concern util serotonin reuptak inhibitor sri late pregnanc onset perinat complic,0,0.794,0.206
triiodothyronin major depress disorder/mdd open trial investig efficaci triiodothyronin num adjuv select serotonin reuptak inhibitor ssri subject major depress disord mdd resist ssri treatment,0,1.0,0.0
oestrogen anovul progestogen without oestrogen irregular uterin bleed associ anovul,0,0.8068,0.19320000000000004
telithromycin cap oral dose telithromycin num3 mg daili seven ten day effect well-toler first-lin treatment mild moder cap adult,0,1.0,0.0
alcohol viral hepat includ requir improv enzymolog screen despit introduct test hepat c imbal popular unexplain chronic aminotransferas elev effort solv inher problem inadequ attempt use metabol chang hepatocyt improv diagnosi prognosi pathophysiolog understand viral liver diseas remark investig num'-num'-oligoadenyl synthetas better control interferon therapi chronic viral hepat use enzym marker etiolog particularli detect alcohol induc liver diseas continu prefer aminotransferas scenario although ratio aspart aminotransferas alanin aminotransferas mitochondri aspart aminotransferas total aspart aminotransferas activ larg depend sever intralobular local damag stage liver diseas,0,1.0,0.0
resveratrol ovarian cancer show previous resveratrol induc autophag cell death ovarian cancer cell,0,0.8112,0.1888
tamoxifen breast cancer/uterin cancer women diagnosi uterin cancer memori sloan-kett cancer center num4 june num4 past histori breast cancer treat tamoxifen identifi,0,0.6071,0.3929
retino acid/tretinoin melasma use broad-spectrum sunscreen import lighten agent like retino acid tretinoin azela acid combin therapi contain hydroquinon tretinoin corticosteroid use treatment melasma thought increas efficaci compar monotherapi,0,1.0,0.0
glucos pain median pain score interquartil rang breast feed held mother 's arm placebo num2 glucos plu pacifi group num num-num num2 num-num2 num2 num-num2 num num-num douleur aiguic nouveau-ni scale num numnum2-num num2 num2num-num2 num2 num-num2 num num-num prematur infant pain profil scale,0,1.0,0.0
zaleplon insomnia zaleplon review novel sed hypnot use treatment insomnia,0,1.0,0.0
acyclovir shingl oral acyclovir also shown efficaci normal adult zoster shingl immunocompet children varicella,0,1.0,0.0
procarbazin ependymoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0
androgen prostat cancer androgen regul prolifer human prostat cancer cell cultur increas transform growth factor-alpha tgf-alpha epiderm growth factor egf /tgf-alpha receptor,0,1.0,0.0
vitamin b num2 testosteron defici frequent strategi includ dietari chang vitamin modif routin rest exercis prescrib medic anemia vitamin b num2 defici testosteron defici,0,1.0,0.0
prednison heart failur num patient activ inflamm receiv prednison num mg. kg-num d-num num week follow numnum2 mg. kg-num d-num num month azathioprin num mg. kg-num d-num num month addit convent drug therapi heart failur,0,1.0,0.0
estrogen pain anim model involv nerv injuri sensit erb-num3 non-steroid estrogen receptor beta ligand evalu sever pain anim model involv nerv injuri sensit,0,1.0,0.0
mpa-glucuronide/mpag mycophenol acid/mpa therapeut drug monitor mycophenol acid mpa combin cyclosporin num-h concentr csa c2 n num2 tacrolimu trough concentr n num2 investig repeat measur mpa mpa-glucuronid mpag trough concentr renal allograft recipi first num month post-transpl,0,1.0,0.0
aspirin asthma aspirin-intoler asthma aia occur asthma exacerb exposur aspirin,1,0.3928,0.6072
linol acid breast cancer anti-prolif pro-apoptot effect trans9 transnum2 conjug linol acid isom mcf-num breast cancer cell associ lxr activ,0,1.0,0.0
paliperidon palmit hallucin studi suggest risperidon long-act inject paliperidon palmit long-act inject may use treatment dd patient specif nonpromin hallucin,0,1.0,0.0
rosuvastatin ifg patient ifg hyperlipidaemia rosuvastatin treatment associ dose-depend increas insulin resist,0,0.8032,0.1968
propofol depress retrospect comparison effect propofol etomid stimulu variabl efficaci electroconvuls therapi depress inpati,0,1.0,0.0
levothyroxin thyroid cancer perform seri neuropsycholog test num2 thyroid cancer patient continu take usual dose levothyroxin lt4 discontinu thyroid hormon,0,0.8266,0.1734
thapsigargin endoplasm reticulum xbp1 mrna splice express endoplasm reticulum stress respons gene determin cell expos thapsigargin presenc absenc quinotrierixin,1,0.397,0.603
indomethacin respiratori distress syndrom antenat indomethacin not associ intraventricular hemorrhag patent ductu arteriosu respiratori distress syndrom bronchopulmonari dysplasia mortal,0,1.0,0.0
azathioprin inflamm num patient activ inflamm receiv prednison num mg. kg-num d-num num week follow numnum2 mg. kg-num d-num num month azathioprin num mg. kg-num d-num num month addit convent drug therapi heart failur,0,1.0,0.0
cilostazol claudic symptomat treatment claudic includ smoke cessat exercis cilostazol statin revascular percutan surgic therapi,0,1.0,0.0
anthracyclin cardiotox establish cancer drug anthracyclin also form ro free radic respons cardiotox anthracyclin,1,0.0,1.0
glucos breast feed investig whether breast feed effect pain relief venepunctur term neonat compar effect oral glucos combin pacifi,0,1.0,0.0
capecitabin head neck squamou cell carcinoma/hnscc evalu whether two molecular biomark thymidin phosphorylas tp dihydropyrimidin dehydrogenas dpd could clinic use predict improv chemotherapeut outcom oral fluoropyrimidin capecitabin num'-dfur xeloda treatment human head neck squamou cell carcinoma hnscc,0,1.0,0.0
corticosteroid allerg contact dermat allerg contact dermat follow ocular use corticosteroid,1,0.0,1.0
auristatin pe tumor tumor growth inhibit t/c tumor growth delay t-c lognum2 kill auristatin pe dolastatin num2 num num2 day numnum2 num2 num day numnum2 respect,0,1.0,0.0
azela acid melasma use broad-spectrum sunscreen import lighten agent like retino acid tretinoin azela acid combin therapi contain hydroquinon tretinoin corticosteroid use treatment melasma thought increas efficaci compar monotherapi,0,1.0,0.0
gemcitabin hodgkin 's diseas gemcitabin effect treatment hodgkin 's diseas,0,1.0,0.0
nvp anaemia age-specif mean haemoglobin level preval anaemia haemoglobin num2 g/dl not significantli differ case babi receiv singl dose nvp case nvp given mother/inf pair addit zdv babi,0,0.7951,0.2049
fenoterol breathless respons regular inhal fenoterol ipratropium bromid meter dose inhal mdi larg volum spacer regular nebul salbutamol ipratropium bromid assess home peak flow record spirometri two subject score rate breathless simpl four-point scale b activ score st georg 's respiratori questionnair,0,0.6013,0.3987000000000001
furosemid thrombocytopenia report describ case furosemid identifi probabl caus drug-induc thrombocytopenia num2-year-old man chronic symptomat idiopath thrombocytopenia seven year discoveri,1,0.1894,0.8106
alcohol bph/prostat cancer alcohol consumpt show no consist associ prostat cancer risk statist signific invers trend risk bph,0,1.0,0.0
loratadin allerg system antihistamin loratadin cetrizin hydrochlorid proven efficaci control mani allerg condit howev patient complain dri effect,0,1.0,0.0
ethanol tumor rh2 dissolv absolut ethanol adjust distil water num num2 num3 microm num ml concentr administ oral canula everi day num2 day next day tumor inocul,0,1.0,0.0
steroid liver failur steroid readministr intens therapi liver failur not prevent death,0,1.0,0.0
metformin preterm deliveri potenti metformin prevent preterm deliveri women polycyst ovari syndrom epi-analysi,0,1.0,0.0
coumadin cardioembol stroke compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0
paliperidon schizophrenia sever random double-blind placebo-control trial shown paliperidon er efficaci manag acut schizophrenia well prevent symptom recurr compar placebo,0,1.0,0.0
clofarabin cll/chronic lymphocyt leukemia base mechanist similar fludarabin cladribin success analogu treatment chronic lymphocyt leukemia cll hypothes clofarabin would effect indol leukemia,0,1.0,0.0
temozolomid tumor tumor control resect achiev patient howev patient mention report receiv radiat instead temozolomid,0,1.0,0.0
hydroxychloroquin dmard establish dmard sulfasalazin hydroxychloroquin also demonstr efficaci use togeth methotrex,0,1.0,0.0
chloroquin cytotox lc3-ii protein increas treatment num-fu chloroquin potenti cytotox num-fu,1,0.1826,0.8174
aspirin stroke risk stroke death num month num year not higher among patient classifi aspirin treatment failur among toast num num2 confid interv ci num-num p .num nind rt-pa trial patient num num2 ci num-num p .num respect,0,0.8105,0.1895
acetylcholin hypertens compar dose-respons curv relat chang coronari blood flow epicardi diamet grade infus acetylcholin num2 african american num2 white subject hypertens left ventricular hypertrophi lvh normal coronari arteri,0,1.0,0.0
atra/all-tran retino acid acut myeloid leukemia atra all-tran retino acid dimethylsulfoxid dmso induc differenti hl-num2 nb4 two human acut myeloid leukemia cell line myelocyt lineag up-regul two enzym variou degre num num2 h treatment,0,1.0,0.0
gbx sleep restrict group receiv either gbx num2 mg placebo sleep restrict night group receiv placebo baselin recoveri night,0,1.0,0.0
sertralin sexual dysfunct index term includ sexual dysfunct antidepress select serotonerg reuptak inhibitor fluoxetin sertralin paroxetin fluvoxamin clomipramin buspiron nefazodon bupropion cyproheptadin amantadin yohimbin central nervou system stimul,0,1.0,0.0
mtx ra acceler nodulosi mtx ra not rare occur despit good clinic respons polyarthr,0,1.0,0.0
carboplatin non-small-cel lung cancer/nsclc patient non-small-cel lung cancer nsclc treat ice chemotherapi ifosfamid num4 mg/m2 day num-num carboplatin num3 mg/m2 day num etoposid num2 mg/m2 day num-num intraven inumv first num maximum four num2 treatment cycl,0,1.0,0.0
phosphatidylcholin metastasi therapeut effect hybrid liposom compos phosphatidylcholin docosahexaeno acid hepat metastasi colon carcinoma along apoptosi vivo,0,1.0,0.0
sunitinib manag neuroendocrin tumor believ studi sunitinib octreotid neoadjuv intent prepar tumor resect warrant strategi improv cur manag neuroendocrin tumor,0,1.0,0.0
colchicin proteinuria success treatment anti-tumor necrosi factor anti-tnf -alpha proteinuria patient famili mediterranean fever fmf resist colchicin anti-tnf drug fmf,0,1.0,0.0
taxan tumor tesetaxel new oral taxan combin capecitabin phase dose-escal studi patient advanc solid tumor,0,1.0,0.0
yohimbin anxieti previous report increas symptom anxieti patient posttraumat stress disord ptsd follow administr beta num-antagonist yohimbin stimul brain norepinephrin releas,1,0.0,1.0
curcumin ag result suggest curcumin inhibit growth ag cell induc apoptosi activ ras/erk signal pathway downstream caspas cascad curcumin might potenti target treatment gastric carcinoma,0,1.0,0.0
lorazepam catatonia lorazepam achiev full resolut catatonia num2 patient,0,0.7974,0.2026
glucos obes curcumin reduc serum glucos cholesterol triglycerid low densiti lipoprotein level high-fat-diet-induc obes rat,0,1.0,0.0
ciprofloxacin cholera conclud ciprofloxacin given day effect standard tetracyclin regimen treatment cholera adult,0,1.0,0.0
corticosteroid cataract found no differ frequenc pe follow cataract surgeri chang postop topic medic mixtur corticosteroid antibiot corticosteroid,0,1.0,0.0
benzodiazepin depress avail option treatment bipolar disord includ mania hypomania depress mainten elderli includ lithium antiepilept antipsychot benzodiazepin antidepress electroconvuls therapi ect psychotherapi,0,1.0,0.0
balnum5 pseudomallei strain studi anti-b pseudomallei efficaci new monosulfactam balnum5 test against laboratori strain num4b num4b sever isogen mutant deriv well collect clinic environment b. pseudomallei strain thailand,0,1.0,0.0
glucos diabet assess impact use autom bolu advisor integr blood glucos meter time frequenc adjust insulin therapi paramet set whether avail technolog would increas blood glucos test strip util diabet patient treat multipl daili insulin inject mdi therapi,0,0.7869,0.2131
azithromycin bronchiti single-blind double-dummi multicentr studi compar oral azithromycin administ tablet num3 mg daili num day versu oral pivampicillin num3 mg twice daili num2 day adult acut exacerb chronic bronchiti not need parenter antibiot therapi hospit oxygen support,0,1.0,0.0
oxygen hypertens reactiv oxygen speci vascular biolog role arteri hypertens,0,0.8025,0.1975
naltrexon psychiatr disord naltrexon disulfiram patient alcohol depend comorbid psychiatr disord,0,0.8055,0.1945
metformin preterm deliveri metformin-tr patient less late miscarriage/preterm deliveri five num vs. num2 num2 placebo group p numnum2,0,1.0,0.0
suramin metastat cancer suramin serum insulin-lik growth factor level metastat cancer patient,0,0.8217,0.1783
tocopherol inflamm pattern dietari intak serum carotenoid tocopherol statu associ biomark chronic low-grad system inflamm cardiovascular risk,1,0.1958,0.8042
progesteron traumat injuri part almost work ht estrogen given primari focu despit fact progesteron import properti enhanc repair neurodegen traumat injuri central nervou system,0,1.0,0.0
bortezomib encephalopathi bortezomib-induc posterior revers encephalopathi syndrom clinic imag featur,1,0.19510000000000005,0.8049
zinc wilson diseas systemat review clinic efficaci chelat agent zinc initi treatment wilson diseas,0,1.0,0.0
arb anemia furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,0.7798,0.22019999999999995
creatinin proteinuria irr num num num2 confid interv num2 ci num-num num num2 ci num-num respect beta num microglobulin measur avail num2 worker form stone num2 worker tubular proteinuria beta num microglobulin num2 micrograms/mmol creatinin -- preval num2,0,1.0,0.0
glucos impair fast glucos rosuvastatin treatment associ increas insulin resist hyperlipidaem patient impair fast glucos,0,1.0,0.0
ascorb acid cytotox cytotox due exposur ndma partial inhibit antioxid n-acetylcystein ascorb acid butyl hydroxyanisol n-t-butyl-alpha-phenylnitron not potenti upon glutathion deplet,0,1.0,0.0
diphenhydramin cn dysfunct children diphenhydramin hydroxyzin effect h1-receptor antagonist medic caus cn dysfunct evidenc increas pnum3 latenc measur cognit function increas subject somnol,1,0.0,1.0
ssri sexual dysfunct manag ssri-induc sexual dysfunct,1,0.18500000000000005,0.815
aspart viral hepat includ requir improv enzymolog screen despit introduct test hepat c imbal popular unexplain chronic aminotransferas elev effort solv inher problem inadequ attempt use metabol chang hepatocyt improv diagnosi prognosi pathophysiolog understand viral liver diseas remark investig num'-num'-oligoadenyl synthetas better control interferon therapi chronic viral hepat use enzym marker etiolog particularli detect alcohol induc liver diseas continu prefer aminotransferas scenario although ratio aspart aminotransferas alanin aminotransferas mitochondri aspart aminotransferas total aspart aminotransferas activ larg depend sever intralobular local damag stage liver diseas,0,1.0,0.0
valproat manic symptom num2-week trial asenapin adjunct therapi lithium valproat asenapin effect placebo improv manic symptom base differ group ymr total score week num primari endpoint,0,1.0,0.0
delapril nephropathi num2 week treatment two patient delapril group one patient manidipin group convert normoalbuminuria urinari albumin creatinin ratio num2 mg/g one patient group progress overt nephropathi urinari albumin creatinin ratio num3 mg/g,0,0.6043,0.3957000000000001
cyclophosphamid breast cancer sequenc compar simultan anthracyclin cyclophosphamid high-risk stage ii breast cancer final analysi int-num4 snum4,0,0.8083,0.1917
gonadotropin-releas hormon myoma gonadotropin-releas hormon agonist gnrh agonist therapi use adjunct myomectomi hysterectomi uterin myoma,0,1.0,0.0
oestrogen menstrual bleed randomis control trial progestogen via rout alon combin oestrogen treatment irregular menstrual bleed associ oligo/anovul,0,1.0,0.0
amoxycillin typhoid fever num2 children bacteriolog and/or serolog diagnos typhoid fever treat kem hospit bombay num4 initi one three recommend drug viz chloramphenicol amoxycillin co-trimoxazol given num day defervesc occur,0,1.0,0.0
platinum hypoton maximum concentr cmax total filter platinum plasma inject hypoton solut significantli higher inject isoton solut,0,1.0,0.0
manidipin diabet effect urinari albumin excret renal function chang delapril manidipin normotens type num diabet patient microalbuminuria,0,1.0,0.0
pazopanib osteosarcoma vitro dose-respons studi topotecan pazopanib conduct sever neuroblastoma osteosarcoma rhabdomyosarcoma cell line,0,0.8114,0.1886
calcium cardiac arrhythmia taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.8067,0.19330000000000006
aspirin gastroduoden disord endoscopi frequent reveal gastroduoden disord among low-dos aspirin user administr ba enteric-co aspirin warrant concern gastroduoden ulcer,1,0.1999,0.8001
iron iron defici anemia investig efficaci co-administr dfaiii water-insolubl iron treatment iron defici anemia vietnames women,0,1.0,0.0
aciclovir enceph case note infant children receiv intraven aciclovir suspect enceph num-month period review,0,0.8074,0.1926
glyceryl trinitr chronic anal fissur local applic glyceryl trinitr avoid surgeri num2 percent patient chronic anal fissur,0,1.0,0.0
coumadin cardioembol stroke three patient nonfat cardioembol stroke aspirin group none coumadin group three year follow-up,0,1.0,0.0
fentanyl opioid rotat twenty-on consecut cancer patient morphine-induc delirium underw opioid rotat fentanyl,0,1.0,0.0
num-fu weight loss synergist effect num-fu ifn-alpha observ co-num nude mice vivo synerg obtain without increment thymidyl synthetas inhibit side effect term death rate bodi weight loss,0,1.0,0.0
amiodaron hp-amr-ip contrast cell observ two out num2 area lp-amr-ip patient one out num2 area ild patient not receiv amiodaron none num2 area amiodarone-tr patient without ild p numnum3 hp-amr-ip versu group,0,1.0,0.0
gabapentin chronic kidney diseas patient suffer chronic kidney disease-associ pruritu gabapentin may option,0,1.0,0.0
pilocarpin ocular hypertens addit intraocular pressure-low effect latanoprost numnum3 daili pilocarpin num tnuminumd patient open-angl glaucoma ocular hypertens num-month random multicent studi,0,1.0,0.0
cocain hypermetabol tradit view cocain caus hypermetabol state increas heat product,1,0.0,1.0
alcohol hepat c. includ requir improv enzymolog screen despit introduct test hepat c imbal popular unexplain chronic aminotransferas elev effort solv inher problem inadequ attempt use metabol chang hepatocyt improv diagnosi prognosi pathophysiolog understand viral liver diseas remark investig num'-num'-oligoadenyl synthetas better control interferon therapi chronic viral hepat use enzym marker etiolog particularli detect alcohol induc liver diseas continu prefer aminotransferas scenario although ratio aspart aminotransferas alanin aminotransferas mitochondri aspart aminotransferas total aspart aminotransferas activ larg depend sever intralobular local damag stage liver diseas,0,0.6061,0.3939
lamotrigin bipolar disord evalu patient age num2 diagnost statist manual mental disord fourth edit text revis dsm-iv-tr bipolar disord outpati clinic treat lamotrigin use clinic global impress cgi scale,0,1.0,0.0
linol acid tumor/canc conjug linol acid inhibit growth number human cancer cell line suppress chemically-induc tumor develop number site anim model,0,1.0,0.0
guanethidin thermal hyperalgesia howev iontophoresi noradrenalin thermal hyperalgesia greater guanethidine-pretr site salin pretreat site,1,0.0,1.0
aviptadil lung diseas total num2 patient ph pah nine ph lung diseas eight chronic thromboembol ph three inhal singl num3-microg dose aviptadil right-heart catheteris,0,0.8101,0.1899
olopatadin sac aim studi compar clinic efficaci topic ketotifen olopatadin eye drop determin effect num drug express cell adhes molecul cam inflammatori marker conjunctiv surfac cell patient sac,0,1.0,0.0
crizotinib anaplast lymphoma total num2 patient stage iv anaplast lymphoma kinas alk -posit non-smal cell lung cancer treat crizotinib identifi,0,0.8055,0.1945
aspirin cardioembol stroke compar studi efficaci coumadin aspirin primari cardioembol stroke prevent chronic rheumat heart diseas mitral stenosi atrial fibril conduct siriraj hospit mahidol univers bangkok thailand,0,1.0,0.0
indomethacin pda cyclo-oxygenas inhibitor indomethacin ibuprofen remain mainstay medic therapi pda use prophylaxi well rescu therapi achiev pda closur,0,1.0,0.0
carbon oa analysi f sc k sa delta oct /f om k oa ratio reveal signific role adsorpt absorpt unusu high element carbon fraction ie low oc/ec ratio fine particl collect wast inciner abnorm high organ carbon fraction ie high oc/ec ratio observ fine particl urban residenti zone respect,0,1.0,0.0
ethanol abdomin pain incid rate abdomin pain procedur ethanol group num2num,1,0.1986,0.8014
aspirin colorect cancer aspirin inhibit mtor signal activ amp-activ protein kinas induc autophagi colorect cancer cell,0,0.6029,0.3971
zotepin seizur advers event zotepin induc seizur publish case report,1,0.0,1.0
feiba thrombosi thrombosi rare well-recogn potenti complic factor viii inhibitor bypass activ feiba infus,1,0.0,1.0
dexamethason necrosi molecular mechan regul glutathion synthesi tumor necrosi factor-alpha dexamethason human alveolar epitheli cell,0,1.0,0.0
silicon human immunodefici viru report case chronic progress granulomat pneumon respons subcutan silicon inject transgend male-to-femal patient infect human immunodefici viru num hiv-num,0,1.0,0.0
camptothecin toxic determin efficaci toxic novel chemotherapeut approach topotecan camptothecin analog progress recur anaplast oligodendroglioma mix oligoastrocytomanumpati seven center recurr progress diseas treat topotecan num mg/m num intraven inumv num2 min dailyx5 day everi num week,0,0.8128,0.18720000000000006
iron infect -supplement infant formula safe improv iron statu decreas diarrhea sever infant rhesu monkey thu may help protect formula-f human infant infect nutrit defici,0,1.0,0.0
escitalopram depress analysi suggest escitalopram effect term qalw less costli duloxetin treatment depress,0,1.0,0.0
fentanyl vomit compar oral opioid advantag transderm fentanyl includ lower incid impact advers effect constip nausea vomit daytim drowsi higher degre patient satisfact improv qualiti life improv conveni complianc result administr everi num2 hour decreas use rescu medic,1,0.1884,0.8116
nac patholog gambl studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,0.6092,0.3908
clopidogrel embol event active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0
colchicin fmf major renal involv fmf occurr amyloidosi prevent daili regimen colchicin,0,1.0,0.0
creatinin plasma glucos no signific chang fast plasma glucos hba1c serum fructosamin creatinin potassium lipid profil num2 week treatment group,0,1.0,0.0
anum5 stomach cancer/colon cancer human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,0.8169,0.18310000000000004
tipifarnib/rnum5 breast cancer biomark anticanc activ rnum5 tipifarnib zarnestra human breast cancer model vitro,0,1.0,0.0
erlotinib brain tumor recent perform analysi tumor obtain phase trial erlotinib patient glioblastoma multiform gbm common malign brain tumor adult,0,1.0,0.0
pcp chronic poison chronic poison occur mainli sawmil worker peopl live log home treat pcp-contain wood protect formul,1,0.0,1.0
enzalutamid ar resist enzalutamid abirateron howev mark return ar signal indic remark addict prostat cancer cell ar pathway,0,0.8037,0.19630000000000006
morphin delirium primari aim studi clarifi efficaci opioid rotat morphin fentanyl symptom palliat morphine-induc delirium,1,0.0,1.0
borrelidin melanoma borrelidin also inhibit spontan lung metastasi bnum2-bl6 melanoma dose inhibit angiogenesi,0,0.8037,0.19630000000000006
nvp aid compar efv adjust hazard ratio hr aids/death numnum2 num2 confid interv ci numnum2-numnum2 nvp numnum2 num2 ci numnum2-numnum2 rtv numnum2 num2 ci numnum2-numnum2 rtv-boost pi,0,1.0,0.0
amphotericin b. indian viscer leishmaniasi single-dos indigen liposom amphotericin b treatment indian viscer leishmaniasi phase num studi,0,1.0,0.0
interferon-alpha symptom depress interferon-alpha ifn-alpha treatment frequent complic symptom depress,1,0.3897000000000001,0.6103
ammonia encephalopathi efficaci variabl fast postprandi ammonia concentr number-connection-test time mental state grade portosystem encephalopathi index,0,1.0,0.0
levodopa parkinson 's diseas herein report case young woman suffer recurr metatars fractur context levodopa-tr early-onset parkinson 's diseas,0,1.0,0.0
bombesin breast cancer inhibitori effect bombesin/gastrin-releas peptid antagonist rc-num4 lutein hormone-releas hormon antagonist sb-num2 growth mcf-num miii human breast cancer xenograft athym nude mice,0,0.8335,0.16649999999999998
sirolimu fibrosi multivari analysi demonstr sirolimu independ predictor minim fibrosi year one year two,0,0.8059,0.19410000000000005
pah pah final author discuss implic bioaccess pah-induc toxic cancer context risk assess,0,1.0,0.0
hbeag/hepat b e antigen hepat b. trial patient hepat b e antigen hbeag -neg chronic hepat b num2 week post-treat biochem virolog respons rate peginterferon alpha-2a without lamivudin significantli higher lamivudin alon,0,0.7946,0.20540000000000005
ethanol tumor day num2 num2 tumor inocul tumor volum group treat rh2 significantli less ethanol-tr control group also cisplatin treat group,0,0.8103,0.1897
dexamethason relaps diseas bortezomib thalidomid lenalidomid improv therapeut armentarium patient refractori relaps diseas often use combin dexamethason chemotherapeut agent,0,1.0,0.0
steroid cataract purpos describ risk cataract among user intranas steroid,0,0.6194,0.3806000000000001
levodopa homocysteinemia calcif tissu int num2 num3-num2 num4 levodopa intak associ increas homocysteinemia known link poorer bone qualiti consequ osteoporot fractur,1,0.0,1.0
vitamin e. cataract role past intak vitamin e earli cataract chang,0,1.0,0.0
tryptophan bad result replic extend previou find suggest ur patient bad suscept low tryptophan avail,0,1.0,0.0
tryptophan manic-depress ill lower mood induc acut tryptophan deplet atd propos candid endophenotyp vulner manic-depress ill,0,0.6149,0.3851
atorvastatin pad high-dos statin therapi atorvastatin significantli reduc incid pad compar usual-dos statin therapi simvastatin,0,1.0,0.0
borrelidin angiogenesi use improv model confirm tnp-num3 well-known inhibitor borrelidin antibiot streptomyc rochei significantli inhibit widr cell-induc angiogenesi,0,1.0,0.0
androgen prostat cancer examin effect num alpha-dihydrotestosteron dht testosteron egf egf-alpha cell prolifer 3h-thymidin incorpor androgen-depend human prostat cancer cell line alvanum3 serum-fre medium,0,0.7906,0.20940000000000006
theophyllin asthma maximum serum level num micrograms/ml num2num micrograms/ml attain num num hour dose t1 t2 coincid perfectli time critic morn dip num-num anumm nocturn excess num2num t1 num2num t2 circadian-tailor asymmetr dosag regimen prove take account chronopatholog asthma chronopharmacokinet theophyllin sustained-releas prepar,0,1.0,0.0
clofarabin cll vitro clofarabin incub leukem lymphocyt num2 cll patient show clofarabin monophosph accumul higher concentr compar triphosph,0,0.6051,0.3949
nelfinavir cancer although presum drug dose need effici er stress reaction ensu apoptosi cancer cell somewhat higher prescrib hiv-infect person nelfinavir repres one clinic applic er stress-induc agent current test clinic studi cancer patient,0,1.0,0.0
sotalol arrhythmia percent patient free recurr symptomat arrhythmia num month num2 propafenon num2 sotalol,0,1.0,0.0
ondansetron t1dm/type num diabet mellitu assess hypothesi ondansetron administr children type num diabet mellitu t1dm present emerg depart ed care intercurr ill vomit improv clinic outcom reduc hospit rate primari length ed stay intraven fluid ivf administr revisit secondari outcom,0,1.0,0.0
fluticason propion bronchial asthma studi fluticason propion efficaci treatment patient bronchial asthma not control inhal corticosteroid,0,1.0,0.0
mangafodipir/manganese-dpdp pancreat lesion magnet reson manganese-dpdp mangafodipir focal solid pancreat lesion,0,1.0,0.0
morphin termin cancer pain doubl blind cross studi design evalu effect ketamin spinal morphin analgesia termin cancer pain patient,0,1.0,0.0
y-num5 hcc find confirm import rho/pnum3rock signal pathway intrahepat metastasi human hcc indic y-num5 may use prevent intrahepat metastasi human hcc,0,1.0,0.0
ciprofloxacin cholera ciprofloxacin treatment cholera random double-blind control clinic trial singl daili dose peruvian adult,0,1.0,0.0
aspirin crc aspirin reduc mtor signal crc cell inhibit mtor effector s6k1 4e-bp1,0,1.0,0.0
fluconazol infect clinic trial report support use fluconazol treatment candidiasi particularli oropharyng esophag infect immunocompromis host,0,1.0,0.0
tyrosin gist/gastrointestin stromal tumour although tyrosin kinas inhibitor imatinib shown activ agent patient gastrointestin stromal tumour gist complet remiss almost never seen patient final experi diseas progress cours treatment,0,1.0,0.0
amiodaron af af recurr success cardiovers num2num num2num dronedaron amiodaron respect,0,1.0,0.0
vincristin sensory/motor neuropathi although first-gener vinca alkaloid vincristin associ sever mix sensory/motor neuropathi deficit associ newer agent class eg vinflunin gener milder limit distal sensori sign symptom,1,0.0,1.0
platinum bladder cancer phase ii studi vinflunin bladder cancer patient progress first-lin platinum-contain regimen,0,1.0,0.0
carvedilol ad found carvedilol treatment significantli improv neuron transmiss improv associ mainten number less stabl learn thin spine brain ad mice,0,1.0,0.0
ribavirin alcohol perform proteom analysi liver specimen num2-year-old woman affect hepat c genotyp 1a alcohol diabet mellitu type num antivir treatment pegyl interferon alpha 2b ribavirin,0,1.0,0.0
arformoterol copd arformoterol singl isom long-act beta num -agonist develop inhal solut mainten treatment bronchoconstrict copd,0,1.0,0.0
retino acid cancer retino acid-induc downmodul telomeras activ human cancer cell,0,0.8024,0.1976
thalidomid hiv review describ emerg immunolog properti thalidomid histor context present-day clinic applic notabl multipl myeloma also cancer inflammatori diseas hiv,0,0.815,0.18500000000000005
loratadin chamber regul humid particip evalu cae chamber regul humid temperatur airflow visual task baselin take num2 mg either loratadin cetirizin hydrochlorid daili num day,0,0.8092,0.1908
levodopa parkinson 's diseas effect entacapon comt inhibitor pharmacokinet levodopa cardiovascular respons patient parkinson 's diseas,0,1.0,0.0
tetracyclin cholera conclud ciprofloxacin given day effect standard tetracyclin regimen treatment cholera adult,0,1.0,0.0
fluoxetin sexual dysfunct ssri-induc sexual dysfunct describ fluoxetin paroxetin sertralin fluvoxamin num-num2 week therapi,1,0.1894,0.8106
capecitabin toxic design studi local advanc rectal cancer determin patholog respons toxic disease-fre surviv df induct capecitabin plu irinotecan follow capecitabine-bas chemoradiotherapi crt analyz gene express enzym involv metabol capecitabin irinotecan associ respons toxic,0,1.0,0.0
amlodipin vascular endotheli dysfunct conclus result suggest angiotensin i-convert enzym inhibitor perindopril superior calcium channel blocker amlodipin reduc vascular endotheli dysfunct co-administ angiotensin receptor blocker patient essenti hypertens,0,1.0,0.0
amino acid critic ill. effect fuel sourc amino acid metabol critic ill patient,0,1.0,0.0
succinylcholin myalgia aim compar effect succinylcholin rocuronium-sugammadex develop myalgia headach electroconvuls therapi ect,0,1.0,0.0
clindamycin infect recommend manag infect consist drainag antimicrobi therapi tetracyclin clindamycin fluoroquinolon,0,1.0,0.0
gaba cognit toxic plasma gaba concentr not appear use marker suscept benzodiazepine-induc cognit toxic elderli,0,0.8235,0.1765
tyrosin system mastocytosi activ mutat codon dnum3 tyrosin kinas receptor kit found major patient system mastocytosi,0,0.622,0.37799999999999995
pioglitazon death pioglitazon group two death two non-fat hospitalis occur due cardiac problem placebo group two occurr cardiac diseas,0,0.7818,0.21819999999999995
lutein melanoma summari mechan lutein 's anti-ag anti-carcinogen effect includ inhibit mmp timp ratio dermal fibroblast melanoma cell inhibit cell loss membran damag elastin express ultraviolet radiat expos fibroblast,0,1.0,0.0
famotidin reflux oesophagitis/gastro-oesophag reflux studi test respons treatment famotidin num week patient reflux oesophag take consider howev case patholog gastro-oesophag reflux acid type,0,1.0,0.0
delta num -thc thc actual propos delta num -thc reschedul schedul iv unit nation convent psychotrop drug not constitut substanti risk public health abus rare,0,1.0,0.0
fluoxetin postnat depress applebi et al num4 report fluoxetin significantli effect placebo initi session counsel effect full cours cognitive-behaviour counsel treatment postnat depress,0,1.0,0.0
aspirin stroke post-hoc analysi num random ischem stroke trial aspirin treatment failur not found associ increas risk recurr stroke death,0,1.0,0.0
chloroquin system lupu erythematosu therapi system lupu erythematosu antimalari drug chloroquin hydroxychloroquin quinacrin use long time,0,1.0,0.0
alcohol cardiovascular diseas presenc cardiovascular diseas howev even small quantiti alcohol might result transient unfavor hemodynam chang,0,0.8047,0.19530000000000006
imatinib he current studi sought confirm preliminari observ he well evalu therapeut valu imatinib eos-cmd not associ num num2 qnum2 pnum2,0,1.0,0.0
idarubicin leukemia anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0
sufentanil ripc/ischemia random single-blind placebo-control prospect studi serum troponin concentr ctni baselin num num num2 num2 num2 num2 h postop measur isoflurane/sufentanil propofol/sufentanil anesthesia without ripc three num-min period intermitt left upper arm ischemia num min reperfus non-diabet patient n num2 three-vessel coronari arteri diseas clinicaltrialsnumgov nctnum5,0,1.0,0.0
tyrosin hypothyroid describ tyrosin kinas inhibitor caus hypothyroid,0,0.6104,0.3896
leucovorin toxic none num2 patient treat outpati requir hospit due advers reaction result suggest s-num achiev similar respons infusion num-fu plu leucovorin show potenti anoth biochem modul easili manag toxic,0,1.0,0.0
thiazid angina calcium channel blocker ccb attract altern thiazid patient uncontrol intoler thiazid specif indic agent eg angina sever diastol dysfunct,0,0.7992,0.2008
nvp death death adjust hr nvp numnum2 num2 ci numnum2-numnum2,0,1.0,0.0
testosteron hypogonad clinic report patient erectil dysfunct ed combin hypogonad receiv testosteron therapi inconsist result,0,1.0,0.0
sodium nausea taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.8121,0.1879
lenalidomid vte sinc introduct immunomodulatori deriv imid thalidomid lenalidomid therapeut armamentarium mm vte emerg one lead complic particular patient newli diagnos mm,1,0.206,0.794
iodin breast carcinoma iodine-label tamoxifen uptak primari human breast carcinoma,0,1.0,0.0
clozapin extrapyramid symptoms/ep unlik clozapin receptor interact profil lend toward increas risk extrapyramid symptom ep hyperprolactinaemia,0,0.6191,0.3809
chloroquin colon cancer chloroquin enhanc chemotherapeut activ num-fluorouracil colon cancer cell line via cell cycl alter,0,0.8032,0.1968
k. pain pain scale decreas num +/- numnum2 p numnum2 phase numnum2 +/- numnum2 p numnum2 phase k effect dose morphin reach,0,1.0,0.0
sevelam carbon ckd patient ckd may requir intraven oral activ vitamin d. investig effect lanthanum carbon sevelam carbon bioavail oral calcitriol,0,1.0,0.0
nucleosid chronic hepat b. suggest thymalfasin may efficaci treatment chronic hepat b c. pilot studi patient chronic hepat b treat thymalfasin combin interferon nucleosid analogu show num2 complet sustain respons rate,0,1.0,0.0
rapamycin tumor review consid data support exploit differ target pancreat net includ peptid receptor receptor tyrosin kinas involv tumor angiogenesi directli support tumor growth intracellular target mammalian target rapamycin mtor central role regul cell growth metabol apoptosi,0,0.8066,0.1934
delta num -thc thc howev long term effect psych cognit not known no report prolong use delta num -thc,0,1.0,0.0
acrylamid neurotox present review focus sever advers health effect acrylamid includ mutagen genotox carcinogen neurotox reproduct toxic possibl outcom childhood exposur babi food infant formula,1,0.0,1.0
no cf extend feno measur separ alveolar bronchial no output cf adult,0,0.8043,0.1957
tzd type furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0
num num-dihydroxybenzaldehyd oncogenesi sinc ckii involv cell prolifer oncogenesi result suggest num num-dihydroxybenzaldehyd may function inhibit oncogen diseas least part inhibit ckii activ,0,0.8267,0.1733
titanium perin hernia repair success preliminari result indic titanium mesh use perin hernia repair perin approach provid rigid support pelvic floor entir surfac ensur stabil without fixat,0,1.0,0.0
budesonid mild asthma allerg rhinit mild asthma random num2-day treatment period either nasal budesonid num3 e_g num puff per nostril twice day placebo,0,0.8178,0.18220000000000006
sulfasalazine/ssz arthriti methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0
vitamin d. chronic renal diseas influenc uv irradi vitamin metabol children chronic renal diseas,0,1.0,0.0
magnesium osteoporosi epidemiolog clinic studi suggest magnesium may reduc frequenc sudden death sodium contribut occurr hypertens calcium may help prevent osteoporosi,0,1.0,0.0
srl fibrosi intent-to-treat analysi srl cohort significantli less advanc fibrosi stage num compar hcv control group year one num2num vs. num2num p numnum4 year two num2num vs. num2num p numnum3,0,1.0,0.0
mitoxantron multipl sclerosi open-label studi perform evalu possibl subclin cardiotox multipl sclerosi patient treat quarterli mitoxantron num2 mg/m num cumul without concomit dexrazoxan use blind serial radionucleid ventriculographi,0,0.8119,0.18810000000000004
cyclophosphamid cognit deficit treatment differ immunotherapi includ cyclophosphamid natalizumab not improv cognit deficit necessit admiss nurs home age num2 year,0,1.0,0.0
dihydrotestosterone/dht ligand-bind domain/lbd prostat cancer pca therapi typic involv administr classic antiandrogen competit inhibitor androgen receptor ar ligand dihydrotestosteron dht testosteron te ligand-bind pocket lbp ligand-bind domain lbd ar,0,1.0,0.0
oxamniquin acut schistosomiasi treatment human acut schistosomiasi oxamniquin induc increas interferon-gamma respons schistosoma mansoni antigen,0,1.0,0.0
vinca alkaloid metastat diseas note respons seen patient rel poor prognost factor short num2 month interv prior platinum therapi num2 includ num2 respons rate progress num month platinum treatment prior treatment metastat diseas num2 prior treatment vinca alkaloid num2 viscer involv num2,0,1.0,0.0
copper california regul howev accord california regul lithium batteri test classifi hazard due excess level cobalt averag num3 num3 mg/kg ia num2 num3 limit num4 copper averag num2 num3 mg/kg ia num2 num3 limit num4 nickel averag num4 mg/kg ia num2 num3 limit num4,0,1.0,0.0
iron hepatocellular carcinoma result indic iron-facilit activ lsnum3 inhibit hif-1 express prolyl-hydroxyl hif-1 might therapeut effect treatment hepatocellular carcinoma,0,1.0,0.0
glucos glucos intoler three criteria metabol syndrom high triglycerid level glucos intoler obes fulfil three subject numnum2,0,1.0,0.0
gossypol toxic addit low toxic gossypol thioderiv revers nitric oxid donor physiolog media,1,0.1914,0.8086
bilirubin liver cirrhosi laboratori data indic sever liver cirrhosi total bilirubin albumin show better valu p numnum2 p numnum2 respect baselin nk cell activ low num +/- num vs num2num +/- num2num p numnum2 affect group unaffect group,0,1.0,0.0
carbamazepin aeds/antiepilept drug nineti percent antiepilept drug a commonli valproat carbamazepin,0,1.0,0.0
cyclophosphamid granulomatosi cours wegen granulomatosi dramat improv daili treatment cyclophosphamid glucocorticoid,0,1.0,0.0
prednisolon cogan 's syndrom describ case cogan 's syndrom neurolog involv earli treatment combin therapi prednisolon cyclosporin fail bring ear inflamm control,0,1.0,0.0
ca hypertens ca-entri blocker work normal intraren hemodynam essenti hypertens dilat affer arteriol alon,0,1.0,0.0
chromium cytotox clonogen assay measur leukemia stem cell kill not detect chromium releas flow cytometr cytotox assay,0,1.0,0.0
sphingosine-num-phosph allerg use highli specif neutral anti-s1p antibodi mab sphingosine-num-phosph receptor num s1pr2 antagonist jte-num3 studi signal contribut s1p s1pr2 mc- ige-depend airway allerg respons mice within minut antigen challeng,0,0.8042,0.1958
prednisolon acut q fever granulomat hepat report rare case acut q fever granulomat hepat remain pyrexia despit sever antibiot therapi num-day cours oral prednisolon,0,0.7795,0.22050000000000006
timolol pain studi evalu effect acetazolamid latanoprost travoprost bimatoprost brimonidin brinzolamid timolol pain phacoemulsif cataract surgeri,0,1.0,0.0
iron cytotox contrast superoxid dismutas abolish cytotox iron ion toward clvnum3 cell wherea lunum3 mel8 cell ineffect,0,0.6134,0.3866000000000001
echinocandin candidemia use echinocandin primari therapi candidemia appear associ better outcom,0,1.0,0.0
spiperon schizophrenia 3h-spiperon bind lymphocyt neuroleptic-naive-schizophrenia effect neurolept treatment,0,1.0,0.0
carvedilol alzheim 's diseas carvedilol potenti novel agent treatment alzheim 's diseas,0,1.0,0.0
oxygen myocardi dysfunct stun myocardium syndrom revers myocardi dysfunct may mediat oxygen-deriv free radic,0,0.8029999999999999,0.19700000000000006
paclitaxel/ptx gastric cancer five cancer cell line resist irinotecan snnum2 paclitaxel ptx etoposid vpnum2 oxaliplatin oxa gemcitabin gem respect establish parent gastric cancer cell line ocum-2m name ocum-2m/snnum2 ocum-2m/ptx ocum-2m/vpnum2 ocum-2m/oxa ocum-2m/gem,0,1.0,0.0
lactic acid/lact necrosi concentr tumor necrosi factor alpha interleukin-num vascular endotheli growth factor lactic acid lactat dehydrogenas hmgb-num measur synovi fluid sf sampl patient inflammatori arthropathi rheumatoid arthriti pseudogout patient noninflammatori arthropathi osteoarthr,0,1.0,0.0
furazolidon aid enterocytozoon bieneusi aid symptomat relief parasit chang furazolidon,0,1.0,0.0
paclitaxel tumor circumstanti data suggest greatest therapeut gain might accru paclitaxel administ greatest proport tumor clone low raf-num kinas activ,0,1.0,0.0
oestrogen menstrual bleed determin effect accept progestogen alon combin oestrogen regul irregular menstrual bleed associ oligo/anovul,0,1.0,0.0
ribavirin hepat c. studi num3 hepat c patient relaps not respond convent interferon ribavirin least num2 week,0,1.0,0.0
num-azadeoxycytidine/num-aza-dc pw furthermor treatment pw cell dna methyltransferas inhibitor num-azadeoxycytidin num-aza-dc induc demethyl snurf-snrpn cpg island restor gene express matern allel,0,1.0,0.0
mannitol turp syndrom report case hyperglycaemia lactic acidosi complic turp syndrom caus massiv absorpt approxim num2 litr sorbitol- mannitol irrig solut,1,0.0,1.0
triiodothyronin mdd triiodothyronin augment ssri may promis treatment strategi ssri-resist mdd particularli subject atyp mdd subtyp,0,1.0,0.0
flavon rb/retinoblastoma mechan underli cell cycl arrest flavon markedli increas mrna protein level univers inhibitor cyclin-depend kinas pnum2/waf1 inhibit phosphoryl retinoblastoma rb protein,0,1.0,0.0
fentanyl pain opioid rotat morphin fentanyl may effect allevi delirium pain cancer patient morphine-induc delirium,0,0.8113,0.1887
tamoxifen breast cancer estim rate endometri patholog prophylact use levonorgestrel-releas intrauterin system women breast cancer treat tamoxifen,0,1.0,0.0
statin cvd investig effect high-dos versu usual-dos statin pre-specifi outcom pad incid addit perform posthoc analysi efficaci high-dos statin reduc cvd risk among patient pad,0,1.0,0.0
fatti acid colorect cancer no statist signific associ colorect cancer risk dietari intak vitamin miner essenti fatti acid examin,0,1.0,0.0
hbeag remiss remiss occur within num month clear antigen hbeag major case,0,0.6199,0.3801
colchicin pericardi effus recent literatur show colchicin therapi use treatment recurr post surgic pericardi effus,0,1.0,0.0
aciclovir viral enceph manag infant children treat aciclovir suspect viral enceph,0,1.0,0.0
lithium california regul howev accord california regul lithium batteri test classifi hazard due excess level cobalt averag num3 num3 mg/kg ia num2 num3 limit num4 copper averag num2 num3 mg/kg ia num2 num3 limit num4 nickel averag num4 mg/kg ia num2 num3 limit num4,0,1.0,0.0
potassium oxon toxic studi set out evalu patient metastat colorect carcinoma efficaci toxic s-num contain tegafur num-chloro-num num-dihydroxypyridin cdhp potassium oxon base biochem modul num-fluorouracil num-fu target inhibit dihydropyrimidin dehydrogenas dpd,0,0.602,0.39799999999999996
mannitol lactic acidosi report case hyperglycaemia lactic acidosi complic turp syndrom caus massiv absorpt approxim num2 litr sorbitol- mannitol irrig solut,0,0.8183,0.1817
taxan tnbc carboplatin gemcitabin cg combin activ unselect anthracycline/taxan pretreat metastat breast cancer patient carri out phase ii studi evalu activ cg combin pretreat metastat tnbc patient,0,1.0,0.0
tunicamycin stomach cancer/colon cancer human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,0.8047,0.19530000000000006
verapamil af intraven beta blocker verapamil diltiazem may given immedi slow rapid ventricular rate af,0,1.0,0.0
acetazolamid pain studi evalu effect acetazolamid latanoprost travoprost bimatoprost brimonidin brinzolamid timolol pain phacoemulsif cataract surgeri,0,0.7979,0.20209999999999995
num-fu/num-fluorouracil colorect cancer purpos studi determin efficaci toxic oxaliplatin combin weekli bolu num-fluorouracil num-fu leucovorin lv patient num-fu-pretr advanc colorect cancer,0,1.0,0.0
cr angiogenesi improv model tumor angiogenesi determin measur blood volum area skin held contact tumor cell-contain chamber use num2cr-label red blood cell rbc,0,1.0,0.0
testosteron t1d higher hba1c neg effect total testosteron cft posit effect shbg level t1d boy,0,1.0,0.0
iron iron defici studi includ num2 end-stag renal diseas esrd patient perform chronic periton home hemodialysi iron defici defin ferritin num3 ng/ml and/or iron satur num2,0,1.0,0.0
mpa mpa csa c2 correl mpag-to-mpa ratio p numnum2 r numnum2 gamma-glutamyl-transpeptidas ggt p numnum2 r numnum2,0,1.0,0.0
cisplatin bladder cancer determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,0,0.8146,0.1854
gentamicin bacteremia chronic bacteremia gentamicin doxycyclin significantli increas resolut rate,0,0.7913,0.2087
terazosin congest heart failur terazosin maintain antihypertens efficaci well toler patient varieti concomit diseas includ congest heart failur peripher vascular diseas chronic obstruct pulmonari diseas benign prostat hyperplasia diabet obes,0,0.6035,0.3965
adenosin syncop syncop associ document paroxysm atrioventricular block reproduc adenosin num triphosph inject,1,0.3975,0.6025
lithium mania/bipolar disord avail option treatment bipolar disord includ mania hypomania depress mainten elderli includ lithium antiepilept antipsychot benzodiazepin antidepress electroconvuls therapi ect psychotherapi,0,1.0,0.0
folat colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.6044,0.3956
pimecrolimu atop dermatitis/ad previou studi suggest earli intervent pimecrolimu cream num first sign and/or symptom relaps atop dermat ad follow remiss may prevent occurr sever flare therefor reduc corticosteroid exposur long term,0,1.0,0.0
tsa inflamm real-tim pcr immunocytochemistri studi show system administr tsa suppress inflamm fibrot respons stroma acceler epitheli heal alkali-burn mous cornea,0,1.0,0.0
heparin postop coagul disturb use heparin-co circuit reduc mean length stay hospit num +/- num num +/- num day p numnum3 postop ventil time num +/- num num +/- num h p numnum3 blood loss num h post surgeri num3 +/- num3 num3 +/- num3 ml p numnum3 individu periop chang haemoglobin loss p numnum3 leukocyt count p numnum3 creatinin elev p numnum3 proport patient expos allogen blood transfus num2num vs num2num p numnum3 postop coagul disturb num vs num p numnum3 postop deviat normal postop cours num2num vs num2num p numnum3 neurolog deviat num vs num p numnum3 atrial fibril num2num vs num2num p numnum3,0,0.7997,0.20030000000000006
cholesterol diabet aim studi examin effect max epa commerci avail fish oil prepar serum cholesterol lipoprotein apolipoprotein insulin-depend diabet iddm men dosag like accept patient,0,1.0,0.0
indomethacin patent ductu arteriosu antenat indomethacin not associ intraventricular hemorrhag patent ductu arteriosu respiratori distress syndrom bronchopulmonari dysplasia mortal,0,1.0,0.0
atorvastatin stroke patient receiv atorvastatin therapi clopidogrel therapi associ signific decreas mortal stroke univari analysi moder trend reduc mortal stroke without statist signific multivari analysi,0,1.0,0.0
sorbitol lactic acidosi propos mechan type b lactic acidosi relat metabol sorbitol,0,0.6131,0.3869
nifedipin hypertens find suggest low-dos combin therapi nifedipin cr candesartan superior up-titr monotherapi candesartan term blood pressur control renal protect patient essenti hypertens,0,1.0,0.0
perindopril vascular endotheli dysfunct conclus result suggest angiotensin i-convert enzym inhibitor perindopril superior calcium channel blocker amlodipin reduc vascular endotheli dysfunct co-administ angiotensin receptor blocker patient essenti hypertens,0,1.0,0.0
aspirin atrial fibril compar studi efficaci coumadin aspirin primari cardioembol stroke prevent chronic rheumat heart diseas mitral stenosi atrial fibril conduct siriraj hospit mahidol univers bangkok thailand,0,1.0,0.0
ethyl acet glycoprotein mous lymphoma present work extract num2 select herb prepar methanol chloroform ethyl acet water effect multidrug resist mdr p-glycoprotein mous lymphoma cell transfect human mdr1 gene human lung alveolar epitheli cell line investig,0,1.0,0.0
aza toxic determin current local practic aza dose identifi aza-rel toxic compar local practic british societi rheumatolog bsr recommend,1,0.21930000000000005,0.7807
mycophenol mofetil graft-versus-host diseas graft-versus-host diseas prophylaxi compris continu infus calcineurin inhibitor without mycophenol mofetil,0,1.0,0.0
morphin pain opioid rotat morphin fentanyl may effect allevi delirium pain cancer patient morphine-induc delirium,0,0.7968,0.20320000000000005
glucos diabet control scheme base fuzzi logic control theori maintain normoglycaem averag num mmol num -num normal condit free plasma insulin concentr sever initi state particular diabet patient subject glucos meal disturb fluctuat measur glucos level due error measur instrument,0,0.8158,0.18420000000000006
aldosteron renal cardiovascular morbid combin therapi calcium channel antagonist calcium channel blocker ccb inhibitor renin-angiotensin-aldosteron system raa ration approach achiev bp goal provid protect against renal cardiovascular morbid mortal,0,1.0,0.0
lorazepam enceph ect deserv seriou consider earli cours malign catatonia catatonia nest encephalopathi secondari enceph unresolv lorazepam,0,1.0,0.0
sunum4 glioblastoma primari isol human umbil vein endotheli cell huvec human dermal microvascular endotheli cell hdmec human glioblastoma unum2 prostat cancer cell pc3 expos pemetrex num h alon combin sunum4 num h,0,1.0,0.0
tacrolimu ulcer colitis/uc although efficaci tacrolimu induc remiss refractori ulcer coliti uc establish efficaci maintain remiss uc not evalu,0,0.818,0.18200000000000005
chloroform poison drug condemn num4 without attempt made determin incid so-cal delay chloroform poison result drug still use chloroform controversi remain unsettl day,1,0.1928,0.8072
mycophenol mofetil gi complic unrestrict literatur search num4-januari num4 perform medlin embas use follow key word drug-drug interact enteric-co mycophenol acid gi complic mycophenol mofetil solid organ transplant proton pump inhibitor includ individu agent within class,0,1.0,0.0
sodium seizur taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.809,0.19099999999999995
warfarin cluster headach two remain cluster headache-fre take warfarin,0,0.8158,0.18420000000000006
iron cytotox catalas suppress cytotox induc iron ion lunum3 cell wherea clvnum3 mel8 cell ineffect,1,0.0,1.0
somatostatin ocd abnorm csf arginin vasopressin corticotropin-releas hormon oxytocin somatostatin level report ocd,0,0.7866,0.21340000000000006
tacrolimu headach headach symptom num2 patient receiv cyclosporin and/or tacrolimu organ transplant retrospect assess,1,0.3921,0.6079
cyclosporin toxic although one larg random studi demonstr proven surviv advantag without increas toxic use cyclosporin inconsist result modul rais doubt util overal strategi use drug efflux blocker patient establish pgp overexpress,0,1.0,0.0
ethanol hcc sixty-four patient ethanol group num2 patient gelfoam group hcc ap respect treat ethanol gelfoam ap routin intervent treatment tumor,0,1.0,0.0
ifosfamid malign long-term consequ ifosfamid survivor childhood cancer term develop bladder cancer malign thought associ alkyl agent not known determin follow-up studi adult survivor,0,0.7925,0.2075
octreotid thymic carcinoid thymic carcinoid respond neoadjuv therapi sunitinib octreotid case report,0,1.0,0.0
mitomycin ocular toxic articl discuss ocular toxic six patient advanc nonpretr colorect cancer receiv megados carmustin mitomycin support autolog bone marrow transplant,0,0.7997,0.20030000000000006
furazolidon aid clinic benefit seen treatment furazolidon six aid patient e bieneusi intestin infect may due damag development stage caus partial inhibit reproduct parasit,0,1.0,0.0
tamoxifen breast cancer assess respons tamoxifen among iraqi patient advanc breast cancer,0,1.0,0.0
simvastatin cortic stroke simvastatin/placebo given num-num2 h symptom onset num2 patient cortic stroke,0,0.8179,0.18210000000000004
calcium hypertens effect calcium-entri blocker nicardipin intraren hemodynam essenti hypertens,0,0.8082,0.1918
calcium pidol involut osteoporosi effect calcium pidol biochem hormon paramet involut osteoporosi,0,0.8204,0.17959999999999998
tam/tamoxifen breast cancer/malign neoplasm recent studi shown antiestrogen tamoxifen tam use treatment malign neoplasm breast cancer,0,1.0,0.0
probenecid pancytopenia sever pancytopenia patient take low dose methotrex probenecid,1,0.0,1.0
tamoxifen breast cancer no signific differ age breast cancer diagnosi bodi mass index pariti stage breast cancer modal breast cancer treatment durat tamoxifen therapi past recent user tamoxifen,0,1.0,0.0
delta num -tetrahydrocannabinol/thc nausea activ principl marijuana delta num -tetrahydrocannabinol thc shown wide therapeut applic number import medic condit includ pain anxieti glaucoma nausea emesi muscl spasm wast diseas,0,1.0,0.0
pivampicillin bronchiti single-blind double-dummi multicentr studi compar oral azithromycin administ tablet num3 mg daili num day versu oral pivampicillin num3 mg twice daili num2 day adult acut exacerb chronic bronchiti not need parenter antibiot therapi hospit oxygen support,0,0.7956,0.20440000000000005
methylphenid attention-deficit hyperact disorder/adhd author describ case num-year-old boy otherwis healthi present symptom consist attention-deficit hyperact disord adhd start trial methylphenid,0,1.0,0.0
fentanyl delirium opioid rotat morphin fentanyl may effect allevi delirium pain cancer patient morphine-induc delirium,0,1.0,0.0
glutathion neuroblastoma tumour growth neuroblastoma tumour inhibit differ mechan l-dopa metabolit dopamin reduc activ tyrosinas bso reduc glutathion level l-dopa tamoxifen rais camp concentr,0,1.0,0.0
primaquin hiv-infect hiv-infect man becam increasingli breathless cyanos receiv clindamycin primaquin treatment pneumocysti jirovecii pneumonia,0,0.8018,0.19820000000000004
clonidin sexual abus twelv women meet prospect dsm-iv criteria pmdd five histori sexual abus particip random placebo-control double-blind cross-ov design studi compar num month oral clonidin num mg/day num month activ placebo,0,0.8270000000000001,0.17299999999999993
hydroxychloroquin urticari vascul num2-year-old woman num yr histori chronic recurr urticari vascul angioedema refractori convent treatment includ glucocorticosteroid h1 h2 blocker nonsteroid antiinflammatori agent methotrex hydroxychloroquin dapson azathioprin intraven gamma globulin plasma exchang success treat interferon alpha 2a,0,1.0,0.0
aldosteron wast infection-trigg life-threaten salt-loss hyperkalaemia develop two male infant wast inappropri low plasma aldosteron concentr elev plasma renin activ,0,0.8205,0.1795
ondansetron ed/emerg depart assess hypothesi ondansetron administr children type num diabet mellitu t1dm present emerg depart ed care intercurr ill vomit improv clinic outcom reduc hospit rate primari length ed stay intraven fluid ivf administr revisit secondari outcom,0,1.0,0.0
statin pad investig effect high-dos versu usual-dos statin pre-specifi outcom pad incid addit perform posthoc analysi efficaci high-dos statin reduc cvd risk among patient pad,0,1.0,0.0
alcohol hepatocellular carcinoma cigarett smoke heavi alcohol consumpt hbsag independ associ increas risk mortal hepatocellular carcinoma not interact synergist,1,0.2036,0.7964
norepinephrin depress aim determin potenti correl num-htt/net gene polymorph suscept depress antidepress respons select serotonin reuptak inhibitor ssri dual select serotonin/norepinephrin reuptak inhibitor snri,0,0.6023,0.3977000000000001
sunitinib renal carcinoma introduct sunitinib oral multitarget receptor tyrosin kinas inhibitor delay diseas progress median overal surviv os num year improv qualiti life becom first-lin standard care metastat renal carcinoma mrcc,0,1.0,0.0
warfarin cluster headach warfarin therapeut option control chronic cluster headach report three case,0,1.0,0.0
levobupivacain toxic cardiac cn toxic levobupivacain strength evid advantag bupivacain,1,0.3865,0.6135
mangafodipir liver lesion mangafodipir-enhanc imag like better spio-enhanc imag distinguish focal liver lesion hepatocellular nonhepatocellular origin,0,0.8065,0.1935
methylprednisolon proteinuria surviv even prolong bindarit num medic diet combin low dose methylprednisolon num mg/kg inump partial modifi proteinuria surviv lupu mice addit group anim n num2,0,1.0,0.0
asenapin dizzi pool analysi monotherapi trial common advers event occur num patient twice incid placebo report acut phase asenapin monotherapi bipolar mania somnol dizzi extrapyramid symptom ep akathisia increas bodyweight similar natur occur longer-term monotherapi asenapin,1,0.203,0.797
clopidogrel less bleed howev significantli less bleed clopidogrel carrier loss-of-funct allel suggest less anti-platelet respons,0,0.7898,0.21020000000000005
cisplatin/cis-diamminedichloroplatinum ii tumor num day tumor inocul num mg/kg cis-diamminedichloroplatinum ii cisplatin administ intraperiton week num week,0,1.0,0.0
aspirin rheumat heart diseas primari prevent cardioembol stroke chronic rheumat heart diseas found effect coumadin aspirin,0,1.0,0.0
podophyllotoxin condylomata evalu clinic efficaci numnum2 num cream formul podophyllotoxin comparison num solut treatment condylomata acuminata compar treatment modal regard side effect,0,1.0,0.0
cholesterol atherosclerosi conjug linol acid atherosclerosi no effect molecular marker cholesterol homeostasi thp-num macrophag,0,1.0,0.0
cisplatin ascit dose cisplatin significantli inhibit hnum2-induc acut ascit develop,0,0.6024,0.3976
methamphetamin depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,0.8105,0.1895
num-hydroperoxycyclophosphamide/num-hc tumor bm purg ex vivo num-hydroperoxycyclophosphamid num-hc num2-num3 micrograms/ml reinfus kill tumor cell,0,1.0,0.0
tacrolimu mycophenol acid/mpa therapeut drug monitor mycophenol acid mpa combin cyclosporin num-h concentr csa c2 n num2 tacrolimu trough concentr n num2 investig repeat measur mpa mpa-glucuronid mpag trough concentr renal allograft recipi first num month post-transpl,0,1.0,0.0
steroid ulcer coliti effect mainten leukocytapheresi patient steroid depend resist ulcer coliti,0,0.7943,0.2057
zotepin schizophrenia zotepine-induc convuls seizur chronic case treatment resist paranoid schizophrenia,0,0.8195,0.1805
furosemid bronchopulmonari dysplasia conclud administr metolazon furosemid enhanc diuresi natriuresi chloruresi overcom rapid develop toler furosemid infant bronchopulmonari dysplasia block compensatori increas renal sodium chlorid absorpt,0,1.0,0.0
sodium bicarbon death patient random receiv sodium bicarbon vs sodium chlorid rate death dialysi myocardi infarct cerebrovascular event not differ significantli num2 day num vs num num vs num num vs num num vs num respect num2 day num month num vs num num vs num num vs num num vs num respect p .num2,0,1.0,0.0
arsen trioxid leukem differenti arsen trioxid methylprednisolon use differ signal transduct pathway leukem differenti,0,1.0,0.0
nscnum5 ovarian cancer human ovarian cancer cell line coc1 cell treat differ nanomolar nscnum5 without cddp cell growth apoptosi evalu respect mtt assay annexin-v assay flow cytometri,0,1.0,0.0
nicotinamid adenin dinucleotide/nadh tumor measur express level three differ reductas enzymes-dt-diaphoras nad p h inume. reduc nicotinamid adenin dinucleotid without phosphat quinon oxidoreductas nadph cytochrom p-num3 reductas nadh inume. reduc nicotinamid adenin dinucleotid cytochrome-b5 reductase- num2 cell line nation cancer institut nci human tumor cell panel see relationship could establish activ enzym cellular sensit bioreduct compound mitomycin c eo9,0,1.0,0.0
vigabatrin epilept vigabatrin anti-epilept drug particularli use drug-resist partial seizur infantil spasm,0,1.0,0.0
ceftazidim neutropenia follow comparison num2 case num2 control match age +/- num year cohabit oncolog unit risk factor colonis vre includ durat neutropenia numnum2 num2 ci num-num2num antibiot therapi numnum2 num2 ci numnum2-num2num number antibiot agent receiv num num2 ci numnum2-num2num durat therapi amikacin num2num num2 ci num-num2num ceftazidim num2num num2 ci num num2num teicoplanin num2num num2 ci numnum2-num2num,0,0.8197,0.1803
num-fu gastric cancer establish num hif-1alpha knockdown gastric cancer cell line order clarifi role hif-1alpha chemo-resist against num-fu,0,1.0,0.0
nevirapin rt nevirapin efavirenz suscept test compar control wild-typ viru rt,0,1.0,0.0
cocain hyperthermia mechan cocaine-induc hyperthermia human,1,0.3792,0.6208
pentoxifyllin malaria pentoxifyllin two analogu hwanum3 hwanum3 concentr exceed num2 micrograms/ml inhibit malaria antigen lipopolysaccharid lp induc tnf-alpha il-num alpha secret not il-num secret human peripher blood mononuclear cell vitro,0,1.0,0.0
lactulos burn injuri lactulose/mannitol ratio increas normal pod +num control numnum3 +/- numnum3 gln numnum3 +/- numnum3 not signific reflect increas intestin permeabl burn injuri,0,1.0,0.0
morphin pain adequ intra-op morphin use minim post-op pain subsequ need rescu analgesia,0,1.0,0.0
azela acid melanoma effect combin taurin azela acid antimelanogenesi murin melanoma cell,0,1.0,0.0
irbesartan mf first clinic trial evalu arb irbesartan versu placebo reduc rate aortic root dilat mf,0,1.0,0.0
retino acid retino acid/ra investig effect retino acid ra retinyl acet rac product reactiv oxygen metabolit releas lysosom enzym human polymorphonuclear leukocyt pmn,0,1.0,0.0
asenapin ep ep not worsen sever longer-term asenapin monotherapi,0,1.0,0.0
pioglitazon diabet pioglitazon not enhanc effect lifestyl modif prevent convers impair glucos toler diabet asian indian result indian diabet prevent programme-num idpp-num,0,1.0,0.0
bortezomib/velcad tumor investig therapeut potenti tumor necrosi factor-rel apoptosis-induc ligand trail/apo2l combin proteasom inhibitor bortezomib velcad human escc cell line,0,1.0,0.0
methylphenidate/mph attent deficit-hyperact disorder/adhd methylphenid mph -ritalin r compound block reuptak synapt releas norepinephrin ne dopamin da brain use num2 year low dose long-term regimen treat attent deficit-hyperact disord adhd juvenil adolesc adult,0,1.0,0.0
oestrogen endometri cancer relationship oestrogen replac treatment risk endometri cancer analys case-control studi num3 histolog confirm incid case age num2 num3 control hospit acut non-neoplast non-hormone-rel condit conduct swiss canton vaud num4-num4,0,0.8187,0.1813
ifosfamid cancer long-term consequ ifosfamid survivor childhood cancer term develop bladder cancer malign thought associ alkyl agent not known determin follow-up studi adult survivor,0,0.8065,0.1935
androgen prostat cancer/pca investig involv prostat androgen-regul par gene androgen receptor ar signal pathway malign phenotyp androgen-independ prostat cancer pca cell,0,1.0,0.0
num- num num-dimethyl-thiazol-num-yl -num num-diphenyltetrazolium bromid cytotox result show nanomolar concentr snum3b protect cell against abeta-medi cytotox assess num- num num-dimethyl-thiazol-num-yl -num num-diphenyltetrazolium bromid mtt termin deoxynucleotidyl transferase-medi dutp-fluorescein isothiocyan nick end-label tunel experi counter abeta-medi decreas express anti-apoptot factor bcl-num,0,1.0,0.0
geldanamycin hcc use svm sever known hcc inhibitor geldanamycin alvespimycin hspnum2 inhibitor doxorubicin chemotherapi drug predict,0,1.0,0.0
propranolol telangiectasia oral propranolol clinic effect reduc volum color infantil hemangioma although reduct not complet telangiectasia scar persist treatment,0,1.0,0.0
bisphosphon breast cancer phase iii studi compar efficaci new potent bisphosphon ibandron placebo intraven i.v therapi metastat bone diseas due breast cancer,0,1.0,0.0
colchicin tumor success treatment anti-tumor necrosi factor anti-tnf -alpha proteinuria patient famili mediterranean fever fmf resist colchicin anti-tnf drug fmf,0,1.0,0.0
anthocyanin breast cancer howev no signific associ flavan-num-ol rr=numnum2 num2 ci numnum2-numnum2 flavanon summari rr=numnum2 num2 ci numnum2-numnum2 anthocyanin summari rr=numnum2 num2 ci numnum2-numnum2 total flavonoid summari rr=numnum2 num2 ci numnum2-numnum2 intak breast cancer risk observ,0,1.0,0.0
irinotecan non-hodgkin 's lymphoma camptothecin deriv irinotecan cpt-num2 shown possess antitumor activ phase ii trial patient carcinoma lung cervix ovari colon rectum patient non-hodgkin 's lymphoma,0,1.0,0.0
testosteron ed review describ relationship low serum testosteron concentr ed obes patient metabol syndrom type num diabet mellitu,0,1.0,0.0
amlodipin hypertens thirty-two patient essenti hypertens treat angiotensin receptor blocker monotherapi random receiv num mg amlodipin n=num2 num mg perindopril n=num2 daili morn num2 week,0,0.8212,0.17879999999999996
olanzapin multipl neurocognit domain robust find signific across multipl neurocognit domain adjac snp show evid associ rsnum5 ehf gene p-valu numnum2 num2 -num q-valu numnum3 mediat effect ziprasidon vigil rsnum5 slcnum2a9 p-valu num num2 -num q-valu numnum3 mediat effect olanzapin process speed rsnum5 il1a p-valu numnum2 num2 -num q-valu numnum3 mediat effect olanzapin work memori,0,0.7902,0.2098
clonidin pmdd/premenstru dysphor disord women meet strict criteria premenstru dysphor disord pmdd examin whether clonidin alpha2-adrenerg receptor ar agonist would differ effect sexual abus versu non-abus pmdd women measur autonom nervou system function,0,1.0,0.0
ixabepilon neuropathi epothilon new class mti may associ grade num/num peripher neuropathi howev neuropathi associ ixabepilon novel epothilon b analog gener mild moder revers baselin grade num level,1,0.0,1.0
tacrolimu uc mainten therapi tacrolimu patient uc could consid altern thiopurin therapi,0,1.0,0.0
epothilon breast cancer microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,0,1.0,0.0
hydroxyzin allerg rhiniti fifteen subject allerg rhiniti test num-num h administr diphenhydramin hydroxyzin placebo double-blind single-dos three-way crossov studi,0,1.0,0.0
tyrosin necrosi retrospect studi conduct quantit plasma level num cytokin regul hematopoiesi name num stimulatori fms-like tyrosin kinas flt3-l stem cell factor scf num inhibitori growth factor tumor necrosi factor-alpha tnfalpha tumor growth factor-beta macrophag inflammatori protein mip-1alpha immunoassay num2 patient enrol clinic trial garden state cancer center bellevil new jersey,0,1.0,0.0
cholesterol coronari arteri disease/cad commonli agre peopl high blood ldl-cholesterol higher risk coronari arteri diseas cad peopl low blood ldl-cholesterol,1,0.0,1.0
salmeterol mdi/metered-dos inhal salmeterol num2 mug bid via metered-dos inhal mdi placebo bid via mdi,0,0.8290000000000001,0.17099999999999993
alcohol cardiovascular diseas cardiovascular diseas due atherosclerosi lead caus death western societi desir effect alcohol use outweigh detriment action result favor find popul studi,0,0.8087,0.19130000000000005
num- num- num- acridin-num-ylamino phenylthio phenyl num-hydroxypropyl amino propan-num-ol/cknum4 multipl cancer two recent develop sulfid deriv num-anilinoacridin num- num- num- acridin-num-ylamino phenylthio phenyl num-hydroxyethyl amino ethan-num-ol cknum4 num- num- num- acridin-num-ylamino phenylthio phenyl num-hydroxypropyl amino propan-num-ol cknum4 display potent cytotox activ multipl cancer cell line,0,0.6165,0.3835
rc-num4 breast cancer inhibitori effect bombesin/gastrin-releas peptid antagonist rc-num4 lutein hormone-releas hormon antagonist sb-num2 growth mcf-num miii human breast cancer xenograft athym nude mice,0,1.0,0.0
methadon hydrochlorid ventricular arrhythmia methadon hydrochlorid may increas risk lethal respiratori depress relat accident overdos life-threaten ventricular arrhythmia,1,0.21650000000000005,0.7835
combretastatin-a4-phosph prostat adenocarcinoma phase ib trial radiotherapi combin combretastatin-a4-phosph patient non-small-cel lung cancer prostat adenocarcinoma squamou cell carcinoma head neck,0,1.0,0.0
aspirin bleed patient receiv heartmat ii lvad directli transit warfarin aspirin therapi without intraven heparin no short-term increas risk thrombot thromboembol event bleed requir transfus significantli reduc,0,0.7971,0.2029
carboplatin cancer april num juli num num4 cancer leukemia group b calgb conduct phase ii studi etoposid carboplatin advanc ajc stage iiib-iv non-small-cel lung cancer nsclc patient whose perform statu ps num-num,0,1.0,0.0
sodium bicarbon nephropathi sodium bicarbon suggest possibl strategi prevent contrast medium-induc nephropathi common caus renal failur associ prolong hospit increas health care cost substanti morbid mortal,0,1.0,0.0
benzo pyren hnscc treatment cell line ahr antagonist num num num'-trimethoxyflavon potent gnfnum3 decreas migrat invas hnscc cell prevent benzo pyrene-medi induct chemotherapi efflux protein abcg2,0,1.0,0.0
fluvoxamin neuropeptid abnorm long-term treatment high-dos clomipramin fluvoxamin fluoxetin tend correct neuropeptid abnorm,0,1.0,0.0
cisplatin tumor smac defici also reduc effect cisplatin long-term cell viabil led cisplatin resist xenograft tumor vivo,0,1.0,0.0
carboplatin metaplast carcinoma ration success use carboplatin albumin-bound paclitaxel patient recurr metaplast carcinoma present multi-organ tumor emboli,0,1.0,0.0
styren cochlear damag ototox effect exposur styren evalu also presenc simultan exposur nois use otoacoust emiss biomark mild cochlear damag,0,0.8074,0.1926
leucovorin colorect cancer purpos studi determin efficaci toxic oxaliplatin combin weekli bolu num-fluorouracil num-fu leucovorin lv patient num-fu-pretr advanc colorect cancer,0,1.0,0.0
atg bone marrow suppress four not receiv atg/alg two aplast anemia two bone marrow suppress,0,0.8043,0.1957
methionin colon cancer fluorin n n-dialkylaminostilben repress colon cancer target methionin s-adenosyltransferas 2a,0,1.0,0.0
oxygen hypoxia hypoxia induc factor-1 hif-1 central role cellular oxygen-sens overexpress mani type cancer consid import tumor progress,0,1.0,0.0
cephalosporin mening dilemma diagnosi manag cephalosporin-resist streptococcu pneumonia mening,0,1.0,0.0
acetylcholin lvh studi demonstr racial differ sensit coronari arteri acetylcholine-stimul relax among lvh,0,1.0,0.0
progesteron anovulatori cycl anovulatori cycl may prolong oestrogen stimul endometrium without progesteron withdraw cycl irregular bleed may heavi,0,0.8155,0.1845
mannitol burn injuri lactulose/mannitol ratio increas normal pod +num control numnum3 +/- numnum3 gln numnum3 +/- numnum3 not signific reflect increas intestin permeabl burn injuri,0,1.0,0.0
fentanyl pain/postop pain contraind manag acut postop pain pain may decreas rapidli circumst fentanyl blood level adjust lead develop life-threaten hypoventil,0,1.0,0.0
anthracyclin breast cancer sequenc compar simultan anthracyclin cyclophosphamid high-risk stage ii breast cancer final analysi int-num4 snum4,0,0.8069,0.19310000000000005
quinolon escherichia escherichia coli resist quinolon comprehens cancer center,0,1.0,0.0
carvedilol ad mous present evid chronic oral administr carvedilol nonselect e_-adrenerg receptor blocker significantli attenu brain oligomer e_-amyloid content cognit deterior num independ ad mous model,0,1.0,0.0
glutam nm glutam releas inhibitor lamotrigin test two nm patient,0,1.0,0.0
thymidin tumor gene express level sequenc use analyz carboxylesterase-convert enzym ces1 ces2 thymidyl synthas ts thymidin phosphorylas tp dehydropyrimidin dehydrogenas dpd topoisomeras topo uridine-diphosph udp glucuronosyl transferas 1a1 pre- post-treat tumor normal tissu sampl,0,1.0,0.0
estrogen tumor/breast cancer also demonstr steap1 transcript correl neg estrogen receptor er immunoreact posit tumor grade breast cancer case,0,1.0,0.0
tacrolimu vernal keratoconjunct therapeut effect numnum2 tacrolimu ointment ocular graft versu host diseas vernal keratoconjunct,0,1.0,0.0
creatinin nephropath characterist nephropath identifi exist screen practic phase albuminuria num2 mg/l three separ urin sampl compar identifi nurse-l manag program phase ii screen nephropathi base albumin-to-creatinin ratio singl random urin specimen,0,1.0,0.0
mpa mpa total mpa concentr increas num month not patient tacrolimu,0,1.0,0.0
alcohol alcohol abus proteom analysi show therapi downregul enzym involv amino acid metabol glycolysis/gluconeogenesi alcohol catabol take place latter probabl due cessat alcohol abus,0,0.7881,0.2119
glucos type rosiglitazon significantli increas glucos uptak wild-typ podocyt associ transloc glut1 plasma membran,0,1.0,0.0
suramin lung cancer decid investig relationship suramin treatment serum level insulin-lik growth factor igf-i ii igf-ii advanc breast prostat lung cancer patient,0,1.0,0.0
fluoroquinolon kerat kerat isol no suscept differ among five fluoroquinolon,0,1.0,0.0
paliperidon schizophrenia paliperidon er potenti offer advantag parent compound second gener agent may aid ensur complianc among person schizophrenia,0,1.0,0.0
imidazol gcse midazolam particularli use treat acut gcse imidazol ring open low ph allow dissolv aqueou solut intramuscular inject close physiolog ph increas lipophil render good intramuscular absorpt brain penetr fast onset action,0,1.0,0.0
dopamin dystonia differ may help distinguish clinic set improv diagnost accuraci support exist causal relationship exposur dopamin antagonist medic chronic dystonia,0,0.8018,0.19820000000000004
pgi2 platelet aggreg ex vivo platelet aggreg paf num2 -num num2 -num mol/l significantli inhibit pgi2,0,0.7957,0.20430000000000004
iron decreas diarrhea sever -supplement infant formula safe improv iron statu decreas diarrhea sever infant rhesu monkey thu may help protect formula-f human infant infect nutrit defici,0,1.0,0.0
serotonin bing eat disord bing eat disord best evid mood disord cognitive-behavior therapi well topiram zonisamid select case select serotonin reuptak inhibitor,0,0.8023,0.1977
num'-dfur hnscc no correl detect sensit num'-dfur rel express level tp dpd multipl hnscc cell line test,0,1.0,0.0
clopidogrel stroke patient receiv atorvastatin therapi clopidogrel therapi associ signific decreas mortal stroke univari analysi moder trend reduc mortal stroke without statist signific multivari analysi,0,1.0,0.0
calcium hypertens arteri wall shear rate ultrasound techniqu profilmet frp iii systo-diastol diamet echotrack techniqu mean blood flow veloc volum common carotid arteri blood viscos rotat viscomet finger arteri blood pressur finapress ohmeda measur num2 young volunt age num2+/-num year num2 elderli hypertens age num2+/-num year treat short-act calcium antagonist num2h studi baselin intraven furosemid infus num5mg/min haematocrit increas least two percentag point,0,1.0,0.0
cisplatin small cell lung cancer present studi aim determin whether erk1/num akt pathway contribut cisplatin resist human small cell lung cancer anum3 cell,0,1.0,0.0
num-deoxyglucos fibrosarcoma human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,0.8241,0.17589999999999995
memantin bradycardia littl known cardiovascular effect memantin report bradycardia reduc cardiovascular surviv associ use,1,0.3779,0.6221
pimecrolimu ad num2-week random control studi conduct num3 patient age or=num2 year histori mild moder ad clear/almost clear diseas random pimecrolimu cream num n=num3 match vehicl cream n=num3,0,0.7894,0.2106
sorbitol lactic acidosi report case hyperglycaemia lactic acidosi complic turp syndrom caus massiv absorpt approxim num2 litr sorbitol- mannitol irrig solut,0,0.6199,0.3801
tyrosin abl chromosom transloc tyrosin kinas c-abl gene chromosom num may gener oncogen kinas exhibit constitut tyrosin kinas activ,0,0.8253,0.17469999999999994
lactic acid/lact rheumatoid arthriti concentr tumor necrosi factor alpha interleukin-num vascular endotheli growth factor lactic acid lactat dehydrogenas hmgb-num measur synovi fluid sf sampl patient inflammatori arthropathi rheumatoid arthriti pseudogout patient noninflammatori arthropathi osteoarthr,0,1.0,0.0
amlodipin hypertens stroke comparison effect amlodipin losartan blood pressur diurnal variat hypertens stroke patient prospect random double-blind compar parallel studi,0,0.8207,0.1793
